

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Marquez, Paige L \(CDC\)](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Zinderman, Craig E](#); [Baer, Bethany](#)
Subject: Data mining
Date: Tuesday, January 12, 2021 1:51:05 PM
Attachments: [DE VAERS data mining_20200110_DRAFT.pptx](#)

Dear John and Tom,

Our core weekly data mining run (previously refreshing monthly) called “VAERS Signals Weekly US All” was just refreshed this afternoon (as of date 1/10/21) and there are no EB05’s >2 for any COVID vaccines. Attached are 3 slides providing contextual information including caveats and limitations that we can discuss at our weekly meeting on Thursday at 2pm.

Best,

David

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported adverse event [AE] for a product relative to other products)
- Hypothesis generating
 - Statistical signal of disproportional reporting (SSDR) \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

DE Data Mining Methods

- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-AE pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
- Results adjusted by gender, year received and age
- Vaccine-AE pairs ranked by lower 5% bound of EBGM confidence interval (EB05)
- Standard threshold for alert: $EB05 \geq 2$

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe program, media reports)
- Potential statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding by indication and other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Marquez, Paige L \(CDC\)](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Zinderman, Craig E](#); [Baer, Bethany](#)
Subject: RE: Data mining
Date: Tuesday, January 12, 2021 5:35:48 PM
Attachments: [DE VAERS data mining_202001_DRAFT.pptx](#)

Hi John and Tom,

In addition to the overall run (mentioned in earlier email below) which now refreshes weekly, we have our pre-existing (refreshing monthly) subset runs (and I've added a line to the second attached slide to describe them) which have an earlier 'as of date' of 1/6/21. For all of these subset runs for both EUA COVID vaccines, a total of 4 PTs had an EB05 of >2, all of which were in the age 45 - <65 year ("Adult2") subset and that output is as follows:

Drug	Event	Adult2 EB05 20210106	N
COVID19 (COVID19 (PFIZER-BIONTECH))	Dysgeusia	2.118	49
COVID19 (COVID19 (PFIZER-BIONTECH))	Flushing	2.408	118
COVID19 (COVID19 (PFIZER-BIONTECH))	Palpitations	2.004	104
COVID19 (COVID19 (PFIZER-BIONTECH))	Paraesthesia oral	2.184	88

Please feel free to share this hypothesis generating output along with the limitations reflected in the slides with your team/command chain, though these are not intended to be shared more broadly.

Best,
David

PS: I'm planning to be on the 6pm call tonight and available to answer any questions

From: Menschik, David
Sent: Tuesday, January 12, 2021 1:51 PM
To: Su, John (CDC) <ezu2@cdc.gov>; Shimabukuro, Tom (CDC) <ayv6@cdc.gov>
Cc: Marquez, Paige L (CDC) <fqv9@cdc.gov>; Narayan Nair (Narayan.Nair@fda.hhs.gov) <Narayan.Nair@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>; Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Baer, Bethany <Bethany.Baer@fda.hhs.gov>
Subject: Data mining

Dear John and Tom,

Our core weekly data mining run (previously refreshing monthly) called "VAERS Signals Weekly US All" was just refreshed this afternoon (as of date 1/10/21) and there are no EB05's >2 for any COVID vaccines. Attached are 3 slides providing contextual information including caveats and limitations that we can discuss at our weekly meeting on Thursday at 2pm.

Best,
David

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported adverse event [AE] for a product relative to other products)
- Hypothesis generating
 - Statistical signal of disproportional reporting (SSDR) \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

DE Data Mining Methods

- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-AE pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
- Results adjusted by gender, year received and age
- Vaccine-PT pairs ranked by lower 5% bound of EBGM confidence interval (EB05)
 - Subsets available monthly for age (0-1, 2-8, 9-18, 19-44, 45-64, ≥65, unknown), gender, and serious/fatal
- Standard threshold for alert: $EB05 \geq 2$

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.

Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe program, media reports)
- Potential statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding by indication and other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#)
Cc: [Marquez, Paige L \(CDC\)](#); [Nair, Narayan](#); [Zinderman, Craig E](#); [Alimchandani, Meghna](#)
Subject: Weekly data mining
Date: Tuesday, February 2, 2021 7:57:05 AM

Good morning John,

Our “VAERS Signals Weekly US All” run had no alerts (EB05>2) for any PT for either EUA COVID vaccine (as of 1/29/21).

Best,

David

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#)
Cc: [Marquez, Paige L \(CDC\)](#); [Nair, Narayan](#); [Zinderman, Craig E](#); [Alimchandani, Meghna](#)
Subject: RE: Weekly data mining
Date: Tuesday, February 2, 2021 5:01:18 PM

Will plan to include you on such future emails – sorry for excluding you Tom!

From: Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Sent: Tuesday, February 02, 2021 5:00 PM
To: Su, John (CDC) <ezu2@cdc.gov>; Menschik, David <David.Menschik@fda.hhs.gov>
Cc: Marquez, Paige L (CDC) <fqv9@cdc.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>; Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>
Subject: RE: Weekly data mining

Thanks. Please include me on these data mining email.
Tom

From: Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>
Sent: Tuesday, February 2, 2021 9:26 AM
To: Menschik, David (FDA/CBER) <David.Menschik@fda.hhs.gov>
Cc: Marquez, Paige L. (CDC/DDID/NCEZID/DHQP) <fqv9@cdc.gov>; Nair, Narayan (FDA/CBER) <Narayan.Nair@fda.hhs.gov>; Zinderman, Craig E (FDA/CBER) <Craig.Zinderman@fda.hhs.gov>; Alimchandani, Meghna (FDA/CBER) <Meghna.Alimchandani@fda.hhs.gov>; Shimabukuro, Tom (CDC/DDID/NCEZID/DHQP) <ayv6@cdc.gov>
Subject: RE: Weekly data mining

Hi David,

Thanks for sharing! Good to know. CCing Tom for his awareness. Thanks again!

- Joh
-

From: Menschik, David <David.Menschik@fda.hhs.gov>
Sent: Tuesday, February 2, 2021 7:57 AM
To: Su, John (CDC/DDID/NCEZID/DHQP) <ezu2@cdc.gov>
Cc: Marquez, Paige L. (CDC/DDID/NCEZID/DHQP) <fqv9@cdc.gov>; Nair, Narayan (FDA/CBER) <Narayan.Nair@fda.hhs.gov>; Zinderman, Craig E (FDA/CBER) <Craig.Zinderman@fda.hhs.gov>; Alimchandani, Meghna (FDA/CBER) <Meghna.Alimchandani@fda.hhs.gov>
Subject: Weekly data mining

Good morning John,

Our “VAERS Signals Weekly US All” run had no alerts (EB05>2) for any PT for either EUA

COVID vaccine (as of 1/29/21).

Best,

David

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Zinderman, Craig E](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Data mining
Date: Tuesday, February 23, 2021 6:48:00 AM

Hi John and Tom,

Our “VAERS Signals Weekly US All” run had no alerts (EB05>2) for any PT for any EUA COVID vaccine (as of 2/18/21).

Thanks,
David

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Zinderman, Craig E](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, March 9, 2021 6:50:13 AM

Good morning John and Tom,

This "US Signals Summary Table" had no alerts (EB05>2) for any PT for any EUA COVID vaccine (as of 3/5/21).

Thanks,
David

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Zinderman, Craig E](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, March 16, 2021 7:13:14 AM
Attachments: [USST 20210311.xls](#)
[DE VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/11/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210311	US Serious EB05 20210311	US Fatal EB05 20210311	US Infant EB05 20210311	US Child EB05 20210311	US Teen EB05 20210311	US Adult1 EB05 20210311	US Adult2 EB05 20210311	US Adult3 EB05 20210311	US Female EB05 20210311	US Male EB05 20210311	
COVID19 (COVID-19 (JANSSEN))	Chills	2.267				0.071		2.092		1.651	1.072	2.194	1.637

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

DE VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and ≥ 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.



Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: [Zinderman, Craig E](#)
To: [Menschik, David](#); [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 23, 2021 2:00:03 PM
Attachments: [USST 2021_0319.xls](#)
[DE VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/19/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
Craig

Drug	Event	US EB05 20210319	US Serious EB05 20210319	US Fatal EB05 20210319	US Infant EB05 20210319	US Child EB05 20210319	US Teen EB05 20210319	US Adult1 EB05 20210319	US Adult2 EB05 20210319	US Adult3 EB05 20210319	US Female EB05 20210319	US Male EB05 20210319	Comment
COVID19 (COVID19 (JANSSEN))	Chills	2.26	0.935	0.892	1.012	2.074	2.085	1.965	2.363	1.742	0.938		
COVID19 (COVID19 (JANSSEN))	Feeling cold	2.47	0.873	0.822	2.822	1.048	1.257	1.048	2.595	0.938			
COVID19 (COVID19 (JANSSEN))	Hypertidrosis	1.898	0.928	0.567	2.04	1.369	1.845	0.554	1.615	1.687			
COVID19 (COVID19 (JANSSEN))	Pyrexia	2.041	0.683	0.971	1.95	1.845	1.553	1.559	2.098	1.651			
COVID19 (COVID19 (JANSSEN))	Tremor	2.074	0.892	1.825	1.825	0.997	1.942	1.276					

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

DE VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and ≥ 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.



Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 30, 2021 7:02:29 AM
Attachments: [DE VAERS data mining methods and limitations 2021_03_DRAFT.pptx](#)
[USST_20210326.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 3/26/21) along with 3 slides providing contextual information including caveats and limitations. Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Data Mining Introduction*



- Statistical method for identifying disproportionality (excess of reported AE for product relative to other products) in large database
- Can be useful for screening and hypothesis generating only
 - Evaluate findings in clinical and epidemiological context (e.g., unexpected?)
 - Compelling hypotheses should be explored (e.g., via case series analyses)
 - Statistical signal of disproportionality \neq safety signal
- Absence of disproportionality does not confirm absence of safety signal nor negate a signal otherwise detected

*Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff (November 2019; Draft). Available at <https://www.fda.gov/media/130216/download>

DE VAERS Data Mining Methods



- Empirica™ Signal software (Oracle)
- Calculates Empiric Bayes Geometric Mean (EBGM) using observed to expected (O/E) vaccine-PT pair ratios
 - EBGM derived from statistical model (Multi-item Gamma Poisson Shrinker; MGPS) that accounts for instability from small numbers*
 - adjusted by age, gender and year received
- Vaccine-PT pairs ranked by lower 5% bound of EBGM CI (EB05)
- Standard alert threshold: EB05 >2
- Weekly US summary table includes subset alerts for age (0-1, 2-8, 9-18, 19-44, 45-64, and ≥ 65 years), gender, and serious/fatal

*Szarfman A, Topping JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy*. 2004 Sep;24(9):1099-104. doi: 10.1592/phco.24.13.1099.38090. PMID: 15460169.



Limitations of Data Mining Include:

- Impacted by stimulated reporting (e.g., V-safe, media reports)
- False alerts from statistical interaction (e.g., If vaccines X and Y often given concomitantly, statistical signal for vaccine X and AE Z may be driven by vaccine Y)
- MedDRA constraints (e.g., Signal X can be reflected in multiple PTs that individually do not reach alert threshold)
- Confounding (e.g., by indication)
- Other VAERS limitations (e.g., underreporting, variable reporting by source, incomplete reporting, duplicate reporting)

Drug	Event	US EB05 20210326	US Serious EB05 20210326	US Fatal EB05 20210326	US Infant EB05 20210326	US Child EB05 20210326	US Teen EB05 20210326	US Adult1 EB05 20210326	US Adult2 EB05 20210326	US Adult3 EB05 20210326	US Female EB05 20210326	US Male EB05 20210326	Comment
COVID19 (COV D19 (JANSSEN))	Chills	1.969	0.951	0.693			1.022	1.862	1.626	2.223	2.068	1.546	
COVID19 (COV D19 (JANSSEN))	Fall	1.002	0.287				0.524	2.037	0.771	0.255	1.038	0.642	
COVID19 (COV D19 (JANSSEN))	Feeling cold	2.186						2.282	1.35	1.448	2.246	1.19	
COVID19 (COV D19 (JANSSEN))	Hypohidrosis	1.875	0.91				0.729	2.003	1.403	0.856	1.741	1.736	
COVID19 (COV D19 (JANSSEN))	Syncope	1.781	0.799					2.194	1.133	0.605	1.67	1.415	
COVID19 (COV D19 (JANSSEN))	Vital signs measurement	2.313						1.739	0.673	0.896	1.497	0.974	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 13, 2021 6:12:45 AM
Attachments: [USST_20210408.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our 'US Signals Summary Table' ('as of date' 4/8/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210408	US Serious EB05 20210408	US Fatal EB05 20210408	US Infant EB05 20210408	US Child EB05 20210408	US Teen EB05 20210408	US Adult1 EB05 20210408	US Adult2 EB05 20210408	US Adult3 EB05 20210408	US Female EB05 20210408	US Male EB05 20210408	Comment
COVID19 (COVID19 (JANSSEN))	Fall	1.653	0.463	0.893			0.506	2.127	0.657	0.276	1.835	0.638	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.968	0.411	0.896				2.141	1.399	1.357	2.013	1.385	
COVID19 (COVID19 (JANSSEN))	Loss of consciousness	1.752	0.907				0.484	2.087	1.343	0.516	1.514	1.701	
COVID19 (COVID19 (JANSSEN))	Syncope	1.614	0.744	0.894			0.359	2.095	1.318	0.549	1.708	1.566	
COVID19 (COVID19 (JANSSEN))	Syringe issue	2.337					0.547	1.651	2.013	0.892	1.614	2.053	
COVID19 (COVID19 (JANSSEN))	Vital signs measurement	2.53	0.706					2.637	1.144	1.292	2.151	1.81	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body temperature	1.839	1.008	0.896		0.536	0.565	1.958	2.095	1.761	1.799	1.653	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, April 20, 2021 6:16:38 AM
Attachments: [USST_20210416.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/16/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210416	US Serious EB05 20210416	US Fatal EB05 20210416	US Infant EB05 20210416	US Child EB05 20210416	US Teen EB05 20210416	US Adult1 EB05 20210416	US Adult2 EB05 20210416	US Adult3 EB05 20210416	US Female EB05 20210416	US Male EB05 20210416	Comment
COVID19 (COVID19 (JANSSEN))	Fall	1.498	0.751	0.887			0.652	2.409	1.007	0.447	1.446	1.318	
COVID19 (COVID19 (JANSSEN))	Loss of consciousness	1.975	0.958	0.89			0.751	2.29	1.569	0.582	1.862	1.857	
COVID19 (COVID19 (JANSSEN))	Syncope	1.979	0.783	0.884			0.843	2.224	1.588	0.58	1.88	1.846	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	2.368		0.904				0.539		0.558	0.992	0.692	
COVID19 (COVID19 (JANSSEN))	Thrombosis	1.252	2.317					0.671	1.094	1.005	1.268	0.903	
COVID19 (COVID19 (JANSSEN))	Vital signs measurement	2.308	0.662					0.525	2.247	1.491	2.245	1.803	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body temperature	1.786	1.028	0.89		0.538		1.028	1.994	2.064	1.758	1.763	1.636

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 27, 2021 8:41:55 AM
Attachments: [USST_20210423.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/23/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210423	US Serious EB05 20210423	US Fatal EB05 20210423	US Infant EB05 20210423	US Child EB05 20210423	US Teen EB05 20210423	US Adult1 EB05 20210423	US Adult2 EB05 20210423	US Adult3 EB05 20210423	US Female EB05 20210423	US Male EB05 20210423	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,026	0,67					0,596	0,428	0,631	1,353	1,077	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	1,354	2,103	0,878			0,541	0,755	1,05	0,847	1,249	0,767	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	1,541	2,601	0,88				1,124	1,001	0,918	1,478	0,854	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	1,838	2,871	0,887			0,541	1,466	1,156	0,639	1,694	0,771	
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,36	0,798					2,399	1,5		2,344		
COVID19 (COVID19 (JANSSEN))	Interchange of vaccine products	1,636											
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,122						0,586	1,058	1,29	2,222	1,554	1,328
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,122							2,047	1,554	2,075	2,075	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,281	2,062	0,887	0,605		0,484	1,047	1,104	1,289	1,349	1,034	
COVID19 (COVID19 (JANSSEN))	Syncope	1,794	0,815	0,88				1,026	2,001	1,557	0,461	1,803	1,647
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,214	3,039	1,986	0,605		0,597	2,001	1,9	2,112	2,372	1,587	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	1,707	2,129	0,882				1,048	1,419	1,271	1,758	1,05	
COVID19 (COVID19 (MODERNA))	Injection site pruritus	1,985	0,958				0,462	2,026	2,03	1,721	1,975	1,948	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,102	1,508	0,883				0,565	1,758	1,837	2,031	1,638	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,075						0,64	1,247	1,632	2,074	1,962	1,79
COVID19 (COVID19 (PFIZER-BIONTECH))	Product use issue	2,086	0,942	0,878				1,94	1,698	1,507	2,031	1,377	
COVID19 (COVID19 (PFIZER-BIONTECH))	Vaccination site pain	2,01	0,778	0,872			0,508	2,165	2,082	1,614	1,905	2,032	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,042	0,983	0,88				1,3	1,527	1,781	1,89	1,455	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 11, 2021 7:07:31 AM

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/7/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 11, 2021 8:40:34 AM
Attachments: [USST_20210507.xls](#)

Apologies all for forgetting the attachment – please see attached.

Thanks,
David

From: Menschik, David
Sent: Tuesday, May 11, 2021 7:07 AM
To: Su, John (CDC) <ezu2@cdc.gov>; Shimabukuro, Tom (CDC) <ayv6@cdc.gov>
Cc: Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>; Marquez, Paige L (CDC) <fqv9@cdc.gov>; Broder, Karen R (CDC) <krb2@cdc.gov>; Harrington, Theresa (CDC) <tsh3@cdc.gov>
Subject: RE: Weekly data mining

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/7/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210507	US Serious EB05 20210507	US Fatal EB05 20210507	US Infant EB05 20210507	US Child EB05 20210507	US Teen EB05 20210507	US Adult1 EB05 20210507	US Adult2 EB05 20210507	US Adult3 EB05 20210507	US Female EB05 20210507	US Male EB05 20210507	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,113	0,991					0,697	0,304	0,734	1,716	1,223	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,338	2,721	0,88				1,06	1,415	3,837	2,955	1,245	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	1,818	2,288					1,071	1,598	1,406	1,873	1,259	
COVID19 (COVID19 (JANSSEN))	Anti-coagulant therapy	2,168	2,976	0,680	0,61			1,542	1,516	2,175	2,408	1,391	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,315	2,771	0,889			0,548	1,642	1,785	0,632	2,058	1,193	
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	1,982	2,344	0,916	0,61		0,548	1,631	1,627	1,446	2,408	1,046	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,118	1,923	0,891				1,768	1,898	2,349	2,373	1,666	
COVID19 (COVID19 (JANSSEN))	Dysmenorrhea	1,96	0,707					2,074	0,941		1,929		
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,389	1,541	0,888			0,501	2,274	1,81	2,264	2,595	1,4	
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,152	0,887					2,075	1,565	0,702	2,295	1,025	
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,365	0,769					2,498	1,552		2,353		
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2,813	2,707	0,884				1,019	1,237	1,411	2,391	0,884	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,519	2,201	0,882			0,547	1,233	0,791	0,644	1,483	0,607	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,692	2,063	0,879				1,613	1,392	1,327	1,769	1,243	
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,174						2,182	1,528		2,143		
COVID19 (COVID19 (JANSSEN))	Platelet count	1,786	2,106	0,89	0,61		0,521	1,235	1,939	1,19	2,068	0,941	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,313	2,259	0,885				1,788	2,243	1,575	2,703	1,362	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,662	1,919	0,888	0,61			0,593	1,176	1,524	1,885	1,265	
COVID19 (COVID19 (JANSSEN))	Syncope	1,797	0,903	0,885	0,61		0,899	2,039	1,566	0,646	1,787	1,71	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,156						0,753	1,12	0,942	1,513	1,419	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,255	2,649	0,999	0,61		0,561	2,034	2,126	3,398	2,564	1,676	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	1,792	2,049	0,881				1,168	0,881	1,237	1,483	0,922	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,021	1,344	0,883			0,548	1,717	1,741	1,613	2,116	1,461	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,306	2,333	0,886				1,507	1,809	2,256	2,612	1,501	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	1,715	2,299	0,881			0,548	1,358	1,211	1,111	1,547	0,902	
COVID19 (COVID19 (JANSSEN))	Venogram normal	3,314	2,832	0,883				2,046	1,409	0,673	3,449	0,869	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,113				0,521		0,768	0,834	0,878	1,059	0,917	
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,038						0,586	0,493	0,57	0,501	0,696	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,134	1,625	0,891				2	2,211	2,087	1,948	1,925	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,212	1,712	0,888				1,862	1,953	2,076	2,136	1,976	
COVID19 (COVID19 (PFIZER-BIONTECH))	Off label use	1,76	1,064	0,882				2,011	1,67	1,687	1,791	1,378	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,035						0,698	1,29	1,569	2,145	1,89	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product use issue	2,117	0,969	0,881				0,512	1,954	1,713	1,619	1,458	
COVID19 (COVID19 (PFIZER-BIONTECH))	SARS-CoV-2 test	1,958	1,612	0,898				1,313	1,953	2,02	1,828	1,91	
COVID19 (COVID19 (PFIZER-BIONTECH))	Vaccination site pain	1,942	0,751	0,875			0,601	2,067	1,953	1,645	1,868	1,92	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,179	1,242	0,894				1,459	1,945	2,022	2,072	1,71	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 18, 2021 7:08:31 AM
Attachments: [USST_20120514.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/14/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210514	US Serious EB05 20210514	US Fatal EB05 20210514	US Infant EB05 20210514	US Child EB05 20210514	US Teen EB05 20210514	US Adult1 EB05 20210514	US Adult2 EB05 20210514	US Adult3 EB05 20210514	US Female EB05 20210514	US Male EB05 20210514	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,064	0,626					0,639	0,379		0,742	1,699	1,236
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,55	2,605		0.884		0.55	1,118	1,468		4,639	2,474	1,301
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	1,983	2,164					1,175	1,735		1,46	2,023	1,36
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,314	2,546			0.611		1,78	1,534		3,24	3,055	1,42
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2,742	2,846				0.55	1,975	1,933		0,633	2,553	1,2
COVID19 (COV D19 (JANSSEN))	Cerebral venous thrombosis	1,84	2,138					1,128	0,937		0,66	1,529	0,811
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,142	2,261			0.611	0.55	1,813	1,705		1,651	2,81	1,171
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,287	1,878				0.527	1,915	2,031		2,682	1,702	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,502	1,532				0.509	1,97	2,238		3,319	2,711	1,611
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,82	1,413				0.563	1,383	1,747		1,39	2,083	0,38
COVID19 (COV D19 (JANSSEN))	Gate palsy	2,239	0,9					2,145	1,642		0,096	2,449	1,063
COVID19 (COV D19 (JANSSEN))	Heavy menstrual bleeding	2,251	0,714					2,376	1,554		2,249	0,54	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	3,732	2,839		0.887			1,128	1,357		2,058	3,887	0,963
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	1,669	2,279		0.866			1,373	0,82		0,644	1,632	0,812
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,877	2,065		0.883		0.563	1,669	1,502		1,608	2,05	1,339
COVID19 (COV D19 (JANSSEN))	Menstruation irregular	2,102						2,05	1,619		2,072	0,565	
COVID19 (COV D19 (JANSSEN))	Peripneal embolism	2,168	1,387		0.885			0,525	0,879		1,965	1,59	0,825
COVID19 (COV D19 (JANSSEN))	Platelet count	1,928	2,12		0.893		0.509	1,402	2,146		1,228	2,229	1,043
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,477	2,178		0.889		0.474	1,885	2,464		1,639	3,028	1,431
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	2,391	2,133		0.886			1,103	1,042		0,676	1,52	0,738
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1,831	1,868		0.891		0.603	1,315	1,67		2,299	2,076	1,399
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	2,889						0,875	1,605		5,402	1,928	1,831
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,105	0,975		0.887		0.55	1,301	1,494		1,44	1,698	1,482
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,293	2,535		1,881		0.575	2,017	2,301		3,465	2,653	1,709
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,253	2,287		0.885			1,286	1,32		0,662	1,907	0,931
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,052	1,285		0.887		0.55	1,87	1,804		1,689	2,302	1,362
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,569	2,36		0.889			1,742	1,981		2,865	3,199	1,611
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1,909	1,15			0.6		1,344	2,019		2,012	1,899	1,641
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1,872	1,022					1,208	1,754		1,153	2,057	0,86
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	2,027	2,455				0.55	1,501	1,841		0,546	0,991	0,991
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,137	3,081		0.887			2,96	1,662		0,676	4,439	0,956
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,152				0.528	0.562	0,606	0,594		0,874	0,91	0,75
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2,997						0,555	0,419		0,811	0,457	0,765
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2,108	1,634		0.895		0.779	1,973	2,162		2,065	1,821	1,914
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2,202	1,735		0.891		0.631	1,844	1,967		2,107	2,129	1,895
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2,115					0.626	1,599	1,778		2,148	1,986	1,968
COVID19 (COV D19 (PFIZER-BIONTECH))	Product use issue	2,085	0,962		0.885		0.5	1,923	1,7		1,619	2,038	1,446
COVID19 (COV D19 (PFIZER-BIONTECH))	Vaccination site pain	1,871	0,718		0.879		0.628	2,007	1,854		1,582	1,798	1,855
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2,16	1,199		0.868		0.631	1,476	1,822		2,017	2,066	1,718

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, May 25, 2021 6:35:48 AM
Attachments: [USST_20120521.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/21/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210521	US Serious EB05 20210521	US Fatal EB05 20210521	US Infant EB05 20210521	US Child EB05 20210521	US Teen EB05 20210521	US Adult EB05 20210521	US Adult2 EB05 20210521	US Adult3 EB05 20210521	US Female EB05 20210521	US Male EB05 20210521	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,125	0,772					0,752	0,352	0,734	1,761	1,229	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,559	2,613	0,878			0,548	1,186	1,55	4,401	2,79	1,275	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	1,965	2,118					1,185	1,868	1,435	2,122	1,37	
COVID19 (COVID19 (JANSSEN))	Arteriovenous malformation	2,206	2,372	0,887	0,611			1,687	1,601	2,405	2,772	1,386	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,007	2,853	0,887			0,557	2,252	1,974	0,632	2,977	1,204	
COVID19 (COVID19 (JANSSEN))	Chills	1,377	0,93	0,888			2,314	1,4	1,229	0,94	1,434	1,149	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,256	2,336	0,901	0,611		0,548	1,939	1,868	1,637	2,944	1,314	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,807	1,87	0,881			0,941	1,424	1,451	1,654	2,019	1,226	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,34	1,886	0,887			0,531	1,963	2,116	2,801	2,782	1,782	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,562	1,45	0,886			0,496	2,369	2,019	2,637	2,787	1,553	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,826	1,378	0,886	0,604		0,56	1,362	1,811	1,337	2,163	0,981	
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,19	0,882					2,102	1,642	0,686	2,53	1,031	
COVID19 (COVID19 (JANSSEN))	Heavy menstrual bleeding	2,14	0,737					2,178	1,654	2,136	0,546	1,031	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,286	2,883	0,881				1,288	1,440	2,582	4,576	1,063	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,93	2,321	0,879				1,682	0,83	0,648	1,944	0,62	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,944	2,09	0,876			0,61	1,688	1,523	1,754	2,129	1,401	
COVID19 (COVID19 (JANSSEN))	Menstruation irregular	2,03	0,679					1,986	1,681	2,001	0,569	1,031	
COVID19 (COVID19 (JANSSEN))	Off label use	1,184					3,192	0,29	0,42	0,78	0,993	0,993	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	2,612	1,508	0,879				0,531	0,894	2,346	1,75	0,836	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,052	2,348	0,893	0,611		0,54	1,639	2,283	1,317	2,382	1,118	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,507	2,217	0,882			0,467	1,85	2,503	1,908	3,216	1,415	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	2,817	2,587	0,879				1,298	1,158	0,679	2,03	0,905	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,793	1,788	0,887	0,611		0,62	1,305	1,636	2,265	2,094	1,336	
COVID19 (COVID19 (JANSSEN))	Pyrexia	1,418	0,904	0,888			2,326	1,446	1,233	0,942	1,476	1,188	
COVID19 (COVID19 (JANSSEN))	Scan with contrast abnormal	1,834	2,055					1,025	1,606	1,081	1,754	1,151	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	3,049						1,012	2,807	5,98	2,462	2,19	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,249	1,011	0,881			0,557	1,404	1,462	1,34	1,86	1,5	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,308	2,513	1,971	0,611		0,592	2,094	2,359	3,628	2,707	1,697	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,164	2,215	0,879				1,298	1,25	0,658	1,827	0,826	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,028	1,182	0,88			0,549	1,787	1,781	1,685	2,951	1,309	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,607	2,284	0,883				1,883	1,98	3,274	3,028	1,725	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,914	1,232		0,602			1,315	2,072	2,043	1,88	1,685	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,913	1,035					1,379	1,797	1,109	2,147	0,848	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	2,503	2,646				0,557	1,83	1,41	0,539	2,559	1,003	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,034	2,963	0,879				3,188	1,67	0,665	4,645	0,913	
COVID19 (COVID19 (JANSSEN))	Vital signs measurement	1,893	0,54					1,893	2,017	1,352	1,245	1,587	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,188			0,528			0,531	0,486	0,546	0,831	0,79	
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,067						0,398	0,312	0,556	0,271	0,484	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,07	1,622	0,894				1,936	2,107	2,055	1,884	1,677	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,153	1,689	0,885				1,841	1,938	2,081	2,091	1,862	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,079						1,44	1,625	1,769	1,979	1,84	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,087	1,212	0,881			0,591	1,465	1,833	1,995	2,023	1,681	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, June 1, 2021 9:02:22 AM
Attachments: [USST_20210528.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/28/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210528	US Serious EB05 20210528	US Fatal EB05 20210528	US Infant EB05 20210528	US Child EB05 20210528	US Teen EB05 20210528	US Adult1 EB05 20210528	US Adult2 EB05 20210528	US Adult3 EB05 20210528	US Female EB05 20210528	US Male EB05 20210528	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,074	0,747					0,755	0,396		1,726	1,297	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,763	2,706	0,881				1,252	1,655		4,6	3,47	1,202
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,004	2,114	0,877				1,245	1,889		1,423	2,04	1,489
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,006	2,125	0,894				1,552	1,61		1,961	2,462	1,281
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,865	2,763	0,888		0,611		2,022	2,056		0,607	2,962	1,151
COVID19 (COVID19 (JANSSEN))	Chills	1,383	0,919	0,891				1,419	1,228		0,925	1,437	1,162
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,306	2,373	0,907		0,611		0,539	1,71		1,976	1,843	1,326
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,852	1,912	0,863				0,521	1,39		1,605	1,647	1,247
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,335	1,894	0,888				0,519	2,031		2,671	2,737	1,797
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,527	1,424	0,887				0,453	2,363		2,1	2,081	1,52
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,185	1,398	0,899		0,602		0,606	1,404		1,185	1,35	0,998
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,823	0,941	0,88				0,542	1,522		1,612	0,741	2,003
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,258	0,877						2,18		1,667	0,764	1,017
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,437	2,96	0,885					1,359		1,673	1,595	4,185
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	2,665	2,041					0,556	1,273		0,96	0,569	0,932
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,011	2,381	0,881					1,828		0,914	1,922	0,7
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,553	2,095	0,88					0,606		1,556	1,872	1,416
COVID19 (COVID19 (JANSSEN))	Off label use	1,245							3,639		0,297	0,429	0,803
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,031	1,594	0,88					0,535		0,905	2,123	1,889
COVID19 (COVID19 (JANSSEN))	Platelet count	2,055	2,32	0,894		0,611		0,54	1,807		2,328	1,285	2,363
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,383	2,082	0,886				0,43	1,797		2,421	1,791	1,356
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	3,498	2,676	0,881					1,359		1,183	0,681	0,919
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,797	1,785	0,893		0,611			0,603		1,26	1,729	2,171
COVID19 (COVID19 (JANSSEN))	Pyrexia	1,421	0,881	0,889					2,3		1,465	1,221	1,472
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	3,219							1,285		3,279	7,907	2,831
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,228	1,043	0,882					1,43		1,432	1,342	1,733
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,292	2,512	1,997		0,611			0,674		2,07	2,392	3,464
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,195	2,21	0,88					1,426		1,189	0,656	1,914
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,03	1,15	0,882				0,549	1,717		1,909	1,515	2,357
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,669	2,317	0,887					2,075		2,034	3,54	3,112
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,941	1,247			0,6			1,352		2,167	1,964	1,938
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	2,03	1,023						1,418		2,015	1,181	2,317
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	2,894	2,778					0,556	2,778		1,459	0,54	1,026
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,155	2,971	0,881					3,414		1,673	0,668	4,845
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,225							0,47		0,546	0,806	0,794
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,142				0,528			0,945		0,331	0,532	0,235
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,059	1,64	0,896					0,723		1,881	2,065	1,864
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,133	1,672	0,888					0,678		1,827	1,899	2,101
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,063							1,513		1,75	1,835	1,978
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,05	1,187	0,881					0,581		1,446	1,773	2,015

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, June 8, 2021 6:55:21 AM
Attachments: [USST_20210604.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/4/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210604	US Serious EB05 20210604	US Fatal EB05 20210604	US Infant EB05 20210604	US Child EB05 20210604	US Teen EB05 20210604	US Adult1 EB05 20210604	US Adult2 EB05 20210604	US Adult3 EB05 20210604	US Female EB05 20210604	US Male EB05 20210604	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,158	0,751					0,732	0,369		0,719	1,777	1,371
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,84	2,638	0,882			0,538	1,299	1,884		4,285	3,816	1,163
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,064	2,094	0,88			0,546	1,257	2,038		1,368	2,113	1,54
COVID19 (COVID19 (JANSSEN))	Anti-coagulant therapy	1,895	1,859	0,864		0,611		1,521	1,48		1,861	2,285	1,175
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,678	1,834	0,895			0,554	1,214	1,468		1,171	2,087	0,844
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,872	2,65	0,891			0,538	2,129	2,148		0,687	3,24	1,082
COVID19 (COVID19 (JANSSEN))	Chills	1,409	0,925	0,889			0,518	2,278	1,462		0,937	1,459	1,194
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,324	2,311	0,909		0,611		0,931	1,719		1,815	3,168	1,314
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,789	1,794	0,883			0,592	1,269	1,656		1,536	2,08	1,206
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,357	1,917	0,893			0,518	2,023	2,105		2,863	2,796	1,796
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,933	1,32	0,888			0,622	2,361	2,106		1,937	2,845	1,488
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,854	1,384	0,89		0,605		0,572	1,388		1,857	1,428	0,972
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,809	0,926	0,881			0,602	1,548	1,542		0,737	2,084	0,929
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,292	0,928	0,881				2,239	1,666		0,838	2,76	1,056
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	3,957	2,842	0,885				1,231	1,881		1,508	5,262	0,933
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	3,365	2,161				0,554	1,355	1,047		0,574	1,955	0,918
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,05	2,343	0,881				1,59	1,032		0,651	2,087	0,691
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,986	2,054	0,88			0,571	1,662	1,625		1,85	2,228	1,419
COVID19 (COVID19 (JANSSEN))	Off label use	1,3					3,741	0,31	0,428		0,824	1,145	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,777	1,684	0,881				0,542	0,916		2,381	2,101	0,845
COVID19 (COVID19 (JANSSEN))	Platelet count	2,13	2,425	0,898		0,611		0,539	1,832		2,472	1,276	1,186
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,42	2,026	0,886			0,403	1,833	2,493		1,879	3,105	1,339
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	4,306	2,809	0,882				0,898	1,217		0,884	3,771	0,938
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,179					0,498	2,211	1,505		0,577	1,599	1,746
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,807	1,757	0,895		0,611		0,689	1,289		2,099	2,083	1,38
COVID19 (COVID19 (JANSSEN))	Pyrexia	1,438	0,897	0,889			2,157	1,489	1,228		0,929	1,483	1,232
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	3,491						1,348	4,359		8,572	3,471	2,781
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,247	1,087	0,883			0,554	1,292	1,685		1,255	1,736	1,681
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,288	2,548	1,975		0,611		0,659	2,032		3,378	2,675	1,714
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,077	1,216	0,884			0,539	1,768	1,899		1,629	2,481	1,278
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,599	2,207	0,889				1,985	2,127		2,855	2,955	1,836
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,894	1,319			0,603		1,338	2,106		1,893	1,915	1,633
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,982	1,043	0,879				1,488	1,683		1,586	2,085	1,3
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,962	0,985					1,382	1,979		1,138	2,247	0,888
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	2,993	2,886				0,547	2,467	1,474		0,54	3,364	1,017
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,172	2,843	0,882				3,761	1,691		0,611	5,117	0,884
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,286					0,528	0,516	0,431		0,792	0,787	0,57
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,133						0,358	0,258		0,511	0,232	0,456
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	1,964	1,683	0,897				0,923	1,988		1,779	1,773	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,053	1,705	0,889				0,712	1,843		2,071	2,001	1,781
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	2,021						1,513	1,777		1,863	2,124	1,947
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,02	1,254	0,884				0,576	1,431		1,744	2,028	1,624

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, June 15, 2021 8:28:58 AM
Attachments: [USST_20210611.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/11/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210611	US Serious EB05 20210611	US Fatal EB05 20210611	US Infant EB05 20210611	US Child EB05 20210611	US Teen EB05 20210611	US Adult1 EB05 20210611	US Adult2 EB05 20210611	US Adult3 EB05 20210611	US Female EB05 20210611	US Male EB05 20210611	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 294	0 610					0 716	0 556	0 722	1 637	1 414	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 008	2 639	0 885			0 532	1 387	1 668	4 511	3 946	1 23	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 128	2 061	0 879			0 54	1 295	2 097	1 414	2 074	1 655	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	1 914	1 859	0 897		0 611		1 656	1 569	1 949	2 418	1 204	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	1 796	2 018	0 885			0 547	0 994	1 269	0 574	1 901	0 732	
COVID19 (COV D19 (JANSSEN))	Body temperature	1 918	0 894				1 418	1 874	2 01	1 569	1 873	1 671	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	1 759	1 874	0 898			0 546	1 329	1 536	1 154	2 169	0 895	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 176	2 689	0 893			0 546	2 052	2 797	0 69	3 991	1 167	
COVID19 (COV D19 (JANSSEN))	Chills	1 436	0 952	0 891			2 099	1 505	1 254	0 938	1 483	1 225	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 326	2 221	0 904		0 611	0 526	1 801	2 028	1 784	3 153	1 331	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1 636	1 754	0 894			0 674	1 334	1 721	1 917	2 093	1 295	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 398	1 939	0 894			0 502	2 098	2 145	2 815	2 834	1 88	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 502	1 252	0 899			0 512	2 366	2 093	1 793	2 842	1 461	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1 94	1 494	0 891		0 608	0 534	1 479	1 934	1 534	2 376	1 042	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 795	0 941	0 882			0 504	1 596	1 551	0 741	2 023	0 957	
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2 361	0 926	0 883			2 332	1 891	0 832	2 87	1 107	1 107	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4 307	3 203	0 887				1 604	2 144	1 551	5 398	1 091	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	4 908	2 66				0 554	1 758	1 448	0 578	4 397	1 079	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 822	1 242	0 886				1 308	1 677	0 876	2	1 011	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 051	2 282	0 883				1 584	1 09	0 65	2 152	0 749	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 018	1 989	0 882			0 556	1 712	1 677	1 631	2 276	1 425	
COVID19 (COV D19 (JANSSEN))	Off label use	1 425	0 189				3 971	0 321	0 544		0 901	1 353	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 72	0 753					1 962	1 031		2 065		
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4 011	1 716	0 883				0 547	0 926	2 13	2 181	0 851	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 248	2 531	0 898		0 611	0 54	2 022	2 637	1 288	2 693	1 253	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 533	2 142	0 898			0 365	1 921	2 681	2 075	3 199	1 435	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	4 719	2 854	0 883				1 699	1 255	0 686	4 456	0 955	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 235					0 495	3 119	1 727	1 881	2 255	2 255	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1 877	1 765	0 896		0 611	0 693	1 382	1 825	2 095	2 129	1 473	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	3 676						1 434	5 032	6 64	3 942	3 384	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 161	1 056	0 885			0 547	1 277	1 628	1 226	1 672	1 663	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 33	2 555	1 959		0 611	0 646	2 028	2 457	3 401	2 67	1 806	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 069	1 947	0 883				1 35	1 242	0 653	1 528	0 886	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 148	1 26	0 886			0 533	1 889	1 95	1 688	1 688	1 292	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 601	2 157	0 888				1 968	2 145	3 104	2 818	1 924	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 192	1 712					2 041	1 384	1 136	2 096	1 396	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 883	1 481			0 605	0 519	1 362	2 077	1 798	1 898	1 64	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	1 974	1 025	0 881				1 562	1 599	1 575	2 101	1 283	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 962	0 965					1 433	1 953	1 947	2 122	1 049	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 334	2 717				0 547	2 962	1 516	0 542	3 837	1 091	
COVID19 (COV D19 (JANSSEN))	Venogram normal	3 993	2 787	0 883				3 098	1 81	0 684	5 318	0 845	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2 354				0 528	0 502	0 379	0 498	0 687	0 717	0 493	
COVID19 (COV D19 (MODERNA))	Product temperature excursion issue	2 155						0 26	0 223	0 351	0 131	0 369	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	1 892	1 689	0 899				0 761	1 779	1 96	2 009	1 714	1 702
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 012	1 704	0 892				0 736	1 721	1 84	2 063	1 75	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	2 008						1 46	1 877	1 927	2 114	1 958	1 912
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	1 983	1 252	0 885				0 617	1 498	1 724	2 012	1 95	1 628

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 22, 2021 6:51:29 AM
Attachments: [USST_20210618.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/18/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210618	US Serious EB05 20210618	US Fatal EB05 20210618	US Infant EB05 20210618	US Child EB05 20210618	US Teen EB05 20210618	US Adult1 EB05 20210618	US Adult2 EB05 20210618	US Adult3 EB05 20210618	US Female EB05 20210618	US Male EB05 20210618	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,323	0,856	0,863				0,701	0,559		0,719	1,947	1,355
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,403	2,766	0,887				1,668	1,971		4,523	4,279	1,441
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,355	2,121	0,88				0,536	1,55		2,304	1,438	2,227
COVID19 (COVID19 (JANSSEN))	Arlicoglutin therapy	1,948	1,946	0,897				1,72	1,72		1,719	1,804	2,377
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,154	2,259	0,865		0.612		0,549	1,017		1,297	0,669	0,808
COVID19 (COVID19 (JANSSEN))	Body temperature	1,963	0,887					1,367	1,958		2,026	1,535	1,927
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,866	1,882	0,9				0,541	1,389		1,734	1,129	0,898
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,906	1,61	0,895				0,948	0,815		1,199	0,855	0,741
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,586	2,787	0,893				0,548	2,335		3,5	0,766	3,948
COVID19 (COVID19 (JANSSEN))	Chills	1,453	0,948	0,89				2,042	1,525		1,266	0,945	1,243
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,49	2,25	0,905		0.612		0,506	2,032		2,236	1,802	3,387
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,965	1,798	0,884				0,557	1,351		1,899	1,64	2,203
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,439	1,936	0,884				0,485	2,121		2,177	2,881	1,903
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,474	1,253	0,889				0,488	2,33		2,138	1,794	2,865
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,011	1,453	0,891		0.608		0,483	1,657		2,031	1,466	2,392
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,819	0,982	0,883				0,493	1,521		1,716	0,813	2,069
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,399	0,945	0,883				2,443	1,722		0,828	2,848	1,162
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,635	3,119	0,887				1,615	2,704		3,288	5,931	1,091
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,602	2,816					0,555	1,954		1,81	5,588	1,109
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,229	2,274	0,883				1,964	1,657		0,652	2,606	0,747
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,099	1,979	0,882				0,542	1,773		1,827	1,838	2,32
COVID19 (COVID19 (JANSSEN))	Off label use	1,487	0,305	0,878				3,778	0,372		0,551	0,369	1,438
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	4,61	0,753					2,254	1,012			2,016	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,295	1,704	0,883				0,551	0,934		2,215	2,435	0,856
COVID19 (COVID19 (JANSSEN))	Platelet count	2,459	2,701	0,899		0.612		0,542	2,206		3,049	1,245	1,446
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,597	2,169	0,888				0,335	1,928		2,843	2,207	1,561
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,186	2,949	0,884				0,542	2,946		0,687	5,086	0,972
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,301		0,563				2,53	1,71		2,807	1,965	2,429
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,004	1,777	0,895		0.612		0,69	1,508		1,943	2,196	1,62
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,269		0,894				1,894	5,979		9,092	4,374	3,816
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,142	1,034	0,885				0,549	1,296		1,584	1,667	1,637
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,395	2,529	1,837		0.612		0,641	2,139		2,488	3,331	1,882
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,168	1,802	0,883				0,53	1,415		1,231	0,655	0,885
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,17	1,253	0,886				0,53	1,867		2,03	1,634	1,317
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,767	2,184	0,889				2,143	2,285		3,227	2,86	2,183
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,395	1,854	0,884				2,497	1,417		1,171	2,358	1,481
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,882	1,448	0,882		0.605		0,505	1,385		2,082	1,897	1,73
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,963	1,054	0,881				0,505	1,552		1,58	1,628	1,303
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,943	0,969					0,505	1,379		1,986	1,296	1,026
COVID19 (COVID19 (JANSSEN))	Venogram	2,352	2,038					0,543	1,769		1,505	2,296	0,82
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,975	2,913					0,543	3,641		1,726	0,632	4,519
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,149	2,736	0,884				0,543	3,208		2,053	0,665	5,261
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,395					0.528	0,449	0,284		0,387	0,595	0,398
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,088	0,904	0,883			0.713	2,125	0,132		0,222	0,732	2,116
COVID19 (COVID19 (MODERNA))	Product temperature excursion issue	2,204						0,157	0,195		0,328	0,087	0,327
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,98	1,725	0,892				0,724	1,69		1,833	2,059	1,942
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,969		0,886				1,403	1,887		1,924	2,095	1,885
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,939	1,261					0,651	1,47		1,712	2,009	1,6

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 29, 2021 8:39:14 AM
Attachments: [USST_20210625.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/25/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210625	US Serious EB05 20210625	US Fatal EB05 20210625	US Infant EB05 20210625	US Child EB05 20210625	US Teen EB05 20210625	US Adult1 EB05 20210625	US Adult2 EB05 20210625	US Adult3 EB05 20210625	US Female EB05 20210625	US Male EB05 20210625	Comment
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,363	0,261	0,079				0,707	0,556	0,711	1,58	1,356	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,414	2,713	0,886				1,657	1,964	4,51	4,284	1,443	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,442	2,166	0,875				1,609	2,411	1,495	2,366	1,945	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,095	1,905	0,903				1,627	1,885	2,051	2,669	1,355	
COVID19 (COVID19 (JANSSEN))	Blood Nitrogen decreased	2,285	2,286	0,882	0,612			1,031	1,318	0,87	2,95	0,816	
COVID19 (COVID19 (JANSSEN))	Body temperature	1,986	0,904					1,379	2,025	2,059	1,555	1,948	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,957	1,923	0,899				0,543	1,483	1,779	1,175	2,584	0,981
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,976	1,636	0,882				0,55	0,821	1,172	0,856	0,746	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,632	2,758	0,89				2,363	3,739	0,763	4,075	1,261	
COVID19 (COVID19 (JANSSEN))	Chills	1,466	0,956	0,888				2,03	1,544	1,279	0,943	1,509	1,229
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,566	2,253	0,905	0,612			0,51	2,146	2,303	1,939	3,481	1,493
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,038	1,834	0,879				1,391	2,031	1,661	2,249	1,475	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,456	1,934	0,893				0,489	2,192	2,897	2,879	1,933	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,476	1,44	0,896				0,45	2,409	2,138	1,783	2,874	1,47
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,057	1,488	0,889	0,608			0,45	1,603	2,219	1,501	2,451	1,209
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,809	0,958	0,879				0,483	1,528	2	0,808	2	0,999
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,438	0,961	0,879				0,879	2,433	1,822	0,814	2,938	1,215
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,61	3,157	0,884				1,633	3,004	3,55	5,8	1,165	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,49	2,749		0,557			2,141	1,64	0,675	5,774	1,088	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,893	1,315	0,883				1,395	1,705	0,994	2,062	1,058	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,382	2,301	0,88				1,853	1,172	0,653	2,777	0,754	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,088	1,959	0,882				0,532	1,77	1,825	1,845	2,295	1,938
COVID19 (COVID19 (JANSSEN))	Off label use	1,506	0,167					4,221	0,377	0,555	0,368	1,479	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,647	0,754					2,544	1,021			2,118	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,712	2,015	0,879				0,688	0,94	0,296	4,212	0,86	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,375	2,536	0,896	0,612			0,531	2,131	3,04	1,228	2,84	1,37
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,662	2,258	0,886				0,316	2,011	3,008	2,194	3,35	1,566
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,034	2,969	0,88				2,42	1,325	0,688	5,061	1,057	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,331						0,565	2,488	1,807	2,024	2,132	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,066	1,807	0,897	0,612			0,68	1,698	1,985	2,247	1,667	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,394	1,08	0,882				2,136	5,887	9,642	4,583	3,928	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,109						1,258	1,587	1,197	1,677	1,576	
COVID19 (COVID19 (JANSSEN))	Thrombosis	3,291	2,544	1,879	0,612			0,84	2,103	2,482	3,25	2,688	1,906
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,354	1,975	0,88				1,572	1,248	0,652	2,308	0,894	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,181	1,267	0,883				0,52	1,884	2,029	1,681	2,584	1,349
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,809	2,197	0,896	0,612			2,196	2,332	3,228	2,902	2,24	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,499	1,924	0,885				2,645	1,463	1,238	2,542	1,514	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,989	1,102	0,877				0,497	1,533	1,663	1,612	2,092	1,308
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,841	0,966					1,297	1,904	1,343	2,046	0,99	
COVID19 (COVID19 (JANSSEN))	Venogram	2,229	1,988					1,619	1,5	0,568	2,274	1,07	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	4,03	2,91					0,545	3,621	1,789	0,633	4,676	1,107
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,195	2,626	0,88					3,475	1,992	0,662	5,372	0,861
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,417					0,528	0,434	0,356	0,5	0,637	0,599	0,498
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,193	0,877	0,879			0,725	2,237	0,126	0,214	0,736	2,15	2,221
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,969	1,736	0,889				0,776	1,694	1,822	2,053	1,933	1,73
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,944						1,376	1,88	1,907	2,084	1,907	1,863
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,929	1,299	0,884				0,646	1,495	1,698	2,016	1,909	1,628

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, July 6, 2021 1:52:18 PM
Attachments: [USST_20210702.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/2/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210702	US Serious EB05 20210702	US Fatal EB05 20210702	US Infant EB05 20210702	US Child EB05 20210702	US Teen EB05 20210702	US Adult1 EB05 20210702	US Adult2 EB05 20210702	US Adult3 EB05 20210702	US Female EB05 20210702	US Male EB05 20210702	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,665	1,665	0,863	0,863			1,721	1,475	1,507	2,109	1,033	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,385	0,86	0,881	0,709			0,638	0,638	1,507	1,952	1,411	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,341	2,659	0,887			0,519	1,683	1,997	4,302	4,321	1,396	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,499	2,101	0,878			0,522	1,566	2,411	1,522	2,380	1,895	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,656	1,866	0,915		0,612		1,742	1,928	2,04	2,691	1,322	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,126	2,297	0,883				1,003	1,319	0,666	2,761	0,793	
COVID19 (COVID19 (JANSSEN))	Body temperature	1,961	0,907					2,008	2,013	1,506	1,922	1,73	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,977	2,037	0,88				1,207	1,775	0,906	1,218	1,794	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,92	1,865	0,901				1,425	1,8	1,137	2,456	0,97	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	1,948	1,809	0,883				0,822	1,171	0,849	2,214	0,742	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,489	2,722	0,891				2,288	3,627	0,758	4,021	1,211	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,561	2,234	0,905		0,612		2,118	2,324	1,841	3,397	1,531	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,031	1,837	0,884				1,396	2,021	1,705	2,333	1,421	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,454	1,928	0,897				0,485	2,183	2,189	2,843	1,913	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,455	1,476	0,887				2,392	2,084	1,901	2,839	1,48	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,009	1,462	0,889		0,608		1,611	2,188	1,494	2,38	1,204	
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,406	0,95	0,88				2,406	1,801	0,813	2,929	1,195	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,651	3,112	0,885				1,641	3,093	3,508	5,657	1,189	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,621	2,865	0,884			0,557	3,245	1,645	0,676	5,948	1,088	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,84	1,272	0,884				1,345	1,652	0,928	2,047	1,019	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,315	2,27	0,881				1,887	1,15	0,653	2,965	0,754	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,071	1,946	0,883			0,512	1,76	1,842	1,841	2,328	1,499	
COVID19 (COVID19 (JANSSEN))	Off label use	1,542	0,156	0,888				4,381	0,368	0,368	0,365	1,461	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,598	0,755					2,19	1,006		1,949		
COVID19 (COVID19 (JANSSEN))	Peripherical embolism	4,711	2,021	0,881				0,669	0,84	2,279	4,218	0,86	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,434	2,567	0,903		0,612		0,526	2,166	3,052	1,448	2,699	1,515
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,611	2,23	0,887				2,003	2,943	2,154	3,277	1,55	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,169	3,046	0,881				3,016	1,522	0,689	4,815	1,245	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,367						0,562	2,802	1,812	2,209	2,209	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,047	1,798	0,9		0,612		1,569	1,983	2,245	2,3	1,644	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,419	1,112	0,883				3,236	6,033	10,959	4,8	3,887	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,117	2,359	0,883				1,227	1,133	1,725	1,725	1,567	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,359	1,908	0,881		0,612		2,145	2,496	3,245	2,722	1,909	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,271	1,934	0,881				1,579	1,217	0,653	0,653	0,881	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,158	1,25	0,884			0,516	1,863	1,998	1,669	2,514	1,371	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,795	2,226	0,889		0,612		2,102	2,355	3,139	2,943	2,211	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,484	1,963	0,883				2,713	1,477	1,274	2,609	1,469	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,81	1,449	0,879		0,601		1,329	2,006	1,654	1,839	1,564	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	1,904	1,157	0,876			0,493	1,517	1,771	1,627	2,108	1,368	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,838	1,021					1,284	1,938	1,442	2,06	1,021	
COVID19 (COVID19 (JANSSEN))	Venogram	2,233	1,887					1,722	1,5	0,565	2,247	0,851	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,758	2,844				0,54	3,156	1,794	0,634	4,603	1,953	
COVID19 (COVID19 (JANSSEN))	Venogram normal	3,978	2,589	0,881				3,257	2,002	0,663	5,291	0,838	
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,023						0,386	0,545	0,46	0,753	0,804	
COVID19 (COVID19 (MODERNA))	No adverse event	1,597				0,501		2,022	0,862	1,005	0,904	1,26	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,418	0,833	0,883			0,528	0,428	0,342	0,499	0,618	0,577	0,49
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,247	0,875	0,88		0,716		0,123	0,215	0,738	2,205	2,271	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,95	1,727	0,89				0,861	1,701	1,814	2,031	1,912	1,727
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,92						1,375	1,871	1,895	2,069	1,884	1,84
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,924	1,31	0,885				0,644	1,512	1,682	2,015	1,905	1,629

From: [Alimchandani, Meghna](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#); [Elaine Miller \(emiller@cdc.gov\)](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Cc: [Nair, Narayan](#); [Menschik, David](#); [Zinderman, Craig E](#)
Subject: Weekly data mining
Date: Wednesday, July 14, 2021 2:51:10 PM
Attachments: [USST_20210709.xls](#)

Good afternoon,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date 7/9/21'). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
Meghna

Drug	Event	US EB05 20210709	US Serious EB05 20210709	US Fatal EB05 20210709	US Infant EB05 20210709	US Child EB05 20210709	US Teen EB05 20210709	US Adult EB05 20210709	US Adult EB05 20210709	US Adult EB05 20210709	US Female EB05 20210709	US Male EB05 20210709	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,927	1,975	0/25				1,554	1,451	1,253	2,565	1,043	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,444	0,887	0,879				0,709	0,712	0,711	2,082	1,413	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,199	2,907	0,964				0,919	1,989	1,827	4,279	4,329	1,331
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,444	2,208	0,875				0,905	1,612	2,447	1,504	2,485	1,904
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,076	1,899	0,907				1,783	1,988	2,03	2,72	1,355	1,355
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,131	1,899	0,979		0,612		0,544	1,001	1,318	0,867	2,792	0,793
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,993	2,067	0,876				1,272	1,773	0,934	1,208	1,828	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,975	1,933	0,899				0,543	1,486	1,799	1,122	2,533	1,007
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,442	2,729	0,863				0,564	2,222	3,633	0,707	4,028	1,189
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,526	2,215	0,904				0,501	2,036	2,305	1,807	3,37	1,498
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,096	1,904	0,936				0,535	1,614	2,109	1,669	2,34	1,528
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,423	1,949	0,898				0,486	2,135	2,165	2,831	1,885	2,904
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,804	0,714	0,876				1,296	2,002	1,542	1,121	1,804	1,45
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,396	1,483	0,864				0,438	2,341	2,062	1,969	2,787	1,465
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,989	1,531	0,886				0,384	1,637	1,508	1,508	2,331	1,241
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,372	0,942	0,876				0,972	2,357	1,779	0,812	2,864	1,185
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,657	0,881						1,642	3,508	2,238	5,588	1,273
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,623	2,872	0,881				0,556	3,276	1,643	0,676	5,396	1,087
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,825	1,28	0,881				1,344	1,681	0,921	2,032	1,011	1,011
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,2	2,284	0,877				1,715	1,149	0,654	2,57	0,74	1,473
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,029	1,921	0,979				0,504	1,715	1,815	1,818	2,286	1,473
COVID19 (COVID19 (JANSSEN))	Off label use	1,567	0,157	0,365				0,641	0,366	0,977	1,454	1,454	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,6	0,755	0,877					2,207	1,026		1,861	
COVID19 (COVID19 (JANSSEN))	Prosthetic embolism	4,29	2,115	0,646				0,647	1,047	1,421	2,238	4,21	0,927
COVID19 (COVID19 (JANSSEN))	Platelet count	2,386	2,554	0,9				0,526	2,1	3,009	1,421	2,801	1,51
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,665	2,296	0,933				0,3	1,977	2,36	2,23	3,261	1,95
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,176	3,057	0,877				3,048	3,048	1,52	0,689	4,832	1,244
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,382						0,687	2,096	1,904	3,324	2,368	2,368
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,049	1,827	0,9				0,612	1,604	2,01	2,22	2,311	1,645
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,434						3,301	6,034	10,893	4,827	3,894	3,894
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,116	1,116	0,879				0,55	1,225	1,699	1,13	1,726	1,564
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,363	2,52	1,867				0,621	2,103	2,465	3,236	1,899	1,899
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,272	1,933	0,877				1,196	1,216	0,663	2,328	0,881	0,881
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,133	1,256	0,882				0,511	1,915	2,011	1,631	2,468	1,389
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,843	2,262	0,889				0,612	2,337	3,375	2,963	2,229	2,229
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,435	1,928	0,879				0,55	1,928	1,433	1,263	1,469	1,469
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,043	1,325	0,873				0,493	1,611	1,872	1,696	2,065	1,556
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,788	1,031						1,201	1,882	1,414	2,03	0,883
COVID19 (COVID19 (JANSSEN))	Varicella	2,256	2,01	1,724				0,539	1,724	1,478	0,566	1,201	0,851
COVID19 (COVID19 (JANSSEN))	Varicella abnormal	3,776	2,901					0,539	2,908	1,793	0,719	4,779	1,042
COVID19 (COVID19 (JANSSEN))	Varicella normal	3,863	2,906					0,877	3,269	2,001	0,663	5,302	0,938
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,016						0,388	0,626	0,481	0,754	0,806	
COVID19 (COVID19 (MODERNA))	No adverse event	1,552	0,833	0,88				0,501	2,043	0,974	0,902	1,227	1,352
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,456						0,528	0,933	0,481	0,597	0,596	0,482
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,28	0,875	0,876				0,716	0,123	0,215	0,739	2,298	2,298
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,946	1,736	0,938				0,956	1,713	1,809	2,032	1,906	1,731
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,891	1,411	0,881				1,411	1,881	1,902	2,068	1,864	1,82
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,916	1,321	0,883				0,641	1,515	1,676	2	1,894	1,63

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#); [Miller, Elaine R \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, July 20, 2021 7:02:23 AM
Attachments: [USST_20210716.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/16/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

Drug	Event	US EB05 20210716	US Serious EB05 20210716	US Fatal EB05 20210716	US Infant EB05 20210716	US Child EB05 20210716	US Teen EB05 20210716	US Adult EB05 20210716	US Adult2 EB05 20210716	US Adult3 EB05 20210716	US Female EB05 20210716	US Male EB05 20210716	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,922	1,92	0,923				1,425	1,425	1,425	2,924	1,924	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,457	0,885	0,882				0,775	0,775	0,718	0,71	2,094	1,408
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,18	2,803	0,889			0,214	1,28	1,28	1,825	4,278	1,383	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,413	2,186	0,88			0,495	1,598	1,598	1,68	2,377	1,936	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,03	1,851	0,906	0,612			1,691	1,691	1,952	1,999	2,623	1,349
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,983	2,272	0,923				0,989	0,989	1,31	0,663	0,792	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	1,97	2,019	0,88				1,809	1,809	0,989	1,133	1,9	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,937	1,885	0,901			0,543	1,478	1,478	1,783	1,196	2,486	0,968
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,258	2,925	0,891			0,328	2,122	2,122	3,236	0,756	3,784	1,181
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,475	2,17	0,909	0,612			0,492	2,023	2,28	1,801	3,204	1,506
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,022	1,852	0,895				0,52	1,483	2,074	1,616	2,264	1,5
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,358	1,9	0,899				0,477	2,067	2,088	2,833	2,845	1,824
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,345	1,495	0,887				0,431	2,279	2,025	1,87	2,685	1,464
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,933	1,472	0,889	0,608			0,362	1,987	1,983	1,6	2,295	1,203
COVID19 (COVID19 (JANSSEN))	Glaze palty	2,4	0,937	0,88				2,482	2,482	1,785	0,805	2,851	1,247
COVID19 (COVID19 (JANSSEN))	Guttain-blare syndrome	1,628	1,647	0,878				1,137	1,137	2,031	0,965	1,382	1,55
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,611	3,125	0,885				1,483	3,365	2,144	1,545	1,265	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,457	2,83	0,856			0,555	3,227	1,622	0,871	5,924	1,045	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,683	1,821	0,88			0,104	1,455	1,455	2,026	1,109	1,586	1,426
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,077	2,225	0,881				1,7	1,127	0,854	2,254	0,739	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,987	1,877	0,922				0,453	1,721	1,78	1,765	2,241	1,428
COVID19 (COVID19 (JANSSEN))	Off label use	1,587	0,154	0,882			4,659	0,362	0,638	0,364	0,988	1,521	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,591	0,755	0,881				2,175	1,604	1,604	1,932		0,904
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	4,315	2,102	0,881			0,649	1,644	1,644	2,144	4,096		
COVID19 (COVID19 (JANSSEN))	Platelet count	2,336	2,481	0,902	0,612		0,52	1,983	2,926	1,387	1,489	1,489	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,624	2,272	0,908			0,296	2,094	2,969	2,117	3,216	1,977	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,255	3,136	0,881				2,996	1,792	0,69	5,046	1,286	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,394		0,901			0,567	3,009	1,956	4,162	2,531	2,388	
COVID19 (COVID19 (JANSSEN))	Pulsmonary embolism	2,015	1,796	0,901	0,612		0,659	1,608	1,949	2,215	1,625	2,275	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,478						3,253	5,987	11,262	4,911	3,906	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,127	1,107	0,883			0,55	1,221	1,142	1,112	1,76	1,549	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,318	2,448	0,907	0,612			2,047	2,404	3,171	2,617	1,88	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,326	1,994	0,881				1,78	1,182	1,182	0,664	0,878	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,113	1,237	0,885			0,593	1,798	1,992	1,808	1,984	1,984	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,717	2,222	0,891	0,612			2,071	2,242	2,242	3,38	2,879	1,261
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,401	1,666	0,881				2,668	1,426	1,426	1,426	1,424	
COVID19 (COVID19 (JANSSEN))	Venogram	2,114	1,928	0,881				1,589	1,535	0,567	2,159	0,826	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,719	2,837	0,881			0,539	3,043	1,701	0,718	4,629	1,103	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,153	2,831	0,881				3,455	2,982	0,754	5,307	0,913	
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,034						0,389	0,528	0,463	0,756	0,874	0,808
COVID19 (COVID19 (MODERNA))	No adverse event	1,524	0,819	0,882		0,458		2,18	0,976	0,8	1,281	1,265	
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,417				0,54		0,435	0,332	0,476	0,578	0,544	0,48
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,29				0,724		2,339	0,116	0,216	0,741	2,282	2,298
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	1,938						0,822	1,709	1,797	2,019	1,896	1,73
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,884						1,405	1,882	1,905	2,066	1,855	1,818
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	1,905	1,325	0,886				0,976	1,512	1,872	2	1,879	1,628

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#); [Miller, Elaine R \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, July 27, 2021 7:09:13 AM
Attachments: [USST_20210723.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/23/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210723	US Serious EB05 20210723	US Fatal EB05 20210723	US Infant EB05 20210723	US Child EB05 20210723	US Teen EB05 20210723	US Adult1 EB05 20210723	US Adult2 EB05 20210723	US Adult3 EB05 20210723	US Female EB05 20210723	US Male EB05 20210723	Comment
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,506	0,909	0,876				0,776	0,716	0,762	2,148	1,466	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,997	2,527	0,883			0,514	1,556	1,834	3,789	4,091	1,356	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,377	2,156	0,875			0,492	1,557	2,385	1,675	2,393	1,899	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,008	1,825	0,911		0,612	0,405	1,725	1,916	1,916	2,534	1,329	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,38	2,416	0,877			0,544	1,068	1,426	0,663	3,284	0,863	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,077	2,102	0,873			0,873	1,249	1,953	0,979	1,295	1,532	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	1,937	1,893	0,898			0,543	1,992	1,703	1,214	2,513	0,961	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,196	2,577	0,898			0,538	2,038	2,922	0,741	3,873	1,117	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,406	2,108	0,908		0,612	0,492	2,023	2,217	1,746	3,122	1,494	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1,982	1,809	0,878			0,521	1,473	2,014	1,591	2,222	1,461	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,373	1,893	0,902			0,477	2,081	2,115	2,853	2,866	1,843	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,354	1,518	0,881			0,419	2,304	2,06	1,88	2,689	1,491	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,919	1,447	0,885		0,609	0,349	1,56	2,065	1,622	2,275	1,212	
COVID19 (COV D19 (JANSSEN))	Gate palsy	2,379	1,952	0,873				2,546	1,726	0,798	2,935	1,257	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,776	1,764	0,872				2,274	3,763	1,025	1,543	1,678	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,74	3,251	0,881				2,096	1,84	0,671	5,717	1,34	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,569	2,923	0,881			0,556	3,263	1,326	0,671	6,078	1,943	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,73	1,88	0,874			0,074	1,509	2,093	1,149	1,647	1,463	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,004	2,171	0,874				1,123	1,592	0,654	2,271	0,724	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,854	1,614	0,874				0,812	2,014	0,696	1,044	1,554	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,947	1,823	0,875			0,486	1,741	1,735	1,71	2,16	1,452	
COVID19 (COV D19 (JANSSEN))	Off label use	1,62	0,148	0,358			4,741	0,358	0,635	0,36	1,016	1,545	
COVID19 (COV D19 (JANSSEN))	On and off phenomemon	1,592	0,758	0,874				2,192	1,022	1,022	1,942	1,942	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4,047	2,022	0,874				0,649	1,018	2,148	2,828	0,922	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,332	2,462	0,894		0,612	0,516	2,107	2,984	1,356	2,77	1,461	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,377	2,271	0,892			0,296	1,58	2,955	2,051	3,195	1,564	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,265	3,133	0,874				3,034	1,793	0,69	5,067	1,237	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,411	0,62	0,215				2,315	1,938	4,224	2,349	2,138	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,002	1,782	0,905		0,612	0,647	1,992	1,979	2,148	2,27	1,613	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,733	1,815	0,881				2,498	6,051	11,269	4,969	3,673	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia superficial	2,073	1,082	0,876			0,434	1,592	1,933	1,033	2,054	1,166	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,314	2,436	1,675		0,612	0,55	2,003	1,702	1,101	1,718	1,526	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,333	1,987	0,874			0,607	2,068	2,389	3,189	2,82	1,677	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,105	1,229	0,88			0,588	1,833	1,942	1,882	2,443	1,372	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,654	2,166	0,89		0,612		2,105	2,192	3,31	2,81	2,125	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,275	1,743	0,877			0,471	1,955	1,969	1,268	2,409	1,394	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2,013	1,29	0,87				1,476	1,873	1,741	2,016	1,558	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	3,516	2,723	0,877				1,945	1,938	1,989	2,007	1,126	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	0,83	1,039	0,846			0,526	1,625	1,625	2,066	1,146	1,302	
COVID19 (COV D19 (JANSSEN))	Venogram	2,191	2,034	0,877				1,699	1,531	0,568	2,281	0,826	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,516	2,723	0,877			0,539	3,066	1,641	0,7	4,527	1,076	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,16	2,623	0,874				3,472	2,088	0,753	5,321	0,912	
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,085						0,392	0,531	0,468	0,758	0,812	
COVID19 (COV D19 (MODERNA))	No adverse event	1,602	0,808	0,875			0,494	2,106	0,968	1,015	0,904	1,366	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,425						0,377	0,309	0,408	0,553	0,474	0,838
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,325	0,878	0,874			0,741	2,379	0,111	0,214	0,718	2,337	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,867						1,396	1,875	1,882	2,056	1,81	

From: [Zinderman, Craig E](#)
To: [Menschik, David](#); [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#); [Miller, Elaine R \(CDC\)](#)
Subject: Weekly data mining
Date: Wednesday, August 4, 2021 4:26:16 PM
Attachments: [USST_2021_0730.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/30/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210730	US Serious EB05 20210730	US Fatal EB05 20210730	US Infant EB05 20210730	US Child EB05 20210730	US Teen EB05 20210730	US Adult EB05 20210730	US Adult EB05 20210730	US Adult3 EB05 20210730	US Female EB05 20210730	US Male EB05 20210730	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,175	1,727	0.85				1,463	1,705	1,124	2,432	1,561	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,522	0,907	0.887				0,763	0,772	0,698	2,146	1,474	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,014	0,992	0.886				0,863	0,762	0,648	1,888	1,511	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,066	2,668	0.892			0,515	1,529	2,021	3,846	4,206	1,137	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,383	2,142	0.886				1,525	2,394	1,703	2,44	1,854	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,015	1,828	0.914		0.612		1,716	1,89	2,017	2,541	1,342	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,557	2,482	0.887				1,21	1,431	0,664	3,646	0,865	
COVID19 (COVID19 (JANSSEN))	ClF protein increased	2,11	2,135	0.884				1,283	2,013	0,976	1,384	1,917	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	1,989	1,852	0.905				0,537	1,066	1,793	1,262	1,026	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,208	2,607	0.895				0,539	2,381	2,851	0,741	3,812	1,225
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,435	2,137	0.914		0.612		0,49	2,082	2,281	1,756	3,143	1,531
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,979	1,802	0.889				0,511	1,505	2,022	1,568	2,255	1,439
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,369	1,884	0.906				0,474	2,114	2,112	2,812	2,881	1,839
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,352	1,965	0.89				0,42	2,335	2,028	1,797	2,878	1,51
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,92	1,468	0.893		0.61		0,34	1,561	1,652	2,256	1,247	
COVID19 (COVID19 (JANSSEN))	Glare palsy	2,346	0,944	0.884					1,734	0,797	2,548	1,246	
COVID19 (COVID19 (JANSSEN))	Guillain-Barre syndrome	1,801	1,81	0.884					1,111	1,056	1,575	1,696	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,811	3,353	0.891					2,125	3,813	4,121	5,748	1,343
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,989	2,91	0.857					3,332	1,942	0,672	6,107	1,044
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,783	1,956	0.885		0.06			1,597	1,522	1,222	1,732	1,494
COVID19 (COVID19 (JANSSEN))	Inguinal vein thrombosis	2,024	2,168	0.885					1,623	1,125	0,665	2,398	0,725
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,749	1,817	0.814					2,05	0,839	1,133	1,634	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,963	1,862	0.896					1,774	1,742	2,202	1,455	
COVID19 (COVID19 (JANSSEN))	Off label use	1,627	0,147	0.891					0,352	0,621	0,363	1,02	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,6	0,757	0.885					2,232	1,003	1,742	1,962	
COVID19 (COVID19 (JANSSEN))	Plaque embolism	3,939	2,016	0.885					0,65	1,019	1,914	2,488	0,922
COVID19 (COVID19 (JANSSEN))	Platelet count	2,313	2,533	0.902		0.612			2,064	2,991	2,782	1,446	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,581	2,259	0.891					1,909	2,921	2,033	3,172	1,552
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	4,987	3,252	0.885					3,108	1,805	0,602	4,867	1,315
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,425							2,24	1,907	4,132	2,297	2,123
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	1,994	1,771	0.907		0.612			1,949	1,974	2,131	2,382	1,59
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	4,549							2,566	6,305	11,82	3,937	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,811	0,889	0.889					0,432	1,674	1,949	2,108	1,253
COVID19 (COVID19 (JANSSEN))	Thrombolytic superficial	2,135	1,143	0.887					1,26	1,688	1,201	1,817	1,529
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,298	2,406	0.895		0.612			2,079	2,369	3,114	2,6	1,879
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,235	1,951	0.885					1,638	1,189	0,664	2,208	0,877
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,129	1,263	0.889					1,889	1,89	2,484	1,383	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,647	2,17	0.897		0.612			2,055	2,18	3,318	2,77	2,145
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,773	1,703	0.882					1,922	1,344	1,305	2,386	1,406
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,014	1,374	0.882					0,473	1,521	1,72	1,994	1,588
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,805	1,03	0.882					1,03	1,238	1,948	1,567	2
COVID19 (COVID19 (JANSSEN))	Vaccination failure	0,956	1,24	0.857					0,956	1,978	3,041	1,209	1,501
COVID19 (COVID19 (JANSSEN))	Venogram	2,282	2,059	0.889					1,675	1,685	0,965	2,326	0,891
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,056	2,635	0.885					2,967	1,683	0,17	4,086	1,062
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,072	2,512	0.885					3,105	2,373	0,754	5,081	0,914
COVID19 (COVID19 (MODERNA))	No adverse event	1,972	0,81	0.885		0.483			0,925	0,977	0,863	1,24	1,134
COVID19 (COVID19 (MODERNA))	Accidental exposure to product	2,114							0,381	0,533	0,47	0,675	0,787
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,456					0.544		0,329	0,278	0,383	0,547	0,406
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,36	0,867	0.885					2,422	0,089	0,24	0,672	2,381
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,849							1,397	1,877	1,887	2,066	1,828

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Marquez, Paige L \(CDC\)](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#); [Miller, Elaine R \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, August 10, 2021 7:22:49 AM
Attachments: [USST_20210806.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/6/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210806	US Serious EB05 20210806	US Fatal EB05 20210806	US Infant EB05 20210806	US Child EB05 20210806	US Teen EB05 20210806	US Adult1 EB05 20210806	US Adult2 EB05 20210806	US Adult3 EB05 20210806	US Female EB05 20210806	US Male EB05 20210806	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,706	1,656	0	0	0	0	1,366	1,416	1,268	1,268	1,043	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1,759	1,736	0	0	0	0	1,45	1,792	1,225	1,225	1,189	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,525	0,904	0	0	0	0	0,758	0,712	0,689	0,689	2,147	1,49
COVID19 (COV D19 (JANSSEN))	Adverse event	2,043	0,980	0	0	0	0	0,949	0,762	0,669	0,669	1,48	1,574
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3,13	2,586	0	0	0	0,517	1,612	2,159	3,54	3,54	4,292	1,384
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,373	2,145	0	0	0	0,478	1,536	2,437	1,716	2,378	1,931	
COVID19 (COV D19 (JANSSEN))	Antibody test	1,894	0	0	0	0	0	0,661	1,832	2,373	1,723	1,452	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,034	1,834	0	0	0	0,921	1,723	1,948	1,992	1,992	1,359	
COVID19 (COV D19 (JANSSEN))	Areflexia	1,758	2,077	0	0	0	0	0,817	1,73	1,026	1,347	1,342	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,655	2,509	0	0	0	0,536	1,21	1,595	0,659	3,866	0,859	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,196	2,205	0	0	0	0	1,427	2,095	0,961	1,659	1,842	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,013	1,979	0	0	0	0,539	1,7	1,843	1,263	2,555	1,087	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,175	2,582	0	0	0	0,541	2,33	2,853	0,74	3,829	1,207	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,453	2,141	0	0	0	0,487	2,021	2,297	1,614	3,154	1,511	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	1,98	1,808	0	0	0	0,51	1,487	1,998	1,655	2,253	1,447	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,348	1,876	0	0	0	0,477	2,098	2,085	2,8	1,819	1,819	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,333	1,546	0	0	0	0,414	2,29	2,067	1,624	2,661	1,513	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,932	1,489	0	0	0,61	0,328	1,557	2,131	1,654	2,275	1,28	
COVID19 (COV D19 (JANSSEN))	Gasze palsy	2,288	0,959	0	0	0	0	2,372	1,72	0,792	2,721	1,209	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,855	1,846	0	0	0	0	1,165	2,351	1,127	1,724	1,69	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,878	3,376	0	0	0	0	2,141	4,123	4,096	5,837	1,342	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,599	2,892	0	0	0	0,558	3,379	1,946	0,672	6,126	1,043	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,811	1,851	0	0	0	0,041	1,694	2,107	1,297	1,798	1,454	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,129	2,219	0	0	0	0	1,472	1,204	0,741	2,732	0,712	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,811	1,894	0	0	0	0	0,907	2,031	0,911	1,276	1,608	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	1,996	1,851	0	0	0	0,471	1,736	1,816	1,765	2,265	1,448	
COVID19 (COV D19 (JANSSEN))	Off label use	1,652	0,243	0	0,89	0	4,86	0,348	0	0	0,346	1,057	1,558
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,603	0,756	0	0	0	0	2,263	1,004	1,004	1,976	1,146	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,017	0	0	0	0	0,54	1,468	1,629	0,87	1,96	0,921	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,037	1,996	0	0,891	0	0	0,651	1,02	1,911	2,503	1,021	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,287	2,457	0	0,612	0	0	2,082	3,083	2,795	1,372	1,438	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,287	2,257	0	0	0	0,281	2,01	2,938	2,024	3,232	1,54	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,165	3,191	0	0	0	0	3,155	1,809	0,691	4,903	1,241	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,463	0	0	0	0	0,569	2,428	2,036	4,031	2,241	2,312	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	1,955	1,763	0	0,612	0	0,652	1,562	1,984	2,131	2,275	1,602	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	4,594	0	0	0	0	0	2,626	6,178	11,918	5,373	4,008	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,798	1,868	0	0	0	0,424	1,598	1,932	1,144	2,09	1,253	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,239	1,122	0	0	0	0,352	1,311	1,777	1,2	1,927	1,59	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,275	2,364	0	0,612	0	0,608	2,08	2,34	3,04	2,586	1,843	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,187	1,902	0	0	0	0	1,59	1,19	0,654	2,122	0,877	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,124	1,302	0	0	0	0,586	1,841	1,959	1,747	2,456	1,413	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,631	2,174	0	0,612	0	0	2,081	2,174	3,266	2,801	2,174	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,207	1,664	0	0	0	0	2,462	1,391	1,257	2,352	1,354	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1,048	1,34	0	0	0,896	0,524	0,966	2,091	3,989	1,4	1,601	
COVID19 (COV D19 (JANSSEN))	Venogram	2,194	2,018	0	0	0	0	1,653	1,634	0,651	2,23	0,924	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,251	2,596	0	0	0	0,532	2,586	1,793	0,699	4,223	1,047	
COVID19 (COV D19 (JANSSEN))	Venogram normal	3,896	2,411	0	0	0,891	0	2,762	2,377	0,747	4,842	0,897	
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,128	0	0	0	0	0,385	0,519	0,471	0,738	0,678	0,77	
COVID19 (COV D19 (MODERNA))	No adverse event	1,568	0,81	0	0	0,47	0	1,127	0,923	0,969	0,891	1,343	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,477	0	0	0	0,545	0	0,287	0,258	0,374	0,565	0,443	0,377
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,373	0,867	0	0,891	0,763	0	2,437	0,964	0,238	0,653	2,331	2,352
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,828	0	0	0	0	0	1,368	1,873	1,854	2,059	1,803	1,772

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, August 17, 2021 7:01:02 AM
Attachments: [USST_20210813.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/13/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210813	US Serious EB05 20210813	US Fatal EB05 20210813	US Infant EB05 20210813	US Child EB05 20210813	US Teen EB05 20210813	US Adult1 EB05 20210813	US Adult2 EB05 20210813	US Adult3 EB05 20210813	US Female EB05 20210813	US Male EB05 20210813	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,76	1,77	0,696			0,435	1,346	1,484	1,352	2,149	0,997	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1,804	1,7	0,678				1,455	1,753	1,287	2,024	1,235	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,813	0,901	0,884				0,885	0,776	0,68	2,18	0,581	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2,97	2,40	0,69			0,514	1,609	2,04	1,366	3,596	4,161	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,307	2,108	0,665			0,479	1,553	2,424	1,721	2,458	1,863	
COVID19 (COV D19 (JANSSEN))	Antibody test	1,998	0,84					0,706	1,84	3,29	1,807	1,567	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2,031	1,792	0,912	0,612		0,472	1,725	1,901	2,013	2,667	1,361	
COVID19 (COV D19 (JANSSEN))	Arteriosclerosis	1,804	2,091	0,881				0,888	1,786	1,02	1,403	1,967	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	2,744	2,505	0,885			0,536	1,213	1,608	0,658	4,004	0,861	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,207	2,194	0,882				1,431	2,124	0,957	1,863	1,857	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,045	1,974	0,902			0,535	1,768	1,882	1,269	2,695	1,064	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3,071	2,51	0,893			0,541	2,353	2,52	0,738	3,718	1,193	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2,447	2,109	0,914	0,612		0,488	1,966	2,292	1,849	3,127	1,565	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2,018	1,816	0,891			0,508	1,471	2,006	1,792	2,273	1,505	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,382	1,887	0,908			0,478	2,172	2,079	2,841	2,932	1,834	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,325	1,52	0,888			0,414	2,287	2,025	1,849	2,677	1,493	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,974	1,547	0,892	0,611		0,374	1,618	2,133	1,713	2,349	1,271	
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2,253	0,94	0,883				2,39	1,685	0,793	2,74	1,188	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	1,842	1,845	0,881				1,203	2,403	1,104	1,698	1,7	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	4,928	3,464	0,889				2,549	3,752	5,122	6,015	1,484	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,755	2,965				0,558	3,458	2,476	0,671	6,328	1,045	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1,81	1,967	0,882			0,035	1,72	2,109	1,298	1,86	1,46	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,071	2,167	0,883				1,561	1,142	0,743	2,664	0,706	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1,817	1,881					0,952	2,001	0,908	1,318	1,588	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,01	1,878	0,885			0,473	1,78	1,812	1,841	2,267	1,508	
COVID19 (COV D19 (JANSSEN))	Off label use	1,757	0,25	0,881			0,022	0,351	0,614	0,441	1,142	1,62	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,628	0,754					2,327	1,005		2,028		
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,16	0,9				0,54	1,622	1,958	0,979	2,019	1,302	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4,022	1,992	0,882				0,651	1,02	2,004	2,696	0,922	
COVID19 (COV D19 (JANSSEN))	Platelet count	2,361	2,489	0,9	0,612		0,5	2,06	3,18	2,927	1,36	1,457	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,581	2,244	0,889			0,277	2,005	2,959	2,029	3,265	1,422	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5,422	3,298	0,883				3,824	2,145	0,691	5,255	1,422	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0,484					0,571	0,484	2,591	4,169	2,608	2,312	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,022	1,755	0,907	0,612		0,735	2,008	2,307	2,161	2,307	1,626	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	4,753						3,483	5,506	12,191	5,638	4,087	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	1,806	1,858	0,886			0,422	1,666	1,995	1,156	2,137	1,242	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2,267	1,122	0,885			0,562	1,305	1,812	1,937	1,937	1,627	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2,325	2,357	1,808	0,612		0,605	2,077	2,341	3,088	2,645	1,877	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2,123	1,988	0,892				1,84	1,195	0,653	2,185	0,855	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2,107	1,289	0,887			0,582	1,811	1,927	1,827	2,43	1,421	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2,882	2,181	0,895	0,612		0,469	2,177	2,167	3,362	2,127	1,508	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2,224	1,687					2,387	1,468	1,31	2,37	1,386	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	0,922	1,476	0,892			0,524	1,059	2,031	3,944	1,392	1,521	
COVID19 (COV D19 (JANSSEN))	Venogram	2,291	2,025					1,783	1,683	0,559	2,343	0,977	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3,306	2,621				0,623	2,436	1,843	0,7	4,329	1,032	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4,01	2,407	0,883				2,815	2,815	0,749	5,086	0,898	
COVID19 (COV D19 (MODERNA))	Accidental exposure to product	2,084						0,388	0,519	0,47	0,65	0,759	
COVID19 (COV D19 (MODERNA))	No adverse event	1,531	0,801	0,883			0,459	2,141	0,914	0,36	0,609	1,214	
COVID19 (COV D19 (MODERNA))	Poor quality product administered	2,429					0,29	0,249	0,385	0,555	0,416	0,376	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2,394	0,869	0,883			0,847	2,47	0,108	0,23	0,657	2,349	2,426
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	1,961	1,795	0,911				0,938	1,778	1,903	2,016	1,719	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0,791	0,799	0,883	2,73			0,587	0,587	0,577	0,577	1,005	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	1,946		0,895				0,895	1,685	1,772	1,901	1,754	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1,814	0,636	0,889				1,367	1,88	1,652	2,084	1,803	1,751
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	1,916	1,966					1,916	1,66	2,039	1,69	1,652	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, August 24, 2021 5:23:45 PM
Attachments: [USST_20210820.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/20/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210820	US Serious EB05 20210820	US Fatal EB05 20210820	US Infant EB05 20210820	US Child EB05 20210820	US Teen EB05 20210820	US Adult1 EB05 20210820	US Adult2 EB05 20210820	US Adult3 EB05 20210820	US Female EB05 20210820	US Male EB05 20210820	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,768	1,679	0,266				0.43	1,228	1,525	1,401	2,169	0,977
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,843	1,703	0,870					1,431	1,837	1,361	2,078	1,266
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,564	0,892	0,884					0,856	0,759	0,643	2,154	1,515
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,127	2,502	0,892				0,517	1,704	2,059	3,196	4,323	1,426
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,413	2,094	0,884				0,479	1,599	1,855	1,855	2,501	1,931
COVID19 (COVID19 (JANSSEN))	Antibody test	2,09	0,84	0,76				0,519	0,876	1,758	3,171	1,902	1,682
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,067	1,766	0,01		0,612		0,462	1,715	1,903	2,196	2,726	1,392
COVID19 (COVID19 (JANSSEN))	Arflexia	1,862	2,108	0,881				0,877	1,911	1,911	1,054	1,507	1,377
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,719	2,462	0,884				0,539	1,072	1,859	0,657	4,198	0,851
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,319	2,237	0,882				0,538	1,544	2,189	0,983	1,816	1,904
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,105	1,946	0,903				0,538	1,62	1,911	1,334	2,857	1,949
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	1,901	1,75	0,884				0,544	0,983	1,519	0,904	2,128	0,909
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,138	2,504	0,893		0,612		0,467	2,278	2,712	0,747	3,738	1,219
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,516	2,1	0,921				0,418	2,319	2,042	1,941	3,239	1,622
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,062	1,81	0,891				0,512	1,447	2,021	1,983	2,344	1,532
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,433	1,871	0,905				0,481	2,155	2,101	3,078	3,011	1,869
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,364	1,498	0,888				0,418	2,319	2,042	1,941	2,731	1,516
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1,979	1,499	0,892		0,611		0,369	1,576	2,157	1,79	2,363	1,275
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,817	0,978	0,882				0,446	1,613	1,69	0,8	2,046	1,072
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,261	0,939	0,893				0,561	2,358	1,893	0,801	2,781	1,164
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	1,979	1,899	0,881				1,234	2,523	3,914	1,262	1,835	1,812
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,063	3,431	0,889				2,597	3,521	2,636	5,568	6,296	1,502
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	5,871	2,989	0,889				0,561	3,521	2,636	0,669	6,465	1,952
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,834	1,95	0,882				0,027	1,705	2,165	1,353	1,897	1,471
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,183	2,208	0,883				1,574	1,165	1,165	0,747	3,148	0,707
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,875	1,899	0,95				0,95	2,007	2,007	0,532	1,334	1,654
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,056	1,874	0,886				0,47	1,758	1,859	1,956	2,292	1,568
COVID19 (COVID19 (JANSSEN))	Off label use	1,803	0,25	0,881				0,029	0,351	0,603	0,432	1,178	1,657
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,679	0,756	0,886				0,543	2,385	1,012	2,121	2,121	1,326
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,339	0,899	0,889				1,61	2,092	2,092	1,084	2,211	0,905
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,874	1,884	0,882				0,053	0,999	0,999	3,378	3,141	1,508
COVID19 (COVID19 (JANSSEN))	Platelet count	2,495	2,489	0,9		0,612		0,274	2,062	3,216	1,414	3,141	1,508
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,633	2,216	0,889				0,274	2,016	3,01	2,173	3,33	1,567
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,709	3,385	0,883				0,425	2,234	0,689	5,671	1,433	2,505
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,528						0,576	2,574	2,072	4,767	3,127	2,505
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,062	1,727	0,905		0,612		0,738	1,587	2,014	2,282	2,362	1,653
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,873	1,738	0,886				1,446	1,349	2,009	1,721	1,557	2,046
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2,208	1,32	0,889				0,561	1,6	1,83	0,543	1,936	2,046
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	5,199						0,56	0,883	5,618	13,351	6,288	4,475
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,861	1,83	0,886				0,418	1,664	1,909	1,239	2,22	1,274
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,3	1,165	0,885				0,555	1,351	1,796	1,263	1,916	1,701
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,439	1,78	0,886		0,612		0,604	2,12	2,369	3,303	2,79	1,943
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,172	1,951	0,882				0,585	1,657	1,205	0,651	2,247	0,859
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,172	1,305	0,887				0,473	1,823	1,987	1,944	2,48	1,495
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,728	2,153	0,898				0,473	2,196	2,16	3,539	3,038	2,142
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,256	1,688	0,889				0,472	2,39	1,453	1,427	2,419	1,42
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,002	1,292	0,879				0,472	1,453	1,875	1,786	1,939	1,64
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,024	1,676	0,891				0,527	1,098	2,07	4,238	1,588	1,691
COVID19 (COVID19 (JANSSEN))	Venogram	2,304	1,999	0,886				0,625	1,766	1,642	0,549	2,351	0,978
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,36	2,85	0,883				0,625	2,61	1,828	0,7	4,318	1,039
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,006	2,413	0,883				0,445	2,774	3,009	0,754	4,89	0,968
COVID19 (COVID19 (MODERNA))	No adverse event	1,453	0,801	0,883				2,134	0,868	0,938	0,807	1,165	1,288
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,209						0,548	0,289	0,388	0,536	0,374	0,346
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,38	0,889	0,883				0,851	0,104	0,222	0,59	2,338	2,418
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,838	0,885	0,885				0,667	0,911	1,157	2,169	1,762	1,443
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,121	1,801	0,911				0,94	1,795	1,925	2,166	1,977	1,89
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,704	0,799	0,883		2,264		0,499	1,673	1,799	2,219	0,51	1,038
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,08	1,735	0,895				0,897	1,673	1,883	2,257	2,012	1,848
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,848	0,638	0,889				1,369	1,9	1,883	2,257	1,842	1,778
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,032	1,363	0,889				0,732	1,528	1,692	2,196	2,017	1,718

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, August 31, 2021 7:48:22 AM
Attachments: [USST_20210827.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 8/27/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210827	US Serious EB05 20210827	US Fatal EB05 20210827	US Infant EB05 20210827	US Child EB05 20210827	US Teen EB05 20210827	US Adult1 EB05 20210827	US Adult2 EB05 20210827	US Adult3 EB05 20210827	US Female EB05 20210827	US Male EB05 20210827	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,731	1,731	0	0	0	0	0.426	1,361	1,619	1,426	2,349	1,011
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,903	1,693	0	0	0	0	0	1,47	1,846	1,487	2,097	1,344
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,515	0	0	0	0	0	0	0.848	0,707	0,63	2,159	1,513
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,063	2,431	0	0	0	0	0.507	1,638	2,055	4,095	4,165	1,434
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,414	0	0	0	0	0	0.469	0	1,617	2,424	1,855	1,904
COVID19 (COVID19 (JANSSEN))	Antibody test	2,287	0	0	0	0	0	0.597	0,753	1,867	2,985	2,086	1,856
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,095	1,174	0	0	0	0	0.459	1,776	1,884	2,221	2,76	1,417
COVID19 (COVID19 (JANSSEN))	Areflexia	1,968	2,162	0	0	0	0	0.612	0	0	1,165	1,628	1,498
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,429	1,174	0	0	0	0	0.309	0,845	2,081	1,056	1,55	1,03
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,591	2,375	0	0	0	0	0.54	1,06	1,914	0,655	3,785	0,857
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,984	2,23	0	0	0	0	0.81	1,544	2,208	1,975	1,839	1,948
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,178	0	0	0	0	0	0.538	1,618	1,987	1,365	2,995	1,128
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	1,954	1,688	0	0	0	0	0.883	0,987	0,939	1,58	2,236	0,916
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,27	2,517	0	0	0	0	0.539	2,407	2,836	0,753	3,89	1,224
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,582	2,066	0	0	0	0	0.569	1,983	2,44	1,968	3,32	1,671
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,091	1,795	0	0	0	0	0.507	1,477	2,022	2,049	2,361	1,569
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,489	1,872	0	0	0	0	0.479	2,151	2,136	3,166	3,096	1,915
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,44	1,204	0	0	0	0	0.886	0	0	1,174	1,589	0,984
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,419	1,566	0	0	0	0	0.415	2,327	2,118	1,971	2,745	1,605
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,032	1,515	0	0	0	0	0.369	1,609	2,205	1,898	2,419	1,337
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,847	0	0	0	0	0	0.45	1,616	1,74	0,806	2,09	1,078
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,261	0	0	0	0	0	0.45	2,351	1,679	0,809	2,753	1,207
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,106	1,93	0	0	0	0	0.88	1,263	2,632	1,39	1,976	1,885
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,158	3,512	0	0	0	0	0.89	3,438	3,786	5,857	6,534	1,673
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6	2,975	0	0	0	0	0.561	3,632	2,86	0,668	6,628	1,059
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1,93	1,962	0	0	0	0	0.025	1,836	2,215	1,451	1,991	1,553
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,258	2,213	0	0	0	0	0.882	1,597	1,176	0,75	3,422	0,709
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,909	1,869	0	0	0	0	0.956	2,063	1,019	1,382	1,665	1,822
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,087	1,853	0	0	0	0	0.534	1,788	1,861	2,015	3,322	1,601
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,44	1,08	0	0	0	0	0.307	0,995	2,058	0,516	0,85	0,85
COVID19 (COVID19 (JANSSEN))	Off label use	1,853	0	0	0	0	0	0.88	5,293	0,343	0,572	1,216	1,672
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,731	0	0	0	0	0	0.706	2,505	1,02	2,223	2,223	2,223
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,474	0	0	0	0	0	0.899	1,71	2,158	1,094	3,351	1,422
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,489	1,8	0	0	0	0	0.544	0,653	0,974	2,63	2,207	0,909
COVID19 (COVID19 (JANSSEN))	Platelet count	2,652	2,517	0	0	0	0	0.612	0,504	2,204	3,367	1,429	1,622
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,745	1,151	0	0	0	0	0.608	0,333	1,481	2,002	1,337	1,333
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,706	2,224	0	0	0	0	0.89	0,429	2,056	2,238	3,405	1,622
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,653	3,466	0	0	0	0	0.882	4,367	2,339	0,688	5,901	1,642
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0,992	0	0	0	0	0	0.58	3,792	2,237	4,884	3,385	2,714
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,626	1,369	0	0	0	0	0.744	0,305	1,255	1,199	2,044	1,116
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,104	1,717	0	0	0	0	0.612	0,643	1,912	2,04	2,34	2,428
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,932	1,724	0	0	0	0	0.885	1,494	1,334	2,129	1,789	1,586
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1,44	1,177	0	0	0	0	0.561	0,98	0,843	0,65	2,008	0,602
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2,463	1,821	0	0	0	0	0.893	0,556	1,663	2,074	0,567	2,094
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	5,709	0	0	0	0	0	0.655	3,209	5,361	14,615	6,957	4,918
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	1,956	1,864	0	0	0	0	0.42	1,682	2,043	1,271	2,347	1,335
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2,344	1,154	0	0	0	0	0.556	1,327	1,876	1,289	1,955	1,732
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,861	2,332	0	0	0	0	0.603	2,178	2,431	3,438	2,929	2,042
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,317	2,045	0	0	0	0	0.881	1,892	1,201	0,65	2,471	0,863
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,204	1,295	0	0	0	0	0.588	1,78	2,005	2,072	2,51	1,532
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,705	2,098	0	0	0	0	0.558	2,244	2,193	3,159	3,159	2,127
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,279	1,685	0	0	0	0	0.475	2,378	1,462	1,923	2,398	1,476
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,036	1,333	0	0	0	0	0.474	1,421	1,929	1,908	1,978	1,682
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,831	1,053	0	0	0	0	0.881	1,18	2,021	1,85	1,966	1,19
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,103	1,864	0	0	0	0	0.528	1,132	2,279	4,595	1,725	1,908
COVID19 (COVID19 (JANSSEN))	Venogram	2,365	2,034	0	0	0	0	0.621	1,71	1,75	0,544	2,4	1,033
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,37	2,845	0	0	0	0	0.621	2,689	1,821	0,703	4,357	1,039
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,217	2,512	0	0	0	0	0.882	3,196	3,265	0,757	5,112	1,959
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1,295	0	0	0	0	0	3.202	0,715	0	0	1,188	0,785
COVID19 (COVID19 (MODERNA))	Poor quality product administered	2,052	0	0	0	0	0	0.535	0,33	0,289	0,408	0,542	0,34
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,309	0,869	0	0	0	0	0.81	2,401	0,149	0,221	0,952	2,351
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,912	0,963	0	0	0	0	0.57	0,918	1,182	2,21	1,858	1,475
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2,036	1,006	0	0	0	0	0.843	1,4	1,572	1,897	2,001	1,502
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,315	1,815	0	0	0	0	0.958	1,868	1,931	2,299	2,16	2,06
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,613	0,8	0	0	0	0	2.412	0,412	0	0	0,439	1,04
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,169	1,74	0	0	0	0	0.896	0,914	1,691	1,85	2,355	1,938
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,898	0,64	0	0	0	0	0.412	1,922	1,937	2,386	1,807	1,619
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,119	1,34	0	0	0	0	0.738	1,542	1,707	2,328	2,114	1,761

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 7, 2021 6:51:39 AM
Attachments: [USST_20210903.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/3/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210903	US Serious EB05 20210903	US Fatal EB05 20210903	US Infant EB05 20210903	US Child EB05 20210903	US Teen EB05 20210903	US Adult1 EB05 20210903	US Adult2 EB05 20210903	US Adult3 EB05 20210903	US Adult4 EB05 20210903	US Female EB05 20210903	US Male EB05 20210903	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.527	1.775	0.552	1.336		0.421	1.336	1.646	1.575	2.479	1.555	2.479	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1.933	1.687	0.871	1.455			1.455	1.950	1.55	2.054	1.55	1.403	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2.803	0.929	0.878	0.835			0.835	0.755	0.696	2.296	1.496	1.496	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3.198	2.465	0.856	1.942	0.509		1.942	2.206	4.057	4.278	1.484	4.278	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.089	2.089	0.88	0.47			1.698	1.698	2.029	1.98	1.98	2.029	
COVID19 (COVID19 (JANSSEN))	Anion gap decreased	1.609	1.472	0.879	0.424			1.107	2.012	0.774	1.167	1.167	1.167	
COVID19 (COVID19 (JANSSEN))	Antibody test	2.293	0.836	0.874	0.598			0.775	1.902	1.902	2.134	1.96	2.134	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2.157	1.755	0.945	0.455	0.612		1.804	1.804	1.936	2.311	1.474	2.311	
COVID19 (COVID19 (JANSSEN))	Areflexia	2.047	2.155	0.876	0.877			1.107	1.965	1.258	1.576	1.515	1.576	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.46	1.201	0.879	0.3	0.609		0.918	2.108	1.038	1.596	1.072	1.596	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2.459	0.876	0.873	0.641			1.153	1.962	1.962	1.974	1.962	1.974	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2.41	2.22	0.875	1.561			1.618	2.286	1.085	1.848	2.002	1.848	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.185	1.918	0.905	0.539			1.618	2.005	1.361	2.972	1.119	2.972	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.039	1.884	0.884	0.95			0.854	1.227	0.958	2.219	0.79	2.219	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2.053	1.725	0.876	1.068			0.997	1.559	1.306	1.013	1.013	1.013	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3.244	2.509	0.888	0.935			2.353	2.897	0.751	3.843	1.218	3.843	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2.666	2.056	0.928	0.571	0.612		2.117	2.511	2.004	3.449	1.711	3.449	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2.189	1.823	0.898	0.51			1.546	2.078	2.241	2.462	1.662	2.462	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.56	1.865	0.902	0.48			2.243	2.181	3.219	1.975	1.975	1.975	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.484	1.232	0.879	0.983			1.625	0.983	1.616	1.037	1.037	1.037	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.807	0.817	0.876	1.211			2.008	1.514	1.052	1.91	1.427	1.91	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.404	1.5	0.884	0.415	0.611		2.317	2.117	1.9	2.722	1.589	2.722	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2.103	1.58	0.893	0.363			1.625	1.625	2.49	2.264	1.411	2.264	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1.889	0.969	0.875	0.45			1.667	1.753	0.806	2.117	1.115	2.117	
COVID19 (COVID19 (JANSSEN))	Gasze palsy	2.296	0.949	0.876	0.876			2.365	1.688	0.892	2.753	1.252	2.753	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2.203	1.932	0.873	1.262			1.262	2.74	1.44	1.987	1.981	1.987	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.225	3.643	0.856	3.265			3.981	3.981	6.541	6.652	1.79	6.652	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.101	2.994	0.874	0.561			3.729	3.309	0.668	6.737	1.065	6.737	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	1.987	1.98	0.874	0.026			1.847	2.277	1.468	2.046	1.572	2.046	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1.87	1.189	0.851	1.303			1.303	1.806	0.953	2.011	1.11	2.011	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2.328	2.229	0.876	1.621			1.621	1.182	3.61	0.712	3.61	0.712	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.697	1.384	0.874	1.001			1.001	2.036	0.986	1.521	1.515	1.515	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1.977	1.908	0.873	0.963			1.027	2.197	1.027	1.39	1.757	1.39	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.135	1.85	0.881	0.533			1.78	1.93	2.048	2.411	1.597	2.411	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1.464	1.087	0.873	0.3			1.025	2.083	0.512	1.693	0.892	1.693	
COVID19 (COVID19 (JANSSEN))	Off label use	1.6	0.332	0.874	5.195			0.315	0.572	0.36	1.178	1.564	1.178	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1.783	0.757	0.873	2.621			2.621	1.024	2.315	1.024	2.315	1.024	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.437	0.888	0.875	0.545			1.64	2.053	1.083	2.311	1.371	2.311	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3.651	1.798	0.875	0.633			0.633	0.977	2.696	0.977	0.913	0.977	
COVID19 (COVID19 (JANSSEN))	Platelet count	2.675	2.433	0.917	0.505	0.612		2.084	3.32	1.434	3.259	1.68	3.259	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.772	1.486	0.887	0.33	0.609		1.502	2.008	1.325	2.086	1.362	2.086	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.748	2.207	0.885	0.427			2.104	3.077	2.26	3.478	1.626	3.478	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5.827	3.499	0.876	4.174			2.512	2.512	6.688	5.792	1.675	6.688	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	0.782			0.579			2.981	2.241	5.017	3.72	2.817	5.017	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1.652	1.365	0.876	0.302	0.744		1.263	2.016	1.22	2.066	1.147	2.066	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.172	1.728	0.916	0.645	0.612		1.638	2.088	2.471	2.488	1.746	2.488	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.01	1.723	0.879	1.498			1.498	1.378	2.241	1.85	1.621	2.241	
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1.448	1.184	0.874	0.561			0.943	0.961	0.65	2.064	0.603	2.064	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2.731	2.215	0.9	0.556			1.722	2.122	0.673	2.312	2.661	2.312	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	6.415			0.656			2.586	6.408	14.711	7.484	5.344	7.484	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2.006	1.862	0.883	0.42			1.865	2.088	2.362	2.362	1.394	2.362	
COVID19 (COVID19 (JANSSEN))	Thrombophlebitis superficial	2.354	1.164	0.878	0.551			1.357	1.898	1.282	1.971	1.749	1.971	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2.645	2.279	1.753	0.608	0.612		2.132	2.437	3.537	2.916	2.096	3.537	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2.579	2.057	0.875	1.933			1.933	1.208	0.65	2.558	0.866	2.558	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2.227	1.922	0.88	0.585			1.772	2.038	2.122	2.528	1.574	2.528	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2.837	2.106	0.893	0.56	0.612		2.332	2.249	3.575	3.281	2.173	3.575	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2.352	1.796	0.872	0.477			2.473	1.539	1.526	2.485	1.534	2.485	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1.773	1.452	0.872	1.191			1.191	1.753	2.041	1.623	1.623	1.623	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2.051	1.335	0.871	0.467			1.421	1.886	1.886	1.984	1.702	1.984	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1.871	1.083	0.876	0.198			1.198	2.024	2.007	1.98	1.225	2.007	
COVID19 (COVID19 (JANSSEN))	Vasculature failure	1.351	2.145	0.908	0.995			0.995	2.134	4.483	1.831	2.002	4.483	
COVID19 (COVID19 (JANSSEN))	Venogram	2.346	2.02	0.876	0.617			1.662	1.777	0.539	2.407	1.024	2.407	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3.368	2.631	0.876	2.662			2.662	1.863	0.704	4.298	1.046	4.298	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4.143	2.443	0.876	3.269			3.269	2.829	5.107	0.758	1.035	5.107	
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1.264	0.755		1.181	3.215	0.715	0.909	1.181	0.516	1.261	0.824	1.261	
COVID19 (COVID19 (MODERNA))	No adverse event	1.263	0.835	0.88	0.336		0.336	2.003	0.909	0.91	0.772	1.115	0.772	
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2.306	0.862	0.876	0.81		0.81	2.422	0.141	0.214	2.313	2.36	2.313	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1.958	0.981	0.878	0.57			0.903	1.235	2.282	1.912	1.501	1.912	
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2.115	1.022	0.874	0.643			1.446	1.606	1.988	2.077	1.565	2.077	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2.459	1.759	0.926	0.971			1.835	1.938	2.236	2.143	1.837	2.236	
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0.575	0.819	0.878	0.78	2.72		0.363	1.911	2.419	0.382	1.021	2.419	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2.238	1.736	0.894	1.736			1.736	2.181	1.911	2.012	2.012	2.012	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1.92	0.643	0.873	1.412			1.939	1.978	1.899	1.837	1.837	1.837	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2.108	1.31	0.884	0.762			1.511	1.683	2.336	2.102	1.77	2.102	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 14, 2021 6:16:57 AM
Attachments: [USST_20210910.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/10/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210910	US Serious EB05 20210910	US Fatal EB05 20210910	US Infant EB05 20210910	US Child EB05 20210910	US Teen EB05 20210910	US Adult1 EB05 20210910	US Adult2 EB05 20210910	US Adult3 EB05 20210910	US Female EB05 20210910	US Male EB05 20210910	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1 971	1 778	0 075			0 425	1 447	1 642	1 671	2 444	1 131	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1 595	1 677	0 086				1 555	1 894	1 526	2 101	1 433	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 905	0 923	0 887				0 832	0 759	0 609	2 397	1 492	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1 712	1 174	0 874				1 176	1 262	1 074	2 031	0 923	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 249	2 446	0 877			0 511	1 997	2 095	4 007	4 351	1 489	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 574	2 071	0 872			0 47	1 737	2 549	2 121	2 857	2 006	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 674	1 539	0 868			0 41	1 157	2 098	0 827	1 926	1 159	
COVID19 (COV D19 (JANSSEN))	Antibody test	2 291	0 929	0 862			0 595	0 762	1 929	1 927	2 027	1 946	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 193	1 743	0 861	0 612			1 847	1 953	2 36	2 87	1 509	
COVID19 (COV D19 (JANSSEN))	Areflexia	2 114	2 093	0 864				0 884	2 003	1 241	1 571	1 606	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1 595	1 284	0 861			0 297	1 015	2 12	1 101	1 241	1 101	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 136	2 499	0 869	0 609			1 587	2 032	1 075	2 03	0 937	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1 642	1 463	0 872			0 274	1 096	1 962	1 122	2 03	1 007	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 548	2 271	0 862				1 587	2 032	1 075	2 03	0 937	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2 258	1 845	0 911			0 541	1 715	2 028	1 409	3 184	1 127	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 358	1 941	0 882			0 552	1 049	1 233	0 958	2 704	0 872	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 004	1 624	0 864				1 037	0 988	1 553	2 244	0 993	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 298	2 5	0 879			0 537	2 442	2 866	3 932	0 752	1 212	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 726	2 103	0 933	0 612		0 574	2 261	2 522	2 066	3 56	1 733	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	1 888	1 443	0 875			0 343	1 618	2	1 329	1 935	1 536	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 228	1 815	0 897			0 514	1 551	2 14	2 255	2 546	1 664	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 573	1 877	0 896			0 484	2 228	2 193	3 26	3 19	1 982	
COVID19 (COV D19 (JANSSEN))	Esatinight count decreased	1 599	1 358	0 871			1 08	2 258	1 223	1 772	1 091	1 291	
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 815	0 801	0 863			1 177	2 021	1 532	1 033	1 92	1 431	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 379	1 388	0 874			0 415	2 305	2 104	1 845	2 705	1 566	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2 132	1 564	0 892	0 611		0 367	1 853	2 314	2 096	2 53	1 425	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 922	1 006	0 863			0 452	1 638	1 903	0 803	2 126	1 177	
COVID19 (COV D19 (JANSSEN))	Gasze palsy	2 293	0 938	0 864			2 42	1 657	2 732	0 889	2 732	1 254	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2 264	1 921	0 891			1 283	2 806	1 425	2 022	2 029	1 079	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	1 295	0 876	0 876			0 29	3 091	4 091	1 83	6 094	1 83	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 303	3 111	0 864			0 563	4 371	6 967	6 969	1 071	1 585	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2 005	1 976	0 865			0 024	1 804	2 32	1 481	2 116	1 385	
COVID19 (COV D19 (JANSSEN))	Intensive care	1 411	1 856	0 943			0 044	1 882	1 882	1 782	2 281	1 281	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 956	1 291	0 871			1 382	1 9	2 064	0 954	1 084	1 195	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 405	2 229	0 864			1 66	1 187	0 752	3 795	0 715	1 585	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 792	1 441	0 861			1 125	2 107	2 107	0 981	1 646	1 554	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1 989	1 883	0 867			0 967	2 23	1 395	1 02	1 768	1 768	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 179	1 854	0 869			0 539	1 874	1 93	2 088	2 489	1 814	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	1 501	1 101	0 859			0 296	1 059	2 090	0 959	1 793	0 888	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 378	1 215	0 935	0 609		0 055	1 744	1 654	2 067	0 882	1 814	
COVID19 (COV D19 (JANSSEN))	Off label use	1 733	0 309	0 862			5 316	0 285	0 55	0 346	1 13	1 556	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 781	0 757	0 867				2 819	1 014	1 014	2 279	1 279	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 332	0 886	0 866			0 546	1 571	2 053	1 05	2 216	1 05	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	4 01	1 982	0 864				0 655	1 076	3 418	2 43	1 912	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 728	2 407	0 914	0 612		0 504	2 066	3 318	1 649	3 288	1 684	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 809	1 486	0 88			0 332	2 039	1 553	1 341	2 134	1 304	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 75	2 155	0 876			0 424	2 122	3 057	2 281	3 487	1 63	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 947	3 52	0 864				4 27	2 851	0 699	5 925	1 719	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 835		0 867			0 647	3 208	2 349	3 934	3 004	3 004	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1 73	1 421	0 868	0 744		0 3	1 37	2 082	1 258	2 167	1 201	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 207	1 716	0 824	0 612		0 639	1 644	2 113	2 563	2 533	1 773	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 055	1 714	0 868				1 613	1 406	1 931	1 635	1 635	
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 496	1 204	0 869			0 563	0 969	0 883	0 651	1 145	0 817	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	2 822	2 267	0 899			0 557	1 763	2 152	0 986	2 334	2 823	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6 887		0 867			0 627	3 446	6 6	14 814	7 815	5 53	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2 041	1 882	0 877			0 42	1 743	2 089	2 465	2 465	1 396	
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 38	1 211	0 867			0 553	1 374	1 965	1 442	2 029	1 735	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 658	2 276	0 871	0 612		0 61	2 108	2 435	3 938	2 922	2 122	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 368	2 01	0 864			2 001	1 192	0 651	2 697	0 858	0 858	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 234	1 275	0 869			0 588	1 771	2 046	2 129	2 52	1 389	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 79	2 026	0 895	0 612		0 566	2 298	2 215	3 474	3 246	2 137	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 374	1 776	0 868			0 48	2 473	1 623	1 489	2 477	1 569	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 786	1 427	0 86	0 608			1 196	2 048	1 951	1 77	1 67	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2 001	1 387	0 858			0 471	1 371	1 973	2 014	1 946	1 74	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 911	1 125	0 864				1 271	2 056	1 988	2 024	1 245	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1 401	2 246	0 913			0 6	0 88	2 221	4 517	1 906	2 055	
COVID19 (COV D19 (JANSSEN))	Venogram	2 54	2 068	0 864				1 802	1 908	0 542	2 733	1 103	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 395	2 593	0 864			0 619	2 793	1 819	0 705	4 389	1 038	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4 307	2 476	0 864				3 589	2 747	0 759	5 354	1 04	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1 28	0 775	0 864		3 748	0 724	1 183	0 517	1 275	0 837	0 837	
COVID19 (COV D19 (MODERNA))	No adverse event	1 266	0 834	0 87			0 288	2 002	0 936	0 783	1 128	1 231	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2 342	0 911	0 867			0 82	2 459	0 169	0 626	2 356	2 391	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1 955	0 979	0 867				0 593	0 891	1 25	2 268	1 497	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2 09	1 031	0 862			0 642	1 442	1 659	2 008	2 069	1 569	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2 35	1 751	0 828			0 966	1 796	1 885	2 169	2 138	2 056	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0 59	0 785	0 864	4 067		0 59	0 379	0 864	0 387	1 004	1 004	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 196	1 726	0 887			0 96	1 719	1 901	2 406	2 149	1 979	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0 299	0 317	0 857		2 175	0 3	0 208	0 118	0 361	0 275	0 322	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1 886	0 651	0 864				1 398	1 898	1 931	2 39	1 806	
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2 082	1 302	0 874			0 784	1 527	1 693	2 31	2 073	1 766	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 21, 2021 6:42:16 AM
Attachments: [USST_20210917.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 ≥ 2) for all EUA SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/17/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

Drug	Event	US EB05 20210917	US Serious EB05 20210917	US Fatal EB05 20210917	US Infant EB05 20210917	US Child EB05 20210917	US Teen EB05 20210917	US Adult1 EB05 20210917	US Adult2 EB05 20210917	US Adult3 EB05 20210917	US Female EB05 20210917	US Male EB05 20210917	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1 553	1 739	0 870			0 411	1 436	1 729	1 576	2 352	1 149	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1 952	1 659	0 857				1 496	1 912	1 598	2 159	1 409	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2 958	0 92	0 865				0 881	0 758	0 608	2 398	1 53	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2 337	0 876	0 876			0 51	2 014	1 892	1 692	3 741	1 432	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2 052	1 663	0 861				1 682	1 842	1 031	1 431	1 431	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 512	2 021	0 872				0 462	1 706	2 491	2 071	1 942	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 644	1 466	0 865				0 404	1 12	2 126	0 797	1 915	1 127
COVID19 (COV D19 (JANSSEN))	Antibody test	2 223	0 854	0 86				0 59	0 795	1 796	1 885	1 842	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 186	1 713	1 722	0 613			1 814	1 964	2 368	2 869	1 504	
COVID19 (COV D19 (JANSSEN))	Areflexia	2 136	2 109	0 861				0 883	2 101	1 983	1 239	1 603	
COVID19 (COV D19 (JANSSEN))	Baclofen count decreased	1 545	1 279	0 867				0 286	0 284	1 075	1 074	1 056	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 339	2 62	0 871			0 526	1 376	2 016	0 757	4 523	0 921	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 505	2 218	0 86				1 568	2 401	1 139	2 072	2 018	
COVID19 (COV D19 (JANSSEN))	Cerebral haematoma	1 908	1 292	0 868				1 34	0 973	2 587	0 628	0 628	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2 268	1 941	0 91			0 54	1 806	2 002	1 409	3 248	1 126	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 223	1 852	0 881			0 551	1 048	1 203	0 96	2 673	0 854	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 029	1 572	0 862				1 035	1 039	1 545	2 259	0 991	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2 485	3 285	0 878				0 536	2 443	2 834	0 751	1 209	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 684	2 069	0 931	0 613			0 565	2 286	2 452	2 073	3 564	1 674
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 166	1 76	0 868				0 496	1 544	2 097	2 134	2 463	1 633
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2 56	1 857	0 894				0 482	2 213	2 196	3 18	3 182	1 972
COVID19 (COV D19 (JANSSEN))	Eosinophili count decreased	1 576	1 324	0 866				1 051	2 294	1 177	1 785	1 06	
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 803	0 786	0 861			1 166	2 009	1 525	1 023	1 91	1 42	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 353	1 364	0 872			0 394	2 281	2 113	1 851	2 654	1 562	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2 121	1 529	0 892	0 611		0 356	1 644	2 323	2 057	2 529	1 419	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 91	0 988	0 861			0 447	1 636	1 887	1 602	2 107	1 171	
COVID19 (COV D19 (JANSSEN))	Gaze palsy	2 262	0 931	0 862				2 418	1 638	0 888	2 69	1 239	1 078
COVID19 (COV D19 (JANSSEN))	Guillain-Barre syndrome	2 254	1 92	0 858				1 247	2 841	1 515	2 05	2 021	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5 432	3 537	0 874				3 378	4 391	6 735	6 749	2 211	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 285	0 862	0 862			0 561	6 102	3 959	6 069	6 069	1 069	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	1 994	1 967	0 862			0 022	1 871	2 341	1 117	1 503	1 578	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 958	1 311	0 869				1 405	1 694	0 952	2 092	1 182	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 393	2 217	0 862				1 659	1 185	0 752	3 768	0 714	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 824	1 455	0 859				1 134	1 028	1 649	1 616	1 616	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1 927	1 809	0 869				0 953	2 157	1 009	1 368	1 713	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 17	1 829	0 867			0 532	1 896	1 908	2 097	2 501	1 597	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1 496	1 094	0 856			0 28	1 067	2 065	1 792	0 598	0 861	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 366	1 201	0 875			0 61	0 049	0 508	1 797	1 821	2 063	0 873
COVID19 (COV D19 (JANSSEN))	Off label use	1 702	0 277	0 86				5 317	0 296	0 919	0 32	1 114	1 517
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 777	0 757	0 871				2 831	1 013	2 267			
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 44	0 879	0 879			0 545	1 568	2 111	1 136	2 39	1 334	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3 984	1 969	0 861				0 656	1 075	3 182	2 396	1 912	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 692	2 397	0 913	0 613			0 503	1 985	3 287	1 633	3 234	1 661
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 912	1 473	0 881	0 609			0 323	1 578	2 021	1 353	2 162	1 347
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 757	2 159	0 874				0 418	2 119	3 066	2 333	3 495	1 633
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 939	3 504	0 862				4 263	2 601	0 688	5 926	1 713	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	0 958						0 785	3 86	2 918	6 069	4 438	3 519
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1 723	1 416	0 868	0 744			0 283	1 351	2 148	1 235	2 154	1 207
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 184	1 689	0 929	0 613			0 619	1 647	2 093	2 496	2 504	1 76
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 029	1 66	0 868				1 585	1 383		2 1	1 885	1 628
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 493	1 197	0 863			0 561	0 968	0 863	0 85	2 134	0 616	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	2 889	2 288	0 918				0 551	1 939	2 217	0 653	2 379	2 873
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6 677						0 656	3 446	6 544	14 741	7 838	5 502
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2 041	1 864	0 874				0 416	1 711	2 108	1 367	2 47	1 403
COVID19 (COV D19 (JANSSEN))	Thrombophlebitis superficial	2 366	1 202	0 865				0 551	1 417	1 846	1 433	1 728	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2 66	2 254	1 738	0 613			0 609	2 075	2 409	3 545	2 903	2 115
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2 268	1 958	0 862				1 907	1 19	0 85	2 469	0 857	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2 255	1 278	0 867			0 67	1 776	2 587	1 278	2 587	1 626	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2 791	2 015	0 883	0 613			0 563	2 281	2 247	3 435	2 375	2 13
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2 38	1 781	0 859			0 475	2 443	1 677	1 52	2 414	1 653	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1 787	1 37	0 857	0 609			1 194	1 979	2 003	1 979	1 739	1 935
COVID19 (COV D19 (JANSSEN))	Ultrasound scan abnormal	2 027	1 338	0 855			0 469	1 383	1 925	1 905	1 946	1 732	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1 917	1 113	0 861				1 29	2 067	1 024	1 924	2 004	1 261
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1 455	1 008	0 862				0 599	1 054	2 265	4 699	1 841	2 121
COVID19 (COV D19 (JANSSEN))	Venogram	2 645	2 145	0 875				1 917	1 836	0 636	2 928	1 028	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3 382	2 577	0 862			0 618	2 795	1 811	0 705	4 38	1 036	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4 389	2 532	0 862				3 584	2 708	0 876	5 477	1 038	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1 259	0 775	0 862	4 564		0 733	1 17	0 517	1 265	1 865	0 878	
COVID19 (COV D19 (MODERNA))	No adverse event	1 263	0 834	0 868			0 309	2 016	0 92	0 938	0 785	1 233	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2 355	0 908	0 865			0 905	2 475	0 163	0 232	0 627	2 405	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1 957	0 978	0 865				0 568	0 889	1 25	1 922	1 497	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2 082	1 039	0 86				0 641	1 449	1 637	2 014	1 571	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2 343	1 746	0 929				0 966	1 767	1 865	2 13	2 045	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0 598	0 794	0 862	4 766				0 4	0 402	0 402	0 976	
COVID19 (COV D19 (PFIZER-BIONTECH))	Investigation	2 189	1 714	0 866			0 981	1 715	1 907	2 401	1 907	1 968	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0 302	0 369	0 856			2 611	0 303	0 224	0 116	0 278	0 324	
COVID19 (COV D19 (PFIZER-BIONTECH))	Product preparation issue	1 885	0 653	0 862				1 401	1 999	1 937	2 391	1 86	1 801
COVID19 (COV D19 (PFIZER-BIONTECH))	Weight	2 063	1 299	0 872				1 511	1 694	2 292	2 051	1 763	

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, September 28, 2021 5:57:17 AM
Attachments: [USST_20210924.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 9/24/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20210924	US Serious EB05 20210924	US Fatal EB05 20210924	US Infant EB05 20210924	US Child EB05 20210924	US Teen EB05 20210924	US Adult1 EB05 20210924	US Adult2 EB05 20210924	US Adult3 EB05 20210924	US Female EB05 20210924	US Male EB05 20210924	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,257	1,724	0	0.96			0.414	1,326	1,775	1,543	2,366	1,171
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	1,987	1,677	1,883					1,479	2,029	1,562	2,177	1,451
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,717	1,212	0,915				0.489	1,175	1,519	1,499	2,017	1,223
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3,036	0,811	0	0.87				0,768	0,848	0,762	2,460	1,511
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,726	1,188	0,881					1,245	1,245	1,222	2	0,874
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,96	2,267	0	0.88			0.511	2,02	1,92	3,635	4,226	1,399
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,071	1,662	0,886					1,739	1,657	1,02	1,971	1,419
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,502	0,879	0,879				0.463	1,668	2,471	2,128	2,809	1,904
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,711	1,482	0	0.87				1,147	2,277	0,783	1,955	1,149
COVID19 (COVID19 (JANSSEN))	Antibody test	2,217	0,843	0,866				0.591	0,834	1,732	1,801	1,976	1,887
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	1,691	1,691	1,547		0.612		0.46	1,834	1,981	2,345	2,873	1,923
COVID19 (COVID19 (JANSSEN))	Areflexia	2,164	2,128	0,867					0,883	2,098	1,337	1,679	1,593
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,617	1,267	0,872		0.61		0.354	1,038	2,427	1,049	1,792	1,148
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,487	1,358	0,876		0.61		0.293	1,157	2,08	1,004	1,725	1,06
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,204	2,585	0,876				0.527	1,323	2,013	0,756	4,558	0,905
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,597	2,255	0,866					1,568	2,538	1,214	2,235	2,07
COVID19 (COVID19 (JANSSEN))	Cerebral haematoma	1,912	1,29	0,873					1,342	0,972	2,623	0,526	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,231	1,892	0,909			0.54		1,783	1,957	1,39	3,188	1,107
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,395	1,944	0,884				0.551	1,047	1,203	1,043	3,338	0,853
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,003	1,486	0,867					1,023	1,032	1,51	2,254	0,984
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,178	2,413	0,882					2,374	2,641	0,747	3,807	1,195
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2,698	2,057	0,937		0.611		0.567	2,26	2,423	2,196	3,476	1,744
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	2,145	1,722	0.9				0.496	1,512	2,095	2,105	2,46	1,909
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,53	1,835	0,895				0.484	2,179	2,165	3,135	3,133	1,95
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,596	1,305	0,871					1.1	2,291	1,158	1,795	1,06
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,795	0,788	0,867			1.169		2,004	1,518	1,005	1,806	1,411
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,325	1,357	0,876				0.397	2,239	2,092	1,849	2,59	1,575
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,121	1,51	0,894		0.612		0.357	1,619	2,345	2,064	2,512	1,444
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,888	0,991	0,867				0.447	1,638	1,85	0,788	2,107	1,114
COVID19 (COVID19 (JANSSEN))	Flare rash	6,294	0,92	0,868				0.438	2,427	1,609	0,886	1,626	1,269
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,272	1,932	0,864				0.275	2,275	2,88	2,073	2,053	1,143
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,407	3,516	0,879				0.561	3,391	4,39	6,46	6,695	2,214
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,294	3,121	0,868				0.561	3,391	4,39	6,46	6,695	2,214
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,047	1,995	0,868				0.021	1,905	2,432	2,155	1,538	1,637
COVID19 (COVID19 (JANSSEN))	International normalized ratio normal	1,57	1,333	0,874					1,388	1,937	0,95	2,07	1,217
COVID19 (COVID19 (JANSSEN))	Intergular vein thrombosis	2,221	1,868	0,868					1,547	1,17	0,751	1,714	1,06
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,817	1,448	0,865					1,117	2,131	1,649	1,608	1,608
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,945	1,781	0,867					0,936	2,249	1,006	1,399	1,722
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,432	1,162	0,869			0.191		0,918	2,002	1,361	1,744	1,038
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,169	1,808	0,872				0.524	1,886	1,892	2,171	2,51	1,593
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,54	1,099	0,862				0.372	1,113	2,1	0,587	1,634	0,883
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,368	1,196	0.86		0.61		0.143	0,889	1,838	2,002	1,573	2,038
COVID19 (COVID19 (JANSSEN))	Off label use	1,681	0,25	0,866					5,494	0,375	0,599	0,343	1,535
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,785	0,757	0,867					2,883	1,014	2,283	2,283	1,443
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,554	0,877	0,867				0.54	1,838	2,15	1,118	2,498	1,443
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,884	1,924	0,867					0,656	1,075	2,316	2,234	1,011
COVID19 (COVID19 (JANSSEN))	Platelet count	2,721	2,483	0,914		0.612		0.504	2,023	3,18	1,686	3,24	1,687
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,909	1,449	0,863		0.61		0.323	1,558	2,035	1,343	2,133	1,361
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,774	2,167	0,878				0.42	2,134	3,072	2,394	3,495	1,678
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5,958	3,523	0,868					4,273	2,585	0,688	5,981	1,716
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1		0			0.789		3,855	3,069	6,042	4,481	3,603
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,743	1,428	0,873		0.745		0.284	1,981	2,179	1,229	2,157	2,335
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,174	1,675	0,936		0.612		0.617	1,619	2,087	2,512	2,482	1,764
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,004	1,603	0,873					1,573	1,372	2,002	1,878	1,598
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1,465	1,195	0,867				0.591	0,987	0,847	0,65	2,149	0,608
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	2,917	2,425	0.93				0.545	1,864	2,305	2,431	2,882	1,882
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	6,843	3,089	0,866				0.656	3,473	6,559	15,105	6,004	5,657
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,104	1,889	0,878				0.418	1,728	2,184	1,384	2,535	1,466
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia superficial	2,281	1,135	0.87				0.552	1,407	1,778	1,365	1,972	1,672
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,641	2,227	1,749		0.612		0.599	2,034	2,388	3,502	2,84	2,144
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,196	1,896	0,867					1,637	3,177	0,65	0,244	0,856
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,266	1,29	0,871				0.672	1,814	2,063	2,14	2,544	1,636
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,794	2,015	0,886		0.612		0.564	2,286	2,256	3,477	3,31	2,121
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,431	1,756	0,868				0.477	2,559	1,745	1,407	2,401	1,76
COVID19 (COVID19 (JANSSEN))	Ultrasound scan abnormal	2,007	1,385	0,861				0.471	1,388	1,921	1,9	1,898	1,705
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,928	1,157	0.87					1,319	2,1	1,783	2,041	1,262
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,471	2,416	1.72				0.586	0,995	2,262	4.7	1,896	2,124
COVID19 (COVID19 (JANSSEN))	Venogram	2,693	2,108	0,867					1,924	1,909	0,633	3,01	1,027
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,246	2,504	0,875				0.619	2,703	1,729	0,704	4,17	1,035
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,45	2,611	0,868					3,643	3,08	5,472	3,108	1,108
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1,265	0,767	0,868			4.152		1,178	0,517	1,278	0,882	
COVID19 (COVID19 (MODERNA))	No adverse event	1,249	0,848	0,875			0.298		2,007	0,914	0,929	0,779	1,126
COVID19 (COVID19 (MODERNA))	Product administered to patient of inappropriate age	2,375	0,908	0.87			0.979		2,505	0,161	0,216	2,395	2,425
COVID19 (COVID19 (MODERNA))	Product dose omission issue	1,885	1,922	0,866					2,002	1,915	1,845	1,784	1,983
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1.94	0,985	0,871				0.603	0,884	1,261	2,264	1,912	1,484
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2,072	1,038	0,866				0.64	1,459	1,664	2,001	2,04	1,507
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,316	1,737	0,932				1.006	1,771	1,856	2,117	2,101	1,025
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0.634	0,817	0.87		6.504			0.87	0,398	0,399	1,08	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,177	1,707	0.89					1,721	1,812	2,393	2,142	1,957
COVID19 (COVID19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0,366	0,366	0,862			3.373		0,306	0,249	0,35	0,329	0,329
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,863	0,659	0,869				1.39	1,893	1,924	2,368	1,845	1,786
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,065	1,287	0,877				0.823	1,518	1,692	2,299	2,052	1,772

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 5, 2021 6:02:15 AM
Attachments: [USST_20211001.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/1/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211001	US Serious EB05 20211001	US Fatal EB05 20211001	US Infant EB05 20211001	US Child EB05 20211001	US Teen EB05 20211001	US Adult1 EB05 20211001	US Adult2 EB05 20211001	US Adult3 EB05 20211001	US Female EB05 20211001	US Male EB05 20211001	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.534	1.560				0.407	1.534	1.534	1.729	1.534	1.144	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2.04	1.717	0.878				1.515	2.043	1.71	1.71	1.459	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1.81	1.261	0.923			0.489	1.221	1.553	1.642	2.057	1.344	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	0.963	0.963	0.864				0.864	2.48	0.752	2.48	1.584	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.744	1.195	0.89				1.373	1.318	1.199	2.027	0.992	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3.014	2.278	0.889			0.511	1.937	1.948	3.949	4.31	1.414	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2.084	1.651	0.879				1.797	1.814	1.822	2.039	1.382	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2.511	1.987	0.865				1.691	2.497	2.152	2.381	1.932	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary normal	1.69	1.439	0.882				1.137	2.251	1.938	1.189	1.189	
COVID19 (COV D19 (JANSSEN))	Antibody test	2.171	0.819	0.878			0.612	0.591	0.829	1.778	1.947	1.797	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2.203	1.469	0.446				1.839	2.376	1.894	2.868	1.544	
COVID19 (COV D19 (JANSSEN))	Areflexia	2.142	2.09	0.879				0.883	2.046	1.339	1.668	1.58	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1.623	1.298	0.882	0.609			0.346	1.022	2.422	1.118	1.821	1.132
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1.505	1.368	0.865			0.609	0.309	1.141	2.053	1.114	1.767	1.056
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1.66	1.303	0.879				1.262	2.001	1.381	1.851	1.311	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3.059	2.535	0.886				0.523	1.296	1.999	0.756	0.906	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1.542	1.39	0.865				0.26	1.094	1.894	2.086	0.977	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2.581	2.226	0.878				1.542	2.54	2.208	2.221	2.058	
COVID19 (COV D19 (JANSSEN))	Cerebral haematoma	1.776	1.223	0.884				1.341	0.941	2.655	2.655	0.618	
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2.26	1.888	0.911			0.54	1.784	1.528	3.346	1.09	1.09	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2.411	1.932	0.893			0.551	1.047	1.203	1.042	3.369	0.654	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2.049	1.549	0.879				1.005	1.09	1.499	2.341	1.016	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3.217	2.421	0.891				2.495	2.587	0.748	3.837	1.196	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2.76	2.075	0.932	0.611			0.649	2.281	2.446	3.569	1.781	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2.174	1.729	0.906				0.492	1.51	2.172	2.091	2.486	1.648
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2.542	1.84	0.904				0.481	2.167	2.195	3.107	1.807	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1.577	1.275	0.862				1.073	1.803	2.245	1.218	1.795	1.053
COVID19 (COV D19 (JANSSEN))	Feeling cold	1.804	0.79	0.879				1.161	1.536	1.008	1.915	1.421	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2.32	1.327	0.886				0.392	2.206	2.089	1.965	1.601	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2.106	1.471	0.899	0.611			0.347	1.635	2.397	1.527	1.403	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1.871	0.985	0.879				0.442	1.613	0.785	2.104	1.12	
COVID19 (COV D19 (JANSSEN))	Galze palsy	2.253	0.93	0.88			0.439	2.324	1.853	0.882	2.671	1.244	
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2.942	2.939	1.942				0.877	1.842	1.657	2.112	2.12	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.36	3.473	0.889				3.398	4.402	6	6.89	1.982	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.307	3.114	0.88			0.561	4.365	3.443	0.669	6.976	1.069	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2.028	1.969	0.919				1.851	2.611	1.696	1.697	1.647	
COVID19 (COV D19 (JANSSEN))	Intensive care	1.68	1.396	0.959			0.003	1.317	1.859	1.828	2.044	1.298	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1.74	1.284	0.874	0.745		0.421	1.58	1.777	1.249	2.063	1.222	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1.94	1.476	0.865				1.276	1.934	1.934	1.934	1.192	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2.161	2.058	1.5				1.17	0.746	2.727	0.714	1.61	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1.83	1.446	0.877				1.194	2.09	1.081	1.674	1.161	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1.963	1.784	0.878				0.926	2.23	1.091	1.445	1.711	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.192	1.808	0.882	0.522			1.877	1.897	2.299	2.549	1.6	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1.553	1.108	0.875				0.364	1.098	2.143	0.629	1.854	0.892
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1.4	1.221	0.889				0.22	0.877	1.872	1.877	2.125	0.881
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1.376	1.133	0.878	0.609			0.112	1.128	1.541	1.028	2.065	0.663
COVID19 (COV D19 (JANSSEN))	Off label use	1.608	0.237	0.878				0.383	0.873	0.376	1.022	1.434	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1.789	0.757	0.878				2.892	1.014	2.295	2.295	1.434	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2.515	0.875	0.54				1.839	2.139	1.095	2.539	1.395	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3.723	1.906	0.879				0.656	1.075	2.447	2.25	0.996	
COVID19 (COV D19 (JANSSEN))	Platelet count	2.729	2.468	0.929	0.612			0.504	1.97	3.141	1.693	1.714	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1.802	1.432	0.862	0.609			0.31	1.558	2.041	1.339	2.133	1.352
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2.772	2.16	0.89				0.416	2.112	2.553	3.484	1.692	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6	3.558	0.88				4.279	3.638	0.689	5.969	2.084	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1.008	1.008	0.866			0.856	3.865	3.865	5.986	4.386	3.636	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1.761	1.432	0.884	0.744			0.273	1.368	1.271	2.211	1.235	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2.264	1.683	0.945	0.612		0.804	1.642	2.129	2.54	2.504	1.802	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2.01	1.59	0.884				1.561	1.402	1.807	1.89	1.595	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1.772	1.245	0.876	0.609			1.123	1.928	1.405	2.012	1.143	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2.213	1.089	0.882				0.574	1.377	1.735	1.354	1.894	1.66
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3.017	2.964	1.572				0.546	1.985	2.309	0.773	2.963	2.979
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6.876	0.613	0.656				3.471	6.58	15.272	8.03	5.677	
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2.169	1.938	0.891				0.412	1.756	2.233	1.413	2.625	1.5
COVID19 (COV D19 (JANSSEN))	Thrombosis	2.634	2.217	1.751	0.612			0.599	2.028	3.322	2.927	2.169	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2.153	1.847	0.88				1.768	1.778	0.652	2.171	0.857	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2.264	1.275	0.883				0.667	1.796	2.065	2.13	2.542	1.635
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2.827	2.056	0.894	0.612			0.551	2.353	2.299	3.511	3.31	2.185
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2.44	1.765	0.884			0.473	0.473	1.735	1.466	2.411	1.78	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1.927	1.137	0.882				1.345	2.081	1.731	2.033	1.274	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1.527	2.841	1.128			0.577	1.052	2.281	4.426	2.006	2.183	
COVID19 (COV D19 (JANSSEN))	Venogram	2.61	2.059	0.831				2.059	1.77	0.631	2.878	1.016	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3.21	2.469	0.879			0.619	2.71	1.692	0.705	4.101	1.036	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4.295	2.522	0.88				3.57	2.517	0.875	5.292	1.093	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1.268	0.766	0.88			3.624	1.179	0.517	1.821	0.686	1.022	
COVID19 (COV D19 (MODERNA))	Headache	0.954	0.955	0.879			2.343	0.303	0.941	1.011	0.952	1.022	
COVID19 (COV D19 (MODERNA))	No adverse event	1.246	0.84	0.884			0.292	0.915	0.926	0.781	1.124	1.216	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2.393	0.909	0.862			1.203	2.528	0.173	0.206	0.598	2.438	
COVID19 (COV D19 (MODERNA))	Product dose omission issue	1.915	1.939	0.879				2.084	1.941	1.87	1.808	2.02	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1.935	0.964	0.882				0.603	0.88	1.286	2.238	1.473	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2.053	1.052	0.878				0.64	1.47	1.967	1.967	1.566	
COVID19 (COV D19 (PFIZER-BIONTECH))	Drug ineffective	2.293	1.704	0.935				1.006	1.751	1.82	2.075	1.988	
COVID19 (COV D19 (PFIZER-BIONTECH))	Exposure via breast milk	0.66	0.846	0.882	7.751			0.					

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, October 12, 2021 6:30:24 AM
Attachments: [USST_20211008.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/8/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211009	US Serious EB05 20211008	US Fatal EB05 20211008	US Infant EB05 20211009	US Child EB05 20211008	US Teen EB05 20211008	US Adult1 EB05 20211008	US Adult2 EB05 20211008	US Adult3 EB05 20211008	US Female EB05 20211009	US Male EB05 20211008	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,011	0,651				0,406	1,568	2,013	1,568	1,571	1,571	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,017	1,661	0,88				1,516	2,046	1,649	1,649	1,442	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,802	1,241	0,92			0,488	1,272	1,81	1,571	2,08	1,345	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3,072	0,885					0,871	0,741	0,749	2,455	1,507	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,017	2,254	0,891			0,51	1,937	2,013	1,937	4,336	3,756	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,065	1,601	0,882				1,729	1,616	1,127	1,842	1,384	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,558	2	0,892			0,455	1,691	2,565	2,223	2,94	1,986	
COVID19 (COVID19 (JANSSEN))	Action gap decreased	1,703	1,428	0,897				1,115	1,638	0,796	1,638	1,217	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,207	0,811	0,882				0,825	1,653	1,884	1,985	1,831	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,22	1,884	0,883	0,612		0,446	1,86	2,009	2,009	2,871	1,576	
COVID19 (COVID19 (JANSSEN))	Areflexia	2,089	2,009	0,883				0,884	1,929	1,917	1,917	1,538	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,689	1,347	0,886	0,61			1,122	2,382	1,181	1,884	1,201	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,531	1,354	0,886	0,61			1,178	2,097	1,076	1,778	1,101	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,714	1,333	0,883			0,415	1,318	2,069	1,409	1,842	1,338	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,73	1,29	0,887				1,279	2,03	1,347	2,046	1,171	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,6	2,726	0,891			0,522	1,677	2,202	0,758	4,862	0,976	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,684	1,448	0,888			0,257	1,13	1,977	1,217	2,207	0,957	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,602	2,198	0,882				1,586	2,538	1,189	2,175	1,223	
COVID19 (COVID19 (JANSSEN))	Cerebral haematoma	1,784	1,22	0,867				1,339	0,841	0,941	2,699	0,618	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,274	1,881	0,914			0,539	1,853	1,524	1,469	3,322	1,121	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,504	1,966	0,901			0,549	1,046	1,299	1,024	3,429	0,916	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,052	1,528	0,883				1,006	1,094	1,478	2,351	1,014	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,356	2,5	0,896			0,535	2,26	2,521	3,992	0,743	1,244	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,739	2,04	0,938	0,611			2,291	2,454	2,555	2,555	1,761	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	1,91	1,403	0,888			0,419	1,605	2,002	1,453	2,063	1,453	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,113	1,656	0,905			0,489	1,485	2,122	1,99	2,432	1,602	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,587	1,862	0,917			0,479	2,183	2,209	3,249	3,135	2,013	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,608	1,285	0,885				1,152	2,208	1,776	1,204	1,129	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,783	0,787	0,862			1,163	2,004	1,521	1,018	1,807	1,411	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,907	1,529	0,89			0,391	2,188	2,118	2,963	1,596	1,596	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,096	1,452	0,905	0,611			1,619	2,374	2,532	1,934	1,395	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,916	0,993	0,882			0,439	1,676	1,883	0,785	2,174	1,146	
COVID19 (COVID19 (JANSSEN))	Goose colony	2,028	0,935	0,882				0,432	2,334	1,665	2,564	1,331	
COVID19 (COVID19 (JANSSEN))	Gaillan-Barre syndrome	2,334	1,902	0,881				1,339	2,847	2,126	1,691	2,101	
COVID19 (COVID19 (JANSSEN))	Haemolysis decreased	1,671	1,289	0,89	0,607		0,446	1,236	1,943	1,531	2,018	1,219	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2,113	3,421	0,891				1,415	4,374	3,471	1,84	1,84	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,627	3,345	0,883			0,56	4,748	5,142	6,669	6,669	1,069	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,046	1,957	0,883			0,019	1,816	2,492	1,548	2,123	1,684	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,702	1,388	0,883				1,307	1,894	1,826	1,926	1,334	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,709	1,234	0,878	0,746		0,419	1,565	1,768	2,059	1,211	1,196	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,947	1,283	0,867				1,353	1,977	0,92	2,089	1,207	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,112	2,083	0,883				1,495	1,153	1,745	2,704	1,704	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,827	1,45	0,881				1,209	2,093	1,067	1,631	1,638	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	1,956	1,746					0,916	2,21	1,417	1,417	1,734	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,166	1,177	0,885			0,52	1,825	1,899	2,543	2,543	1,567	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1,875	1,337	0,88	0,611			1,349	1,967	1,253	2,1	1,105	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,587	1,128	0,88				1,17	2,161	0,641	1,873	0,946	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,473	1,268	0,895	0,61			0,22	0,957	1,843	1,731	0,932	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,428	1,17	0,884				1,109	1,581	1,066	2,104	0,711	
COVID19 (COVID19 (JANSSEN))	Off label use	1,565	0,288	0,883				5,691	0,37	0,549	0,441	1,399	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,789	0,758	0,886				1,758	2,899	1,017	2,315	1,399	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,501	0,86	0,88			0,539	1,735	2,253	2,469	1,084	1,427	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,758	1,895	0,883				0,656	1,077	2,545	1,077	0,996	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,881	2,449	0,929	0,612		0,488	1,919	3,134	1,734	3,109	1,74	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,82	1,439	0,899	0,61			0,307	1,543	2,042	1,45	1,384	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,787	2,138	0,892			0,413	2,125	3,092	2,451	1,694	1,694	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,023	3,54	0,883				4,296	3,171	0,888	6,007	2,09	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,941					0,86	3,913	2,978	5,887	4,478	3,67	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,785	1,438	0,889	0,745			1,438	2,159	2,284	1,289	1,249	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,21	1,676	0,952	0,612		0,601	1,662	2,132	2,521	2,529	1,797	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	1,966	1,559	0,889				1,521	1,967	2,149	1,918	1,548	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,742	1,298	0,886	0,609		0,561	1,347	2,013	1,419	1,802	1,409	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	1,795	1,263	0,879	0,61		0,371	1,233	1,943	1,396	2,103	1,115	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,204	1,105	0,885				1,397	1,76	1,711	1,711	1,711	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,074	2,663	1,788				2,012	2,392	0,833	2,654	3,019	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	6,927	0,61				0,655	3,498	6,553	15,574	8,083	5,763	
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,2	1,862	0,899			0,408	1,822	2,197	1,511	2,614	1,56	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,638	2,205	1,825	0,612			2,028	2,377	3,557	2,832	2,152	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,287	1,934	0,883				1,768	1,288	0,652	2,4	0,857	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,295	1,292	0,888			0,656	1,842	2,084	2,197	2,582	1,653	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	2,782	2	0,895	0,612		0,551	2,287	2,275	3,335	3,242	2,137	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,448	0,89	0,88			0,473	2,686	1,769	1,472	2,411	1,759	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan	1,744	1,3	0,88	0,609			1,195	1,934	2,044	1,648	1,648	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,976	1,159	0,885				1,984	2,178	1,787	1,787	1,294	
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,406	2,696	2,173			0,577	1,061	2,343	1,982	2,161	2,16	
COVID19 (COVID19 (JANSSEN))	Venogram	2,765	2,105					2,207	1,751	0,723	3,167	1,015	
COVID19 (COVID19 (JANSSEN))	Venogram abnormal	3,266	2,473	0,883			0,619	2,119	1,963	1,894	1,529	2,045	
COVID19 (COVID19 (JANSSEN))	Venogram normal	4,291	2,479	0,883				3,58	2,438	0,863	5,28	1,092	
COVID19 (COVID19 (MODERNA))	Exposure via breast milk	1,274	0,767	0,886	5,651	0,797		1,187	0,515	1,283	0,835	0,835	
COVID19 (COVID19 (MODERNA))	Headache	0,967	0,656	0,88	4,09			0,944	0,966	1,014	1,014	1,026	
COVID19 (COVID19 (MODERNA))	No adverse event	1,227	0,842	0,888	0,294			0,9	0,906	0,766	0,766	1,211	
COVID19 (COVID19 (MODERNA))	Product administration to patient of inappropriate age	2,384	0,928	0,885			1,316	2,56	0,172	0,107	0,991	2,437	
COVID19 (COVID19 (MODERNA))	Product dose omission issue	1,847	1,953	0,882				2,119	1,963	1,894	1,529	1,529	
COVID19 (COVID19 (PFIZER-BIONTECH))	Body height	1,93	1,002	0,886				0,804	0,879	1,288	2,218	1,476	
COVID19 (COVID19 (PFIZER-BIONTECH))	Disease recurrence	2,056	1,051	0,882				0,641	1,509	1,671	1,961	1,587	
COVID19 (COVID19 (PFIZER-BIONTECH))	Drug ineffective	2,292	1,799	0,884				0,996	2,765	2,069	2,069	1,587	
COVID19 (COVID19 (PFIZER-BIONTECH))	Exposure via breast milk	0,695	0,847	0,885	9,271			0,384	0,384	0,406	1,108	0,406	
COVID19 (COVID19 (PFIZER-BIONTECH))	Investigation	2,158	1,701	0,9				1,012	1,725	1,918	2,127	1,936	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product administered to patient of inappropriate age	0,307	0,340	0,878		4,258		0,307	0,307	0,339	0,339	0,339	
COVID19 (COVID19 (PFIZER-BIONTECH))	Product preparation issue	1,84	0,753	0,883				1,381	1,881	1,833	2,312	1,773	
COVID19 (COVID19 (PFIZER-BIONTECH))	Weight	2,035	1,295	0,89				0,846	1,513	1,704	2,219	2,02	1,762

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 19, 2021 6:14:00 AM
Attachments: [USST_20211015.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/15/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211015	US Serious EB05 20211015	US Fatal EB05 20211015	US Infant EB05 20211015	US Child EB05 20211015	US Teen EB05 20211015	US Adult1 EB05 20211015	US Adult2 EB05 20211015	US Adult3 EB05 20211015	US Female EB05 20211015	US Male EB05 20211015	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.392	1.613	1.836	0.405	1.606	2.119	1.671	1.671	1.671	1.671	1.671	1.171
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	1.892	1.892	1.892	1.452	1.452	2.119	1.654	1.654	1.654	1.654	1.654	1.38
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1.337	1.253	0.923	0.486	1.227	1.694	1.605	1.605	1.605	1.605	1.605	1.362
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	1.630	0.807	0.871	0.86	0.782	2.444	1.785	1.785	1.785	1.785	1.785	1.585
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.756	1.202	0.889	1.324	1.324	1.344	1.279	1.344	1.344	1.344	1.344	1.034
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2.997	2.232	0.879	0.507	1.875	2.074	3.606	2.074	3.606	2.074	3.606	1.378
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2.088	1.585	0.868	0.868	1.737	1.682	1.104	1.682	1.104	1.682	1.104	1.353
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2.57	2.008	0.883	0.453	1.72	2.598	2.197	2.598	2.197	2.598	2.197	1.997
COVID19 (COV D19 (JANSSEN))	Arion gap decreased	1.784	1.529	0.873	0.379	1.193	2.404	0.771	2.404	0.771	2.404	0.771	1.248
COVID19 (COV D19 (JANSSEN))	Antibody test	2.249	0.812	0.867	0.584	0.82	1.658	2.002	1.658	2.002	1.658	2.002	1.83
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2.224	1.681	1.005	0.445	1.875	2.01	2.42	1.875	2.01	2.42	1.875	1.933
COVID19 (COV D19 (JANSSEN))	Arteriogram carotid abnormal	1.823	1.172	0.868	0.911	1.172	1.401	1.172	1.401	1.172	1.401	1.172	0.937
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1.731	1.375	0.87	0.342	1.144	2.408	1.211	1.144	2.408	1.211	1.144	1.968
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1.587	1.404	0.869	0.302	1.217	2.188	1.109	1.217	2.188	1.109	1.217	1.158
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1.759	1.366	0.869	0.413	1.324	2.154	1.444	1.324	2.154	1.444	1.324	1.37
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1.829	1.381	0.878	0.471	1.283	2.179	1.495	1.283	2.179	1.495	1.283	1.259
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3.376	2.847	0.879	0.519	1.524	2.484	0.743	1.524	2.484	0.743	1.524	1.019
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1.717	1.443	0.879	0.264	1.114	1.998	1.285	1.114	1.998	1.285	1.114	0.992
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1.672	1.549	0.865	0.194	1.296	2.068	1.211	1.296	2.068	1.211	1.296	0.876
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2.626	2.203	0.867	0.307	1.571	2.602	1.255	1.571	2.602	1.255	1.571	1.128
COVID19 (COV D19 (JANSSEN))	Cerebral haematomata	1.671	1.176	0.874	0.442	1.266	0.942	1.176	1.266	0.942	1.176	0.942	0.613
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2.248	1.849	0.908	0.531	1.794	1.927	1.45	1.794	1.927	1.45	1.794	1.107
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2.554	2.011	0.892	0.548	1.147	1.009	3.342	1.147	1.009	3.342	1.147	0.978
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2.021	1.444	0.868	0.532	1.005	1.366	2.273	1.005	1.366	2.273	1.005	1.015
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3.415	2.509	0.886	0.532	2.626	2.504	0.823	2.626	2.504	0.823	2.626	1.231
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2.719	2.002	0.944	0.649	2.242	2.479	1.526	2.242	2.479	1.526	2.242	1.784
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	1.932	1.426	0.878	0.415	1.639	1.989	1.513	1.639	1.989	1.513	1.639	1.472
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2.084	1.627	0.896	0.485	1.465	2.14	1.905	1.465	2.14	1.905	1.465	1.38
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax normal	2.553	1.841	0.905	0.477	2.193	2.102	3.194	2.193	2.102	3.194	2.102	1.98
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	1.649	1.469	0.861	0.621	1.841	2.264	1.849	1.841	2.264	1.849	1.841	1.533
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	2.281	1.309	0.877	0.385	2.159	2.082	1.949	2.159	2.082	1.949	2.082	1.585
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2.122	1.479	0.9	0.342	1.653	2.363	1.959	1.653	2.363	1.959	1.653	1.42
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1.915	1.803	0.836	0.436	1.868	1.908	1.179	1.868	1.908	1.179	1.868	1.42
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	2.301	0.978	0.874	0.342	2.346	1.757	0.933	2.346	1.757	0.933	2.346	1.355
COVID19 (COV D19 (JANSSEN))	Galium-Barre syndrome	2.277	1.872	0.865	0.442	1.322	2.837	1.659	1.322	2.837	1.659	1.322	2.051
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1.718	1.384	0.86	0.442	1.926	2.033	1.549	1.926	2.033	1.549	1.926	1.585
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.42	3.584	0.879	0.343	3.843	4.472	5.482	3.843	4.472	5.482	3.843	2.105
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.722	3.447	0.869	0.557	5.027	5.136	0.668	5.027	5.136	0.668	5.027	1.966
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2.047	1.865	0.869	0.418	1.847	2.492	1.52	1.847	2.492	1.52	1.847	1.947
COVID19 (COV D19 (JANSSEN))	Intensive care	1.728	1.402	0.949	0.027	1.356	1.809	2.13	1.356	1.809	2.13	1.356	1.318
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1.748	1.255	0.861	0.413	1.588	1.867	1.223	1.588	1.867	1.223	1.588	1.228
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1.931	1.283	0.873	0.387	1.963	2.059	1.913	1.963	2.059	1.913	1.963	1.22
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2.128	2.026	0.869	0.584	1.142	1.584	2.484	1.142	1.584	2.484	1.142	0.774
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1.823	1.419	0.866	0.205	2.072	1.053	1.662	2.072	1.053	1.662	1.053	1.618
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	1.971	1.164	0.866	0.806	1.086	2.266	1.469	1.086	2.266	1.469	1.086	1.172
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.155	1.745	0.871	0.516	1.806	2.255	2.521	1.806	2.255	2.521	1.806	1.558
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	1.9	1.35	0.861	0.47	1.333	2.108	1.214	1.333	2.108	1.214	1.333	1.15
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1.682	1.283	0.863	0.359	1.318	2.008	2.28	1.318	2.008	2.28	1.318	1.012
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1.515	1.296	0.823	0.223	0.95	2.048	1.731	0.95	2.048	1.731	0.95	0.972
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1.501	1.238	0.871	0.121	1.249	1.674	1.093	1.249	1.674	1.093	1.249	0.788
COVID19 (COV D19 (JANSSEN))	Off label use	1.577	0.267	0.867	5.817	0.37	0.962	0.345	0.37	0.962	0.345	0.37	1.4
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1.809	0.757	0.867	2.927	2.927	2.46	1.019	2.927	2.46	1.019	2.927	1.4
COVID19 (COV D19 (JANSSEN))	Pain assessment	2.502	0.856	0.536	2.213	1.738	2.213	1.084	2.213	1.084	2.213	1.084	1.43
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3.768	1.895	0.869	0.656	1.078	2.616	2.32	1.078	2.616	2.32	1.078	0.995
COVID19 (COV D19 (JANSSEN))	Platelet count	2.697	2.454	0.924	0.496	1.91	3.129	3.065	1.91	3.129	3.065	1.91	1.753
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1.841	1.436	0.891	0.303	1.572	2.06	1.44	1.572	2.06	1.44	1.572	1.406
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2.796	2.13	0.882	0.413	2.106	3.052	2.406	2.106	3.052	2.406	2.106	1.704
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6.039	3.56	0.859	4.305	2.975	2.975	0.668	4.305	2.975	0.668	4.305	2.07
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1.101	1.101	0.864	3.969	3.969	2.96	5.913	3.969	2.96	5.913	2.96	3.68
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1.829	1.48	0.877	0.274	1.473	2.261	1.272	1.473	2.261	1.272	1.473	1.291
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2.204	1.672	0.866	0.596	1.666	2.115	2.567	1.666	2.115	2.567	1.666	1.787
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2.005	1.55	0.877	0.516	1.549	1.391	1.519	1.549	1.391	1.519	1.391	1.58
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1.789	1.333	0.871	0.551	1.415	2.094	1.983	1.415	2.094	1.983	1.415	1.425
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1.877	1.325	0.869	0.368	1.301	2.068	1.432	1.301	2.068	1.432	1.301	1.169
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2.222	1.145	0.872	0.547	1.396	1.794	1.277	1.396	1.794	1.277	1.396	1.755
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3.143	2.642	1.836	0.541	2.018	2.364	0.89	2.018	2.364	0.89	2.018	3.068
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	7.566	0.603	0.653	3.897	3.897	6.602	15.3	3.897	6.602	15.3	3.897	5.807
COVID19 (COV D19 (JANSSEN))	Therapy partial responder	2.075	1.602	0.877	0.531	1.337	1.515	0.582	1.337	1.515	0.582	1.337	1.019
COVID19 (COV D19 (JANSSEN))	Thrombectomy	2.037	1.602	0.877	0.531	1.337	1.515	0.582	1.337	1.515	0.582	1.337	1.019
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2.217	1.957	0.889	0.407	1.797	2.218	1.539	1.797	2.218	1.539	1.797	1.595
COVID19 (COV D19 (JANSSEN))	Thrombosis	2.656	2.186	0.891	0.591	1.02	2.385	3.517	1.02	2.385	3.517	1.02	2.156
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2.26	1.923	0.869	0.591	1.935	1.237	0.647	1.935	1.237	0.647	1.935	0.913
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2.277	1.298	0.878	0.656	1.812	2.065	2.223	1.812	2.065	2.223	1.812	1.833
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2.746	2.002	0.884	0.612	2.273	2.278	3.265	2.273	2.278	3.265	2.273	2.129
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2.484	1.781	0.877	0.47	2.692	1.885	1.485	2.692	1.885	1.485	2.692	1.841
COVID19 (COV D19 (JANSSEN))	Ultrasound scan	1.744	1.283	0.865	0.16	1.861	2.005	1.702	1.861	2.005	1.702	1.861	1.538
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1.98	1.171	0.871	0.61	1.373	2.174	2.104	1.373	2.174	2.104	1.373	1.298
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1.125	2.705	0.575	1.083	2.312	4.585	1.773	1.083	2.312	4.585	1.773	1.957
COVID19 (COV D19 (JANSSEN))	Venogram	2.791	2.076	0.867	0.611	2.114	1.831	0.722	2.114	1.831	0.722	2.114	1.015

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 26, 2021 7:13:34 AM
Attachments: [USST_20211022.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/22/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211022	US Serious EB05 20211022	US Fatal EB05 20211022	US Infant EB05 20211022	US Child EB05 20211022	US Teen EB05 20211022	US Adult1 EB05 20211022	US Adult2 EB05 20211022	US Adult3 EB05 20211022	US Female EB05 20211022	US Male EB05 20211022	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	0.96		0.86			0.402	2.61	1.42	1.71	1.21	1.16	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2.086	1.699	0.873				1.576	2.15	1.71	1.64	1.38	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1.86	1.257	0.93			0.478	1.209	1.763	1.62	1.35	1.418	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	0.902	0.902	0.874				0.861	0.753	0.737	2.475	1.621	
COVID19 (COV D19 (JANSSEN))	Adverse event	2.043	1.015	0.877				1.019	0.683	0.723	1.451	1.455	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.821	1.247	0.895				1.373	1.362	1.369	1.051	1.098	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	2.957	2.191	0.885			0.503	1.859	2.102	3.367	4.215	1.383	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2.113	1.605	0.872				1.726	1.76	1.76	1.211	1.341	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2.546	1.969	0.886				1.446	1.686	2.272	2.816	2.035	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary normal	1.914	1.695	0.885				0.373	1.298	2.453	0.996	1.319	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	2.337	0.863	0.871				0.981	0.898	1.732	1.936	1.936	
COVID19 (COV D19 (JANSSEN))	Antibody test	2.226	1.672	0.956	0.612			0.443	1.863	2.004	2.47	1.589	
COVID19 (COV D19 (JANSSEN))	Arflexia	2.011	1.886	0.873				0.862	1.867	1.331	1.681	1.452	
COVID19 (COV D19 (JANSSEN))	Atrioagram carotid abnormal	1.81	1.155	0.872				0.899	1.175	1.369	2.136	0.939	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1.811	1.507	0.875	0.609			1.186	2.424	1.418	1.249	1.201	
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1.655	1.478	0.873	0.608			0.3	1.26	2.211	1.247	1.153	
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1.833	1.421	0.88				0.413	1.362	2.211	1.962	2.102	
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1.936	1.491	0.891				0.467	1.33	2.292	1.653	1.292	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3.237	2.584	0.882				0.515	1.67	2.113	0.737	1.429	1.003
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1.762	1.479	0.882				1.134	2.016	1.36	2.4	0.997	
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1.691	1.564	0.871				1.339	2.039	1.198	1.198	0.863	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2.647	2.206	0.871				0.527	1.617	2.612	1.173	2.345	2.13
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2.233	1.828	0.907				0.542	1.723	1.914	1.452	1.284	1.086
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2.513	1.969	0.894				0.542	1.148	1.302	0.977	3.279	0.974
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2.027	1.436	0.872				0.973	1.194	1.354	2.291	1.035	
COVID19 (COV D19 (JANSSEN))	Cerebral venous thrombosis	3.398	2.491	0.889				0.520	2.574	2.522	4.072	1.217	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2.717	1.984	0.934	0.611			0.647	2.259	2.48	2.206	1.772	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	1.969	1.451	0.885				0.413	1.648	2.019	1.589	1.486	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2.076	1.599	0.894				0.477	1.452	2.15	1.893	1.994	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2.782	2.173	0.863				0.473	1.656	2.246	3.176	2.009	
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1.765	1.462	0.87				0.282	1.298	2.286	1.373	1.169	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2.278	1.336	0.881				0.382	2.194	2.069	1.89	2.55	1.583
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	2.127	1.465	0.862	0.611			0.338	1.632	2.382	1.449	1.287	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1.964	1.007	0.872				0.433	1.968	1.968	2.206	1.709	
COVID19 (COV D19 (JANSSEN))	Galacty	2.321	1.009	0.88				0.423	2.341	1.79	0.989	2.591	1.413
COVID19 (COV D19 (JANSSEN))	Galactin-Baire syndrome	2.295	1.914	0.874				0.423	1.333	2.877	1.629	1.929	
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1.758	1.326	0.89	0.606			0.439	2.072	1.62	1.233	1.286	
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1.707	1.28	0.887	0.607			0.34	1.375	1.971	1.497	1.277	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.097	3.707	0.873				0.897	1.859	4.185	5.922	1.291	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.755	3.489	0.873				0.553	5.044	0.667	7.467	1.208	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2.054	1.943	0.872				0.02	1.856	2.475	1.554	1.658	
COVID19 (COV D19 (JANSSEN))	Intensive care	1.743	1.4	0.956				0.326	1.352	1.954	1.523	1.347	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1.793	1.286	0.872	0.746			0.409	1.596	1.27	2.182	1.82	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1.901	1.238	0.878				1.359	1.944	0.907	2.036	1.202	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2.124	1.681	0.873				0.671	1.589	1.937	1.744	0.781	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1.861	1.494	0.87				1.199	1.053	1.688	1.688	1.688	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2.047	1.825	0.878				0.902	2.361	1.175	1.515	1.786	
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1.635	1.201	0.877	0.184			1.01	1.516	2.016	1.91	2.016	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.171	1.745	0.879	0.515			0.515	1.927	1.315	2.515	1.598	
COVID19 (COV D19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1.966	1.403	0.873	0.611			0.468	1.344	2.226	1.251	1.207	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1.717	1.227	0.872				0.357	1.43	2.275	0.863	1.017	
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2.018	1.515	0.955				0.5	1.628	2.023	1.915	1.632	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1.531	1.302	0.881	0.61			0.225	0.987	1.734	2.337	0.972	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1.581	1.32	0.879				0.13	1.225	1.806	1.243	0.791	
COVID19 (COV D19 (JANSSEN))	Off label use	1.499	0.23	0.872				0.699	0.347	0.902	0.41	1.339	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1.764	0.758	0.878				0.279	1.008	1.008	2.203		
COVID19 (COV D19 (JANSSEN))	Pain assessment	2.541	0.855		0.532			1.827	2.172	1.171	2.541	1.459	
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3.441	1.769	0.873				0.656	1.957	1.957	2.551	0.979	
COVID19 (COV D19 (JANSSEN))	Platelet count	2.719	2.497	0.923	0.611			1.883	3.104	1.796	3.124	1.791	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1.842	1.419	0.894	0.609			0.299	1.549	2.033	1.469	1.413	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2.764	2.1	0.887				0.41	2.104	3.036	2.933	3.445	1.71
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6.067	3.544	0.874				4.321	3.034	0.686	6.069	2.084	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1.151		0.863				3.986	2.903	6.155	4.56	3.718	
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1.879	1.519	0.893	0.744			0.289	1.495	2.33	1.333	1.338	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2.209	1.672	1.006	0.612			0.591	1.654	2.139	2.557	1.796	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2.027	1.549	0.881				1.514	1.451	2.077	1.902	1.807	
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1.847	1.377	0.877	0.607			0.546	1.435	1.625	1.543	1.468	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	1.971	1.403	0.88	0.609			0.363	1.308	1.286	1.546	1.211	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2.247	1.182	0.876				0.543	1.4	1.776	1.406	1.744	
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1.56	1.237	0.872				0.553	1.033	0.825	1.148	0.668	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3.219	2.742	1.941				0.537	2.045	2.341	1.163	2.685	3.191
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	6.996	0.737		0.651			3.574	6.684	15.215	7.897	5.883	
COVID19 (COV D19 (JANSSEN))	Therapy partial responder	2.158			0.654				0.634	0.589	0.589	1.021	
COVID19 (COV D19 (JANSSEN))	Thrombectomy	2.097	1.676	0.885				0.527	1.413	1.582	1.405	2.083	1.405
COVID19 (COV D19 (JANSSEN))	Thrombocytopenia	2.295	2.009	0.9				1.782	2.316	1.642	2.743	1.621	
COVID19 (COV D19 (JANSSEN))	Thrombosis	2.655	2.179	0.814	0.612			0.582	2.002	2.39	3.528	2.147	
COVID19 (COV D19 (JANSSEN))	Transverse sinus thrombosis	2.274	1.957	0.873				1.949	1.239	0.646	2.322	0.913	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler	2.332	1.365	0.884	0.65			1.851	2.14	2.219	2.654	1.66	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler abnormal	2.74	1.985	0.887	0.612			0.547	2.306	2.283	3.137	2.141	
COVID19 (COV D19 (JANSSEN))	Ultrasound Doppler normal	2.551	1.814	0.886				0.463	2.656	1.973	1.642	1.844	
COVID19 (COV D19 (JANSSEN))	Ultrasound scan normal	1.948	1.156	0.875				1.361	2.118	1.747	2.059	1.289	
COVID19 (COV D19 (JANSSEN))	Vaccination failure	1.182	2.797	2.377				0.563	1.15	2.337	4.791	1.834	2.013
COVID19 (COV D19 (JANSSEN))	Vasodilation	2.003	0.881	0.868				0.968	1.506	0.972	1.773	1.912	
COVID19 (COV D19 (JANSSEN))	Venogram	2.674	2.031	1.176				0.608	1.749	3.085	0.993	1.859	
COVID19 (COV D19 (JANSSEN))	Venogram abnormal	3.354	2.532					2.931	1.87	0.703	4.161	1.189	
COVID19 (COV D19 (JANSSEN))	Venogram normal	4.164	2.444	0.873				1.685	2.181	1.952	0.951	1.452	
COVID19 (COV D19 (MODERNA))	Exposure via breast milk	1.334	0.831	1.197	7.31	0.871		0.513	0.513	1.014	0.955	1.025	
COVID19 (COV D19 (MODERNA))	Headache	0.969	0.963	0.876				0.305	0.945	0.985	1.014	0.955	
COVID19 (COV D19 (MODERNA))	No adverse event	1.197	1.844	0.817	5.803			0.602	0.917	0.762	1.197	1.295	
COVID19 (COV D19 (MODERNA))	Product administered to patient of inappropriate age	2.373	0.944	0.12				0.778	0.26	0.051	0.534	2.378	2.422
COVID19 (COV D19 (MODERNA))	Product dose omission issue	2.02	1.986	0.872				2.16	1.988	1.933	1.57	2.102	
COVID19 (COV D19 (PFIZER-BIONTECH))	Body height	1.931		0.602				0.602	0.602	1.675	1.32	1.469	
COVID19 (COV D19 (PFIZER-BIONTECH))	Disease recurrence	2.058											

From: [Menschik, David](#)
To: [Nair, Narayan](#)
Subject: RE: Weekly data mining
Date: Tuesday, October 26, 2021 8:03:10 AM

Appreciate it – managing ok – nothing needed now – thanks again
David

From: Nair, Narayan <Narayan.Nair@fda.hhs.gov>
Sent: Tuesday, October 26, 2021 7:50 AM
To: Menschik, David <David.Menschik@fda.hhs.gov>
Subject: RE: Weekly data mining

Thanks David,
Just checking in. Is everything OK? Is there anything you need?
Narayan

From: Menschik, David <David.Menschik@fda.hhs.gov>
Sent: Tuesday, October 26, 2021 7:14 AM
To: Su, John (CDC) <ezu2@cdc.gov>; Shimabukuro, Tom (CDC) <ayv6@cdc.gov>
Cc: Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>; Broder, Karen R (CDC) <krb2@cdc.gov>; Harrington, Theresa (CDC) <tsh3@cdc.gov>
Subject: RE: Weekly data mining

Good morning John and Tom,
Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/22/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, November 2, 2021 12:09:29 PM
Attachments: [USST_20211029.xls](#)

Hi John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 10/29/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211029	US Serious EB05 20211029	US Fatal EB05 20211029	US Infant EB05 20211029	US Child EB05 20211029	US Teen EB05 20211029	US Adult1 EB05 20211029	US Adult2 EB05 20211029	US Adult3 EB05 20211029	US Female EB05 20211029	US Male EB05 20211029	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	2 153	1 861	0	0	0	0 596	1 611	1 911	1 761	1 291	1 453	
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2 203	1 784	0	0	0	0	1 639	2 225	1 925	1 805	1 453	
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1 951	1 312	0 94	0	0	0 467	1 25	1 793	1 763	2 201	1 536	
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	3 059	2 083	0 841	0	0	0	0 841	2 379	2 383	0 731	1 564	
COVID19 (COV D19 (JANSSEN))	Adverse event	2 054	1 084	0	0	0	0	0 997	1 664	0 72	1 599	1 436	
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1 933	1 327	0 901	0	0	0	1 536	1 533	3 377	1 533	1 092	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3 034	2 206	0 894	0	0	0 499	2 273	2 061	4 396	3 279	1 354	
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	2 188	1 691	0 881	0	0	0	1 731	1 803	1 242	1 903	1 366	
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2 544	1 949	0 831	0	0	0	1 713	2 5	2 36	2 781	2 056	
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1 911	1 663	0 895	0	0	0	1 313	2 417	1 022	2 318	1 301	
COVID19 (COV D19 (JANSSEN))	Antion gap increased	1 911	1 348	0 88	0	0	0	0 898	1 74	1 904	1 614	1 094	
COVID19 (COV D19 (JANSSEN))	Anticoagulant therapy	2 243	1 669	0 862	0 612	0	0 434	1 863	1 996	2 599	2 886	1 613	
COVID19 (COV D19 (JANSSEN))	Arflexia	2 083	1 919	0 882	0	0	0	0 864	1 913	1 423	1 772	1 527	
COVID19 (COV D19 (JANSSEN))	Arteriogram carotid abnormal	1 919	1 224	0 881	0	0	0	1 18	1 179	1 356	2 493	1 635	
COVID19 (COV D19 (JANSSEN))	Basophil count decreased	1 886	1 591	0 882	0 609	0	0 336	1 239	2 441	1 579	2 299	1 229	
COVID19 (COV D19 (JANSSEN))	Basophil percentage decreased	1 719	1 542	0 88	0 608	0	0 296	1 292	2 276	1 363	2 09	1 189	
COVID19 (COV D19 (JANSSEN))	Blood albumin decreased	1 765	1 253	0 885	0	0	0 339	1 504	1 812	1 521	2 075	1 25	
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1 919	1 486	0 893	0	0	0 407	1 43	2 254	1 728	2 244	1 466	
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	1 993	1 539	0 901	0	0	0 459	1 439	2 252	1 768	2 38	1 351	
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	3 517	2 66	0 89	0	0	0 511	1 852	2 44	0 738	4 604	1 073	
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1 889	1 633	0 894	0	0	0 266	1 166	2 144	1 545	2 602	1 094	
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1 745	1 607	0 88	0	0	0 214	1 401	2 056	1 241	2 059	0 92	
COVID19 (COV D19 (JANSSEN))	COVID-19 pneumonia	1 915	1 326	1 003	0	0	0	1 336	1 762	1 81	2 002	1 676	
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2 655	2 194	0 88	0	0	0	1 687	2 6	1 159	2 37	2 15	
COVID19 (COV D19 (JANSSEN))	Cerebral hemorrhage	2 306	1 863	0 913	0 611	0	0 523	2 049	1 915	1 443	3 456	1 098	
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2 55	1 961	0 899	0	0	0 538	1 291	1 268	1 098	0 995	0 971	
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2 113	1 537	0 881	0	0	0	1 123	1 189	1 356	2 497	1 04	
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	3 489	2 496	0 903	0	0	0 525	2 672	2 562	0 825	4 162	1 229	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head abnormal	2 749	1 987	0 932	0 611	0	0 636	2 375	2 48	2 271	3 618	1 773	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram head normal	2 03	1 493	0 897	0	0	0 409	1 709	2 036	1 752	2 036	1 502	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax abnormal	2 144	1 636	0 907	0	0	0 467	1 494	2 172	2 063	2 473	1 64	
COVID19 (COV D19 (JANSSEN))	Computerised tomogram thorax normal	2 605	1 872	0 923	0	0	0 466	2 176	2 273	3 254	3 227	2 027	
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	1 919	1 491	0 877	0	0	0	1 296	1 45	1 121	1 45	1 121	
COVID19 (COV D19 (JANSSEN))	Feeling cold	1 785	0 784	0 88	0	0	0	2 001	1 504	1 084	1 894	1 404	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2 295	1 293	0 888	0	0	0 377	2 208	2 089	1 924	2 543	1 633	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1 915	2 16	0 812	0 611	0	0 333	1 692	2 141	2 483	2 148	1 983	
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1 953	0 994	0 881	0	0	0 427	1 707	1 971	1 824	2 224	1 448	
COVID19 (COV D19 (JANSSEN))	Flaccid palsy	2 356	1 038	0 889	0	0	0 419	2 288	1 79	1 136	2 621	1 448	
COVID19 (COV D19 (JANSSEN))	Glucose urine present	1 993	1 287	0 887	0	0	0	1 192	1 21	1 291	1 135	1 093	
COVID19 (COV D19 (JANSSEN))	Guillain-Barre syndrome	2 297	1 894	0 88	0	0	0	1 399	2 84	1 742	2 162	1 339	
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1 831	1 372	0 899	0 606	0	0 433	1 372	2 118	1 689	2 226	1 339	
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1 767	1 098	0 896	0 607	0	0 339	1 447	2 023	1 59	1 847	1 367	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5 66	3 695	0 89	0	0	0	4 027	4 858	6 152	7 14	2 473	
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 814	3 509	0 882	0	0	0 549	5 092	5 536	6 666	7 529	3 388	
COVID19 (COV D19 (JANSSEN))	Hypoxia	1 79	0 863	0 883	0	0	0	1 254	1 788	1 61	1 236	1 512	
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2 073	1 941	0 881	0	0	0 019	1 874	2 479	1 654	2 217	1 667	
COVID19 (COV D19 (JANSSEN))	Intensive care	1 787	1 422	0 884	0	0	0 029	1 404	1 978	1 906	2 186	1 382	
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1 831	1 312	0 862	0 746	0	0 401	1 382	1 626	1 382	1 626	1 382	
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1 905	1 225	0 886	0	0	0	1 367	1 945	2 038	1 904	1 205	
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2 149	2 006	0 882	0	0	0	1 599	1 139	0 744	2 78	0 785	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1 8	1 037	0 88	0	0	0	1 251	1 681	1 696	1 173	1 173	
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2 039	1 797	0 9	0	0	0	2 342	1 497	1 173	1 497	1 785	
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1 598	1 243	0 889	0	0	0 184	1 037	2 042	1 66	2 002	1 137	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 186	1 736	0 887	0 611	0	0 506	1 811	1 937	2 319	2 539	1 605	
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head normal	2 952	1 483	0 892	0	0	0 465	1 699	1 407	1 427	1 427	1 427	
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1 78	1 078	0 885	0	0	0 351	1 275	2 226	1 031	2 127	1 064	
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2 055	1 533	0 937	0 61	0	0 496	1 986	2 061	1 654	1 968	1 645	
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1 919	1 586	0 889	0	0	0	1 324	0 864	2 111	1 693	1 022	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1 616	1 348	0 886	0	0	0 15	1 222	1 839	1 342	1 818	1 018	
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage increased	1 645	1 267	0 886	0	0	0 24	1 138	2 011	1 594	1 999	1 256	
COVID19 (COV D19 (JANSSEN))	Off label use	1 449	0 216	0 881	0	0	0	5 946	0 324	0 471	0 911	1 253	
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1 746	0 757	0 88	0	0	0	3 03	0 998	0 98	2 15	1 473	
COVID19 (COV D19 (JANSSEN))	Pain assessment	2 582	0 876	0 882	0 611	0	0 524	1 782	2 289	1 165	2 634	1 473	
COVID19 (COV D19 (JANSSEN))	Peripneumonia	3 51	1 765	0 886	0	0	0	1 058	1 058	2 671	2 482	0 974	
COVID19 (COV D19 (JANSSEN))	Platelet count	2 735	2 489	0 927	0 611	0	0 485	1 886	3 113	1 789	3 13	1 816	
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1 848	1 405	0 897	0 609	0	0 295	1 563	2 027	1 463	2 161	1 415	
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2 762	2 085	0 894	0	0	0 404	2 095	3 1	2 302	3 484	1 7	
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	5 998	3 519	0 882	0	0	0	4 363	3 241	0 685	6 13	1 931	
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1 205	1 577	0 902	0 744	0	0 865	4 019	3 183	0 153	4 622	3 771	
COVID19 (COV D19 (JANSSEN))	Proliferation time prolonged	1 945	1 496	0 889	0	0	0 265	1 521	2 337	1 598	2 523	1 375	
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2 246	1 679	1 041	0 612	0	0 584	1 667	2 164	2 68	2 577	1 63	
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2 084	1 552	0 888	0	0	0	1 53	1 473	2 101	1 91	1 664	
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	2 189	1 402	0 889	0 607	0	0 537	1 515	2 147	1 571	2 102	1 664	
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	2 021	1 434	0 89	0 609	0	0 358	1 35	2 183	1 646	2 41	1 249	
COVID19 (COV D19 (JANSSEN))	Subarachnoid hemorrhage	1 73	1 171	0 935	0	0	0 549	1 615	1 074	0 899	2 082	1 089	
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2 227	1 169	0 884	0	0	0 539	1 374	1 776	1 416	1 676	1 735	
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1 66	1 351	0 883	0	0	0 549	1 132	0 826	0 648	2 785	0 67	
COVID19 (COV D19 (JANSSEN))	Suspected COV D-19	3 245	2 722	1 99	0	0	0 533	1 99	3 279	1 155	2 73	3 154	
COVID19 (COV D19 (JANSSEN))	Therapy non-responder	7 038	0 797										

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, November 9, 2021 8:33:48 AM
Attachments: [USST_20211105.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/5/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211105	US Serious EB05 20211105	US Fatal EB05 20211105	US Infant EB05 20211105	US Child EB05 20211105	US Teen EB05 20211105	US Adult1 EB05 20211105	US Adult2 EB05 20211105	US Adult3 EB05 20211105	US Female EB05 20211105	US Male EB05 20211105	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,777	1,841	0.863			0.355	1,525	1,970	1,671	2,312	1,327	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,777	1,841	0.863				1,673	1,673	2,295	2,074	1,478	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,972	1,32	0.961			0.462	1,283	1,778	1,819	2,275	1,534	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,978	0,878	0.875				0,867	0,721	2,362	0,722	1,532	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,052	0,992	0.876				0,945	0,745	1,968	2,443	1,388	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,896	1,312	0.903				1,495	1,346	1,512	2,345	1,085	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	3,05	2,202	0.89			0.498	2,245	2,062	2,344	4,433	1,362	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,202	1,672	0.877				1,779	1,822	1,982	2,443	1,336	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,534	1,931	0.888				1,714	2,492	2,784	3,262	2,059	
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,914	1,657	0.887				1,289	2,463	1,041	2,35	1,295	
COVID19 (COVID19 (JANSSEN))	Arthopy test	2,36	0,872	0.888				0,888	1,738	1,963	2,108	1,108	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,238	1,656	0.877	0.612			1,869	2,011	2,522	2,855	1,628	
COVID19 (COVID19 (JANSSEN))	Areflexia	2,12	1,948	0.878				0,899	1,917	1,527	1,84	1,548	
COVID19 (COVID19 (JANSSEN))	Atherosclerotic carotid abnormal	1,956	1,244	0.876				1,181	1,18	1,416	2,702	0,93	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,955	1,651	0.877	0.609		0.335	1,202	2,585	1,711	2,37	1,29	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,751	1,559	0.874	0.608			0,292	1,271	2,34	1,438	2,149	1,202
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,755	1,28	0.875				0,333	1,472	1,785	1,562	2,114	1,22
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,946	1,502	0.886				1,421	2,273	1,819	2,304	1,475	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2,02	1,565	0.897				0,452	1,439	2,271	1,963	2,438	1,36
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,412	2,595	0.885				0,51	1,857	2,118	4,416	1,075	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,839	1,559	0.888				0,28	1,179	2,087	1,507	2,579	1,046
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,712	1,544	0.87			0.217	1,359	2,02	1,296	2,064	0,877	
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,762	1,289	0.872				1,042	1,904	1,527	2,016	1,394	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1,938	1,334	1,067				1,322	1,818	1,812	2,028	1,692	
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,708	2,215	0.873				0,872	1,673	2,737	1,162	2,403	2,212
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,328	1,867	0.918			0.521	2,143	1,869	1,492	3,32	1,108	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,364	1,86	0.893				0,537	1,256	1,23	0,997	2,863	0,959
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,106	1,527	0.873				1,124	1,201	1,362	2,471	1,041	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,402	2,432	0.899			0.523	2,534	2,455	0,822	4,118	1,93	
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2,732	1,939	0.893	0.611		0.635	2,089	3,732	2,456	1,744	2,688	
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head normal	2,026	1,492	0.896				1,692	2,018	1,768	2,245	1,516	
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	2,116	1,605	0.907			0.462	1,502	2,125	2,056	2,437	1,63	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,019	1,691	0.867			0.46	1,001	2,178	2,294	2,814	2,035	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,817	1,505	0.888				1,288	2,363	1,516	2,133	1,212	
COVID19 (COVID19 (JANSSEN))	Feeling cold	1,779	0,802	0.872				1,131	2,003	1,495	0,992	1,883	1,414
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,278	1,271	0.861				2,207	1,827	1,847	2,517	1,547	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,156	1,512	0.705	0.611		0.33	1,705	2,327	2,585	2,212	1,485	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,153	0,997	0.873				0,423	1,696	1,931	0,75	2,154	1,189
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,329	1,02	0.88				0,418	2,278	1,131	1,761	1,429	
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,857	1,382	0.882				1,373	1,514	1,499	2,014	1,219	
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,756	1,261	0.882				1,171	1,244	1,39	2,046	1,047	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,302	1,822	0.872				1,394	1,784	2,825	2,063	1,394	
COVID19 (COVID19 (JANSSEN))	Haematocrit decreased	1,833	1,386	0.896	0.606		0.426	1,37	2,108	1,72	2,238	1,345	
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,755	1,303	0.897	0.607			0,327	1,423	1,98	1,996	2,088	1,386
COVID19 (COVID19 (JANSSEN))	Hepatitis-induced thrombocytopenia test	5,605	3,68	0.884				4,841	6,011	4,841	6,011	4,841	
COVID19 (COVID19 (JANSSEN))	Hepatitis-induced thrombocytopenia test positive	6,836	3,516	0.874				5,116	5,116	0,665	7,553	1,389	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,803	1,234	0.89				1,312	1,798	1,612	2,08	1,405	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,074	1,821	0.875			0.019	1,872	2,504	1,683	2,074	1,681	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,791	1,01	0.875				1,408	1,948	1,959	2,207	1,38	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,834	1,315	0.882	0.746		0.395	1,639	1,888	1,425	2,378	1,23	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1,922	1,415	0.879				1,416	1,935	1,935	2,889	1,197	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,104	1,681	0.874				1,602	0,744	1,122	2,831	0,755	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,897	1,531	0.871				1,231	2,162	1,155	1,705	1,723	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,022	1,784	0.886				0,896	2,323	1,163	1,488	1,78	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,733	1,628	0.888			0.182	1,628	1,001	1,779	1,147	1,407	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,174	1,718	0.882			0.502	1,773	1,956	1,507	2,536	1,283	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,08	1,524	0.889	0.611		0.46	1,295	2,348	1,507	2,33	1,567	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin decreased	1,977	1,547	0.884				1,441	1,904	1,913	2,094	0,895	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,773	1,289	0.877				1,26	2,207	1,077	2,072	1,123	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,04	1,495	0.935			0.494	0,993	2,025	1,671	1,927	1,683	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,876	1,377	0.863	0.61		0.17	1,377	0,965	2,13	1,617	1,027	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,596	1,317	0.878				1,221	1,823	1,313	2,337	0,809	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,882	1,295	0.883			0.241	1,106	1,962	1,712	1,962	1,276	
COVID19 (COVID19 (JANSSEN))	Off label use	1,987	0,872	0.872				0,809	0,298	1,429	0,961	1,236	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,752	0,758	0.859				0,509	0,998	0,998	2,172		
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,575	0,874	0.874			0.517	1,767	2,297	1,169	2,631	1,469	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,393	1,716	0.874				0,656	1,059	2,083	2,544	0,966	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,752	2,503	0.922	0.61		0.483	1,86	3,158	1,786	3,136	1,837	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,855	1,406	0.893	0.609		0.291	1,595	2,019	1,466	2,187	1,411	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,73	2,087	0.888				2,087	3,09	2,201	3,611	1,683	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,018	3,523	0.875			0.4	4,382	3,335	0,685	6,151	1,933	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,227					0.866	4,034	3,298	4,62	6,151	3,842	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,155	1,586	0.903	0.744		0.326	1,514	2,321	1,53	2,548	1,379	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,246	1,879	0.883	0.612			1,697	2,15	2,68	2,581	1,829	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,046	1,532	0.883				1,546	1,453	1,887	2,066	1,661	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,885	1,382	0.88	0.607		0.528	1,486	2,137	1,602	2,119	1,496	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,043	1,44	0.884	0.609		0.356	1,307	2,291	1,639	2,458	1,264	
COVID19 (COVID19 (JANSSEN))	Subarachnoid haemorrhage	1,736	1,178	0.959				1,056	0,901	1,056	2,206	0,787	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,262	1,2	0.879			0.538	1,486	1,78	1,377	1,957	1,749	
COVID19 (COVID19 (JANSSEN))	Superior sagittal sinus thrombosis	1,655	1,369	0.875				1,132	0,827	0,847	2,857	0,67	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,215	2,643	1,727			0.531	1,892	2,334	1,206	2,677	3,109	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7,077	0,797	0.875			0.647	3,642	6,746	15,322	8,003	5,996	
COVID19 (COVID19 (JANSSEN))	Therapy partial responder	2,299						0,635	0,635	0,635	1,025		
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2,116	1,675	0.886				0,516	1,416	1,656	2,27	1,346	
COVID19 (COVID19 (JANSSEN))	Thrombolytic	2,374	2,044	0.916			0.39	1,846	2,378	1,688	2,817	1,701	
COVID19 (COVID19 (JANSSEN))	Thrombosis	2,464	2,17	0.884	0.612			2,464	2,007	1,809	3,809	1,66	
COVID19 (COVID19 (JANSSEN))	Transverse sinus thrombosis	2,255	1,907	0.874				1,974	1,224	0,644	2,402	0,904	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler	2,397	1,445	0.893			0.648	1,928	2,165	2,371	2,786	1,68	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler abnormal	1,971	1,671	0.882	0.612		0.504	1,752	2,388	1,924	2,151	1,383	
COVID19 (COVID19 (JANSSEN))	Ultrasound Doppler normal	2,53	1,811	0.882				2,484	1,983	1,777	2,651	1,805	
COVID19 (COVID19 (JANSSEN))	Ultrasound scan normal	1,933	1,152	0.875				1,358	2,078	1,782	2,056	1,263	
COVID19 (COVID19 (JANSSEN))	Urobilinogen urine increased	1,973	1,677	0.876	0.611		0.309	0,86	1,876	1,291	1,845	1,045	
COVID19 (COVID19 (JANSSEN))	Vaccination failure	1,257	2,99										

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, November 16, 2021 6:48:39 AM
Attachments: [USST_20211112.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/12/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211112	US Serious EB05 20211112	US Fatal EB05 20211112	US Infant EB05 20211112	US Child EB05 20211112	US Teen EB05 20211112	US Adult1 EB05 20211112	US Adult2 EB05 20211112	US Adult3 EB05 20211112	US Female EB05 20211112	US Male EB05 20211112	Comment
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,159	1,604	0.895			0.592	1,022	2,893	1,558			
COVID19 (COV D19 (JANSSEN))	Activated partial thromboplastin time shortened	2,254	1,804	0.892				1,646	2,268	2,087		3,072	1,466
COVID19 (COV D19 (JANSSEN))	Acute respiratory failure	1,976	1,314	0.962			0.458	1,303	1.8	1.81		2,273	1,549
COVID19 (COV D19 (JANSSEN))	Adverse drug reaction	2,952	0.683	0.683				0.697	0.717	0.689		2,205	1,557
COVID19 (COV D19 (JANSSEN))	Adverse event	2,048	1,694	0.886				0.808	0.718	0.631		2,036	1,416
COVID19 (COV D19 (JANSSEN))	Angiogram abnormal	1.89	1.3	0.904				1.468	1.378	1.495		2,328	1,078
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral abnormal	3.01	2.172	0.901			0.497	2.266	2.068	3.255		4,336	1,407
COVID19 (COV D19 (JANSSEN))	Angiogram cerebral normal	1.64	1.644	0.88				1.753	1.653	1.376		1,362	1,362
COVID19 (COV D19 (JANSSEN))	Angiogram pulmonary abnormal	2,544	1,931	0.895				1,748	2,437	2,852		2,852	2,037
COVID19 (COV D19 (JANSSEN))	Anion gap decreased	1,905	1,647	0.896				0.398	1,241	2,451		1,121	1,327
COVID19 (COV D19 (JANSSEN))	Antibody test	2,348	0.895	0.86				0.572	0.899	1.75		1,831	1,886
COVID19 (COV D19 (JANSSEN))	Arthrocentesis	2,218	1,633	0.895		0.612		0.432	1.858	1,998		2,466	1,619
COVID19 (COV D19 (JANSSEN))	Areflexia	2,162	1,975	0.892				0.892	2,027	1,509		1,824	1,544
COVID19 (COV D19 (JANSSEN))	Atrioagram carotid abnormal	1,976	1,292	0.893				1,295	1,164	1,423		2,559	1,298
COVID19 (COV D19 (JANSSEN))	Basophils count decreased	1,948	1,623	0.886		0.609		0.329	1,216	2,597		1,627	1,243
COVID19 (COV D19 (JANSSEN))	Basophils percentage decreased	1,819	1,608	0.887		0.608		0.291	1,291	2,356		1,818	1,257
COVID19 (COV D19 (JANSSEN))	Blood albumin decreased	1,755	1,271	0.884				0.333	1,478	1,773		1,578	1,237
COVID19 (COV D19 (JANSSEN))	Blood calcium decreased	1,949	1,496	0.896				0.4	1,423	2,262		1,843	1,485
COVID19 (COV D19 (JANSSEN))	Blood chloride increased	2,043	1,579	0.908				0.451	1,417	2,288		1,956	1,399
COVID19 (COV D19 (JANSSEN))	Blood fibrinogen decreased	1,939	2,891	0.894				0.509	1,863	2,817		0.83	4,888
COVID19 (COV D19 (JANSSEN))	Blood magnesium increased	1,841	1,529	0.901				0.263	1,204	2.05		1,514	1,05
COVID19 (COV D19 (JANSSEN))	Blood urea decreased	1,79	1,641	0.88				0.215	1,389	2,101		1,508	1,139
COVID19 (COV D19 (JANSSEN))	Blood urea increased	1,784	1,215	0.878				1,073	1,967	1,508		2,021	1,43
COVID19 (COV D19 (JANSSEN))	COVID-19 pneumonia	1,971	1,349	1.337				1,404	1,846	1,846		2,033	1,747
COVID19 (COV D19 (JANSSEN))	CSF protein increased	2,698	2,192	0.88				1,676	2,772	1,147		2,343	2,234
COVID19 (COV D19 (JANSSEN))	CSF red blood cell count positive	2,019	1,763	0.88				1,227	1,827	1,627		1,576	1,483
COVID19 (COV D19 (JANSSEN))	Cerebral haemorrhage	2,324	1,849	0.904			0.521	1,848	2.08	1,887		1,465	1,539
COVID19 (COV D19 (JANSSEN))	Cerebral mass effect	2,636	1,988	0.916				1,326	1,228	1.11		1,676	1,066
COVID19 (COV D19 (JANSSEN))	Cerebral thrombosis	2,155	1,582	0.882				1,125	1.25	1,353		2,647	1,031
COVID19 (COV D19 (JANSSEN))	Cerebral venous sinus thrombosis	2,019	2,442	0.916			0.522	2,442	2,404	1,815		1,179	1,179
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head abnormal	2,737	1,958	0.961		0.611		0.636	2,382	2,434		3,637	1,754
COVID19 (COV D19 (JANSSEN))	Computerized tomogram head normal	2,022	1,469	0.901				0.397	1,674	2,007		2,227	1,526
COVID19 (COV D19 (JANSSEN))	Computerized tomogram thorax abnormal	2,114	1,916	0.914				0.456	1,482	2,119		2,119	1,823
COVID19 (COV D19 (JANSSEN))	Deep vein thrombosis	2,604	1,873	0.97				0.456	2,159	2,283		3,232	2,034
COVID19 (COV D19 (JANSSEN))	Eosinophil count decreased	1,838	1,504	0.889				1,302	2,348	1,552		2,175	1,219
COVID19 (COV D19 (JANSSEN))	Eosinophil percentage decreased	1,985	1,866	0.89			0.301	1,866	2,041	1,964		2,161	1,295
COVID19 (COV D19 (JANSSEN))	Feeling cold	1,78	0.836	0.887		0.61		1,117	1.49	1.81		1,881	1,425
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer	2,291	1,323	0.885				0.372	2.17	2,019		2,523	1,867
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer increased	1,983	1,903	0.893		0.611		0.325	1,887	2,385		2,217	1,648
COVID19 (COV D19 (JANSSEN))	Fibrin D dimer normal	1,964	1,021	0.881				0.425	1,731	1,861		2,19	1,253
COVID19 (COV D19 (JANSSEN))	Galactosemia	2,297	1,015	0.887				0.416	2,258	1,752		1,13	2,894
COVID19 (COV D19 (JANSSEN))	Gait abnormal	1,948	1,893	0.893				0.398	1,406	1,616		1,54	1,294
COVID19 (COV D19 (JANSSEN))	Glucose urine present	1,764	1,255	0.893				1.16	1,286	1,371		2,096	1,037
COVID19 (COV D19 (JANSSEN))	Gullain-Barre syndrome	2,289	1,872	0.879				1,378	2,869	1.75		2,129	2,995
COVID19 (COV D19 (JANSSEN))	Haemolysis decreased	1,841	1,904	0.894		0.607		0.426	1,767	1,227		1,363	1,363
COVID19 (COV D19 (JANSSEN))	Haemoglobin decreased	1,769	1,306	0.904				0.322	1,423	1,992		2,088	1,366
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,579	3,662	0.893				3,989	4,855	6,228		6,998	2,888
COVID19 (COV D19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,863	3,149	0.882			0.546	6,13	5,875	6,665		5,389	3,889
COVID19 (COV D19 (JANSSEN))	Hypoxia	1,836	1,248	0.9				1,357	1,817	1,817		2,172	1,396
COVID19 (COV D19 (JANSSEN))	Immunoglobulin therapy	2,074	1,918	0.883			0.019	1,917	2,492	1,631		2,214	1,885
COVID19 (COV D19 (JANSSEN))	Intensive care	1,828	1,433	0.893			0.028	1,401	2,048	1,589		2,245	1,417
COVID19 (COV D19 (JANSSEN))	International normalised ratio increased	1,855	1,322	0.894		0.746		0.397	1,625	1,941		1,433	1,222
COVID19 (COV D19 (JANSSEN))	International normalised ratio normal	1,966	1,294	0.886				1,381	1,979	1,026		2,103	1,257
COVID19 (COV D19 (JANSSEN))	Jugular vein thrombosis	2,131	1,854	0.885				1,606	1,152	0.735		3,111	0,746
COVID19 (COV D19 (JANSSEN))	Lumbar puncture	1,896	1,532	0.896				1,532	1,758	1,704		1,723	1,723
COVID19 (COV D19 (JANSSEN))	Lumbar puncture abnormal	2,005	1,731	0.887				0.887	2,317	1,167		1,515	1,753
COVID19 (COV D19 (JANSSEN))	Lymphocyte percentage decreased	1,657	1,278	0.886			0.179	1,03	2,089	1,807		2,103	1,137
COVID19 (COV D19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,157	1,686	0.889			0.453	1,771	1,513	1,497		1,863	1,563
COVID19 (COV D19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,128	1,558	0.901		0.611		0.459	1,275	2,468		1,539	1,319
COVID19 (COV D19 (JANSSEN))	Mean cell haemoglobin decreased	1,863	1,24	0.885				0.339	2,098	1,113		1,918	0,922
COVID19 (COV D19 (JANSSEN))	Mean platelet volume increased	1,923	1,891	0.891				0.34	1,268	1,923		1,159	1,15
COVID19 (COV D19 (JANSSEN))	Mechanical ventilation	2,025	1,457	0.938				0.49	0.988	2,061		1.63	1,918
COVID19 (COV D19 (JANSSEN))	Monocyte percentage increased	1,619	1,371	0.893		0.61		0.256	0.985	2,109		1,982	1,037
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage decreased	1,985	1,287	0.887				0.12	1,212	1.8		1,918	1,028
COVID19 (COV D19 (JANSSEN))	Neutrophil percentage increased	1,711	1,307	0.891				0.24	1,133	2,057		1,749	1,881
COVID19 (COV D19 (JANSSEN))	Off label use	1,341	0,203	0.88				0,031	0,282	0,409		0,339	1,301
COVID19 (COV D19 (JANSSEN))	On and off phenomenon	1,751	0,768	0.887				0,989	3,089	2,186		1,168	1,219
COVID19 (COV D19 (JANSSEN))	Pain assessment	2,537	0,875	0.871			0.512	1,771	2,279	1,168		2,637	1,44
COVID19 (COV D19 (JANSSEN))	Peripheral embolism	3,38	1,71	0.882				0.656	1.06	2,091		2,581	0,967
COVID19 (COV D19 (JANSSEN))	Platelet count	2,768	2,804	0.912		0.61		0.483	1,864	3,159		1,941	1,841
COVID19 (COV D19 (JANSSEN))	Platelet count decreased	1,869	1,409	0.9		0.609		0.289	1,605	1,515		2,202	1,429
COVID19 (COV D19 (JANSSEN))	Platelet count normal	2,726	2,067	0.896				0.394	2,019	3,128		3,468	1,883
COVID19 (COV D19 (JANSSEN))	Platelet factor 4	6,041	3,492	0.882				4,394	3,399	6,683		6,175	1,935
COVID19 (COV D19 (JANSSEN))	Poor quality product administered	1,259						0,869	4,014	3,383		5,896	3,831
COVID19 (COV D19 (JANSSEN))	Prothrombin time prolonged	1,995	1,597	0.913		0.744		0,325	1,519	2,374		1,602	1,39
COVID19 (COV D19 (JANSSEN))	Pulmonary embolism	2,239	1,669	0.893		0.612		0,584	1,69	2,154		2,65	1,833
COVID19 (COV D19 (JANSSEN))	Pulmonary thrombosis	2,064	1,543	0.894				1,557	1,482	2,009		1,879	1,684
COVID19 (COV D19 (JANSSEN))	Red blood cell count decreased	1,917	1,413	0.891				0,527	1,475	2,19		1,663	1,545
COVID19 (COV D19 (JANSSEN))	Red cell distribution width increased	2,082	1,469	0.899				0,355	1,321	2,321		1,701	1,319
COVID19 (COV D19 (JANSSEN))	Subarachnoid haemorrhage	1,761	1,199	0.886		0.609		0,546	1,657	1,058		0,884	0,779
COVID19 (COV D19 (JANSSEN))	Superficial vein thrombosis	2,311	1,217	0.886				0,537	1.85	1,384		2,048	1,736
COVID19 (COV D19 (JANSSEN))	Superior sagittal sinus thrombosis	1,583	1,242	0.881				0,548	1,132	0,827		2,368	1,067
COVID19 (COV D19 (JANSSEN))	Suspected COVID-19	3,178											

From: [Zinderman, Craig E](#)
To: [Menschik, David](#); [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, November 23, 2021 3:14:28 PM
Attachments: [USST_20211119.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/19/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211119	US Serious EB05 20211119	US Fatal EB05 20211119	US Infant EB05 20211119	US Child EB05 20211119	US Teen EB05 20211119	US Adult EB05 20211119	US Adult2 EB05 20211119	US Adult3 EB05 20211119	US Female EB05 20211119	US Male EB05 20211119	Comment
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,244	1,555	0	0	0	0	0	2,244	1,555	2,046	1,446	
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,229	1,769	0	0	0	0	0	2,229	1,769	2,087	1,483	
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	1,988	1,337	0	0	0	0	0	1,988	1,337	2,309	1,595	
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,869	2,085	0	0	0	0	0	2,869	2,085	3,142	2,289	1,559
COVID19 (COV D19 (ANSEN))	Adverse event	2,052	0,997	0	0	0	0	0	2,052	0,997	1,602	1,446	
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,84	1,374	0	0	0	0	0	1,84	1,374	2,432	1,135	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	3,008	2,008	0	0	0	0	0	3,008	2,008	3,442	2,008	1,453
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	1,715	1,074	0	0	0	0	0	1,715	1,074	1,931	1,449	1,45
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,538	1,912	0	0	0	0	0	2,538	1,912	2,488	2,045	1,449
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary normal	1,883	1,597	0	0	0	0	0	1,883	1,597	2,233	1,325	1,305
COVID19 (COV D19 (ANSEN))	Antioncology therapy	2,352	0,861	0	0	0	0	0	2,352	0,861	2,819	1,754	1,901
COVID19 (COV D19 (ANSEN))	Antipsychotic therapy	2,224	1,614	0	0	0	0	0	2,224	1,614	1,992	2,803	1,623
COVID19 (COV D19 (ANSEN))	Areflexia	1,134	0,943	0	0	0	0	0	1,134	0,943	2,003	1,492	1,527
COVID19 (COV D19 (ANSEN))	Arterogram carotid abnormal	2,021	1,299	0	0	0	0	0	2,021	1,299	1,502	2,782	0,979
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,569	1,619	0	0	0	0	0	1,569	1,619	1,72	2,571	1,273
COVID19 (COV D19 (ANSEN))	Basophil percentage decreased	1,817	1,583	0	0	0	0	0	1,817	1,583	2,292	2,23	1,273
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,793	1,292	0	0	0	0	0	1,793	1,292	1,488	2,078	1,32
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,995	1,498	0	0	0	0	0	1,995	1,498	2,262	2,308	1,52
COVID19 (COV D19 (ANSEN))	Blood chloride increased	2,079	1,608	0	0	0	0	0	2,079	1,608	2,025	2,342	2,469
COVID19 (COV D19 (ANSEN))	Blood fibrinogen decreased	3,39	2,633	0	0	0	0	0	3,39	2,633	1,865	2,583	1,136
COVID19 (COV D19 (ANSEN))	Blood magnesium increased	1,907	1,577	0	0	0	0	0	1,907	1,577	1,225	2,593	1,132
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,625	1,677	0	0	0	0	0	1,625	1,677	1,432	2,161	1,006
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,613	1,227	0	0	0	0	0	1,613	1,227	1,041	1,538	1,477
COVID19 (COV D19 (ANSEN))	COV D19 pneumonia	1,983	1,371	0	0	0	0	0	1,983	1,371	1,403	1,862	1,788
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,697	2,19	0	0	0	0	0	2,697	2,19	1,864	2,88	2,292
COVID19 (COV D19 (ANSEN))	CSF red blood cell count positive	2,022	1,176	0	0	0	0	0	2,022	1,176	1,129	1,54	1,524
COVID19 (COV D19 (ANSEN))	Cerebral hemorrhage	2,333	1,855	0	0	0	0	0	2,333	1,855	1,981	1,923	3,628
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	2,603	1,976	0	0	0	0	0	2,603	1,976	1,227	1,327	0,962
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,156	1,526	0	0	0	0	0	2,156	1,526	1,127	1,339	2,626
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	3,302	2,318	0	0	0	0	0	3,302	2,318	2,272	2,32	1,171
COVID19 (COV D19 (ANSEN))	Complicated tomogram head abnormal	2,702	1,929	0	0	0	0	0	2,702	1,929	2,382	2,416	1,769
COVID19 (COV D19 (ANSEN))	Complicated tomogram head normal	2,449	2,022	0	0	0	0	0	2,449	2,022	3,366	1,665	1,302
COVID19 (COV D19 (ANSEN))	Complicated tomogram thorax abnormal	1,128	1,613	0	0	0	0	0	1,128	1,613	1,484	2,447	1,685
COVID19 (COV D19 (ANSEN))	Complicated tomogram thorax normal	2,605	1,663	0	0	0	0	0	2,605	1,663	2,17	3,219	3,469
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	2,806	1,663	0	0	0	0	0	2,806	1,663	1,811	2,398	2,198
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,492	1,891	0	0	0	0	0	1,492	1,891	1,296	2,198	1,226
COVID19 (COV D19 (ANSEN))	Eosinophil percentage decreased	1,71	1,355	0	0	0	0	0	1,71	1,355	1,27	2,043	1,243
COVID19 (COV D19 (ANSEN))	Fasting glucose	1,778	1,883	0	0	0	0	0	1,778	1,883	1,132	1,481	1,422
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,283	1,317	0	0	0	0	0	2,283	1,317	2,542	2,136	1,622
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	2,182	1,502	0	0	0	0	0	2,182	1,502	1,707	2,332	1,566
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,075	1,016	0	0	0	0	0	1,075	1,016	1,737	1,965	1,242
COVID19 (COV D19 (ANSEN))	Gaze palsy	1	0	0	0	0	0	0	1	0	1,119	2,825	1,398
COVID19 (COV D19 (ANSEN))	Globulins increased	1,943	1,478	0	0	0	0	0	1,943	1,478	1,398	1,562	1,061
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,769	1,247	0	0	0	0	0	1,769	1,247	1,305	2,093	1,051
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,303	1,851	0	0	0	0	0	2,303	1,851	1,402	2,876	2,118
COVID19 (COV D19 (ANSEN))	Haemoglobin decreased	1,852	1,364	0	0	0	0	0	1,852	1,364	1,377	2,095	1,417
COVID19 (COV D19 (ANSEN))	Haemoglobin increased	1,795	1,309	0	0	0	0	0	1,795	1,309	1,441	1,993	1,39
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test	5,553	3,685	0	0	0	0	0	5,553	3,685	3,948	4,971	2,857
COVID19 (COV D19 (ANSEN))	Heparin-induced thrombocytopenia test positive	6,877	3,5	0	0	0	0	0	6,877	3,5	5,591	7,622	5,047
COVID19 (COV D19 (ANSEN))	Hypoxia	1,833	1,263	0	0	0	0	0	1,833	1,263	1,375	1,879	1,445
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,077	1,906	0	0	0	0	0	2,077	1,906	1,611	2,235	1,099
COVID19 (COV D19 (ANSEN))	International normalized ratio	1,824	1,409	0	0	0	0	0	1,824	1,409	2,019	2,134	1,407
COVID19 (COV D19 (ANSEN))	International normalized ratio increased	1,877	1,355	0	0	0	0	0	1,877	1,355	1,483	1,977	1,278
COVID19 (COV D19 (ANSEN))	International normalized ratio normal	2,011	1,308	0	0	0	0	0	2,011	1,308	1,611	2,235	1,099
COVID19 (COV D19 (ANSEN))	Jugular vein thrombosis	2,129	1,683	0	0	0	0	0	2,129	1,683	1,961	2,153	2,147
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,502	1,877	0	0	0	0	0	1,502	1,877	1,133	2,168	1,236
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,018	1,73	0	0	0	0	0	2,018	1,73	1,869	2,424	1,816
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	1,677	1,088	0	0	0	0	0	1,677	1,088	1,077	1,075	1,088
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,176	1,706	0	0	0	0	0	2,176	1,706	1,999	2,522	1,616
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head normal	2,144	1,566	0	0	0	0	0	2,144	1,566	1,456	1,865	2,407
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin decreased	1,687	1,686	0	0	0	0	0	1,687	1,686	1,028	1,807	1,503
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin increased	1,842	1,354	0	0	0	0	0	1,842	1,354	1,291	1,259	1,183
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	2,048	1,501	0	0	0	0	0	2,048	1,501	1,682	1,128	1,723
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	1,82	1,363	0	0	0	0	0	1,82	1,363	1,969	2,473	1,059
COVID19 (COV D19 (ANSEN))	Monocyte percentage increased	1,62	1,294	0	0	0	0	0	1,62	1,294	1,447	2,277	0,863
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,732	1,317	0	0	0	0	0	1,732	1,317	1,951	1,981	1,353
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	2,181	0,723	0	0	0	0	0	2,181	0,723	0,61	1,337	0,865
COVID19 (COV D19 (ANSEN))	Non-specific reaction	1,335	0,315	0	0	0	0	0	1,335	0,315	0,33	2,005	1,226
COVID19 (COV D19 (ANSEN))	Off label use	1,751	0,766	0	0	0	0	0	1,751	0,766	3,105	2,191	1,81
COVID19 (COV D19 (ANSEN))	On and off phenomenon	2,531	0,869	0	0	0	0	0	2,531	0,869	1,742	2,285	1,148
COVID19 (COV D19 (ANSEN))	Pain assessment	3,398	1,715	0	0	0	0	0	3,398	1,715	1,066	2,582	0,968
COVID19 (COV D19 (ANSEN))	Peripheral embolism	2,775	2,016	0	0	0	0	0	2,775	2,016	1,86	3,115	1,877
COVID19 (COV D19 (ANSEN))	Platelet count	1,874	1,407	0	0	0	0	0	1,874	1,407	1,547	2,198	1,451
COVID19 (COV D19 (ANSEN))	Platelet count decreased	2,731	2,037	0	0	0	0	0	2,731	2,037	2,275	3,123	3,437
COVID19 (COV D19 (ANSEN))	Platelet count normal	6,054	5,01	0	0	0	0	0	6,054	5,01	4,422	6,21	1,937
COVID19 (COV D19 (ANSEN))	Platelet factor 4	1,294	0	0	0	0	0	0	1,294	0	0	0	0
COVID19 (COV D19 (ANSEN))	Poor quality product administered	2,028	1,619	0	0	0	0	0	2,028	1,619	3,976	3,357	3,872
COVID19 (COV D19 (ANSEN))	Prothrombin time prolonged	2,233	1,661	0	0	0	0	0	2,233	1,661	1,662	2,635	1,455
COVID19 (COV D19 (ANSEN))	Pulmonary embolism	2,071	1,574	0	0	0	0	0	2,071	1,574	1,507	2,153	1,833
COVID19 (COV D19 (ANSEN))	Pulmonary thrombosis	1,162	1,409	0	0	0	0	0	1,162	1,409	1,967	1,93	1,71
COVID19 (COV D19 (ANSEN))	Red blood cell count decreased	2,076	1,454	0	0	0	0	0	2,076	1,454	1,685	2,152	1,527
COVID19 (COV D19 (ANSEN))	Red cell distribution width increased	1,729	1,15	0	0	0	0	0	1,729	1,15	1,27	2,449	1,345

From: [Menschik, David](#)
To: [Su, John \(CDC\)](#); [Shimabukuro, Tom \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, November 30, 2021 6:30:27 AM
Attachments: [USST_20211126.xls](#)

Good morning John and Tom,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 11/26/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211126	US Serious EB05 20211126	US Fatal EB05 20211126	US Infant EB05 20211126	US Child EB05 20211126	US Teen EB05 20211126	US Adult1 EB05 20211126	US Adult2 EB05 20211126	US Adults EB05 20211126	US Female EB05 20211126	US Male EB05 20211126	Comment
COVID19 (COV D19) (ANSEN)	Activated partial thromboplastin time prolonged	2,222	1,922	0.903	1.591	0.611	0.394	1.228	1.591	2.222	2.531	1.454	
COVID19 (COV D19) (ANSEN)	Activated partial thromboplastin time shortened	2,222	1,759	0.891	1.642	0.611	0.394	1.642	2.222	2,032	2,932	1,492	
COVID19 (COV D19) (ANSEN)	Acute respiratory failure	2,001	1,361	0.979	1,323	0.455	0.455	1,323	1,944	1,88	3,356	1,842	
COVID19 (COV D19) (ANSEN)	Adverse drug reaction	0.972	0.972	0.972	0.972	0.972	0.972	0.972	0.972	0.972	0.972	0.972	
COVID19 (COV D19) (ANSEN)	Adverse event	2,052	0,985	0,885	0,767	0,821	0,821	0,767	1,625	1,625	1,625	1,471	
COVID19 (COV D19) (ANSEN)	Angiogram abnormal	1,932	1,347	0,909	1,502	0,926	0,926	1,502	1,403	1,601	2,386	1,135	
COVID19 (COV D19) (ANSEN)	Angiogram cerebral abnormal	2,199	1,996	0,996	2,297	0,497	0,497	2,297	2,068	2,068	3,365	1,464	
COVID19 (COV D19) (ANSEN)	Angiogram cerebral normal	2,212	1,674	0,88	1,869	0,427	0,427	1,869	1,906	1,428	2,428	1,235	
COVID19 (COV D19) (ANSEN)	Angiogram pulmonary abnormal	2,519	1,89	0,608	1,706	0,608	0,608	1,706	2,448	2,708	2,068	2,068	
COVID19 (COV D19) (ANSEN)	Anion gap decreased	1,807	1,591	0,806	1,231	0,806	0,806	1,231	1,807	2,411	1,305	1,305	
COVID19 (COV D19) (ANSEN)	Antibody test	2,353	0,856	0,877	0,887	0,569	0,569	0,887	1,752	1,906	2,154	1,875	
COVID19 (COV D19) (ANSEN)	Anticoagulant therapy	2,228	1,599	0,965	1,853	0,435	0,435	1,853	1,599	2,445	2,869	1,84	
COVID19 (COV D19) (ANSEN)	Areflexia	2,131	1,966	0,89	0,895	0,895	0,895	0,895	2,088	1,485	2,031	1,529	
COVID19 (COV D19) (ANSEN)	Arteriogram carotid abnormal	1,976	1,275	0,879	1,204	0,17	0,17	1,204	2,027	1,716	2,422	1,55	
COVID19 (COV D19) (ANSEN)	Basophil count decreased	1,947	1,805	0,801	1,204	0,329	0,329	1,204	2,027	1,716	2,422	1,55	
COVID19 (COV D19) (ANSEN)	Basophil percentage decreased	1,817	1,59	0,89	1,282	0,609	0,609	1,282	2,352	1,679	2,224	1,304	
COVID19 (COV D19) (ANSEN)	Blood albumin decreased	1,785	1,295	0,884	1,509	0,332	0,332	1,509	1,798	1,861	2,084	1,35	
COVID19 (COV D19) (ANSEN)	Blood calcium decreased	1,994	1,496	0,904	1,399	0,399	0,399	1,399	1,807	2,317	1,544	1,544	
COVID19 (COV D19) (ANSEN)	Blood chloride increased	2,078	1,606	0,913	1,412	0,455	0,455	1,412	2,382	2,004	2,482	1,478	
COVID19 (COV D19) (ANSEN)	Blood fibrinogen decreased	3,564	2,618	0,822	0,508	0,508	0,508	0,508	2,615	0,813	4,599	1,133	
COVID19 (COV D19) (ANSEN)	Blood fibrinogen increased	1,892	1,539	0,906	1,215	0,373	0,373	1,215	2,077	1,639	2,077	1,522	
COVID19 (COV D19) (ANSEN)	Blood urea decreased	1,811	1,684	0,879	1,428	0,225	0,225	1,428	2,235	2,185	1,995	1,995	
COVID19 (COV D19) (ANSEN)	Blood urea increased	1,817	1,833	0,884	1,059	0,884	0,884	1,059	2,012	1,56	2,022	1,487	
COVID19 (COV D19) (ANSEN)	COV D-19 pneumonia	1,878	1,381	0,968	1,372	0,368	0,368	1,372	1,956	1,506	2,151	1,788	
COVID19 (COV D19) (ANSEN)	CSF protein increased	2,722	2,204	0,877	1,739	0,877	0,877	1,739	2,906	1,134	2,42	2,29	
COVID19 (COV D19) (ANSEN)	CSF red blood cell count positive	2,022	1,811	0,877	1,282	0,877	0,877	1,282	1,666	1,113	1,624	1,522	
COVID19 (COV D19) (ANSEN)	Cerebral haemorrhage	2,336	1,845	0,929	1,906	0,519	0,519	1,906	1,931	1,54	3,606	1,608	
COVID19 (COV D19) (ANSEN)	Cerebral mass effect	2,606	1,92	0,911	1,227	0,534	0,534	1,227	1,331	1,092	3,235	0,964	
COVID19 (COV D19) (ANSEN)	Cerebral thrombosis	2,154	1,484	0,879	1,139	0,668	0,668	1,139	1,299	1,342	2,004	1,004	
COVID19 (COV D19) (ANSEN)	Cerebral venous sinus thrombosis	3,306	2,299	0,916	2,245	0,521	0,521	2,245	2,335	0,82	3,906	1,175	
COVID19 (COV D19) (ANSEN)	Computerised tomogram head abnormal	2,702	1,918	0,947	0,633	0,243	0,243	0,633	2,436	2,257	3,685	1,763	
COVID19 (COV D19) (ANSEN)	Computerised tomogram head normal	1,005	1,005	1,005	1,005	1,005	1,005	1,005	1,005	1,005	1,005	1,005	
COVID19 (COV D19) (ANSEN)	Computerised tomogram thorax abnormal	2,121	1,591	0,921	1,481	0,213	0,213	1,481	2,147	2,147	2,85	1,876	
COVID19 (COV D19) (ANSEN)	Deep vein thrombosis	2,611	1,851	0,956	1,451	0,451	0,451	1,451	2,384	2,381	2,017	1,676	
COVID19 (COV D19) (ANSEN)	Eosinophil count decreased	1,851	1,486	0,885	1,284	0,885	0,885	1,284	2,326	1,65	2,173	1,268	
COVID19 (COV D19) (ANSEN)	Eosinophil percentage decreased	1,707	1,358	0,886	1,265	0,406	0,406	1,265	2,06	1,977	2,074	1,274	
COVID19 (COV D19) (ANSEN)	Fasting glucose	1,778	1,628	0,877	1,212	0,134	0,134	1,212	1,477	1,817	1,817	1,426	
COVID19 (COV D19) (ANSEN)	Fibrin D dimer	2,29	1,308	0,884	2,186	0,225	0,225	2,186	2,021	2,56	1,651	1,651	
COVID19 (COV D19) (ANSEN)	Fibrin D dimer increased	2,155	1,49	0,916	1,693	0,328	0,328	1,693	2,329	2,504	1,546	1,546	
COVID19 (COV D19) (ANSEN)	Fibrin D dimer normal	1,917	1,513	0,878	1,428	0,682	0,682	1,428	1,862	1,661	2,225	1,225	
COVID19 (COV D19) (ANSEN)	Gaze palsy	2,276	1,019	0,884	2,008	0,408	0,408	2,008	1,723	2,525	1,434	1,434	
COVID19 (COV D19) (ANSEN)	Glucobulin increased	1,928	1,442	0,892	1,482	0,4	0,4	1,482	1,554	1,64	2,096	1,293	
COVID19 (COV D19) (ANSEN)	Glucose urine present	1,768	1,24	0,892	1,299	0,892	0,892	1,299	1,84	1,84	1,84	1,84	
COVID19 (COV D19) (ANSEN)	Guillain-Barre syndrome	2,317	1,844	0,971	2,864	0,874	0,874	2,864	1,758	2,151	2,225	1,225	
COVID19 (COV D19) (ANSEN)	Haemagglutination decreased	1,849	1,368	0,916	1,386	0,425	0,425	1,386	2,117	1,79	2,224	1,434	
COVID19 (COV D19) (ANSEN)	Haemagglutination normal	1,917	1,315	0,906	1,451	0,321	0,321	1,451	2,027	1,469	2,468	1,468	
COVID19 (COV D19) (ANSEN)	Heparin-induced thrombocytopenia test	5,558	3,684	0,95	3,966	0,895	0,895	3,966	4,998	6,279	2,873	2,873	
COVID19 (COV D19) (ANSEN)	Heparin-induced thrombocytopenia test positive	6,887	3,547	0,879	5,201	0,687	0,687	5,201	7,688	5,71	6,887	6,887	
COVID19 (COV D19) (ANSEN)	Hypoxia	1,843	1,3	0,914	1,373	0,152	0,152	1,373	1,722	2,227	1,911	1,911	
COVID19 (COV D19) (ANSEN)	Immunoglobulin therapy	2,09	1,912	0,88	1,939	0,021	0,021	1,939	2,567	1,61	1,726	1,726	
COVID19 (COV D19) (ANSEN)	Intensive care	1,421	1,421	1,421	1,421	1,421	1,421	1,421	1,421	1,421	1,421	1,421	
COVID19 (COV D19) (ANSEN)	International normalised ratio increased	1,877	1,347	0,892	1,402	0,746	0,746	1,402	2,016	1,472	2,501	1,277	
COVID19 (COV D19) (ANSEN)	International normalised ratio normal	2,013	1,336	0,883	1,399	0,883	0,883	1,399	2,082	1,018	2,112	1,253	
COVID19 (COV D19) (ANSEN)	Jugular vein thrombosis	1,917	1,336	0,883	1,662	0,883	0,883	1,662	1,994	2,747	1,443	1,443	
COVID19 (COV D19) (ANSEN)	Lumbar puncture	1,902	1,489	0,875	2,166	0,875	0,875	2,166	1,735	1,12	2,525	1,732	
COVID19 (COV D19) (ANSEN)	Lumbar puncture abnormal	2,015	1,727	0,901	0,871	0,871	0,871	0,871	2,441	1,147	1,487	1,818	
COVID19 (COV D19) (ANSEN)	Lumbar puncture normal	1,768	1,24	0,892	1,299	0,892	0,892	1,299	1,84	1,84	1,84	1,84	
COVID19 (COV D19) (ANSEN)	Magnetic resonance imaging head abnormal	2,172	1,69	0,885	1,488	0,184	0,184	1,488	1,943	2,528	2,328	1,605	
COVID19 (COV D19) (ANSEN)	Mean cell haemoglobin concentration decreased	1,847	1,571	0,897	0,456	0,456	0,456	0,456	1,712	2,448	1,415	1,415	
COVID19 (COV D19) (ANSEN)	Mean cell haemoglobin increased	1,669	1,26	0,884	1,335	0,469	0,469	1,335	2,065	1,239	1,969	0,975	
COVID19 (COV D19) (ANSEN)	Mean platelet volume increased	2,187	1,439	0,897	1,317	0,339	0,339	1,317	2,336	1,356	2,282	1,282	
COVID19 (COV D19) (ANSEN)	Mechanical ventilation	2,052	1,471	0,946	1,402	0,402	0,402	1,402	2,168	1,659	2,168	1,716	
COVID19 (COV D19) (ANSEN)	Monocyte percentage increased	1,609	1,354	0,892	0,261	0,892	0,892	0,261	1,984	1,236	1,08	1,08	
COVID19 (COV D19) (ANSEN)	Neutrophil percentage decreased	1,859	1,318	0,886	1,196	0,143	0,143	1,196	1,812	1,493	1,812	0,894	
COVID19 (COV D19) (ANSEN)	Neutrophil percentage increased	1,732	1,325	0,897	1,511	0,897	0,897	1,511	1,698	2,38	1,371	1,371	
COVID19 (COV D19) (ANSEN)	Nonspecific reaction	2,189	0,724	0,881	0,761	0,881	0,881	0,761	0,81	1,602	0,896	0,896	
COVID19 (COV D19) (ANSEN)	Off label use	1,339	0,301	0,882	6,014	0,276	0,276	0,276	0,4	0,828	0,85	1,24	
COVID19 (COV D19) (ANSEN)	On and off phenomenon	1,753	0,759	0,879	3,198	0,759	0,759	3,198	1,802	2,16	2,16	2,16	
COVID19 (COV D19) (ANSEN)	Pain assessment	2,535	0,869	0,869	1,746	0,297	0,297	1,746	2,59	1,144	3,354	1,433	
COVID19 (COV D19) (ANSEN)	Peripheral embolism	3,372	1,709	0,879	0,656	0,656	0,656	0,656	1,863	2,144	2,621	0,969	
COVID19 (COV D19) (ANSEN)	Platelet count	2,779	2,494	0,921	1,845	0,482	0,482	1,845	3,139	2,269	3,167	1,967	
COVID19 (COV D19) (ANSEN)	Platelet count decreased	1,886	1,414	0,901	0,292	0,292	0,292	0,292	1,543	2,202	1,483	1,483	
COVID19 (COV D19) (ANSEN)	Platelet count normal	2,707	2,03	0,894	2,004	0,39	0,39	2,004	3,142	2,24	3,689	1,689	
COVID19 (COV D19) (ANSEN)	Platelet factor 4	6,06	3,505	0,88	4,447	0,629	0,629	4,447	3,576	6,229	1,944	1,944	
COVID19 (COV D19) (ANSEN)	Poor quality product administered	1,303	0,681	0,681	0,958	0,681	0,681	0,958	3,414	5,92	1,354	1,354	
COVID19 (COV D19) (ANSEN)	Prothrombin time prolonged	2,037	1,617	0,914	0,326	0,326	0,326	0,326	2,488	1,614	2,488	1,461	
COVID19 (COV D19) (ANSEN)	Pulmonary embolism	2,237	1,666	0,912	1,703	0,583	0,583	1,703	2,15	2,73	2,567	1,855	
COVID19 (COV D19) (ANSEN)	Pulmonary thrombosis	2,069	1,563	0,894	1,588	0,588	0,588	1,588	1,53	1,939	1,945	1,724	
COVID19 (COV D19) (ANSEN)	Red blood cell count decreased	1,902	1,402	0,895	1,48	0,895	0,895	1,48	2,181	1,684	2,12	1,578	
COVID19 (COV D19) (ANSEN)	Red cell distribution width increased	2,061	1,456	0,904	1,319	0,352	0,352	1,319	2,276	2,478	2,478	1,362	
COVID19 (COV D19) (ANSEN)	Subarachnoid haemorrhage	1,73	1,132	0,845	1,52	0,544	0,544	1,52	1,05	0,972	2,048	0,782	
COVID19 (COV D19) (ANSEN)	Superficial vein thrombosis	2,42	1,94	0,935	1,665	0,665	0,665	1,665	1,978	1,522	2,324	1,753	
COVID19 (COV D19) (ANSEN)	Superior sagittal sinus thrombosis	1,585	1,206	0,877	0,828	0,206	0,206	0,828	2,096				

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, December 7, 2021 6:23:13 AM
Attachments: [USST_20211203.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/3/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211203	US Serious EB05 20211203	US Fatal EB05 20211203	US Infant EB05 20211203	US Child EB05 20211203	US Teen EB05 20211203	US Adult1 EB05 20211203	US Adult2 EB05 20211203	US Adult3 EB05 20211203	US Female EB05 20211203	US Male EB05 20211203	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2.22	1.51		0.657			1.60	2.22	2.22	2.22	2.22	1.54
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2.227	1.758		0.95		0.596	1.651	2.217	2.081	2.081	2.081	1.497
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2.001	1.333		0.978		0.457	1.361	1.931	1.84	1.84	2.292	1.646
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2.965	2.088		1.52		0.52	0.969	1.805	1.805	1.805	2.539	1.555
COVID19 (COVID19 (JANSSEN))	Adverse event	2.047	1.007		0.886			0.954	0.716	0.812	0.812	1.632	1.448
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1.946	1.325		0.909			1.377	1.393	1.628	1.628	2.364	1.128
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2.972	2.158		1.902		0.493	2.478	2.17	3.242	3.242	4.282	1.494
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2.212	1.817		0.881			1.624	1.89	1.14	1.14	1.449	1.149
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.501	1.859		0.906		0.427	1.713	2.412	2.418	2.418	2.749	2.047
COVID19 (COVID19 (JANSSEN))	Angion cap decreased	1.816	1.486		0.898		0.371	1.192	2.322	1.155	1.155	2.17	1.305
COVID19 (COVID19 (JANSSEN))	Antibody test	2.367	0.949		0.876			0.864	1.773	2.095	2.095	2.199	1.896
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2.228	1.585		0.954	0.612	0.433	1.864	1.987	2.407	2.407	2.787	1.646
COVID19 (COVID19 (JANSSEN))	Areflexia	2.117	1.94		0.887			0.897	2.063	1.461	1.461	2.013	1.52
COVID19 (COVID19 (JANSSEN))	Atherosgram carotid abnormal	1.976	1.27		0.976			1.205	1.172	1.545	1.545	2.946	0.946
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.919	1.551		0.891	0.61	0.332	1.206	2.547	1.672	1.672	2.375	1.298
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1.811	1.564		0.893	0.609	0.298	1.298	2.336	1.834	1.834	2.18	1.332
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1.804	1.307		0.889		0.336	1.533	1.873	1.631	1.631	2.111	1.376
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1.96	1.482		0.904		0.403	1.487	2.263	1.873	1.873	2.31	1.554
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2.053	1.574		0.915		0.458	1.416	2.371	1.942	1.942	2.447	1.484
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3.51	2.957		1.92		0.505	1.869	2.604	2.604	2.604	4.477	1.129
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen increased	1.818	1.583		0.886		0.333	1.051	2.102	0.954	0.954	1.669	1.323
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1.917	1.536		0.916		0.279	1.222	2.138	1.646	1.646	2.533	1.207
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1.803	1.661		0.877		0.231	1.421	2.222	1.454	1.454	2.195	0.98
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1.815	1.232		0.889			1.109	2.027	1.564	1.564	1.993	1.544
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1.977	1.393		1.367			1.438	2.026	1.9	1.9	2.186	1.819
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2.737	2.191		0.877			1.806	2.926	1.113	1.113	2.379	2.304
COVID19 (COVID19 (JANSSEN))	CSF red blood cell count positive	2.04	1.768		0.876			1.354	1.67	1.113	1.113	1.691	1.507
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.333	1.829		0.923		0.52	1.94	1.932	1.532	1.532	3.557	1.114
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.606	1.916		0.911		0.534	1.228	1.333	1.09	1.09	3.281	0.964
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2.154	1.446		0.879			1.1	1.879	1.331	1.331	1.676	1.129
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3.295	2.289		0.916		0.521	2.252	2.341	3.919	3.919	4.173	1.173
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2.676	1.889		0.847	0.611	0.636	2.426	2.412	2.206	2.206	3.519	1.768
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	2.068	1.421		0.892			0.396	1.927	1.777	1.777	2.19	1.516
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2.109	1.577		0.917			1.454	2.133	2.149	2.149	2.446	1.768
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.613	1.834		1.007		0.458	2.143	2.293	3.139	3.139	3.247	2.014
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.839	1.454		0.896			1.274	2.34	2.15	2.15	2.372	1.372
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1.717	1.356		0.888	0.61	0.304	1.259	2.09	1.48	1.48	1.938	1.31
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.778	0.834		0.886		1.142	2.009	1.474	1.01	1.01	1.868	1.425
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.295	1.923		0.925	0.611	0.373	1.323	2.211	2.1	2.1	2.719	1.529
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2.162	1.488		0.925	0.611	0.329	1.718	2.333	1.615	1.615	2.544	1.544
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1.965	1.024		0.879		0.429	1.704	1.954	0.742	0.742	1.259	1.259
COVID19 (COVID19 (JANSSEN))	Gate delay	2.287	1.037		0.887		0.402	1.493	1.749	1.119	1.119	1.496	1.119
COVID19 (COVID19 (JANSSEN))	Globulins increased	1.903	1.387		0.892		0.4	1.436	1.553	1.584	1.584	2.111	1.282
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1.852	1.318		0.891			1.323	1.378	1.376	1.376	2.27	1.106
COVID19 (COVID19 (JANSSEN))	Guillain-Barre syndrome	2.312	1.859		1.02		1.42	1.821	2.159	1.714	1.714	2.159	1.568
COVID19 (COVID19 (JANSSEN))	Haemastrol decreased	1.857	1.914		0.607	0.607	0.429	1.407	2.113	1.789	1.789	2.22	1.456
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1.775	1.315		0.91		0.321	1.457	2.04	1.647	1.647	2.104	1.43
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.863	3.712		0.896		0.563	1.693	5.112	6.755	6.755	7.134	3.123
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.896	3.654		0.88		0.544	5.224	5.729	6.772	6.772	7.012	2.102
COVID19 (COVID19 (JANSSEN))	Hypoxia	1.842	1.305		0.915			1.427	1.964	1.722	1.722	2.263	1.522
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2.059	1.916		0.893		0.022	1.839	2.249	2.534	2.534	2.743	1.743
COVID19 (COVID19 (JANSSEN))	Intensive care	1.844	1.422		1.063		0.03	1.432	2.012	2.066	2.066	2.272	1.522
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1.898	1.36		0.898	0.746	0.408	1.659	2.079	2.029	2.029	2.268	1.304
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2.013	1.329		0.884			1.402	2.087	2.029	2.029	2.296	1.296
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2.113	1.896		0.896			1.594	1.986	1.729	1.729	2.744	1.744
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.899	1.469		0.876			1.232	2.18	1.101	1.101	1.707	1.718
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2.046	1.776		0.904			0.955	2.544	1.138	1.138	1.557	1.189
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1.726	1.668		0.896		0.187	1.479	2.066	1.87	1.87	2.066	1.298
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.167	1.663		0.885		0.486	1.829	1.922	2.279	2.279	2.514	1.588
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2.153	1.577		0.91	0.611	0.458	1.269	2.505	1.72	1.72	2.444	1.432
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration increased	1.651	1.241		0.886			1.337	1.444	2.068	2.068	2.14	1.986
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1.896	1.437		0.949		0.34	1.312	2.328	2.128	2.128	2.406	1.297
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2.048	1.473		0.901		0.484	1.012	2.116	1.698	1.698	2.955	1.74
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1.598	1.322		0.893	0.61	0.265	1.893	2.269	1.933	1.933	2.377	1.377
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1.598	1.327		0.884		0.15	1.248	1.782	1.475	1.475	2.286	0.91
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1.736	1.322		0.902		0.244	1.151	2.099	1.827	1.827	2.002	1.384
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	2.189	1.725		0.881			1.725	0.61	1.605	1.605	1.966	1.111
COVID19 (COVID19 (JANSSEN))	Off label use	1.339	0.29		0.88		6.71	0.329	0.394	0.324	0.324	0.842	1.265
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1.753	0.758		0.879			1.322	1.003	2.17	2.17	2.17	1.27
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.535	0.968		0.887		0.511	1.687	2.302	1.142	1.142	2.558	1.424
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3.211	1.633		0.879			0.656	1.064	1.883	1.883	2.637	0.962
COVID19 (COVID19 (JANSSEN))	Platelet count	2.779	2.485		0.922	0.61	0.469	1.841	3.139	2.199	2.199	3.136	1.856
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.898	1.407		0.905	0.609	0.291	1.591	2.125	2.029	2.029	2.149	1.489
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.734	2.006		0.884		0.388	2.038	3.081	2.23	2.23	3.387	1.704
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6.06	3.06		0.88			4.466	3.609	0.682	0.682	6.249	1.824
COVID19 (COVID19 (JANSSEN))	Plur quality product administered	1.304			0.964			4.059	3.449	6.226	6.226	4.576	4.014
COVID19 (COVID19 (JANSSEN))	Protrombin time prolonged	2.056	1.624		0.923	0.745	0.331	1.587	2.485	1.629	1.629	2.696	1.497
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.234	1.561		0.916	0.612	0.586	1.706	2.137	2.55	2.55	2.859	1.859
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.067	1.549		0.894			1.574	1.563	1.9			

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, December 14, 2021 7:20:05 AM
Attachments: [20211210_USST.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/10/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211210	US Serious EB05 20211210	US Fatal EB05 20211210	US Infant EB05 20211210	US Child EB05 20211210	US Teen EB05 20211210	US Adult1 EB05 20211210	US Adult2 EB05 20211210	US Adult3 EB05 20211210	US Female EB05 20211210	US Male EB05 20211210	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,157	1,750	0,803			0,396	1,525	1,761	2,356	1,761	2,362	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,239	1,764	0,889				1,678	2,199	2,135	2,966	1,615	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,993	1,314	0,985			0,459	1,368	1,883	1,818	2,257	1,618	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,832	2,086	0,868			0,521	1,871	2,629	2,629	3,084	2,494	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,035	1,019	0,885				0,939	0,679	1,659	1,617	1,425	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,923	1,315	0,908				1,455	1,371	1,659	2,314	1,141	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,833	2,097	0,905			0,494	2,214	2,079	2,922	4,176	1,489	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,179	1,643	0,876				1,847	1,126	1,882	2,372	1,442	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,482	1,828	0,904			0,429	1,672	2,396	2,349	2,686	2,02	
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,795	1,471	0,897			0,373	1,205	2,281	1,126	2,174	1,279	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,368	0,847	0,877				0,566	0,875	1,768	2,051	1,887	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,228	1,57	0,965	0,612		0,437	1,874	1,968	2,352	2,767	1,642	
COVID19 (COVID19 (JANSSEN))	Arterfexia	2,117	1,931	0,887				0,885	2,062	1,455	2,015	1,506	
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1,943	1,242	0,876				1,174	1,134	1,592	2,885	1,92	
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1,911	1,547	0,89	0,609		0,333	1,173	2,522	1,713	2,327	1,314	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,806	1,557	0,889	0,609		0,3	1,276	2,307	1,675	2,151	1,341	
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,765	1,28	0,885			0,339	1,49	1,835	1,607	2,075	1,35	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,941	1,464	0,901			0,409	1,463	2,21	1,881	2,297	1,526	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	2,012	1,539	0,913			0,462	1,385	2,349	1,892	2,407	1,457	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3,599	2,596	0,892			0,506	1,871	2,629	2,629	3,798	1,129	
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen increased	1,786	1,504	0,885			0,335	1,022	2,021	0,944	1,666	1,28	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,864	1,469	0,916			0,278	1,228	2,059	1,585	2,411	1,186	
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,764	1,805	0,875			0,237	1,424	2,137	1,417	2,182	1,095	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1,968	1,404	0,928				1,557	1,328	1,989	1,93	2,256	1,797
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,737	2,205	0,877				1,838	2,931	1,111	2,383	2,319	
COVID19 (COVID19 (JANSSEN))	CSF total blood cell count positive	2,034	1,765	0,877				1,355	1,669	1,105	1,684	1,508	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,319	1,664	0,908			0,52	1,918	1,632	1,503	3,48	1,126	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,685	1,967	0,929			0,529	1,184	1,332	1,197	3,723	0,943	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,185	1,584	0,878				1,13	1,229	1,327	2,734	1,014	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	2,642	3,267	0,926			0,522	2,327	2,377	0,813	2,937	1,014	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2,642	1,869	0,958	0,611		0,638	2,342	2,395	2,195	3,471	1,755	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	2,004	1,41	0,902			0,394	1,651	2,003	1,754	2,195	1,513	
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2,092	2,549	0,921			0,484	1,44	2,192	2,4	1,651	1,851	
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,611	1,827	1,013			0,46	2,282	2,153	3,127	2,021	2,021	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,789	1,386	0,894				1,246	2,226	1,569	2,082	1,244	
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,699	1,320	0,886			0,307	1,050	2,043	1,995	2,905	1,305	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,295	1,303	0,883	0,61		0,376	2,207	2,126	2,021	2,545	1,686	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,154	1,469	0,93	0,611		0,332	1,686	2,306	2,157	2,473	1,554	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,963	1,023	0,876			0,433	1,007	2,074	1,921	2,741	1,301	
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,274	1,027	0,886			0,405	2,34	1,731	1,102	2,463	1,492	
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,874	1,36	0,891			0,4	1,435	1,55	1,537	2,124	1,236	
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,815	1,029	0,89				1,391	1,34	2,202	1,341	1,071	
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,311	1,862	0,878				1,462	2,913	1,695	2,177	2,144	
COVID19 (COVID19 (JANSSEN))	Haematoct decreased	1,846	1,355	0,911	0,606		0,434	1,388	2,089	1,79	2,218	1,442	
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,713	1,306	0,908	0,607		0,327	1,45	2,018	1,645	1,428	1,428	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,664	3,714	0,915				3,994	5,116	6,752	7,146	3,167	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,584	3,57	0,879			0,544	4,684	5,734	0,771	7,693	1,778	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,839	1,508	0,917				1,489	1,84	1,738	2,277	1,524	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,105	1,921	0,882			0,024	1,928	2,637	1,565	2,292	1,733	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,854	1,43	0,997			0,031	1,443	1,996	2,065	2,288	1,462	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,878	1,332	0,896	0,746		0,409	1,844	2,45	2,468	2	1,291	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,014	1,329	0,883				1,404	2,076	1,007	1,152	1,255	
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2,056	1,876	0,882			0,197	1,497	1,197	0,729	2,979	0,733	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,899	1,453	0,875				1,226	2,164	1,086	1,69	1,716	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,046	1,761	0,891			0,189	1,119	1,561	1,542	1,861	1,166	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,654	1,267	0,899			0,189	1,042	2,063	1,848	2,079	1,226	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,137	1,643	0,884			0,485	1,846	1,896	2,217	2,494	1,517	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,117	1,529	0,911	0,611		0,461	1,461	1,208	1,624	1,624	1,389	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin decreased	1,632	1,224	0,885			0,334	1,014	1,485	1,233	1,908	0,969	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,898	1,439	0,903			0,344	1,29	2,329	1,417	2,2	1,313	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,075	1,495	0,895			0,405	1,44	1,908	2,192	1,673	1,872	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,574	1,309	0,89	0,61		0,268	0,947	2,034	1,966	2,359	1,081	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,565	1,288	0,883			0,166	1,229	1,733	1,44	2,229	0,896	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,727	1,311	0,886			0,247	1,149	2,07	1,915	1,372	1,372	
COVID19 (COVID19 (JANSSEN))	Nonspecific reaction	2,188	0,724	0,88			0,761	0,81	0,61	0,81	1,767	0,896	
COVID19 (COVID19 (JANSSEN))	Off label use	1,34	0,232	0,886			0,708	0,757	0,629	0,421	1,051	1,544	
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,752	0,76	0,879				1,134	1,003	1,003	2,17	1,025	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,522	0,865	0,879			0,512	1,689	2,381	1,14	2,579	1,494	
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3,208	1,842	0,896	0,61		0,47	0,656	1,063	1,849	2,618	0,962	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,779	2,439	0,921				1,869	3,144	2,165	2,139	1,813	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,901	1,414	0,904	0,608		0,292	1,591	2,138	1,518	2,208	1,503	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,735	2,015	0,894			0,393	2,05	3,029	2,244	3,376	1,708	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,062	3,496	0,909				4,482	3,633	0,892	6,265	1,838	
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1,305		0,97			0,403	4,053	3,445	6,104	4,524	4,055	
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	2,024	1,588	0,923	0,745		0,334	1,569	2,419	1,612	2,604	1,492	
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,236	1,646	0,903	0,612		0,589	1,716	2,124	2,676	2,529	1,86	
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,067	1,521	0,891				1,559	1,562	1,866	1,938	1,723	
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,873	1,373	0,898	0,607		0,536	1,447	2,134	1,664	2,089	1,557	
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,103	1,421	0,905	0,61		0,353	1,28	2,281	1,759	2,42	1,375	
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2,386	1,342	0,884			0,53	1,648	1,908	1,457	1,666	1,666	
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3,228	2,597	0,929			1,739	1,947	2,255	1,177	2,654	3,048	
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7,0											

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, December 21, 2021 10:44:00 AM
Attachments: [USST_20211217.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/17/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211217	US Serious EB05 20211217	US Fatal EB05 20211217	US Infant EB05 20211217	US Child EB05 20211217	US Teen EB05 20211217	US Adult1 EB05 20211217	US Adult2 EB05 20211217	US Adult3 EB05 20211217	US Female EB05 20211217	US Male EB05 20211217	Comment	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1 747	1 747	0 592				0 401	1 535	1 704	2 267	2 202	3 074	1 693
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2 284	1 812	0 887					1 704	2 267	2 202	3 074	1 693	1 639
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1 987	1 319	0 984				0 461	1 35	1 893	1 821	2 229	2 229	1 572
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2 52	0 832	0 348				0 522	0 862	0 867	0 867	2 582	1 427	1 516
COVID19 (COVID19 (JANSSEN))	Adverse event	2 028	1 029	0 885					0 961	0 785	0 872	1 597	1 516	1 516
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1 967	1 373	0 905					1 432	1 432	1 441	1 757	1 229	1 229
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2 823	2 104	0 909				0 496	2 224	2 056	2 072	4 149	1 513	1 513
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2 177	1 622	1 127					1 925	1 953	1 953	2 347	2 347	2 347
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2 467	1 808	0 903				0 429	1 691	2 36	2 36	2 654	2	2
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	1 773	1 435	0 895				0 376	1 199	2 276	2 111	1 098	2 11	1 289
COVID19 (COVID19 (JANSSEN))	Antibody test	2 038	1 838	0 875				0 569	0 569	1 745	1 687	1 745	1 865	1 865
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2 231	1 558	0 965		0 612		0 441	1 842	1 958	2 347	2 74	1 635	1 635
COVID19 (COVID19 (JANSSEN))	Arrhythmia	2 103	1 899	0 885					0 873	2 044	1 442	1 935	1 506	1 506
COVID19 (COVID19 (JANSSEN))	Atherosclerotic carotid abnormal	1 929	1 221	0 876					1 159	1 134	1 552	2 734	0 914	0 914
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1 905	1 527	0 888		0 609		0 338	1 179	2 519	1 705	2 296	1 34	1 34
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1 776	1 521	0 888		0 609		0 305	1 238	2 285	1 67	2 125	1 324	1 324
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1 754	1 285	0 882				0 343	1 466	1 868	1 801	2 056	1 379	1 379
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1 923	1 449	0 898				0 413	1 438	2 214	1 853	2 261	1 538	1 538
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1 986	1 508	0 912				0 467	1 353	2 322	1 969	2 364	1 445	1 445
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	3 41	2 516	0 89				0 507	1 783	2 65	0 786	4 455	1 106	1 106
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1 836	1 431	0 914				0 28	1 187	2 046	1 587	2 349	1 194	1 194
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1 745	1 552	0 873				0 238	1 43	2 1	1 363	2 156	0 936	0 936
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1 763	1 223	0 881					1 053	2 006	1 587	1 97	1 529	1 529
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	1 978	1 443	1 384					1 596	2 036	1 973	2 319	1 83	1 83
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2 71	2 213	0 875					1 81	3 007	1 1	2 466	2 301	2 301
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2 335	1 786	0 925			0 521		1 882	1 92	1 486	3 472	1 109	1 109
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2 75	2 005	0 91				0 53	1 31	1 307	1 194	3 968	0 931	0 931
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2 215	1 572	0 876					1 101	1 222	1 394	2 764	1 001	1 001
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3 303	2 313	0 924			0 523		2 337	2 384	0 869	3 978	1 214	1 214
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	2 856	2 036	0 909				0 611	1 613	2 395	1 616	3 472	1 74	1 74
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	1 999	1 401	0 9				0 392	1 657	1 966	1 783	2 184	1 516	1 516
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	2 094	1 525	0 919				0 468	1 413	2 087	2 082	2 377	1 643	1 643
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax normal	2 808	2 008	0 927				0 462	1 807	2 277	2 077	3 095	1 711	1 711
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1 781	1 359	0 882					1 284	2 241	1 498	2 052	1 254	1 254
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1 681	1 313	0 884		0 61		0 311	1 262	2 037	1 407	1 873	1 302	1 302
COVID19 (COVID19 (JANSSEN))	Fading cold	1 933	1 383	0 863				0 521	1 129	1 471	1 897	2 002	1 427	1 427
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2 288	1 302	0 884				0 375	2 204	2 124	1 988	2 541	1 667	1 667
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2 149	1 456	0 929		0 611		0 338	1 659	2 298	2 138	2 446	1 555	1 555
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1 96	1 361	0 873				0 437	1 621	2 019	1 834	2 019	1 302	1 302
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2 289	1 069	0 887				0 408	2 35	1 771	1 164	2 453	1 561	1 561
COVID19 (COVID19 (JANSSEN))	Globulins increased	1 852	1 316	0 889				0 403	1 433	1 826	1 518	2 115	1 212	1 212
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1 792	1 392	0 883					1 302	1 33	1 133	1 058	1 058	1 058
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2 297	1 856	0 876					1 518	2 866	1 677	2 157	1 213	1 213
COVID19 (COVID19 (JANSSEN))	Haemolysis decreased	1 837	1 344	0 909		0 606		0 34	1 368	2 111	1 759	2 191	1 452	1 452
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1 771	1 301	0 883		0 607		0 432	1 618	2 023	1 618	2 073	1 436	1 436
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5 64	3 65	0 894				0 406	4 005	4 992	6 197	7 101	2 99	2 99
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6 498	3 555	0 877				0 544	4 694	5 745	6 762	7 708	1 712	1 712
COVID19 (COVID19 (JANSSEN))	Hypoxia	1 851	1 309	0 879				0 462	1 562	1 946	1 845	2 468	1 548	1 548
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2 115	1 927	0 88				0 025	1 958	2 65	1 531	2 319	1 748	1 748
COVID19 (COVID19 (JANSSEN))	Intensive care	1 856	1 44	1 113				0 032	1 433	2 029	2 074	2 268	1 502	1 502
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1 879	1 325	0 884			0 747		1 613	2 008	1 444	2 268	1 291	1 291
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2 029	1 342	0 881				0 413	1 39	2 089	1 995	2 149	1 279	1 279
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	2 056	1 863	0 878					1 459	2 925	1 197	1 024	0 733	0 733
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1 895	1 441	0 873					1 234	2 15	1 769	1 709	1 889	1 889
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2 023	1 815	0 876					1 815	0 856	1 612	1 685	1 112	1 112
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1 663	1 279	0 897				0 192	1 043	2 113	1 836	2 091	1 244	1 244
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2 141	1 54	0 885				0 489	1 843	2 208	2 465	2 465	1 567	1 567
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2 152	1 152	0 890				0 464	1 302	2 143	1 451	2 451	1 375	1 375
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin decreased	1 651	1 232	0 883				0 336	1 004	2 046	1 315	1 945	0 944	0 944
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1 874	1 417	0 901				0 349	1 251	2 331	1 418	2 144	1 335	1 335
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2 094	1 964	0 897					1 009	1 692	2 173	1 765	1 682	1 682
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1 567	1 296	0 888		0 61		0 27	0 951	2 023	1 848	2 363	1 075	1 075
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1 553	1 285	0 881				0 172	1 212	2 075	1 396	2 204	0 891	0 891
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1 732	1 302	0 895				0 249	1 32	2 119	1 792	2 001	1 302	1 302
COVID19 (COVID19 (JANSSEN))	Nonspecific reaction	2 188	0 725						0 761	0 811	0 811	1 956	0 895	0 895
COVID19 (COVID19 (JANSSEN))	Off label use	1 34	0 228	0 878				7 528	1 25	1 382	1 161	1 392	1 952	1 952
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1 752	0 76	0 877					3 17	1 002	1 002	2 183	1 183	1 183
COVID19 (COVID19 (JANSSEN))	Pain assessment	2 522	0 864					0 513	1 677	2 304	1 131	2 511	1 479	1 479
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3 305	1 648	0 877					0 656	1 083	1 834	2 65	0 962	0 962
COVID19 (COVID19 (JANSSEN))	Platelet count	2 762	2 458	0 919		0 61		0 472	1 886	3 107	2 578	3 194	1 838	1 838
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1 894	1 397	0 901		0 608		0 298	1 564	2 145	1 498	2 206	1 495	1 495
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2 73	1 978	0 893				0 394	2 027	2 978	2 176	3 298	1 709	1 709
COVID19 (COVID19 (JANSSEN))	Platelet factor	6 063	3 513	0 878					4 453	3 726	0 681	6 271	1 847	1 847
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1 305						0 977	4 068	3 443	6 177	4 557	0 885	0 885
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	2 029	1 586	0 922		0 745		0 339	1 568	2 438	1 602	2 597	1 51	1 51
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2 23	1 634	1 542		0 612		0 592	1 691	2 094	2 698	2 519	1 842	1 842
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2 056	1 557	0 894					1 603	1 905	1 923	1 957	1 781	1 781
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1 858	1 358	0 885		0 607			1 426	2 154	2 062	1 629	1 563	1 563
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2 017	1 407	0 903		0 61		0 357	1 241	2 32	1 728	2 369	1 402	1 402
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2 278	1 278	0 882				0 531	1 639	1 891	1 452	2 377	1 645	1 645
COVID19 (COVID19 (JANSSEN))	Suspected COVID-19	3 227	2 533	1 676				0 53	2 026	2 237	1 169	2 644	2 644	2 644
COVID19 (COVID19 (JANSSEN))	Therapy non-responder	7 028	0 789	0 878				0 646	3 52	6 721	15 803	7 878	5 962	5 962
COVID19 (COVID19 (JANSSEN))	Therapy partial responder	2 373										0 672	0 672	0 672
COVID19 (COVID19 (JANSSEN))	Thrombectomy	2 152	1 551	0 891					1 407	1 664	1 362	2 214	1 353	1 353
COVID19 (COVID19 (JANSSEN))	Thrombocytopenia	2 34	1 947	0 94				0 379	1 695	2 49	2 669	1 809	1 787	1 787
COVID19 (COVID19 (JANSSEN))	Thrombosis	2 078	1 789	0										

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, January 4, 2022 6:39:06 AM
Attachments: [USST_20211231.xls](#)

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/31/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20211231	US Serious EB05 20211231	US Fatal EB05 20211231	US Infant EB05 20211231	US Child EB05 20211231	US Teen EB05 20211231	US Adult EB05 20211231	US Adult2 EB05 20211231	US Adults EB05 20211231	US Female EB05 20211231	US Male EB05 20211231	Comment
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,12	1,14	1,97			0,405	1,59	2,14	2,15	2,14	1,415	
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,284	1,177	0,887				1,747	2,236	2,268	1,517	1,572	
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	2,019	1,333	0,982			0,461	1,42	1,949	1,835	2,3	1,651	
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,911	0,843	0,876			0,523	0,957	2,222	2,004	2,611	1,925	
COVID19 (COV D19 (ANSEN))	Adverse event	2,022	1,088	0,861				0,961	0,718	1,485	0,78	1,684	
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,948	1,374	0,903				1,473	1,431	1,609	1,69	1,268	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	2,749	1,966	1,269			0,491	2,022	2,002	2,222	1,472	2,022	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	2,243	1,231	0,876				1,96	1,868	1,724	1,224	1,479	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,485	1,868	1,263			0,43	1,834	2,421	1,967	2,369	1,807	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary normal	1,787	1,431	0,893			0,38	1,179	2,268	1,988	1,187	1,208	
COVID19 (COV D19 (ANSEN))	Antibody test	2,359	0,822	0,872			0,568	0,858	1,692	1,923	2,083	1,8	
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,245	1,553	0,995			0,437	1,856	1,862	2,359	2,177	1,638	
COVID19 (COV D19 (ANSEN))	Areflexia	1,893	0,883	0,883				0,875	2,113	1,931	1,434	1,532	
COVID19 (COV D19 (ANSEN))	Arterogram carotid abnormal	1,883	1,175	0,873				1,147	1,101	1,534	2,485	0,903	
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,906	1,492	0,884	0,61		0,34	1,199	2,514	1,677	2,323	1,33	
COVID19 (COV D19 (ANSEN))	Basophil percentage decreased	1,773	1,487	0,884	0,609			1,246	2,284	1,681	2,151	1,311	
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,775	1,294	0,886			0,345	1,473	1,85	1,683	2,119	1,373	
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,918	1,434	0,896			0,416	1,446	2,296	1,841	2,291	1,511	
COVID19 (COV D19 (ANSEN))	Blood chloride increased	1,976	1,488	0,915			0,464	1,352	2,301	1,896	2,363	1,438	
COVID19 (COV D19 (ANSEN))	Blood thrombin decreased	3,368	2,525	0,888			0,505	1,928	2,47	0,785	4,425	1,101	
COVID19 (COV D19 (ANSEN))	Blood thrombin increased	1,851	1,427	0,916			0,293	1,245	2,398	1,897	1,594	1,612	
COVID19 (COV D19 (ANSEN))	Blood sodium increased	1,507	1,08	0,902				1,359	1,376	2,009	2,009	0,795	
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,737	1,516	0,874	0,247			1,44	2,078	1,833	2,17	1,919	
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,833	1,244	0,879				1,141	2,063	1,61	2,037	1,543	
COVID19 (COV D19 (ANSEN))	COV D-19 pneumonia	1,995	1,441	1,358				1,603	2,084	1,987	2,328	1,862	
COVID19 (COV D19 (ANSEN))	CSF immunoglobulin increased	2,034	1,177	0,883				0,953	1,453	0,868	1,583	0,868	
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,761	2,202	0,873				1,825	3,05	2,519	1,086	2,312	
COVID19 (COV D19 (ANSEN))	CSF red blood cell count positive	2,004	1,724	0,873				1,305	1,751	1,081	1,742	1,46	
COVID19 (COV D19 (ANSEN))	Cerebral haemorrhage	2,357	1,729	0,92	0,518			1,876	1,881	1,49	3,436	1,087	
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	3,038	2,068	0,907	0,527			1,473	1,309	1,263	0,919	1,263	
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,289	1,679	0,875				1,086	1,334	1,45	2,912	1,2	
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	3,309	2,217	0,918	0,524			2,407	2,983	1,667	2,983	1,667	
COVID19 (COV D19 (ANSEN))	Computed tomogram head abnormal	2,031	1,832	0,943	0,611			2,333	3,397	2,19	1,742	2,19	
COVID19 (COV D19 (ANSEN))	Computed tomogram head normal	2,017	1,384	0,919	0,395			1,845	2,034	2,255	1,582	1,768	
COVID19 (COV D19 (ANSEN))	Computed tomogram thorax abnormal	2,075	0,983	0,407	0,611			1,455	2,067	2,032	1,636	1,636	
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	2,607	1,796	0,978	0,485			2,171	2,597	2,015	3,219	2,015	
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,769	1,328	0,883				1,271	2,058	1,663	2,058	1,663	
COVID19 (COV D19 (ANSEN))	Eosinophil percentage decreased	1,685	1,309	0,879	0,61			1,284	2,054	1,382	1,908	1,289	
COVID19 (COV D19 (ANSEN))	Feeling cold	1,78	0,833	0,881			1,133	2,018	1,471	0,98	1,805	1,421	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,286	1,379	0,881				1,278	1,767	2,543	1,917	1,69	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	2,145	1,451	0,928	0,612			1,656	2,285	2,211	1,577	2,447	
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,953	1,022	0,874	0,442			1,889	2,028	0,729	2,131	1,314	
COVID19 (COV D19 (ANSEN))	Glucose palsy	2,337	1,114	0,885	0,411			1,763	1,693	2,463	1,632	1,304	
COVID19 (COV D19 (ANSEN))	Glucosuria	1,865	1,328	0,889	0,407			1,428	1,559	1,205	1,585	1,205	
COVID19 (COV D19 (ANSEN))	Glomerular filtration rate decreased	1,775	1,161	0,886				1,014	2,03	1,74	1,965	1,36	
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,845	1,185	0,862				1,511	1,303	1,979	1,379	1,303	
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,301	1,85	0,873				1,516	2,927	1,689	1,689	1,689	
COVID19 (COV D19 (ANSEN))	Haemolysis	1,948	1,343	0,888	0,422			1,368	2,168	2,027	1,446	1,446	
COVID19 (COV D19 (ANSEN))	Haemolysis decreased	1,782	1,13	0,902	0,608			1,422	2,105	1,644	2,127	1,644	
COVID19 (COV D19 (ANSEN))	Hepatin-induced thrombocytopenia test	5,616	3,658	0,892				4,036	5,197	7,239	5,876	2,96	
COVID19 (COV D19 (ANSEN))	Hepatin-induced thrombocytopenia test positive	6,499	3,567	0,875	0,545			4,723	6,298	7,144	6,173	3,144	
COVID19 (COV D19 (ANSEN))	Hypoxia	1,872	1,327	0,912				1,535	1,972	1,759	1,559	1,759	
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,114	1,887	0,877	0,027			1,969	2,593	1,517	1,725	1,725	
COVID19 (COV D19 (ANSEN))	Intensive care	1,861	1,434	0,903	0,434			1,907	2,033	2,08	1,523	1,523	
COVID19 (COV D19 (ANSEN))	International normalised ratio increased	1,911	1,366	0,891	0,747			1,646	2,048	1,522	1,348	1,522	
COVID19 (COV D19 (ANSEN))	International normalised ratio normal	2,016	1,39	0,879				1,472	2,163	0,99	2,225	1,329	
COVID19 (COV D19 (ANSEN))	Jugular vein thrombosis	2,045	1,456	0,878	0,47			1,759	1,959	1,72	2,887	1,72	
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,884	1,433	0,87				1,919	2,186	1,708	1,083	1,708	
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,02	1,765	0,886	0,196			0,979	2,066	1,873	1,056	1,736	
COVID19 (COV D19 (ANSEN))	Lumbar puncture decreased	1,574	1,048	0,874	0,216			1,056	1,968	1,967	2,018	1,967	
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	1,668	1,275	0,896	0,16			1,055	2,059	1,847	2,128	1,234	
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,153	1,829	0,888	0,608			1,884	2,589	1,884	2,209	1,811	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin concentration decreased	2,143	1,516	0,91	0,612			1,234	2,405	1,744	2,436	1,368	
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin decreased	1,645	1,224	0,882	0,335			1,035	2,006	1,318	1,922	1,318	
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	1,861	1,361	0,902	0,35			1,247	2,145	1,45	2,165	1,45	
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	2,088	1,518	0,977	0,486			1,219	2,199	1,768	1,855	1,768	
COVID19 (COV D19 (ANSEN))	Mechanical ventilation percentage increased	1,588	1,252	0,89	0,61			0,939	2,048	1,972	2,389	1,084	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,549	1,252	0,878	0,185			1,182	1,789	0,866	1,454	1,454	
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	1,732	1,315	0,897	0,251			1,145	2,104	1,376	2,034	1,376	
COVID19 (COV D19 (ANSEN))	Nospecific reaction	2,191	0,725	0,878				0,762	0,611	1,965	1,069	1,069	
COVID19 (COV D19 (ANSEN))	Off label use	1,339	0,266	0,878	0,766			1,234	1,334	0,821	1,374	1,334	
COVID19 (COV D19 (ANSEN))	On and off phenomenon	1,754	0,759	0,875				3,246	1,003	2,205	2,205	2,205	
COVID19 (COV D19 (ANSEN))	Pain assessment	2,523	0,86	0,878	0,514			1,874	2,182	1,114	2,445	1,431	
COVID19 (COV D19 (ANSEN))	Peripartum embolism	3,214	1,631	0,875				0,657	1,063	1,82	2,689	1,82	
COVID19 (COV D19 (ANSEN))	Platelet count	2,772	2,352	0,921	0,611			1,848	3,003	2,61	3,163	1,793	
COVID19 (COV D19 (ANSEN))	Platelet count decreased	1,887	1,362	0,899	0,809			1,556	2,116	1,502	2,191	1,481	
COVID19 (COV D19 (ANSEN))	Platelet count normal	2,725	1,978	0,991	0,394			2,046	2,95	3,296	2,203	1,708	
COVID19 (COV D19 (ANSEN))	Platelet factor 4	6,003	3,517	0,876				4,527	3,803	0,817	6,294	2,614	
COVID19 (COV D19 (ANSEN))	Poor quality product administered	1,305	0,305	0,968				4,127	3,304	5,945	4,499	4,499	
COVID19 (COV D19 (ANSEN))	Prothrombin time prolonged	2,038	1,598	0,92	0,746			1,584	2,469	1,652	2,689	1,517	
COVID19 (COV D19 (ANSEN))	Pulmonary embolism	2,222	1,606	1,508	0,612			1,703	2,059	2,677	2,507	1,824	
COVID19 (COV D19 (ANSEN))	Pulmonary thrombosis	2,047	1,541	0,896	0,612			1,687	1,601	1,878	1,596	1,596	
COVID19 (COV D19 (ANSEN))	Red blood cell count decreased	1,881	1,387	0,897	0,608			1,432	2,143	1,556	1,696	1,556	
COVID19 (COV D19 (ANSEN))	Red cell distribution width increased	2,033	1,469	0,905	0,611			0,949	1,273	2,338	1,427	1,427	
COVID19 (COV D19 (ANSEN))	Superficial vein thrombosis	2,403	1,362	0,88				1,091	1,815	2,366	1,815	1,678	
COVID19 (COV D19 (ANSEN))	Suspected COV D-19	3,228	2,434	1,038	0,531			2,378	2,647	3,084	1,207	3,084	
COVID19 (COV D19 (ANSEN))	Therapy non-responder	7,03	0,786	0,876	0,646			3,575	0,692	15,662	7,823	5,922	
COVID19 (COV D19 (ANSEN))	Therapy partial responder	3,777	0,876	0,876	0,646			0,646	0,637	0,572	0,568	1,019	
COVID19 (COV D19 (ANSEN))	Thrombectomy	2,171	1,594	0,889	0,511			1,467	1,632	1,528	2,345	1,364	
COVID19 (COV D19 (ANSEN))	Thrombocytopenia	1,904	1,338	0,941	0,382			1,091	2,488	2,488	1,776	1,776	
COVID19 (COV D19 (ANSEN))	Thrombosis	2,675	2,124	1,738	0,612			1,953	2,404	3,51	2,21	2,21	
COVID19 (COV D19 (ANSEN))	Thrombosis with thrombocytopenia syndrome	4											

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Wednesday, January 12, 2022 5:27:15 AM

Good morning all,

Please note we are having technical difficulties accessing our data mining and I'll forward weekly output when able. Apologies for the delay.

Best,

David

From: Menschik, David
Sent: Tuesday, January 04, 2022 6:39 AM
To: Shimabukuro, Tom (CDC) <ayv6@cdc.gov>; Su, John (CDC) <ezu2@cdc.gov>; Moro, Pedro L (CDC) <psm9@cdc.gov>
Cc: Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>; Broder, Karen R (CDC) <krb2@cdc.gov>; Harrington, Theresa (CDC) <tsh3@cdc.gov>
Subject: RE: Weekly data mining

Good morning,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 12/31/21). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: Weekly data mining
Date: Wednesday, January 12, 2022 9:03:53 AM
Attachments: [USST_20220107.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/7/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220107	US Serious EB05 20220107	US Fatal EB05 20220107	US Infant EB05 20220107	US Child EB05 20220107	US Teen EB05 20220107	US Adult1 EB05 20220107	US Adult2 EB05 20220107	US Adult3 EB05 20220107	US Female EB05 20220107	US Male EB05 20220107	Comment
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time prolonged	2,146	1,762	0,925				0,404	1,635	1,976	1,713	1,488	
COVID19 (COV D19 (ANSEN))	Activated partial thromboplastin time shortened	2,254	1,774	0,984				0,404	1,735	2,222	2,202	1,545	
COVID19 (COV D19 (ANSEN))	Acute respiratory failure	2,032	1,332	0,977				0,461	1,417	1,849	1,843	2,328	
COVID19 (COV D19 (ANSEN))	Adverse drug reaction	2,941	2,142	1,077				0,523	0,942	2,012	0,843	2,008	
COVID19 (COV D19 (ANSEN))	Adverse event	2,02	1,054	0,954				0,881	0,712	1,488	0,772	1,488	
COVID19 (COV D19 (ANSEN))	Angiogram abnormal	1,954	1,134	0,901				0,491	1,502	1,423	1,684	2,25	1,253
COVID19 (COV D19 (ANSEN))	Angiogram cerebral abnormal	2,142	1,242	1,007				0,491	2,206	2,012	2,511	1,486	
COVID19 (COV D19 (ANSEN))	Angiogram cerebral normal	2,257	1,641	0,872				0,491	1,963	1,879	1,619	1,461	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary abnormal	2,484	1,718	1,020				0,399	0,43	1,626	2,304	2,713	
COVID19 (COV D19 (ANSEN))	Angiogram pulmonary normal	1,789	1,422	0,889				0,378	1,232	1,232	1,332	1,132	
COVID19 (COV D19 (ANSEN))	Anticoagulant therapy	2,359	0,823	0,869	0,612			0,355	0,854	1,088	1,925	2,088	
COVID19 (COV D19 (ANSEN))	Arteriojugular catheter	2,144	1,544	0,925				0,435	1,84	1,885	2,379	1,688	
COVID19 (COV D19 (ANSEN))	Areflexia	1,923	0,881	0,875				0,335	0,875	2,192	1,425	2,019	1,528
COVID19 (COV D19 (ANSEN))	Arterigram carotid abnormal	1,878	1,185	0,873				0,34	1,146	1,146	1,516	2,491	0,936
COVID19 (COV D19 (ANSEN))	Arterigram carotid decreased	1,521	1,518	0,881	0,61			0,34	1,221	2,485	1,76	2,368	1,527
COVID19 (COV D19 (ANSEN))	Basophil count decreased	1,777	1,5	0,883	0,609			0,304	1,265	2,253	2,179	1,319	
COVID19 (COV D19 (ANSEN))	Blood albumin decreased	1,78	1,316	0,883				0,344	1,485	1,858	1,744	2,184	1,372
COVID19 (COV D19 (ANSEN))	Blood calcium decreased	1,501	1,446	0,896				0,415	1,458	2,188	1,988	2,311	1,522
COVID19 (COV D19 (ANSEN))	Blood chloride increased	1,976	1,503	0,919				0,461	1,368	2,262	1,972	2,364	1,461
COVID19 (COV D19 (ANSEN))	Blood fibrinogen decreased	3,371	2,505	0,886				0,505	1,897	2,477	0,785	4,377	1,101
COVID19 (COV D19 (ANSEN))	Blood fibrinogen increased	1,84	1,84	0,918				0,284	1,231	1,972	1,703	1,853	
COVID19 (COV D19 (ANSEN))	Blood potassium decreased	1,676	1,125	0,899				0,548	1,237	1,481	2,031	1,874	1,193
COVID19 (COV D19 (ANSEN))	Blood urea decreased	1,725	1,508	0,887				0,243	1,471	2,011	1,915	1,953	
COVID19 (COV D19 (ANSEN))	Blood urea increased	1,628	1,251	0,871				0,548	1,138	2,027	1,642	2,102	1,936
COVID19 (COV D19 (ANSEN))	COV D-19 pneumonia	2	1,433	1,28				0,659	1,659	2,083	1,988	2,297	1,878
COVID19 (COV D19 (ANSEN))	CSF immunoglobulin increased	2,037	1,701	0,881				0,953	1,431	1,545	0,565	1,585	
COVID19 (COV D19 (ANSEN))	CSF protein increased	2,788	2,199	0,869				1,827	3,057	3,057	1,078	2,487	2,316
COVID19 (COV D19 (ANSEN))	Cerebral haemorrhage	2,344	1,707	0,919				0,519	1,841	1,875	1,47	3,388	1,073
COVID19 (COV D19 (ANSEN))	Cerebral mass effect	3,011	2,142	0,906				0,527	1,474	1,308	1,242	4,161	0,919
COVID19 (COV D19 (ANSEN))	Cerebral thrombosis	2,29	1,656	0,872				1,075	1,334	2,807	1,425	2,807	1,2
COVID19 (COV D19 (ANSEN))	Cerebral venous sinus thrombosis	3,31	2,267	0,917				0,524	2,414	2,296	0,883	3,94	1,246
COVID19 (COV D19 (ANSEN))	Computerized tomogram head abnormal	2,613	0,945	0,921	0,611			0,621	1,945	2,291	2,342	2,342	1,72
COVID19 (COV D19 (ANSEN))	Computerized tomogram head normal	2,013	1,384	0,898				0,394	2,074	2,004	1,485	1,485	
COVID19 (COV D19 (ANSEN))	Computerized tomogram thorax abnormal	2,074	1,984	0,914				0,465	1,431	2,012	1,662	1,984	1,62
COVID19 (COV D19 (ANSEN))	Deep vein thrombosis	2,607	2,607	0,959				0,462	2,181	2,045	2,288	3,209	2,01
COVID19 (COV D19 (ANSEN))	Eosinophil count decreased	1,737	1,319	0,884				0,314	1,281	1,476	1,496	1,223	1,223
COVID19 (COV D19 (ANSEN))	Eosinophil percentage decreased	1,78	1,319	0,871	0,61			1,78	1,326	1,522	1,862	1,368	
COVID19 (COV D19 (ANSEN))	Feeling cold	1,78	0,838	0,879				1,13	2,002	1,466	0,976	1,854	1,473
COVID19 (COV D19 (ANSEN))	Fibrin D dimer	2,286	1,253	0,878				0,379	2,192	2,148	1,903	1,675	1,675
COVID19 (COV D19 (ANSEN))	Fibrin D dimer increased	2,14	1,444	0,925	0,612			0,333	1,857	2,27	2,438	2,373	1,53
COVID19 (COV D19 (ANSEN))	Fibrin D dimer normal	1,959	1,037	0,87				0,441	1,673	2,052	0,8	1,139	1,329
COVID19 (COV D19 (ANSEN))	Gate palsy	2,313	1,101	0,883				0,411	2,293	1,763	2,94	2,485	1,27
COVID19 (COV D19 (ANSEN))	Glaucoma increased	1,878	1,366	0,845				0,465	1,415	1,656	1,524	1,948	1,556
COVID19 (COV D19 (ANSEN))	Glucose urine present	1,847	1,279	0,89				1,482	1,287	1,293	1,423	1,103	1,103
COVID19 (COV D19 (ANSEN))	Gullain-Barre syndrome	2,313	1,845	0,87				1,534	2,884	2,178	1,661	2,178	2,178
COVID19 (COV D19 (ANSEN))	Haemoglobin decreased	1,85	1,352	0,877	0,607			0,445	1,377	1,979	1,444	1,844	1,444
COVID19 (COV D19 (ANSEN))	Haemoglobin increased	1,783	1,306	0,901	0,608			0,331	1,431	2,028	1,68	1,41	1,68
COVID19 (COV D19 (ANSEN))	Hepain-induced thrombocytopenia test	6,616	6,655	0,989				0,409	4,329	5,201	2,342	2,37	2,37
COVID19 (COV D19 (ANSEN))	Hepain-induced thrombocytopenia test positive	6,499	6,499	0,972				0,545	4,729	5,913	2,469	2,469	
COVID19 (COV D19 (ANSEN))	Hypoxia	1,869	1,333	0,922				0,577	1,987	1,987	1,767	1,562	1,562
COVID19 (COV D19 (ANSEN))	Immunoglobulin therapy	2,111	1,852	0,874				0,027	1,986	2,574	1,428	2,262	1,763
COVID19 (COV D19 (ANSEN))	Intensive care	1,858	1,424	0,873				1,033	2,038	2,038	2,241	1,528	1,528
COVID19 (COV D19 (ANSEN))	International normalised ratio increased	1,897	1,346	0,888	0,747			0,409	1,651	2,019	1,492	2,044	1,319
COVID19 (COV D19 (ANSEN))	International normalised ratio normal	2,017	1,395	0,876				1,472	1,928	1,928	0,939	1,237	1,237
COVID19 (COV D19 (ANSEN))	Jugular vein thrombosis	2,046	1,843	0,875				1,511	1,917	2,703	0,719	1,319	1,319
COVID19 (COV D19 (ANSEN))	Lumbar puncture	1,905	1,425	0,867				1,213	2,176	1,177	1,027	1,671	1,671
COVID19 (COV D19 (ANSEN))	Lumbar puncture abnormal	2,047	1,769	0,892				1,769	0,992	1,992	1,768	1,768	1,768
COVID19 (COV D19 (ANSEN))	Lymphocyte count decreased	1,561	1,142	0,872				0,209	1,692	2,013	1,507	2,003	1,507
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage decreased	1,607	1,262	0,884				1,607	1,607	2,066	1,862	1,264	1,264
COVID19 (COV D19 (ANSEN))	Lymphocyte percentage increased	1,405	1,146	0,894	0,608			1,034	1,546	1,546	0,7	1,141	1,141
COVID19 (COV D19 (ANSEN))	Magnetic resonance imaging head abnormal	2,14	1,615	0,887				0,484	1,882	1,908	2,448	1,608	1,608
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin concentration decreased	2,135	1,52	0,862	0,612			0,462	1,221	1,863	2,448	1,379	1,379
COVID19 (COV D19 (ANSEN))	Mean cell haemoglobin decreased	1,616	1,215	0,879				0,334	1,028	1,909	1,292	1,959	1,292
COVID19 (COV D19 (ANSEN))	Mean platelet volume increased	1,882	1,451	0,902				0,349	1,29	2,302	2,202	1,354	1,354
COVID19 (COV D19 (ANSEN))	Mechanical ventilation	2,076	1,486	0,876				0,466	1,508	2,218	1,762	1,869	1,762
COVID19 (COV D19 (ANSEN))	Monocyte percentage increased	1,59	1,297	0,893	0,61			0,275	2,002	2,407	2,041	1,088	1,088
COVID19 (COV D19 (ANSEN))	Neutrophil percentage decreased	1,551	1,264	0,875				0,183	1,239	1,748	1,446	2,262	1,446
COVID19 (COV D19 (ANSEN))	Neutrophil percentage increased	1,724	1,374	0,896				1,311	1,316	2,083	1,443	1,837	1,837
COVID19 (COV D19 (ANSEN))	Non-specific reaction	2,194	0,724	0,762				0,611	0,611	1,088	1,088	1,088	1,088
COVID19 (COV D19 (ANSEN))	Off label use	1,34	0,324	0,875				7,692	1,229	1,133	0,821	1,372	1,372
COVID19 (COV D19 (ANSEN))	On and off phenomenon	1,759	0,759	0,865				3,295	1,003	1,003	2,313	1,003	1,003
COVID19 (COV D19 (ANSEN))	Pain assessment	2,525	0,86	0,874				0,514	1,675	2,193	1,114	2,448	1,431
COVID19 (COV D19 (ANSEN))	Peripheral embolism	3,668	1,367	0,872				0,657	1,083	1,083	1,688	2,714	0,865
COVID19 (COV D19 (ANSEN))	Platelet count	2,773	2,351	0,92	0,611			1,84	3,053	3,053	3,179	1,793	1,793
COVID19 (COV D19 (ANSEN))	Platelet count decreased	1,893	0,3	0,898	0,609			0,3	1,551	2,113	1,546	2,199	1,491
COVID19 (COV D19 (ANSEN))	Platelet count normal	2,723	2,033	0,889				0,365	2,065	2,944	3,325	3,325	1,72
COVID19 (COV D19 (ANSEN))	Platelet factor 4	6,063	3,504	0,972				0,983	4,529	3,85	6,295	2,64	2,64
COVID19 (COV D19 (ANSEN))	Poor quality product administered	1,306						0,988	4,13	3,315	5,947	4,501	4,028
COVID19 (COV D19 (ANSEN))	Protein total decreased	1,355	1,268	0,885	0,611			1,416	1,676	1,676	1,59	2,006	1,59
COVID19 (COV D19 (ANSEN))	Prothrombin time prolonged	2,025	1,687	0,918	0,746			0,339	2,438	2,438	2,84	1,647	1,514
COVID19 (COV D19 (ANSEN))	Pulmonary embolism	2,224	1,604	1,537	0,613			0,59	1,716	2,055	2,85	2,504	1,627
COVID19 (COV D19 (ANSEN))	Pulmonary thrombosis	2,047	1,824	0,895				1,711	1,953	1,953	1,851	1,956	1,851
COVID19 (COV D19 (ANSEN))	Red blood cell count decreased	1,883	0,546	0,896	0,608			1,451	1,732	2,114	1,563	1,427	1,427
COVID19 (COV D19 (ANSEN))	Red cell distribution width increased	2,027	1,426	0,904	0,611			0,348	1,286	2,379	2,089	1,453	1,453
COVID19 (COV D19 (ANSEN))	Superficial vein thrombosis	2,4	1,386	0,877				0,532	1,731	1,902	1,379	1,346	1,379
COVID19 (COV D19 (ANSEN))	Suspected COV D-19	3,229	2,389	1,145				0,531	2,35	2,419	2,682	3,094	3,094
COVID19 (COV D19 (ANSEN))	Therapy non-responder	7,031	0,781	0,872				0,646	6,659	6,659	15,657	7,765	5,722
COVID19 (COV D19 (ANSEN))	Therapy partial responder	2,388						0,511	0,637	0,637	0,572	1,068	1,068
COVID19 (COV D19 (ANSEN))	Thrombectomy	2,148	1,558	0,887				0,646	1,451	1,632	1,485	2,308	1,349
COVID19 (COV D19 (ANSEN))	Thrombocytopenia	2,333	1,892	0,937				0,38	1,675	2,495	1,815	2,589	1,781
COVID19 (COV D19 (ANSEN))	Thrombosis	2,67											

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Harrington, Theresa \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, January 25, 2022 6:41:14 AM
Attachments: [USST_20220121.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/21/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020/2021	US Serious EB05 2020/2021	US Fatal EB05 2020/2021	US Infant EB05 2020/2021	US Child EB05 2020/2021	US Teen EB05 2020/2021	US Adult EB05 2020/2021	US Adult2 EB05 2020/2021	US Adult3 EB05 2020/2021	US Female EB05 2020/2021	US Male EB05 2020/2021	Comment
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time prolonged	2,138	1,771	0,950				0,402	1,558	1,952	2,171	1,454	
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time shortened	2,23	1,736	0,88					1,698	2,128	2,286	1,491	
COVID19 (COV D19) (ANSENSE)	Acute respiratory failure	2,024	1,327	0,999				0,457	1,423	1,986	2,312	1,641	
COVID19 (COV D19) (ANSENSE)	Adverse drug reaction	2,892	1,832	0,814				0,518	1,987	2,465	2,811	1,623	
COVID19 (COV D19) (ANSENSE)	Adverse event	2,022	1,07						0,926	0,763	1,516	0,765	
COVID19 (COV D19) (ANSENSE)	Angiogram abnormal	1,932	1,331	0,9					1,476	1,413	1,704	2,235	1,257
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral abnormal	1,932	0,902				0,486		2,240	1,967	2,465	1,446	
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral normal	2,235	1,617	0,999					1,875	1,201	1,768	1,468	
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary abnormal	2,481	1,726	0,897					1,704	2,369	2,589	1,844	
COVID19 (COV D19) (ANSENSE)	Arion gas decreased	1,826	1,46	0,89					1,375	2,241	1,324	1,318	
COVID19 (COV D19) (ANSENSE)	Antibody test	2,36	0,817	0,869				0,563	1,843	1,647	1,866	2,054	
COVID19 (COV D19) (ANSENSE)	Anticoagulant therapy	2,241	1,55	0,432		0,612			1,809	1,998	2,398	1,616	
COVID19 (COV D19) (ANSENSE)	Areflexia	2,134	1,883	0,882					0,85	2,171	1,477	1,56	
COVID19 (COV D19) (ANSENSE)	Arteriogram carotid abnormal	1,843	1,18	0,871					1,145	1,194	1,47	2,581	0,918
COVID19 (COV D19) (ANSENSE)	Basophil count decreased	1,923	1,481	0,881		0,61		0,332	1,226	2,468	1,762	2,393	1,311
COVID19 (COV D19) (ANSENSE)	Basophil percentage decreased	1,783	1,487	0,885		0,609			1,256	1,252	2,166	1,318	
COVID19 (COV D19) (ANSENSE)	Blood albumin decreased	1,778	1,303	0,883					1,432	1,84	1,758	2,171	1,365
COVID19 (COV D19) (ANSENSE)	Blood calcium decreased	1,995	1,402	0,866					1,431	2,127	1,852	2,274	1,478
COVID19 (COV D19) (ANSENSE)	Blood chloride increased	1,953	1,464	0,924					1,356	2,021	2,322	1,441	
COVID19 (COV D19) (ANSENSE)	Blood fibrinogen decreased	3,226	2,454	0,885					0,503	1,843	2,266	0,784	4,29
COVID19 (COV D19) (ANSENSE)	Blood magnesium increased	1,816	1,816	0,913					1,178	2,398	1,848	1,722	1,171
COVID19 (COV D19) (ANSENSE)	Blood potassium decreased	1,685	1,241	0,909					0,538	1,211	1,498	2,043	1,205
COVID19 (COV D19) (ANSENSE)	Blood sodium increased	1,506	1,09	0,964					1,331	1,465	0,85	2,024	
COVID19 (COV D19) (ANSENSE)	Blood urea decreased	1,668	1,401	0,868					0,235	1,855	1,292	0,877	2,502
COVID19 (COV D19) (ANSENSE)	Blood urea increased	1,825	1,239	0,874					1,105	2,018	1,624	2,062	1,536
COVID19 (COV D19) (ANSENSE)	COV D-19 pneumonia	2,005	1,44	1,365					1,684	2,117	1,963	2,293	1,888
COVID19 (COV D19) (ANSENSE)	CSF protein increased	2,777	2,161	0,87					1,806	2,989	1,061	2,398	2,305
COVID19 (COV D19) (ANSENSE)	Cerebral haemorrhage	2,314	1,618	0,917				0,517	1,711	1,855	1,433	3,23	1,1
COVID19 (COV D19) (ANSENSE)	Cerebral mass effect	2,042	1,072	0,912					1,473	1,769	1,228	1,689	0,969
COVID19 (COV D19) (ANSENSE)	Cerebral thrombosis	2,29	1,635	0,87					1,305	1,733	1,47	1,224	1,47
COVID19 (COV D19) (ANSENSE)	Cerebral venous sinus thrombosis	3,246	2,193	0,907					0,519	2,299	0,878	3,926	1,191
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head abnormal	2,011	1,396	0,895		0,611			0,622	2,192	2,32	1,514	1,221
COVID19 (COV D19) (ANSENSE)	Computerized tomogram head normal	2,011	1,398	0,895					0,387	1,735	2,107	2,234	1,514
COVID19 (COV D19) (ANSENSE)	Computerized tomogram thorax abnormal	2,001	1,473	0,903					0,461	1,41	2,084	2,031	2,359
COVID19 (COV D19) (ANSENSE)	Deep vein thrombosis	2,601	1,775	0,903					0,461	1,775	2,288	3,042	1,214
COVID19 (COV D19) (ANSENSE)	Embolic stroke	1,496	1,089	0,874					0,455	0,962	1,259	0,867	1,665
COVID19 (COV D19) (ANSENSE)	Eosinophil count decreased	1,742	1,368	0,897					1,253	1,253	2,12	1,237	2,043
COVID19 (COV D19) (ANSENSE)	Eosinophil percentage decreased	1,719	1,352	0,881		0,61		0,306	1,292	2,037	1,265	2,006	1,295
COVID19 (COV D19) (ANSENSE)	Feeling cold	1,78	0,84	0,877					1,117	2,007	1,453	0,974	1,405
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer	2,294	1,294	0,886					0,378	2,172	1,965	1,673	1,673
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer increased	2,146	1,448	0,937		0,612			0,428	1,647	2,259	2,402	1,59
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	1,966	1,065	0,869					0,335	1,657	0,853	2,13	1,359
COVID19 (COV D19) (ANSENSE)	Gate palsy	1,296	1,077	0,869					0,48	1,748	1,62	1,978	1,48
COVID19 (COV D19) (ANSENSE)	Globulins increased	1,877	1,33	0,887					1,385	1,57	2,189	1,237	1,237
COVID19 (COV D19) (ANSENSE)	Glucose urine present	1,821	1,247	0,888					1,429	1,309	1,397	1,102	2,229
COVID19 (COV D19) (ANSENSE)	Gullain-Barre syndrome	1,919	1,319	0,872					0,922	2,422	1,829	1,29	2,422
COVID19 (COV D19) (ANSENSE)	Haematocrit decreased	1,824	1,315	0,904		0,607			1,336	2,044	1,793	2,103	1,432
COVID19 (COV D19) (ANSENSE)	Haemoglobin decreased	1,776	1,288	0,911		0,608			0,432	2,003	1,648	1,386	1,648
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test	5,59	3,587	0,889					5,191	5,962	7,214	2,830	
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test positive	6,496	3,607	0,87				0,543	4,727	5,899	0,761	7,741	2,065
COVID19 (COV D19) (ANSENSE)	Hypoxia	1,873	1,303	0,899					1,872	1,509	1,951	1,565	1,565
COVID19 (COV D19) (ANSENSE)	Immunoglobulin therapy	2,092	1,837	0,925					0,871	2,514	2,237	1,713	1,713
COVID19 (COV D19) (ANSENSE)	Intensive care	1,851	1,417	1,055					0,031	1,415	2,045	2,048	1,52
COVID19 (COV D19) (ANSENSE)	International normalised ratio increased	1,896	1,306	0,866		0,747			0,402	1,596	1,453	2,249	1,563
COVID19 (COV D19) (ANSENSE)	International normalised ratio normal	2,016	1,306	0,875					1,441	2,078	1,238	1,963	1,238
COVID19 (COV D19) (ANSENSE)	Jugular vein thrombosis	1,952	1,685	0,874					1,376	1,195	0,714	2,486	0,734
COVID19 (COV D19) (ANSENSE)	Lumbar puncture	1,906	1,306	0,866					1,212	1,664	1,61	1,629	1,61
COVID19 (COV D19) (ANSENSE)	Lumbar puncture abnormal	2,049	1,736	0,998					0,998	1,693	1,743	1,743	1,743
COVID19 (COV D19) (ANSENSE)	Lumbar puncture normal	1,966	1,269	0,923					1,233	1,633	1,734	1,404	1,404
COVID19 (COV D19) (ANSENSE)	Lung opacity	1,669	1,27	0,895				0,184	1,022	2,074	1,923	2,105	2,105
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage increased	1,386	1,128	0,891		0,608			1,008	1,508	1,193	0,669	0,669
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,114	1,581	0,899					1,82	1,897	2,171	2,384	1,623
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin concentration decreased	2,124	1,495	0,9		0,612			1,459	1,213	2,318	1,362	1,362
COVID19 (COV D19) (ANSENSE)	Mean platelet volume increased	1,903	1,435	0,903					0,342	1,311	2,34	1,459	1,373
COVID19 (COV D19) (ANSENSE)	Mechanical ventilation	1,479	0,993	0,893					0,972	2,186	1,852	1,859	1,859
COVID19 (COV D19) (ANSENSE)	Monocyte percentage increased	1,569	1,272	0,889		0,61			0,917	1,945	2,034	1,362	1,362
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage decreased	1,512	1,223	0,872					0,152	1,672	1,472	2,263	0,843
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage increased	1,729	1,313	0,9					0,543	1,112	2,088	2,017	1,807
COVID19 (COV D19) (ANSENSE)	Nonspecific reaction	2,194	0,725	0,871					0,612	0,812	1,959	1,069	1,069
COVID19 (COV D19) (ANSENSE)	Off label use	1,34	0,414	0,875				7,887	1,246	1,105	0,801	1,381	1,918
COVID19 (COV D19) (ANSENSE)	On and off phenomenon	1,764	0,76						0,273	1,001	2,213	2,213	2,213
COVID19 (COV D19) (ANSENSE)	Pain assessment	2,515	0,857	0,873					0,513	1,61	2,139	1,095	2,284
COVID19 (COV D19) (ANSENSE)	Peripheral embolism	3,063	1,563	0,87					0,607	1,061	1,69	0,954	0,954
COVID19 (COV D19) (ANSENSE)	Platelet count	2,763	2,259	0,91		0,611			0,472	1,804	3,052	1,786	3,159
COVID19 (COV D19) (ANSENSE)	Platelet count decreased	1,874	1,317	0,896		0,609			0,297	1,483	2,077	1,513	1,442
COVID19 (COV D19) (ANSENSE)	Platelet count normal	2,723	1,935	0,888					0,223	2,834	2,175	3,231	1,667
COVID19 (COV D19) (ANSENSE)	Platelet factor 4	6,028	3,384	0,871					4,266	2,803	0,817	1,838	1,838
COVID19 (COV D19) (ANSENSE)	Poor quality product administered	1,305		0,966					4,153	3,378	5,968	4,508	4,027
COVID19 (COV D19) (ANSENSE)	Positive airway pressure therapy	1,761	1,334	0,936		0,611			0,973	1,673	1,713	2,004	1,629
COVID19 (COV D19) (ANSENSE)	Protein total decreased	1,747	1,247	0,883					1,364	1,633	1,611	1,328	2,004
COVID19 (COV D19) (ANSENSE)	Prothrombin time prolonged	2,031	1,558	0,919		0,746			0,334	2,459	1,642	2,693	1,496
COVID19 (COV D19) (ANSENSE)	Pulmonary embolism	2,215	1,577	1,013		0,613			0,588	1,704	2,021	2,662	1,812
COVID19 (COV D19) (ANSENSE)	Pulmonary thrombosis	2,048	1,46	0,873					1,54	1,999	1,563	1,796	1,796
COVID19 (COV D19) (ANSENSE)	Red blood cell count decreased	1,87	1,345	0,884		0,608			0,539	1,412	2,088	1,711	2,114
COVID19 (COV D19) (ANSENSE)	Red cell distribution width increased	2,003	1,38	0,895		0,611			0,34	1,281	2,273	1,734	2,368
COVID19 (COV D19) (ANSENSE)	Superficial vein thrombosis	2,354	1,354	0,876					0,717	1,865	1,443	1,443	1,443
COVID19 (COV D19) (ANSENSE)	Suspected D-19	3,225	2,23	1,062					0,526	2,679	2,72	1,178	2,649
COVID19 (COV D19) (ANSENSE)	Therapy non-responder	7,024	0,779	0,871					3,544	3,544	15,36	7,795	5,841
COVID19 (COV D19) (ANSENSE)	Therapy partial responder	2,387		0,866					0,508	6,638	0,572	0,568	1,02
COVID19 (COV D19) (ANSENSE)	Thrombectomy	2,141	1,516	0,886					1,429	1,588	1,641	2,31	1,327
COVID19 (COV D19) (ANSENSE)	Thrombocytopenia	2,313	1,838	0,939					1,76	2,451	1,749	2,562	1,749
COVID19 (COV D19) (ANSENSE)	Thrombosis	2,698	2,097	1,066		0,613			0,653	2,398	3,481	2,227	2,227
COVID19 (COV D19) (ANSENSE)	Thrombosis with thrombocytopenia syndrome	4,962	2,963	0,869					0,962	1,181	0,763	0,68	0,68
COVID19 (COV D19)													

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, February 1, 2022 6:00:27 AM
Attachments: [USST_20220128.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 1/28/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220128	US Series EB05 20220128	US Fatal EB05 20220128	US Infant EB05 20220128	US Child EB05 20220128	US Teen EB05 20220128	US Adult1 EB05 20220128	US Adult2 EB05 20220128	US Adult3 EB05 20220128	US Female EB05 20220128	US Male EB05 20220128	Comment
COVID19 (COV D19 (ANSENSE))	Activated partial thromboplastin time prolonged	2,112	1,956	0.903				0.397	1,593	1,825	1,825	2,174	1.41 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Activated partial thromboplastin time shortened	2,23	1,73	0.876					1,732	2,117	2,233	3,026	1.515 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Acute respiratory failure	2,04	1,331	0.999				0.457	1,448	1,976	1,831	2,301	1.662 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Adverse drug reaction	2,865	0.867	0.87				0.518	2,865	2,943	2,943	2,943	1.463 Other
COVID19 (COV D19 (ANSENSE))	Adverse event	2,019	1,061	0.877					0,748	0,748	1,734	1,734	1,505 Other
COVID19 (COV D19 (ANSENSE))	Angiogram abnormal	1,948	1,379	0.898					1,463	1,428	1,813	2,24	1.322 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Angiogram cerebral abnormal	1,094	1,094	0.891			0.487		2,264	1,943	1,943	1,783	1.428 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Angiogram cerebral normal	2,229	1,653	0.874					1,937	1,851	2,476	1,322	1.476 Not an AE
COVID19 (COV D19 (ANSENSE))	Angiogram pulmonary abnormal	2,464	1,706	0.894					1,835	2,331	2,331	2,162	1.949 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Angion cap decreased	1,628	1,487	0.89					1,211	1,211	2,223	2,19	1.316 Other
COVID19 (COV D19 (ANSENSE))	Antibody test	2,359	0.824	0.866				0.174	0,866	1,659	1,923	2,079	1.759 Not an AE
COVID19 (COV D19 (ANSENSE))	Anticoagulant therapy	2,244	1,539	0.432	0.612				1,807	2,015	2,015	2,329	1.622 Other
COVID19 (COV D19 (ANSENSE))	Arflexia	1,134	1,869	0.878					0,85	2,17	1,451	1,507	1.554 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Arteriogram carotid abnormal	1,831	1,157	0.867					1,136	1,194	1,427	2,499	0.903 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Basophil count decreased	1,929	1,477	0.878		0.81	0.329		1,233	2,415	1,736	2,397	1.315 Other
COVID19 (COV D19 (ANSENSE))	Basophil percentage decreased	1,789	1,485	0.882		0.609			1,261	2,257	1,717	2,171	1.316 Other
COVID19 (COV D19 (ANSENSE))	Blood albumin decreased	1,796	1,306	0.88					1,467	1,842	1,758	2,188	1.374 Other
COVID19 (COV D19 (ANSENSE))	Blood calcium decreased	1,989	1,392	0.894					1,425	2,118	1,936	2,27	1.461 Other
COVID19 (COV D19 (ANSENSE))	Blood chloride increased	1,965	1,486	0.931					1,383	2,192	1,98	2,334	1.439 Other
COVID19 (COV D19 (ANSENSE))	Blood thrombin decreased	3,273	2,459	0.986					1,844	2,108	0,975	4,407	1.076 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Blood urea nitrogen increased	1,787	1,36	0.914					1,156	1,915	1,713	2,403	1.133 Other
COVID19 (COV D19 (ANSENSE))	Blood potassium decreased	1,698	1,243	0.911					1,209	1,514	2,033	1,882	1.197 Other
COVID19 (COV D19 (ANSENSE))	Blood sodium increased	1,598	1,123	0.903					1,38	1,491	1,844	2,131	0.87 Other
COVID19 (COV D19 (ANSENSE))	Blood urea decreased	1,668	1,397	0.964		0.234			1,401	1,84	0,889	0,788	1.482 Other
COVID19 (COV D19 (ANSENSE))	Blood urea increased	1,837	1,234	0.872					1,086	2,03	1,819	2,027	1.557 Other
COVID19 (COV D19 (ANSENSE))	COVID-19 pneumonia	2,013	1,417	1.286					1,69	2,124	1,905	2,218	1.903 Other
COVID19 (COV D19 (ANSENSE))	CSF protein increased	2,775	2,159	0.866					1,775	2,965	1.1	2,518	2.253 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Cerebral haemorrhage	2,311	1,643	0.918				0.518	1,712	1.85	1,474	3,275	1.1 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Cerebral mass effect	2,916	1,956	0.906				0.922	1,473	1,328	1,205	3,055	1.949 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Cerebral thrombosis	2,289	1,619	0.862					1,13	1,305	2,842	1,198	1.198 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Cerebral venous sinus thrombosis	2,049	2,186	0.908				0.519	2,763	2,238	3,919	1,184	1.184 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Completed tomogram head abnormal	2,415	0.949	0.875		0.611		0.615	2,29	2,31	1,733	2,064	2.31 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Completed tomogram head normal	2,003	1,401	0.897					1,979	1,979	2,254	1.53	1.53 Not an AE
COVID19 (COV D19 (ANSENSE))	Completed tomogram thorax abnormal	2,088	0.821	0.458					1,386	2,063	0,644	1,888	1.981 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Deep vein thrombosis	2,601	1,77	0.991				0.457	2,488	2,255	1,981	1,981	1.981 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Embolic stroke	1,497	1,083	0.87					0,446	0,862	2,031	1,726	0.861 Reviewed, Branch Mfg
COVID19 (COV D19 (ANSENSE))	Eosinophil count decreased	1,789	1,323	0.867					1,287	1,615	1,523	0,079	1.24 Other
COVID19 (COV D19 (ANSENSE))	Eosinophil percentage decreased	1,741	1,364	0.877		0.609		0.304	1,293	2,079	1,967	2,028	1.311 Other
COVID19 (COV D19 (ANSENSE))	Feeling cold	1,78	0.838	0.874					2,007	1,458	1,852	1,487	1.487 Labeled
COVID19 (COV D19 (ANSENSE))	Fibrin D dimer	2,284	1,378	0.883					2,119	2,139	1,922	2,139	1.922 Other
COVID19 (COV D19 (ANSENSE))	Fibrin D dimer increased	2,178	1,463	0.945		0.612			1,684	2,272	2,435	2,192	1.608 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Fibrin D dimer normal	1,961	1,063	0.864					1,646	2,066	2,136	2,136	1.961 Not an AE
COVID19 (COV D19 (ANSENSE))	Gate patly	2,265	0.875	0.426					1,747	1,747	1,416	1,668	1.668 Labeled
COVID19 (COV D19 (ANSENSE))	Globulins increased	1,88	1,329	0.882				0.401	1,388	1,615	1,235	2,206	1.235 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Glucose urine present	1,835	1,228	0.888					1,414	2,016	1,437	2,216	1.21 Other
COVID19 (COV D19 (ANSENSE))	Gullain-Barre syndrome	2,329	884	0.872					1,872	2,389	2,251	2,165	2.165 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Haemoglobin decreased	1,838	1,314	0.904		0.606		0.428	1,353	2,055	1,769	2,212	1.409 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Haemoglobin increased	1,788	1,285	0.895					1,419	2,006	2,104	1,498	1.498 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Heparin-induced thrombocytopenia test	5,589	3,592	0.885				0.541	3,951	5,16	5,16	5,868	5.745 Not an AE
COVID19 (COV D19 (ANSENSE))	Heparin-induced thrombocytopenia test positive	6,409	3,562	0.866				0.544	4,723	5,918	0,753	7,737	1.975 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Hypoxia	1,668	1,291	0.904					1,489	1,934	2,278	2,278	1.929 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Immunoglobulin therapy	2,095	1,837	0.867					1,969	2,528	1,708	2,24	1.708 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Intensive care	1,861	1,425	1.05					1,441	2,05	2,261	2,274	1.534 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	International normalised ratio increased	1.65	1,273	0.988		0.747		0.303	1,415	1,953	1,402	1,953	1.259 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	International normalised ratio normal	2,016	1,295	0.871					1,436	2,072	0,958	2,171	1.27 Not an AE
COVID19 (COV D19 (ANSENSE))	Jugular vein thrombosis	1,951	1,628	0.87					1,376	1,179	0,774	2,468	0.726 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Lumbar puncture	1.91	0.988	0.897					1,502	1,468	0,691	1,146	1.146 Not an AE
COVID19 (COV D19 (ANSENSE))	Lumbar puncture abnormal	2,049	1,723	0.888					0,984	2,588	1,688	1,731	1.731 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Lumbar puncture normal	1,707	1,037	0.918					1,338	1,688	1,754	1,754	1.426 Other
COVID19 (COV D19 (ANSENSE))	Lymphocyte count decreased	1,688	1,149	0.864				0.197	1,076	1,076	1.1	1,5	1.5 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Lymphocyte percentage decreased	1,689	1,274	0.892					1,04	2,082	1,923	2,117	1.277 Other
COVID19 (COV D19 (ANSENSE))	Metabolic measure integrating head abnormal	2,117	1,578	0.883					1,478	1,623	1,987	2,152	1.623 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Mean cell haemoglobin concentration decreased	0	1,491	0.9		0.612			1,212	2,33	1,817	2,423	1.378 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Mean platelet volume increased	1.89	1,413	0.899					0,338	1,13	2,307	1,457	1.364 Other
COVID19 (COV D19 (ANSENSE))	Mechanical ventilation	2,092	1,498	0.868					1,478	1,969	2,274	1,969	1.969 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Monocyte percentage increased	1.58	1,271	0.891		0.609			0,919	1,852	2,025	2,348	1.087 Other
COVID19 (COV D19 (ANSENSE))	Neutrophil percentage decreased	1,527	1,229	0.871					1,208	1,65	1,536	2,234	1.646 Other
COVID19 (COV D19 (ANSENSE))	Neutrophil percentage increased	2,117	1,303	0.895					1,719	1,933	2,148	1,983	1.983 Other
COVID19 (COV D19 (ANSENSE))	Non-specific reaction	2,192	0.783	0.871				0.876	0,781	0,612	1,061	1,061	0.68 Other
COVID19 (COV D19 (ANSENSE))	Off label use	1.34	0.426	0.876					1,226	1,116	1,116	1,391	1.391 Not an AE
COVID19 (COV D19 (ANSENSE))	On and off phenomenon	1,793	0.781	0.871					3,279	1,901	2,214	2,214	1.901 Other
COVID19 (COV D19 (ANSENSE))	Pain assessment	2,514	0.859	0.873				0.513	1,584	2.11	1,077	2.28	1.372 Not an AE
COVID19 (COV D19 (ANSENSE))	Peripheral embolism	2,931	1,492	0.860					0,657	1,06	1,584	2,455	1.616 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Platelet count	2,762	2,236	0.911		0.611		0.472	1,781	3,085	2,481	3,178	1.772 Not an AE
COVID19 (COV D19 (ANSENSE))	Platelet count decreased	1,875	1,308	0.892		0.609		0.292	1,483	2,057	1,516	2,159	1.44 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Platelet count normal	2,722	1,878	0.885				0.391	2,015	2,803	3,174	2,023	1.638 Not an AE
COVID19 (COV D19 (ANSENSE))	Platelet factor 4	6,027	3,374	0.867					4,274	2,592	0,816	6,288	1.845 Not an AE
COVID19 (COV D19 (ANSENSE))	Poor quality product administered	1,305		0.966					4,159	3,381	5,873	4.55	4.059 Not an AE
COVID19 (COV D19 (ANSENSE))	Prolonged labour	1,098	1,066						3,152	1,778			1.778 Other
COVID19 (COV D19 (ANSENSE))	Protein total decreased	1,776	1,255	0.885		0.611			1,39	1,634	2,026	1,344	1.344 Other
COVID19 (COV D19 (ANSENSE))	Prothrombin time prolonged	2,009	1,531	0.919					1,548</				

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, February 8, 2022 6:52:05 AM
Attachments: [USST_20220204.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/4/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220204	US Serious EB05 20220204	US Fatal EB05 20220204	US Infant EB05 20220204	US Child EB05 20220204	US Teen EB05 20220204	US Adult EB05 20220204	US Adult2 EB05 20220204	US Adult3 EB05 20220204	US Female EB05 20220204	US Male EB05 20220204	Comment
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time prolonged	1,051	1,056					0.397	1.35	1.32	1.41	1.41	1.41 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Activated partial thromboplastin time shortened	2,208	1,706	0.874				1.686	2.125	2.197	2.197	2.197	1.497 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Acute respiratory failure	2,04	1,341	1,005				0.455	1.435	2,009	1,827	2,298	1.676 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Adverse drug reaction	2,862	0.967	0.867				0.519	0.977	1,604	0.805	1,554	1.442 Other
COVID19 (COV D19) (ANSENSE)	Adverse event	2,018	1,059	0.875				0.908	0.739	1,789	1,755	1,755	1.478 Other
COVID19 (COV D19) (ANSENSE)	Angiogram abnormal	1,941	1,396	0.903				0.487	1.454	1,444	1,789	2,252	1.296 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral abnormal	2,591	1,89	0.904				0.487	2,591	2,604	1,925	1,773	1.419 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Angiogram cerebral normal	1,296	1,586	0.871				1.895	1,817	1,789	1,789	2,252	1.421 Not an AE
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary abnormal	2,426	1,607	0.886				1,550	2,309	2,180	2,009	2,501	1.942 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Angiogram pulmonary normal	1,812	1,429	0.888				1,351	1,184	1,688	1,351	1,193	1.603 Other
COVID19 (COV D19) (ANSENSE)	Antibody test	2,359	0.807	0.86				0.563	0.834	1,651	1,889	2,028	1.757 Not an AE
COVID19 (COV D19) (ANSENSE)	Anticoagulant therapy	2,234	1,514	0.956	0.612			1,799	1,99	2,256	1,99	2,75	1.603 Other
COVID19 (COV D19) (ANSENSE)	Areflexia	2,133	1,835	0.876				0.819	2,234	1,434	1,655	1,572	1.572 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Arterogram carotid abnormal	1,81	1,141	0.864				1,135	1,186	1,404	1,404	2,424	0.895 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Basophil count decreased	1,905	1,437	0.876	0.61			0.329	1,226	2,348	1,713	2,364	1.262 Other
COVID19 (COV D19) (ANSENSE)	Basophil percentage decreased	1,789	1,466	0.883	0.609			1,237	2,238	2,162	1,713	2,162	1.313 Other
COVID19 (COV D19) (ANSENSE)	Blood albumin decreased	1,789	1,3	0.883				0.333	1,459	1,628	1,761	2,169	1.381 Other
COVID19 (COV D19) (ANSENSE)	Blood calcium increased	1,873	1,374	0.866				0.369	1,441	2,074	1,835	2,341	1.448 Other
COVID19 (COV D19) (ANSENSE)	Blood chloride increased	1,923	1,423	0.936				1,323	2,121	1,921	1,921	2,296	1.396 Other
COVID19 (COV D19) (ANSENSE)	Blood thrombin decreased	2,273	2,429	0.885				1,844	2,108	1,98	1,86	4,355	1.067 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Blood magnesium increased	1,835	1,396	0.867				1,173	1,932	2,462	1,932	2,462	1.558 Other
COVID19 (COV D19) (ANSENSE)	Blood potassium decreased	1,875	1,221	0.909				1,192	1,478	1,781	1,857	1,857	1,171 Other
COVID19 (COV D19) (ANSENSE)	Blood sodium increased	1,584	1,12	0.862				1,426	1,45	1,656	2,146	1,46	0.87 Other
COVID19 (COV D19) (ANSENSE)	Blood urea decreased	1,654	1,36	0.861				1,377	1,926	1,251	1,087	2,043	0.872 Other
COVID19 (COV D19) (ANSENSE)	Blood urea increased	1,828	1,233	0.874				1,066	2,013	1,634	2,032	2,032	1.548 Other
COVID19 (COV D19) (ANSENSE)	COVID-19 pneumonia	2,003	1,413	1,157				1,65	2,111	1,603	2,211	1,888	1.888 Other
COVID19 (COV D19) (ANSENSE)	CSF protein increased	2,779	2,146	0.863				1,815	2,937	1,083	2,43	2,267	2.267 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Cerebral haemorrhage	2,307	1,616	0.917				0.514	1,711	1,823	1,459	3,214	1.088 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Cerebral mass effect	2,283	1,966	0.912				0.522	1,445	1,387	1,203	3,881	1.002 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Cerebral thrombosis	2,289	0.86	1,129				1,304	1,304	2,945	1,23	2,945	1.23 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Cerebral venous sinus thrombosis	3,243	2,176	0.905				0.518	2,265	2,236	0.877	3,857	1.183 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Computed tomogram head abnormal	2,586	1,728	0.876				2,586	2,149	1,152	2,32	1,152	1.728 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Computed tomogram head normal	1,987	0.381	0.888	0.611			1,707	1,969	1,969	1,814	1,969	1.517 Not an AE
COVID19 (COV D19) (ANSENSE)	Computed tomogram thorax abnormal	2,074	1,422	0.921				0.458	1,376	2,049	1,879	2,288	1.618 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Deep vein thrombosis	1,777	1,253	0.859				1,019	1,248	1,977	1,977	2,24	1.977 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Endotracheal intubation	1,925	1,396	1,216				0.478	1,324	2,075	1,92	1,828	1.828 Other
COVID19 (COV D19) (ANSENSE)	Eosinophil count decreased	1,781	1,381	0.861				1,781	1,287	1,423	1,287	1,287	1.287 Other
COVID19 (COV D19) (ANSENSE)	Eosinophil percentage decreased	1,755	1,070	0.876	0.609			0.304	1,295	2,081	1,81	2,024	1.81 Other
COVID19 (COV D19) (ANSENSE)	Feeling cold	1,78	0.836	0.871				1,109	2,012	1,452	0.988	1,848	1.413 Labeled
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	2,324	1,324	0.881				0.442	2,157	1,477	1,477	1,477	1.477 Other
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer increased	2,164	1,445	0.95	0.612			0.319	1,856	2,258	1,585	2,429	1.585 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Fibrin D dimer normal	1,961	1,078	0.866				0.438	1,642	2,049	0.986	2,121	1.356 Not an AE
COVID19 (COV D19) (ANSENSE)	Gate study	1,409	1,059	0.829				0.429	1,727	1,388	1,61	1,388	1.625 Labeled
COVID19 (COV D19) (ANSENSE)	Gilouins increased	1,862	1,328	1,361				0.401	1,628	1,647	1,242	2,228	1.242 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Glucose urine present	1,811	1,227	0.886				1,369	1,369	1,403	1,306	2,184	1.102 Other
COVID19 (COV D19) (ANSENSE)	Gullain-Barre syndrome	1,636	0.87	0.835				0.87	2,031	2,24	2,162	2,162	2.162 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Haematuria decreased	1,822	1,295	0.901				0.426	1,333	2,023	1,753	2,196	1.384 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Haemoglobin decreased	1,803	1,089	0.869	0.607			1,177	1,663	2,094	1,968	2,094	1.381 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test	5,565	3,155	0.883				3,871	5,208	5,262	5,262	1,103	2.462 Not an AE
COVID19 (COV D19) (ANSENSE)	Heparin-induced thrombocytopenia test positive	6,409	3,492	0.864				4,723	6,581	0.753	7,738	7,738	1.803 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Hypoxia	1,862	1,296	0.922				1,498	1,941	2,498	1,941	2,264	1.544 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Immunoglobulin therapy	2,08	0.812	0.864				0.203	1,918	1,457	2,236	1,685	1.685 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Intensive care	1,849	1,43	1,049				0.433	1,433	2,047	2,048	2,289	1.538 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	International normalised ratio increased	1,865	0.863	0.863	0.747			0.963	1,456	1,283	1,381	1,381	1.283 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	International normalised ratio normal	2,016	0.868	1,267				1,435	2,047	2,048	2,153	2,047	1.253 Not an AE
COVID19 (COV D19) (ANSENSE)	Jugular vein thrombosis	1,951	1,626	0.868				1,375	1,178	1,718	2,463	2,463	0.726 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Lumbar puncture	1,908	0.857	0.869				0.857	1,122	1,698	1,698	1,698	1.698 Not an AE
COVID19 (COV D19) (ANSENSE)	Lumbar puncture abnormal	2,049	1,691	0.877				0.977	1,053	2,556	1,718	1,665	1.718 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Lumbar puncture normal	1,345	1,694	0.826				1,311	1,876	1,876	1,876	2,113	1.458 Other
COVID19 (COV D19) (ANSENSE)	Lymphocyte percentage decreased	1,691	1,273	0.861			0.179	1,041	1,041	2,06	1,041	2,106	1,041 Other
COVID19 (COV D19) (ANSENSE)	Magnetic resonance imaging head abnormal	2,103	1,554	0.895				0.476	1,81	1,876	2,35	2,35	1.62 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Mean cell haemoglobin concentration decreased	2,108	1,452	0.862				1,489	1,884	2,31	1,884	2,365	1.884 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Mean platelet volume increased	1,806	1,375	0.866				1,279	2,264	1,421	1,331	2,144	1.331 Other
COVID19 (COV D19) (ANSENSE)	Mechanical ventilation	2,079	1,531	0.878				0.478	0.957	2,248	1,868	1,881	1.868 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Monocyte percentage increased	1,867	1,364	0.887				1,581	1,926	1,926	1,926	1,325	1.926 Other
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage decreased	1,526	1,036	0.868				1,191	1,54	1,64	0.833	2,231	0.833 Other
COVID19 (COV D19) (ANSENSE)	Neutrophil percentage increased	1,733	1,302	0.896				0.239	1,896	2,069	1,833	1,399	1.399 Other
COVID19 (COV D19) (ANSENSE)	Non-specific reaction	2,191	0.792	0.861				0.781	0.912	1,682	0.912	2,237	1.682 Other
COVID19 (COV D19) (ANSENSE)	Off label use	1,34	0.491	0.875				7.877	1,229	1,13	0.827	1,392	1.899 Not an AE
COVID19 (COV D19) (ANSENSE)	On and off phenomenon	1,753	0.762	0.868				3,296	1,13	0.827	2,212	2,212	1.899 Not an AE
COVID19 (COV D19) (ANSENSE)	Packed red blood cell transfusion	1,724	1,307	0.885				1,134	1,226	1,196	1,196	2,037	0.898 Other
COVID19 (COV D19) (ANSENSE)	Pain assessment	2,518	0.858					0.514	1,582	2,202	2,021	2,321	1.41 Not an AE
COVID19 (COV D19) (ANSENSE)	Peripheral embolism	2,628	1,488	0.863				0.657	1,38	1,587	2,448	2,448	0.953 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Platelet count	2,773	2,249	0.908	0.611			1,776	3,095	2,593	1,786	3,145	1.786 Not an AE
COVID19 (COV D19) (ANSENSE)	Platelet count decreased	1,865	1,295	0.887	0.609			0.292	1,477	2,059	1,499	2,16	1.429 Reviewed, Regulatory Action
COVID19 (COV D19) (ANSENSE)	Platelet count normal	2,722	1,843	0.883				0.388	2,207	2,748	1,891	3,124	1.627 Not an AE
COVID19 (COV D19) (ANSENSE)	Platelet factor 4	6,028	3,382	0.865				0.388	4,274	2,592	2,688	1,842	1.842 Not an AE
COVID19 (COV D19) (ANSENSE)	Poor quality product administered	1,306						0.966	4,151	3,371	5,811	4,621	4.058 Not an AE
COVID19 (COV D19) (ANSENSE)	Prolonged labour	1,098	1,066	</									

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, February 15, 2022 7:01:40 AM
Attachments: [USST_20220211.xls](#)

Hi All,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/11/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB06 20220211	US Serious EB06 20220211	US Fatal EB06 20220211	US Infant EB06 20220211	US Child EB06 20220211	US Teen EB06 20220211	US Adult EB06 20220211	US Adult2 EB06 20220211	US Adult3 EB06 20220211	US Female EB06 20220211	US Male EB06 20220211	Comment	
COVID19 (COV D19 (ANSENSE))	Activated partial thromboplastin time prolonged	2,591	1,863	0.91				0.397	1,505	1,941	2,561	1,912	1,472 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Activated partial thromboplastin time shortened	2,194	1,686	0.872				1.692	2,098	2,098	2,915	2,162	1,499 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Acute respiratory failure	2,058	1,334	1,012				1.4	1,993	1,845	2,262	1,694	1,694 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Adverse drug reaction	2,871	0,861	0.865				0.918	0,977	0,861	2,637	1,674	1,674 Other	
COVID19 (COV D19 (ANSENSE))	Adverse event	2,018	1,055	0.878				0.905	0,738	0,738	1,507	0,753	1,507 Other	
COVID19 (COV D19 (ANSENSE))	Angiogram abnormal	1,504	1,306	0.902				1.443	1,463	1,463	2,192	1,776	1,320 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Angiogram cerebral abnormal	2,914	1,891	0.911				2.181	1,891	1,891	2,111	1,719	1,444 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Angiogram cerebral normal	2,173	1,542	0.869		0.485		1.884	1,802	1,733	1,407	1,073	1,407 Not an AE	
COVID19 (COV D19 (ANSENSE))	Angiogram pulmonary abnormal	2,445	1,706	0.897				1.165	1,805	2,546	1,396	1,196	1,396 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Angiogram pulmonary normal	1,818	1,427	0.89				1,184	1,241	1,241	1,293	0,948	1,293 Other	
COVID19 (COV D19 (ANSENSE))	Antibody test	2,359	0,808	0.858				0.823	1,658	1,658	1,807	1,761	1,761 Not an AE	
COVID19 (COV D19 (ANSENSE))	Anticoagulant therapy	2,228	1,518	0.857	0.613			1.833	1,599	2,24	1,833	1,599	1,607 Other	
COVID19 (COV D19 (ANSENSE))	Areflexia	2,121	1,833	0.874				0.862	2,219	1,428	1,906	1,518	1,518 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Arterigram carotid abnormal	1,795	1,128	0.862				1.135	1,178	1,386	2,344	1,386	0,891 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Basophil count decreased	1,898	1,436	0.88	0.61			1,222	2,32	1,773	2,344	1,472	1,472 Other	
COVID19 (COV D19 (ANSENSE))	Basophil percentage decreased	1,789	1,468	0.892	0.609			0.286	1,215	2,239	1,774	1,266	1,327 Other	
COVID19 (COV D19 (ANSENSE))	Blood albumin decreased	1,785	1,297	0.888				0.33	1,469	1,812	1,767	1,135	1,403 Other	
COVID19 (COV D19 (ANSENSE))	Blood calcium increased	1,862	1,381	0.905				0.937	1.4	2,085	1,862	2,23	1,472 Other	
COVID19 (COV D19 (ANSENSE))	Blood chloride increased	1,907	1,411	0.944				1,306	2,096	1,988	2,278	1,391	1,391 Other	
COVID19 (COV D19 (ANSENSE))	Blood fibrinogen decreased	3,22	2,384	0.883				1,797	2,024	2,024	4,281	1,059	1,059 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Blood magnesium increased	1,826	1,383	0.923				1,157	1,853	1,853	2,413	1,386	1,386 Other	
COVID19 (COV D19 (ANSENSE))	Blood potassium decreased	1,682	1,231	0.911				1,197	1,489	1,489	1,853	2,044	1,813 Other	
COVID19 (COV D19 (ANSENSE))	Blood sodium increased	1,618	1,069	0.866				1,506	1,421	1,421	2,149	1,115	1,115 Other	
COVID19 (COV D19 (ANSENSE))	Blood urea decreased	1,655	1,354	0.858				0.227	1,389	1,837	1,223	0,874	0,874 Other	
COVID19 (COV D19 (ANSENSE))	Blood urea increased	1,832	1,246	0.878				1,075	2,002	2,002	1,681	2,029	1,584 Other	
COVID19 (COV D19 (ANSENSE))	COV D-19 pneumonia	2,028	1.4	1.1				1.67	2,126	1,876	2,191	1,876	1,888 Other	
COVID19 (COV D19 (ANSENSE))	CSF protein increased	2,752	2,118	0.861				1,773	2,104	2,485	2,21	1,083	2,21 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Cerebral haemorrhage	2,307	1,612	0.918				0.514	1,702	1,826	1,454	3.2	1,089 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Cerebral mass effect	2,862	1,197	0.922				1,446	1,39	1,304	3,902	1,024	1,024 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Cerebral thrombosis	2,278	1,635	0.857				1.12	1,305	1,522	2,99	1,211	1,211 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Cerebral venous sinus thrombosis	2,042	2.18	0.904				0.518	2,267	2,238	3,863	1,185	1,185 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Computerised tomogram head abnormal	2,667	1,704	0.956	0.612			1,467	2,177	2,088	1,723	1,723	1,723 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Computerised tomogram head normal	1,992	1,371	0.899				1,885	1,965	2,234	1,823	1,152	1,152 Not an AE	
COVID19 (COV D19 (ANSENSE))	Computerised tomogram thorax abnormal	2,085	1,443	0.858				1,408	2,287	2,287	2,006	1,654	1,654 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Computerised tomogram thorax normal	2,666	1,787	1,014				1,014	2,445	2,246	3,102	2,486	2,486 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Deep vein thrombosis	1,927	1,387	0.878				1,297	2,062	2,062	1,723	1,889	1,811 Labeled	
COVID19 (COV D19 (ANSENSE))	Endotracheal intubation	1,783	1,362	0.862				1,288	1,683	1,683	2,098	1,594	1,594 Other	
COVID19 (COV D19 (ANSENSE))	Eosinophil count decreased	1,772	1,395	0.885	0.609			0.302	1,303	1,683	2,025	1,39	1,39 Other	
COVID19 (COV D19 (ANSENSE))	Eosinophil percentage decreased	1,779	0,843	0.869				1,106	2,01	1,455	0,964	1,844	1,414 Labeled	
COVID19 (COV D19 (ANSENSE))	Feeling cold	2,384	1,241	0.879				0,441	2,178	2,132	2,48	1,811	1,811 Other	
COVID19 (COV D19 (ANSENSE))	Fibrin D dimer increased	2,17	1,453	0.966	0.612			0.316	1,669	2,192	2,434	1,59	1,59 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Fibrin D dimer normal	1,958	1,092	0.883				0,435	1,831	2,038	1,103	2,118	1,261	1,261 Not an AE
COVID19 (COV D19 (ANSENSE))	Gain weight	2,308	1,084	0.808				0,408	0,877	1,754	1,94	1,94	1,94 Labeled	
COVID19 (COV D19 (ANSENSE))	Globulins increased	1,873	1,303	0.877	0.4			1,345	1,627	1,828	2,188	1,231	1,231 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Glucose urine present	1,771	1,21	0.889				1,349	1,289	1,429	1,429	1,087	1,087 Other	
COVID19 (COV D19 (ANSENSE))	Gullain-Barre syndrome	2,331	1,836	0.87				1,607	1,609	1,609	2,143	1,609	1,609 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Haematuria decreased	1,823	1,291	0.906	0.606			0,425	2,006	1,751	1,395	1,751	1,395 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Haemoglobin decreased	1,767	1,207	0.9	0.607			0,319	1,861	2,077	1,626	1,386	1,386 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Haemoglobin increased	5,57	5.12	0.882				4,083	5,207	5,205	2,099	1,611	2,099 Not an AE	
COVID19 (COV D19 (ANSENSE))	Heparin-induced thrombocytopenia test	6,408	3,498	0.861	0.544			4,722	5.62	6.72	7,733	1,821	1,821 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Heparin-induced thrombocytopenia test positive	1.88	1.3	0.924				1,469	1,58	1,749	2,248	1,573	1,573 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Hypoxia	2,095	1,797	0.861				1,911	2,515	2,515	2,251	1,665	1,665 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Immunoglobulin therapy	1,845	1,425	1,043				0,029	1,479	2,055	2,023	2,289	1,54	1,54 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Intensive care	1,862	1,287	0.865	0.747			0.396	1,617	1,617	1,471	1,34	1,34 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	International normalised ratio increased	2,016	1,246	0.866				1,432	2,045	2,045	1,247	1,021	1,247 Not an AE	
COVID19 (COV D19 (ANSENSE))	International normalised ratio normal	1,951	1,627	0.885				1,374	1,171	1,293	0.727	1,021	0.727 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Jugular vein thrombosis	1,911	1,358	0.853				1,223	1,55	1,604	1,604	1,106	1,106 Not an AE	
COVID19 (COV D19 (ANSENSE))	Lumbar puncture abnormal	2,069	1,722	0.891				1,012	2,199	1,656	1,701	1,701	1,701 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Lumbar puncture normal	1,712	1,276	0.902				1,405	1,706	1,806	2,179	1,486	1,486 Other	
COVID19 (COV D19 (ANSENSE))	Lymphocyte percentage decreased	2,002	1,286	0.904				1,034	2,105	1,984	1,613	1,034	1,613 Other	
COVID19 (COV D19 (ANSENSE))	Magnetic resonance imaging head abnormal	2,09	1,576	0.894	0.612			1,792	2,328	2,108	1,615	1,615	1,615 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Magnetic resonance imaging head normal	2,098	1,476	0.911				1,211	1,587	1,587	1,428	1,287	1,428 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Mean platelet volume increased	1,863	1,372	0.895				1,266	2,272	1,426	1,332	0,787	1,332 Other	
COVID19 (COV D19 (ANSENSE))	Mechanical ventilation	2,098	1,529	1,023	0.609			0,478	0,999	2,254	1,842	1,903	1,976	1,976 Reviewed, Regulatory Action
COVID19 (COV D19 (ANSENSE))	Mechanical ventilation increased	1,588	1,263	0.889				0,257	0,911	1,463	1,613	1,112	1,112 Other	
COVID19 (COV D19 (ANSENSE))	Neutrophil percentage decreased	1,506	1,202	0.869				0.13	1,179	1,519	2,199	0,841	0,841 Other	
COVID19 (COV D19 (ANSENSE))	Neutrophil percentage increased	1,752	1,302	0.902				1,132	2,092	1,879	2,016	1,423	1,423 Other	
COVID19 (COV D19 (ANSENSE))	Non-specific reaction	2,917	0.791	0.748				0.748	0.612	0.612	1,049	0.612	1,049 Other	
COVID19 (COV D19 (ANSENSE))	Off label use	1.34	0.496	0.873				7.951	2.19	1.143	1.388	1.914	1.914 Not an AE	
COVID19 (COV D19 (ANSENSE))	On and off phenomenon	1,753	0.781	0.882				3.285	1.1	2.214	2.214	1.1	1.1 Other	
COVID19 (COV D19 (ANSENSE))	Packed red blood cell transfusion	1,746	1,283	0.882				1,214	1,193	1,193	1,175	0.879	0,879 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Pain assessment	2,556	0.878	0.813				1,586	2.23	1.06	2.261	1,442	1,442 Not an AE	
COVID19 (COV D19 (ANSENSE))	Peripheral embolism	2,927	1,486	0.861				0,637	1,561	1,609	0,953	0,953	0,953 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Platelet count	2,772	2,246	0.906	0.611			0,472	1,769	2,572	0,483	1,779	1,779 Not an AE	
COVID19 (COV D19 (ANSENSE))	Platelet count decreased	1,871	1,301	0.891	0.609			0.29	1,492	2,067	1,496	1,428	1,428 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSENSE))	Platelet count normal	2,728	1,829	0.881				0,388	2,011	2,716	3,101	1,617	1,617 Not an AE	
COVID19 (COV D19 (ANSENSE))	Platelet factor 4	6,027	3,391	0.862				4,285	2,593	6,284	0,814	1,849	1,849 Not an AE	
COVID19 (COV D19 (ANSENSE))	Poor quality product administered	1,306	0.967	0.825				4,151	3,402	5,755	4,506	4,		

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, February 22, 2022 5:29:33 AM
Attachments: [USST_20220218.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/18/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20202018	US Serious EB05 20202018	US Fatal EB05 20202018	US Infant EB05 20202018	US Child EB05 20202018	US Teen EB05 20202018	US Adult1 EB05 20202018	US Adult2 EB05 20202018	US Adult3 EB05 20202018	US Female EB05 20202018	US Male EB05 20202018	Comment	
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time prolonged	2,267	1,671	0.909				0.397	1,214	2,353	1,771	2,144	1,471 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Activated partial thromboplastin time shortened	2,186	1,687	0.873				1,683	2,118	2,013	2,112	2,144	1,504 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Acute respiratory failure	2,062	1,342	1.02				0,452	1,431	2,024	1,886	2,321	1,7 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Adverse drug reaction	0,981	0,827	0.918				0,518	0,972	0,807	0,881	1,448	Other	
COVID19 (COV D19 (ANSSEN))	Adverse event	2,018	1,055	0.874				0.9	0,769	0,751	1,786	1,509	Other	
COVID19 (COV D19 (ANSSEN))	Angiogram abnormal	1,524	1,365	0.903				0,485	1,444	1,457	1,789	2,18	1,328 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral abnormal	2,571	1,883	0.903				0,455	1,917	2,013	2,170	2,170	1,444 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Angiogram cerebral normal	2,157	1,505	0.871				0,485	1,777	1,849	2,383	1,778	Not an AE	
COVID19 (COV D19 (ANSSEN))	Angiogram pulmonary abnormal	2,454	1,702	0.901				0,425	1,666	2,331	2,174	1,962	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Anion gap increased	1,805	1,407	0.869				0,368	1,171	1,806	1,35	1,283	Other	
COVID19 (COV D19 (ANSSEN))	Antibody titer	2,359	0,818	0.567				0,859	0,815	1,276	1,192	2,044	1,765 Not an AE	
COVID19 (COV D19 (ANSSEN))	Anticoagulant therapy	2,237	1,519	0.962	0.612			0,427	1,845	2,014	2,238	2,161	1,629 Other	
COVID19 (COV D19 (ANSSEN))	Areflexia	2,131	1,831	0.875				0,859	2,257	1,413	1,899	1,527	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Arterigram carotid abnormal	1,795	1,126	0.863				1,135	1,179	1,381	2,328	0,862	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Basophil count decreased	1,892	1,444	0.886	0.61			0,326	1,214	1,771	2,381	1,659	Other	
COVID19 (COV D19 (ANSSEN))	Basophil percentage decreased	1,788	1,479	1.002	0.608			0,286	1,26	1,801	1,318	1,318	Other	
COVID19 (COV D19 (ANSSEN))	Blood albumin decreased	1,792	1,309	0.896				0,327	1,467	1,865	1,767	2,17	1,409 Other	
COVID19 (COV D19 (ANSSEN))	Blood calcium decreased	1.88	1,381	0.929				0,396	1,389	2,112	1,847	2,233	1,473 Other	
COVID19 (COV D19 (ANSSEN))	Blood chloride increased	1,906	1,41	1,296				0,442	1,984	2,13	1,384	2,283	1,384 Other	
COVID19 (COV D19 (ANSSEN))	Blood fibrinogen decreased	1,123	2,345	0.884				0,504	1,798	1,528	0,856	4,249	1,048 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Blood lactate dehydrogenase increased	1,604	1,253	0.876	0.612			1,056	2,003	1,153	1,597	1,601	1,597 Other	
COVID19 (COV D19 (ANSSEN))	Blood magnesium increased	1,818	1,384	0.925				0,283	1.14	1,935	1,818	1,187	Other	
COVID19 (COV D19 (ANSSEN))	Blood potassium decreased	1,872	1,224	0.874				0,527	1.19	1,483	1,652	1,201	Other	
COVID19 (COV D19 (ANSSEN))	Blood sodium decreased	1,821	1,529	0.878	0.609			1,342	2,017	1,605	1,904	1,586	Not an AE	
COVID19 (COV D19 (ANSSEN))	Blood sodium increased	1,634	1,157	0.912				1,491	1,509	1,112	2,206	0,945	Other	
COVID19 (COV D19 (ANSSEN))	Blood urea decreased	1,673	1,359	0.863				0,224	1,403	1,939	1,214	2,06	0,871 Other	
COVID19 (COV D19 (ANSSEN))	Blood urea increased	1,842	1,257	0.881				1,083	2,052	2,068	1,59	1,59	Other	
COVID19 (COV D19 (ANSSEN))	COV D-19 pneumonia	2,031	1,405	1.108				1,698	2,166	1,888	1,888	1,882	Other	
COVID19 (COV D19 (ANSSEN))	CSF protein increased	2,731	2,123	0.862				1,774	2,93	1,084	2,486	2,215	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral hemorrhage	2.32	1,602	0.921				1,843	1,45	1,164	1,364	1,112	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral mass effect	2,883	1,943	0.913				1,445	1,381	1,197	3,789	1,004	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral thrombosis	2,279	1,859	0.878				1,814	1,28	1,281	1,955	1,955	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Cerebral venous sinus thrombosis	3,243	2,174	0.905				2,018	2,223	2,382	1,187	1,187	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Chest X-ray abnormal	1,771	1,201	0.93				1,349	1,669	1,79	1,919	2,018	1,557 Confounded/indication	
COVID19 (COV D19 (ANSSEN))	Computed tomogram head abnormal	2,877	1,704	0.965	0.611			2,517	2,124	2,321	2,647	3,048	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Computed tomogram head normal	1,988	1,362	0.901				0,385	1,693	1.96	1,804	1,509	Not an AE	
COVID19 (COV D19 (ANSSEN))	Computed tomogram thorax abnormal	2,078	1,428	0.858				1,428	1,12	2,037	2,037	2,037	1,448 Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Deep vein thrombosis	2,588	1,78	1,043				2,152	2,287	3,028	1,353	1,978	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Endotracheal intubation	1,935	1,376	1.213				1,296	2,082	2,082	3,024	1,807	Labeled	
COVID19 (COV D19 (ANSSEN))	Eosinophil count decreased	1,755	1,305	0.862				1,318	1,95	1,618	2,045	1,618	1,618	Other
COVID19 (COV D19 (ANSSEN))	Eosinophil percentage decreased	1,771	1,406	0.897	0.609			1,301	2,104	1,698	1,698	1,373	Other	
COVID19 (COV D19 (ANSSEN))	Feeling cold	1.78	0,837	1,206				2,013	1,47	1,407	1,85	1,85	1,418 Labeled	
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer	2,365	1,246	0.863				2,365	2,143	1,98	2,486	1,688	Other	
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer increased	2,166	1,443	0.965	0.612			1,684	2.25	2,175	2.42	1,581	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Fibrin D dimer normal	1,958	1,107	0.886				0,434	1,63	2,109	1,103	1,392	Not an AE	
COVID19 (COV D19 (ANSSEN))	Gate palsy	2,305	1,09	0,405				1,09	2,257	1,76	1,76	1,615	Labeled	
COVID19 (COV D19 (ANSSEN))	Glaucoma increased	1,871	1,315	0.882				0.4	1,329	1.65	1,656	1,213	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Glucose urine present	1,784	2,421	1.328				1.33	1,362	2,315	1,981	1,981	Other	
COVID19 (COV D19 (ANSSEN))	Guillain-Barre syndrome	2,337	1,848	0.911				1,551	2,977	2,169	1,959	1,634	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Haematuria decreased	1,825	1,295	0.909	0.606			0,425	1,339	2,038	1,746	2,191	1,399	Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Haemoglobin decreased	1,768	1,298	0.919	0.607			1,298	1,409	1,817	1,625	2,086	1,389	Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test	5.57	3,623	4,086				5,207	5,341	7,209	3,008	3,008	Not an AE	
COVID19 (COV D19 (ANSSEN))	Heparin-induced thrombocytopenia test positive	6,409	3,503	0.863	0.544			4,723	5,631	0,763	7,729	1,825	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Hypoxia	1,863	1,311	0.934				1,472	1,974	1,984	2,083	1,533	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Immunglobulin therapy	2,108	1,804	0.883				1,927	2,517	2,252	1,674	1,674	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Intensive care	1,837	1,42	1,057				1,428	2,084	2,022	2,303	1,533	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	International normalised ratio increased	1,856	1,286	0.865	0.747			1,452	1.98	1,55	1,98	1,35	Not an AE	
COVID19 (COV D19 (ANSSEN))	International normalised ratio normal	2,018	1,243	0.888				1,469	2,042	2,12	1.25	1,25	Not an AE	
COVID19 (COV D19 (ANSSEN))	Jugular vein thrombosis	1,951	1,627	1,374				1,374	1,171	1,174	1,406	0,727	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture	1,812	1,344	1,219				1,855	2,149	1,009	1,009	1,682	Not an AE	
COVID19 (COV D19 (ANSSEN))	Lumbar puncture abnormal	2,096	1,728	1,012				1,012	2,608	1,059	1,743	1,743	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Lung aedema	1,717	1,274	0,536				1,607	1,726	1,186	1,815	1,459	Other	
COVID19 (COV D19 (ANSSEN))	Lymphocyte percentage decreased	1,702	1,289	0.91				1,028	2,111	1,958	1,129	1,306	Other	
COVID19 (COV D19 (ANSSEN))	Magnetic resonance imaging head abnormal	2,087	1,532	0.883				0,476	1,794	1,873	2,327	1,618	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	On and off phenomenon	1,763	0,762	0.863				3,288	2,143	1,68	2,221	1,528	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Packed red blood cell transfusion	1,741	1,258	0.883				1,214	1,183	2,049	1,804	1,427	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Pain assessment	2,552	0,876					0,513	1,569	2,224	1,051	1,429	Not an AE	
COVID19 (COV D19 (ANSSEN))	Peripheral embolism	2,163	1,487	0.883				0,657	1,059	1,582	2,469	0,953	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Platelet count	2,773	2,243	0.908	0.611			0,472	1,805	3.05	3,122	1,781	Not an AE	
COVID19 (COV D19 (ANSSEN))	Platelet count decreased	1,868	1,298	0.896	0.609			0,289	1,484	2,078	1,486	1,418	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Platelet count normal	2,726	1,841	0.902				0,388	1,984	2,716	1,984	1,641	Not an AE	
COVID19 (COV D19 (ANSSEN))	Platelet factor 4	6,027	3,397	0.884				4,294	2.8	2.8	0,814	1,855	Not an AE	
COVID19 (COV D19 (ANSSEN))	Poor quality product administered	1,306						0,965	3,807	2,948	4,607	4,236	3,729	Not an AE
COVID19 (COV D19 (ANSSEN))	Prolonged intuse	1,058	1,064					4,911					Other	
COVID19 (COV D19 (ANSSEN))	Prothrombin time prolonged	1,985	1,511	0.927	0.746			1,518	1,674	2,352	2,531	1,674	1,518	Reviewed, Regulatory Action
COVID19 (COV D19 (ANSSEN))	Pulmonary embolism	2,232	1,572	1,738	0.613			1,482	2,018	2,587	2,867	1,838	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Pulmonary thrombosis	2,045	1,503	0.902				1.69	1,979	2,029	1,69	1,883	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Red blood cell count decreased	1,839	1,303	0.901				0,607	1,373	2,053	1,659	1,501	Other	
COVID19 (COV D19 (ANSSEN))	Red cell distribution width increased	2,004	1,381	0.914	0.611			0,333	1,329	2,265	2,366	1,428	Other	
COVID19 (COV D19 (ANSSEN))	Russell's viper venom time abnormal	1,364	1,021	2,312				0,499	0,499	1,096	0,731	1,096	Reviewed, Regulatory Action	
COVID19 (COV D19 (ANSSEN))	Superficial vein thrombosis	2,407	1,517	0.87										

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 1, 2022 5:57:24 AM
Attachments: [USST_20220225.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 2/25/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBOS 2020/2021	US Serious EBOS 2020/2021	US Fatal EBOS 2020/2021	US Infant EBOS 2020/2021	US Child EBOS 2020/2021	US Teen EBOS 2020/2021	US Adult EBOS 2020/2021	US Adult EBOS 2020/2021	US Adult EBOS 2020/2021	US Female EBOS 2020/2021	US Male EBOS 2020/2021	Comment
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,515	1,515	0	0	0	0	1,515	1,515	1,515	1,515	1,515	1.45 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,174	1,672	0,873	0	0	0	1,676	2,111	2,112	2,112	2,112	1.5 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,888	1,241	0,452	0	0	0	1,452	2,034	2,034	2,034	2,034	1.72 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	2,871	0,961	0,37	0	0	0	0,518	0,875	0,875	0,875	0,875	1.603 Other
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,018	1,064	0,877	0	0	0	0,925	0,765	0,765	0,765	0,765	1.51 Other
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	0,135	0,135	0	0	0	0	0,135	0,135	0,135	0,135	0,135	1.326 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,556	1,881	0,902	0	0	0,485	2,134	2,015	2,015	2,015	2,015	1.437 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,154	1,522	0,873	0	0	0	1,874	1,811	1,811	1,811	1,811	1.407 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	1,443	1,088	0,425	0	0	0	1,088	1,237	1,237	1,237	1,237	1.903 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary normal	1,812	1,421	0,803	0	0	0	1,168	2,216	2,216	2,216	2,216	1.308 Other
COVID-19 (COVID-19 (JANSSEN))	Antibody test	0,359	0,317	0,181	0	0	0	0,317	0,161	0,161	0,161	0,161	1.744 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,229	1,516	0,96	0,612	0	0	0,427	0,826	0,826	0,826	0,826	2.77 Other
COVID-19 (COVID-19 (JANSSEN))	Areflexia	2,118	1,809	0,876	0	0	0	0,86	2,258	2,258	2,258	2,258	1.519 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Aterogram carotid abnormal	1,78	1,112	0,676	0	0	0	1,109	1,178	1,178	1,178	1,178	0.883 Other
COVID-19 (COVID-19 (JANSSEN))	Basophil count decreased	1,891	1,431	0,886	0	0	0,61	0,325	1,21	2,339	1,385	1,385	1.314 Other
COVID-19 (COVID-19 (JANSSEN))	Basophil percentage decreased	1,797	1,477	0,906	0	0,008	0	0,286	1,206	2,251	1,83	1,83	2.203 Other
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,791	1,306	0,9	0	0	0	0,327	1,456	1,873	1,472	1,472	1.619 Other
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,878	1,38	0,912	0	0	0	0,394	1,378	2,113	1,86	1,86	2.224 Other
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,997	1,384	0,842	0	0	0	0,442	1,202	1,115	1,584	1,584	2.265 Other
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	3,124	2,342	0,886	0	0	0	0,504	1,803	1,926	0,987	0,987	4.253 Other
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,896	1,391	0,863	0	0	0	0,263	1,14	1,961	1,812	1,812	2.462 Other
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,681	1,236	0,92	0	0	0	0,527	1,192	1,5	2,071	1,865	1.235 Other
COVID-19 (COVID-19 (JANSSEN))	Blood sodium decreased	1,819	1,324	0,881	0,609	0	0	1,331	2,019	1,665	1,897	1,897	1.597 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Blood sodium increased	1,652	1,162	0,912	0	0	0	1,476	1,932	1,135	1,335	1,335	2.148 Other
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,675	1,36	0,885	0	0	0,225	1,285	1,36	1,983	2,049	1,983	0.991 Other
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,854	1,257	0,89	0	0	0	1,008	2,044	1,711	2,087	2,087	1.59 Other
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,04	1,416	1,122	0	0	0	1,731	2,186	1,923	2,083	2,083	1.912 Other
COVID-19 (COVID-19 (JANSSEN))	CFP protein increased	2,716	2,108	0,866	0	0	0	1,762	2,037	1,077	2,482	2,482	2.2 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central haemorrhage	2,32	1,823	0,912	0,514	0	0	1,681	1,883	1,448	3,158	3,158	1.145 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central mass effect	2,887	1,885	0,912	0,522	0	0	1,409	1,383	1,174	3,703	3,703	0.993 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central thrombosis	2,279	1,609	0,862	0,512	0	0	1,12	1,617	1,617	1,617	1,617	1.205 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Central venous sinus thrombosis	3,243	2,168	0,907	0,517	0	0	2,257	2,226	2,226	3,847	3,847	1.189 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,779	1,27	0,929	0,348	0	0	1,329	1,876	1,791	2,023	2,023	1.564 Confounded-indication
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram head abnormal	2,566	1,956	0,929	0,511	0	0	1,684	2,327	2,028	3,028	3,028	1.741 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram head normal	1,991	1,383	0,802	0,391	0	0	1,062	1,987	1,804	2,233	2,233	1.516 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Completed tomogram thorax abnormal	2,073	0,914	0,314	0,485	0	0	0,438	2,031	1,693	2,283	2,283	1.974 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,885	1,77	0,957	0,457	0	0	2,155	2,263	1,974	3,248	3,248	1.974 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	1,346	1,376	1,183	0,375	0	0	1,348	2,094	1,734	2,042	2,042	1.816 Labeled
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,792	1,392	0,89	0,512	0	0	1,295	1,617	1,617	2,027	2,027	1.417 Other
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,773	1,408	0,902	0,301	0	0,609	1,301	2,088	1,734	2,077	2,077	1.384 Other
COVID-19 (COVID-19 (JANSSEN))	Fasting creatinine	1,779	1,379	0,912	0,295	0	0	1,293	1,615	0,967	1,85	1,85	1.85 Labeled
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,305	1,241	0,886	0,44	0	0	2,184	2,15	1,816	2,494	2,494	1.693 Other
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	2,161	1,443	0,964	0,314	0	0	1,683	2,241	2,182	2,462	2,462	1.602 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,963	1,453	0,964	0,452	0	0	1,1	2,062	1,024	2,139	2,139	1.372 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Gaze palsy	2,305	1,09	0,881	0,405	0	0	0,881	2,26	1,752	1,302	2,343	1.608 Labeled
COVID-19 (COVID-19 (JANSSEN))	Gilvian increased	1,877	0,4	0,881	0,4	0	0	0,881	1,285	1,693	1,693	1,693	2.208 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,799	1,236	0,895	0,31	0	0	1,37	1,485	2,344	1,485	1,485	1.068 Other
COVID-19 (COVID-19 (JANSSEN))	Gullström-Barro syndrome	2,338	1,846	0,871	0,428	0,006	0	1,579	2,078	1,633	2,344	2,344	1.712 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,832	1,399	0,919	0,424	0,007	0	1,209	2,037	1,773	2,179	2,179	1.411 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,771	1,257	0,909	0,317	0,007	0	1,166	1,641	1,641	2,078	2,078	1.397 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hepatitis-induced thrombocytopenia test	6,408	4,918	2,512	0,518	0	0	4,518	5,207	5,34	7,214	7,214	1.925 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Hepatitis-induced thrombocytopenia test positive	6,408	3,449	0,866	0,543	0,067	0	4,721	5,662	5,746	7,507	7,507	1.837 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	1,885	1,299	0,931	0,468	0	0	1,468	1,977	1,776	2,119	2,119	1.581 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Immunoagglutination therapy	2,104	1,606	0,905	0,422	0	0	1,405	2,44	1,44	2,44	2,44	1.602 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,843	1,055	0,629	0,209	0	0	1,46	2,038	1,773	2,32	2,32	1.535 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio increased	0,853	0,884	0,747	0,394	0,047	0	0,884	1,071	1,463	2,339	2,339	1.318 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio normal	2,016	1,237	0,819	0,413	0	0	1,43	2,045	0,922	2,114	2,114	1.252 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,817	1,522	0,869	0,469	0	0	1,522	1,105	1,059	2,414	2,414	0.714 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,906	1,341	0,858	0,341	0	0	1,216	1,613	1,1	1,678	1,678	1.074 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,096	1,733	0,919	0,469	0	0	1,054	2,815	1,959	1,618	1,618	1.782 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture normal	1,72	1,066	0,629	0,341	0	0	1,066	1,295	1,824	1,901	1,901	1.501 Other
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,699	1,283	0,932	0,173	0,101	0	1,02	2,1	1,964	2,164	2,164	1.101 Other
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,39	1,624	0,886	0,428	0	0	1,533	0,88	2,127	2,318	2,318	1.682 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head normal	1,479	0,921	0,511	0,449	0,012	0,147	1,248	2,317	1,842	2,318	2,318	1.444 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,936	1,391	0,886	0,336	0	0	1,285	2,345	1,445	2,231	2,231	1.338 Other
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,097	1,024	0,518	0,475	0,024	0	1,024	1,264	1,991	1,991	1,991	1.978 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,58	1,255	0,892	0,257	0,009	0	0,911	1,936	2,008	1,104	1,104	1.104 Other
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,499	1,202	0,872	0,129	0	0	1,186	1,646	1,501	2,209	2,209	0.844 Other
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,746	1,293	0,811	0,231	0	0	1,911	1,884	2,117	1,884	1,884	1.417 Other
COVID-19 (COVID-19 (JANSSEN))	Nonspecific reaction	2,193	0,793	0,461	0,749	0	0	0,612	0,612	1,824	2,303	2,303	1.05 Other
COVID-19 (COVID-19 (JANSSEN))	Off-label use	1,134	0,166	0,877	0,103	0	0	1,193	1,175	0,851	1,405	1,405	1.931 Not an AE
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,754	0,762	0,461	0,397	0	0	2,397	1	1	2,218	2,218	Other
COVID-19 (COVID-19 (JANSSEN))	Packed red blood cell transfusion	1,73	1,217	0,884	0,884	0	0	1,213	1,178	1,148	2,028	2,028	0.865 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,192	1,595	0,876	0,513	0	0	1,55	2,206	1,644	2,22	2,22	1.428 Not an AE
COVID-19 (COVID-19 (JANSSEN))	Peripneumonia	2,932	1,487	0,866	0,								

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 8, 2022 5:23:58 AM
Attachments: [USST_20220304.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/4/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBRS 2020/2024	US Serious EBRS 2020/2024	US Fatal EBRS 2020/2024	US Infant EBRS 2020/2024	US Child EBRS 2020/2024	US Teen EBRS 2020/2024	US Adult EBRS 2020/2024	US Adult/GE EBRS 2020/2024	US Adult/GE EBRS 2020/2024	US Female EBRS 2020/2024	US Female EBRS 2020/2024	US Male EBRS 2020/2024	Comments
COVID-19 (COVID-19) (JANSEN)	Activated partial thromboplastin time prolonged	2,261	1,511	0.872	0.154	0.154	0.154	1,673	2,105	2,092	2,851	2,851	1,489	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Activated partial thromboplastin time shortened	1,263	1,652	0.872	0.207	0.207	0.207	1,473	2,105	2,092	2,851	2,851	1,489	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Acute respiratory failure	2,057	1,647	0.872	0.449	0.449	0.449	1,684	2,105	2,092	2,851	2,851	1,489	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Adverse drug reaction	2,859	0,968	0.871	0.518	0.518	0.518	0,974	0,804	0,686	0,686	0,686	1,471	Other
COVID-19 (COVID-19) (JANSEN)	Adverse event	2,016	1,581	0.871	0.518	0.518	0.518	0,974	0,804	0,686	0,686	0,686	1,471	Other
COVID-19 (COVID-19) (JANSEN)	Angiogram abnormal	1,509	1,321	0.91	0.609	0.609	0.609	1,437	1,755	1,755	2,307	2,307	1,508	Other
COVID-19 (COVID-19) (JANSEN)	Angiogram cerebral abnormal	2,325	2,061	0.991	0.485	0.485	0.485	2,124	2,053	2,052	2,627	2,627	1,476	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Angiogram normal	2,166	1,684	0.991	0.485	0.485	0.485	2,124	2,053	2,052	2,627	2,627	1,476	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Angiogram pulmonary abnormal	2,454	1,682	0.991	0.485	0.485	0.485	1,883	2,053	2,052	2,627	2,627	1,476	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Angiogram pulmonary normal	1,788	1,44	0.991	0.307	0.307	0.307	1,883	2,053	2,052	2,627	2,627	1,476	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Antibody test	2,371	0,824	0.864	0.591	0.591	0.591	0,818	1,666	1,666	1,87	2,033	1,756	Not an AE
COVID-19 (COVID-19) (JANSEN)	Anticoagulant therapy	2,237	1,251	0.902	0.371	0.371	0.371	1,216	1,622	1,622	2,006	2,006	1,506	Other
COVID-19 (COVID-19) (JANSEN)	Anuria	2,109	1,11	0.868	0.591	0.591	0.591	0,818	1,666	1,666	1,87	2,033	1,756	Not an AE
COVID-19 (COVID-19) (JANSEN)	Atrial fibrillation	1,701	1,11	0.868	0.591	0.591	0.591	0,818	1,666	1,666	1,87	2,033	1,756	Not an AE
COVID-19 (COVID-19) (JANSEN)	Basophils count decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Basophils percentage abnormal	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood albumin decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood calcium decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood chloride decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood chloride increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood creatinine decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood creatinine increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood ferritin increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood lactate dehydrogenase increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood magnesium increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood potassium decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood sodium decreased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood sodium increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Blood uric acid increased	1,805	1,45	0.864	0.609	0.609	0.609	1,226	2,406	1,763	2,316	2,316	0,919	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Breast apnea abnormal	1,871	1,282	0.908	0.225	0.225	0.225	1,088	2,068	1,871	2,112	2,112	1,664	Other
COVID-19 (COVID-19) (JANSEN)	Breast apnea normal	1,747	1,282	0.908	0.225	0.225	0.225	1,088	2,068	1,871	2,112	2,112	1,664	Other
COVID-19 (COVID-19) (JANSEN)	Cardiac hypertrophy	2,048	1,417	0.908	0.225	0.225	0.225	1,088	2,068	1,871	2,112	2,112	1,664	Other
COVID-19 (COVID-19) (JANSEN)	CFP protein increased	2,892	2,121	0.908	0.518	0.518	0.518	1,762	1,013	1,075	2,094	2,094	1,274	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Cardiac hypertrophy	2,329	1,639	0.908	0.518	0.518	0.518	1,762	1,013	1,075	2,094	2,094	1,274	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Cardiac mass effect	2,071	2,031	0.902	0.521	0.521	0.521	1,871	1,871	1,871	2,316	2,316	1,508	Other
COVID-19 (COVID-19) (JANSEN)	Cardiac hypertrophy	2,034	2,034	0.902	0.521	0.521	0.521	1,871	1,871	1,871	2,316	2,316	1,508	Other
COVID-19 (COVID-19) (JANSEN)	Cardiac sinus sinus thrombosis	1,342	2,197	0.909	0.517	0.517	0.517	2,256	2,33	0,879	3,011	3,011	1,344	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Chest X-ray abnormal	1,735	1,386	0.908	0.342	0.342	0.342	1,308	1,308	1,308	1,844	1,844	1,344	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Complicated bronchitis head abnormal	2,564	1,398	0.908	0.517	0.517	0.517	2,308	2,356	2,356	3,064	3,064	1,757	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Complicated bronchitis head normal	1,398	1,398	0.908	0.342	0.342	0.342	1,308	1,308	1,308	1,844	1,844	1,344	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Complicated bronchitis thorax abnormal	2,074	1,425	0.901	0.456	0.456	0.456	1,448	2,041	2,041	2,266	2,266	1,606	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Death	1,594	1,17	0.957	0.456	0.456	0.456	1,115	1,566	1,566	2,015	2,015	1,05	Not an AE
COVID-19 (COVID-19) (JANSEN)	Deep vein thrombosis	2,386	1,174	0.957	0.456	0.456	0.456	1,115	1,566	1,566	2,015	2,015	1,05	Not an AE
COVID-19 (COVID-19) (JANSEN)	Endotracheal intubation	1,541	1,408	0.921	0.373	0.373	0.373	1,375	1,219	1,219	2,029	2,029	1,871	Labelled
COVID-19 (COVID-19) (JANSEN)	Endotracheal intubation	1,771	1,118	0.921	0.373	0.373	0.373	1,375	1,219	1,219	2,029	2,029	1,871	Labelled
COVID-19 (COVID-19) (JANSEN)	Endotracheal intubation	1,787	1,425	0.911	0.373	0.373	0.373	1,375	1,219	1,219	2,029	2,029	1,871	Labelled
COVID-19 (COVID-19) (JANSEN)	Fasting glucose	0,944	0,944	0.877	0.061	0.061	0.061	1,468	1,468	1,468	1,844	1,844	1,344	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Fibrin D dimer	2,304	1,3	0.89	0.456	0.456	0.456	2,124	2,194	2,194	2,088	2,088	1,753	Other
COVID-19 (COVID-19) (JANSEN)	Fibrin D dimer increased	2,169	1,463	0.891	0.31	0.31	0.31	1,713	2,262	2,262	2,211	2,462	1,613	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Fibrin D dimer normal	1,959	1,959	0.891	0.456	0.456	0.456	2,124	2,194	2,194	2,088	2,088	1,753	Other
COVID-19 (COVID-19) (JANSEN)	Gait gait	2,304	1,084	0.881	0.456	0.456	0.456	2,258	1,762	1,762	1,289	2,047	1,806	Labelled
COVID-19 (COVID-19) (JANSEN)	Gait gait	1,899	1,31	0.881	0.456	0.456	0.456	2,258	1,762	1,762	1,289	2,047	1,806	Labelled
COVID-19 (COVID-19) (JANSEN)	Glomerular filtration rate decreased	1,772	1,171	0.952	0.301	0.301	0.301	1,043	1,956	1,956	2,342	2,342	1,444	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Glucose urine present	1,898	1,398	0.908	0.301	0.301	0.301	1,043	1,956	1,956	2,342	2,342	1,444	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Gullain-Barre syndrome	2,327	1,839	0.875	0.456	0.456	0.456	1,884	2,083	1,608	2,369	2,369	1,216	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Haemoglobin decreased	1,836	1,336	0.908	0.456	0.456	0.456	1,347	2,083	1,887	2,219	2,219	1,426	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Haemoglobin increased	1,779	1,336	0.908	0.456	0.456	0.456	1,347	2,083	1,887	2,219	2,219	1,426	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Heparin-induced thrombocytopenia test	2,527	3,546	0.886	0.456	0.456	0.456	4,034	5,403	4,702	7,288	7,288	3,348	Not an AE
COVID-19 (COVID-19) (JANSEN)	Heparin-induced thrombocytopenia test positive	3,429	3,429	0.886	0.456	0.456	0.456	4,034	5,403	4,702	7,288	7,288	3,348	Not an AE
COVID-19 (COVID-19) (JANSEN)	Hypoxia	1,892	1,303	0.901	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Immunoglobulin therapy	2,096	1,502	0.902	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Intensive care	1,844	1,42	0.876	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	International normalized ratio increased	1,854	1,081	0.882	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	International normalized ratio normal	2,018	1,224	0.876	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Jugular vein thrombosis	1,916	1,425	0.901	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Jugular vein thrombosis	1,594	1,36	0.876	0.563	0.563	0.563	1,474	2,006	1,871	2,331	2,331	1,603	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Lumbar puncture	2,086	1,726	0.942	0.563	0.563	0.563	1,051	2,652	1,952	1,729	1,729	1,777	Reviewed, Regulatory Action
COVID-19 (COVID-19) (JANSEN)	Lung capacity	1,726	1,396	0.908	0.563	0.563	0.563	1,051	2					

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 15, 2022 6:22:15 AM
Attachments: [USST_20220311.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/11/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020/2011	US Serious EB05 2020/2011	US Fatal EB05 2020/2011	US Infant EB05 2020/2011	US Child EB05 2020/2011	US Teen EB05 2020/2011	US Adult EB05 2020/2011	US Adult EB05 2020/2011	US Adult EB05 2020/2011	US Female EB05 2020/2011	US Male EB05 2020/2011	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,715	0	0	0	0	0	0	0	0	0	0	1,451 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,115	1,632	0	0	0	0	1,646	2,111	2,111	2,111	2,111	1,476 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2,074	1,338	0	0	0	0	0	2,074	2,074	2,074	2,074	1,791 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,653	0	0	0	0	0	0	0	0	0	0	1,472 Other
COVID19 (COVID19 (JANSSEN))	Adverse event	2,017	1,063	0	0	0	0	0	0	0	0	0	1,511 Other
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,918	1,607	0	0	0	0	1,329	1,465	1,465	1,465	1,465	1,135 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,529	1,865	0	0	0	0	0	2,133	2,043	2,087	2,087	3,6
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,175	1,555	0	0	0	0	1,855	1,828	1,828	1,135	2,368	1,477 Not an AE
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,446	2,446	0	0	0	0	0	2,446	2,446	2,446	2,446	2,201 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1,799	1,406	0	0	0	0	1,163	2,198	2,198	1,446	2,136	1,321 Other
COVID19 (COVID19 (JANSSEN))	Antibody test	0,563	0	0	0	0	0	0	0	0	0	0	1,141 Not an AE
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,232	1,51	0	0	0	0	0	0	0	0	0	1,673 Other
COVID19 (COVID19 (JANSSEN))	Areflexia	2,064	1,793	0	0	0	0	0	0	0	0	0	1,497 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Arterogram carotid abnormal	1,717	1,124	0	0	0	0	0	1,274	1,274	1,274	1,274	2,265
COVID19 (COVID19 (JANSSEN))	Arterogram carotid decreased	1,919	1,470	0	0	0	0	0	0	0	0	0	1,831 Other
COVID19 (COVID19 (JANSSEN))	Asaphot percentage decreased	1,506	1,482	0	0	0	0	0	0	0	0	0	1,315 Other
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,799	1,316	0	0	0	0	1,469	1,86	1,839	1,839	1,839	1,454 Other
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,829	1,396	0	0	0	0	1,394	2,103	2,103	1,921	2,25	
COVID19 (COVID19 (JANSSEN))	Blood chloride decreased	1,829	1,429	0	0	0	0	1,065	2,031	2,031	1,487	1,921 Other	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,881	1,39	0	0	0	0	1,274	2,085	2,085	2,009	2,247	1,408 Other
COVID19 (COVID19 (JANSSEN))	Blood fluorine decreased	3,041	2,263	0	0	0	0	1,923	1,668	1,668	1,668	1,668	1,441 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,839	1,405	0	0	0	0	1,155	1,957	1,957	1,866	2,472	1,222 Other
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,188	1,24	0	0	0	0	1,21	1,15	2,099	1,852	1,852	1,273 Other
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,822	1,324	0	0	0	0	1,346	2,23	1,68	1,68	1,89	1,615 Not an AE
COVID19 (COVID19 (JANSSEN))	Blood sodium increased	1,622	1,159	0	0	0	0	1,459	1,508	1,508	1,211	1,126	1,126
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,652	1,267	0	0	0	0	1,419	1,979	1,979	1,389	2,048	0
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,869	1,282	0	0	0	0	1,078	2,047	1,804	2,112	1,804	1,161 Other
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,056	1,407	0	0	0	0	1,749	2,213	2,213	1,967	2,309	1,943 Other
COVID19 (COVID19 (JANSSEN))	CIE protein increased	2,657	2,657	0	0	0	0	2,657	2,657	2,657	2,657	2,657	2,222 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral hemorrhage	2,329	1,649	0	0	0	0	1,513	1,936	1,936	1,499	3,295	1,169 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,969	2,032	0	0	0	0	1,413	1,87	1,87	1,182	1,362	1,126 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,297	1,633	0	0	0	0	1,676	1,271	1,624	1,624	1,624	1,212 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,222	2,174	0	0	0	0	0	2,255	2,284	0	0	3,884
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1,777	1,777	0	0	0	0	1,269	0	0	0	0	1,101 Confirmed indication
COVID19 (COVID19 (JANSSEN))	Completed tomogram head abnormal	1,953	1,690	0	0	0	0	1,203	2,074	2,074	2,074	2,074	1,748 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Completed tomogram head normal	2	2	0	0	0	0	0	0	1,984	1,984	1,984	1,362 Not an AE
COVID19 (COVID19 (JANSSEN))	Completed tomogram thorax abnormal	1,978	1,428	0	0	0	0	1,439	2,056	2,056	2,013	2,284	1,688 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Death	1,594	1,166	0	0	0	0	1,139	1,139	1,139	1,511	2,005	1,501 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,598	1,958	0	0	0	0	1,777	2,228	2,228	2,228	2,228	1,909 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	1,954	1,427	0	0	0	0	1,393	2,132	2,132	1,897	2,08	1,877 Labeled
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,753	1,344	0	0	0	0	1,341	2,128	2,128	1,703	2,058	1,703
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,797	1,427	0	0	0	0	1,29	2,136	2,136	1,802	2,083	1,433 Other
COVID19 (COVID19 (JANSSEN))	Falling coils	1,778	1,865	0	0	0	0	1,268	2,014	1,467	0	0	1,851
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	0	0	0	0	0	0	0	0	0	0	0	1,758 Other
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,177	1,467	0	0	0	0	1,72	2,262	2,262	2,243	2,481	1,62 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fibrin D monomer	1,851	1,463	0	0	0	0	1,068	2,068	2,068	1,448	1,448	1,145 Not an AE
COVID19 (COVID19 (JANSSEN))	Glaze palsy	2,301	1,083	0	0	0	0	2,258	1,756	1,756	1,281	2,33	1,207 Labeled
COVID19 (COVID19 (JANSSEN))	Globulin increased	1,882	1,314	0	0	0	0	1,279	1,689	1,689	1,711	2,241	1,237 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Glomerular filtration rate decreased	1,708	1,158	0	0	0	0	1,158	1,708	1,708	1,708	1,708	1,219
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,787	1,269	0	0	0	0	1,312	1,466	1,466	1,46	2,447	1,099 Other
COVID19 (COVID19 (JANSSEN))	Gulfian-bary syndrome	2,329	1,649	0	0	0	0	1,432	2,065	2,065	1,633	2,359	1,633 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haematocrit decreased	1,839	1,405	0	0	0	0	1,342	2,029	2,029	1,819	2,204	1,434 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,772	1,261	0	0	0	0	1,409	1,963	1,963	1,695	2,099	1,418 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	6,484	4,841	0	0	0	0	4,331	6,435	4,733	6,433	7,29	2,452 Not an AE
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	1,619	1,341	0	0	0	0	4,723	5,439	0	0	7,274	1,782 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,887	1,369	0	0	0	0	1,995	1,995	1,995	1,995	1,995	1,303 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,093	1,796	0	0	0	0	1,934	2,044	2,044	2,044	2,244	1,721 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Intensive care	1,843	1,291	0	0	0	0	1,091	2,081	2,081	2,081	2,328	1,968 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,846	1,393	0	0	0	0	1,607	1,962	1,962	1,48	2,351	1,320 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,015	1,222	0	0	0	0	1,42	2,036	2,036	0	0	2,107
COVID19 (COVID19 (JANSSEN))	IgA1 vein thrombosis	1,915	1,403	0	0	0	0	1,358	1,958	1,958	1,708	2,358	1,531 Other
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,923	1,354	0	0	0	0	1,256	2,17	2,17	1,045	1,673	1,718 Not an AE
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,062	1,725	0	0	0	0	1,268	2,654	2,654	1,048	1,789	1,789 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lung capacity	1,714	1,247	0	0	0	0	1,398	1,758	1,758	1,758	1,758	1,541 Other
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,691	1,129	0	0	0	0	1,017	2,093	2,093	1,937	2,094	1,323 Other
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,362	0	0	0	0	0	1,121	1,523	1,523	1,523	1,523	1,21
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,091	1,535	0	0	0	0	1,503	1,903	1,903	1,166	2,336	1,658 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,128	1,522	0	0	0	0	1,248	2,307	2,307	2,004	2,441	1,498 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,908	1,398	0	0	0	0	1,427	1,933	1,933	1,156	2,121	1,881 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,117	1,547	0	0	0	0	0	0	0	0	0	2,017 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,577	1,028	0	0	0	0	1,256	2,265	2,265	2,018	2,227	1,645 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,152	1,228	0	0	0	0	1,155	1,689	1,689	1,655	0	0
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,745	1,312	0	0	0	0	1,114	2,118	2,118	1,88	2,021	1,443 Other
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	2,189	1,646	0	0	0	0	1,074	0	0	0	0	2,093
COVID19 (COVID19 (JANSSEN))	OT label use	1,339	0	0	0	0	0	1,195	1,225	1,225	1,087	1,416	1,416
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,752	1,272	0	0	0	0	0	0	0	0	0	2,207
COVID19 (COVID19 (JANSSEN))	Packed red blood cell transfusion	1,771	1,29	0	0	0	0	1,214	1,222	1,222	1,29	2,146	0
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,55	0	0	0	0	0	0	0	0	0	0	1,444 Not an AE
COVID19 (COVID19 (JANSSEN))	Peripartum embolism	2,922	1,415	0	0	0	0	1,627	1,052	1,052	1,574	2,227	1,954 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet count	2,762	2,257	0	0	0	0	1,795	2,969	2,969	2,477	3,014	1,918 Not an AE
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,872	1,311	0	0	0	0	0	0	0	0	0	1,465 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,726	1,83	0	0	0	0	2,056	2,709	2,066	3,139	3,139	1,645 Not an AE
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,026	3,366	0	0	0	0	4,323	2,562	2,562	0	0	6,28
COVID19 (COVID19 (JANSSEN))	Protein a1r2 pressure therapy	1,796	1,276	0	0	0	0	1,277	1,971	1,971	1,647	2,04	1,633 Other
COVID19 (COVID19 (JANSSEN))	Product administered to patient of inappropriate age	1,625	0	0	0	0	0	0	0	0	0	0	1,882 Not an AE
COVID19 (COVID19 (JANSSEN))	Prolonged labour	1,098	1,065	0	0	0	0	1,026	0	0	0	0	1,946
COVID19 (COVID19 (JANSSEN))	Protein total decreased	1,779	1,265	0	0	0	0	1,406	1,623	1,623	1,765	2,025	1,425 Other
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1,966	1,482	0	0	0	0	1,493	2,333	2,333	1,703	2,53	1,498 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2,234	1,465	0	0	0	0	1,787	2,465	2,465	2,569	2,467	2,467
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2,044	1,47	0	0	0	0	1,695	1,561	1,561	2,009	2,117	1,864 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1,844	1,311	0	0	0	0	1,365	2,042	2,042	1,734	2,06	1,531 Other
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	2,012											

From: [Baer, Bethany](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#); [Menschik, David](#)
Subject: Weekly data mining
Date: Tuesday, March 22, 2022 7:24:24 AM
Attachments: [USST_20220318.xls](#)

Good morning,

I am providing the data mining alerts this week as David is on leave. Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/18/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
Bethany

Drug	Event	US EBUS 2020/2019	US Serious EBUS 2020/2019	US Fatal EBUS 2020/2019	US Infant EBUS 2020/2019	US Child EBUS 2020/2019	US Teen EBUS 2020/2019	US Adult EBUS 2020/2019	US Adult EBUS 2020/2019	US Adult EBUS 2020/2019	US Adult EBUS 2020/2019	US Female EBUS 2020/2019	US Male EBUS 2020/2019	Comment
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,171	1,622	0.878				1,448	1,642	2,117	2,033	2,793	1,474	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,139	1,622	0.878				1,448	1,642	2,117	2,033	2,793	1,474	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	1,207	1,207	0.648				0.448	1,486	2,068	1,989	2,688	1,788	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	2,854	1,953	0.851				0.915	0.972	0.764	0.687	0.627	0.727	Other
COVID19 (COVID19 (JANSSEN))	Adverse event	2,016	1,097	0.887					0.978	0.764	0.733	1,866	1,52	Other
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,323	1,323	0.963					1,426	1,426	1,443	2,119	1,338	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,509	1,839	0.484					2,139	2,01	2,069	3,53	1,468	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,157	1,522	0.884					1,846	1,818	1,337	2,332	1,46	Not an AE
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2,468	1,683	0.462					2,063	2,119	2,265	2,512	2,172	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	1,783	1,392	0.905					1,155	2,205	1,423	2,135	1,31	Other
COVID19 (COVID19 (JANSSEN))	Antibody test	2,371	1,838	0.876					1,638	1,638	1,638	2,024	1,771	Not an AE
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2,226	1,563	0.96	0.613				1,835	2,27	2,777	2,026	1,62	Other
COVID19 (COVID19 (JANSSEN))	Arrhythmia	2,069	1,809	0.891					0.919	2,374	1,319	2,138	1,488	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Arrhythmia cardiac abnormal	1,765	1,311	0.862					1,112	1,31	1,337	2,194	1,51	Other
COVID19 (COVID19 (JANSSEN))	Basophils count decreased	1,897	1,462	0.904	0.61			0.369	2,019	1,803	2,309	2,309	1,303	Other
COVID19 (COVID19 (JANSSEN))	Basophils percentage decreased	1,799	1,461	0.919	0.608				1,19	2,291	1,834	2,2	1,345	Other
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,794	1,366	0.921					1,491	1,834	1,827	2,185	1,435	Other
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,891	1,39	0.936					1,401	2,165	1,926	2,25	1,516	Other
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,852	1,363	0.953					1,263	2,096	1,971	2,35	1,35	Other
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2,915	2,269	0.894					1,724	1,922	0,843	4,021	1,941	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,827	1,376	0.928					1,145	1,928	1,843	2,447	1,215	Other
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,684	1,241	0.937					1,489	2,119	1,856	1,279	1,279	Other
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,817	1,32	0.994	0.609				1,341	2,025	1,695	1,907	1,612	Not an AE
COVID19 (COVID19 (JANSSEN))	Blood sodium increased	1,595	1,141	0.916					1,427	1,49	1,185	2,071	1,01	Other
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,683	1,38	0.986			0.217		1,416	2,019	1,52	2,076	0,92	Other
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1,859	1,275	0.913					1,603	2,045	1,752	2,103	1,643	Other
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,051	1,417	1.137					1,795	2,227	1,984	2,34	1,824	Other
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2,667	2,091	0.878					1,901	2,949	1,063	2,587	2,234	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Central haemorrhage	1,960	2,332	0.931			0.512		1,373	1,687	1,489	1,987	1,166	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,865	1,962	0.93			0.52		1,355	1,645	1,181	3,978	1,101	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,297	1,613	0.877					1,122	1,263	1,605	3,217	1,204	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3,233	2,142	0.913			0.516		2,224	2,283	0,874	3,856	1,232	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Chen X-ray abnormal	1,774	1,272	0.936			0.343		1,309	1,909	1,837	2,067	1,606	Corbunded-indication
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head abnormal	1,929	1,426	0.962	0.611		0.343		1,116	1,329	1,329	2,027	1,738	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Computerised tomogram head normal	1,999	1,367	0.906			0.917		1,977	1,848	2,848	2,262	1,831	Not an AE
COVID19 (COVID19 (JANSSEN))	Computerised tomogram thorax abnormal	1,425	1,043	0.875			0.425		1,043	2,052	1,404	2,062	1,066	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Death	1,594	1,172	0.96			1,598		1,149	1,589	1,208	2,026	1,516	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,58	1,778	0.867			0,454		2,168	2,291	3,024	3,279	1,997	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	1,845	1,405	0.933			1,805		1,383	1,937	1,868	2,887	1,856	Labeled
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,773	1,324	0.904			0,116		1,247	2,162	1,56	2,03	1,365	Other
COVID19 (COVID19 (JANSSEN))	Eosinophils percentage decreased	1,799	1,369	0.878	0.609		0,369		1,268	2,127	1,62	2,072	1,417	Other
COVID19 (COVID19 (JANSSEN))	Fatigue	1,778	1,266	0.915			1,206		1,041	1,455	0,976	1,848	1,421	Labeled
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,296	1,262	0.895			0,439		2,217	2,198	1,328	2,822	1,73	Other
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,169	1,069	0.969	0.612		0,31		1,715	2,476	2,275	2,475	1,626	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,94	1,096	0.846			0,429		1,098	2,088	1,022	2,162	1,35	Not an AE
COVID19 (COVID19 (JANSSEN))	Gate palsy	2,903	1,893	0.902			0,903		2,402	2,269	1,269	2,269	1,269	Labeled
COVID19 (COVID19 (JANSSEN))	Globose increased	1,874	1,297	0.895			0,399		1,27	1,699	1,679	2,006	1,246	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Glomerular filtration rate decreased	1,756	1,148	0.927			1,024		1,903	1,548	2,001	2,067	1,362	Other
COVID19 (COVID19 (JANSSEN))	Glycosuria present	1,765	1,249	0.966			1,249		1,249	1,45	1,449	2,45	1,018	Other
COVID19 (COVID19 (JANSSEN))	Gullain-Barre syndrome	2,329	1,859	0.885			0,432		1,638	2,953	1,629	2,428	2,168	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemorrhoid increased	1,386	1,041	0.864	0.605		1,386		1,041	1,386	1,224	1,433	1,204	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,768	1,262	0.934			1,143		1,109	1,697	1,697	2,12	1,41	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Haemoglobin-induced thrombocytopenia test	3,522	3,522	0.994			4,47		4,434	4,766	4,766	3,268	2,01	Not an AE
COVID19 (COVID19 (JANSSEN))	Haemoglobin-induced thrombocytopenia test positive	1,738	1,346	0.872			0,542		1,719	2,334	0,741	3,716	1,735	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,892	1,295	0.927			1,892		1,295	2,034	1,816	2,309	1,824	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,099	1,78	0.876			1,78		1,969	2,051	1,409	2,051	1,731	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Intensive care	1,837	1,409	1,008	0.746		0,029		1,432	2,094	2,045	2,313	1,564	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,842	1,386	0.982			1,842		1,386	1,997	1,479	2,359	1,318	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,015	1,416	0.965			2,015		1,416	2,065	0,926	2,018	1,275	Not an AE
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1,916	1,489	0.881			1,361		1,158	2,167	1,367	2,167	0,715	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,824	1,324	0.871			1,324		1,265	2,157	1,927	2,624	1,708	Not an AE
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,105	1,735	1,008			2,105		1,008	2,749	1,047	2,387	1,838	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Lung opacity	1,735	1,274	0.937			1,735		1,274	1,756	1,689	2,223	1,542	Other
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,829	1,329	0.915			1,829		1,297	2,086	1,006	2,014	1,319	Other
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,409	1,141	0.904	0.607		0,235		1,005	1,522	1,278	2,082	1,676	Other
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,064	1,516	0.909			2,064		1,516	1,895	2,023	2,164	1,644	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,106	1,502	0.937	0.612		0,443		1,281	2,278	1,972	2,451	1,468	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,591	1,415	0.917			1,591		1,286	2,394	1,563	2,204	1,422	Other
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,195	1,529	0.912			2,195		1,529	2,271	1,913	2,073	1,903	Reviewed, Regulatory Action
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,563	1,25	0.909	0.609		0,246		0,922	1,917	2,019	2,265	1,12	Other
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,51	1,223	0.868			1,51		1,108	1,617	1,164	2,038	1,838	Other
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,73	1,295	0.916			0,28		1,103	2,102	1,858	2,011	1,433	Other
COVID19 (COVID19 (JANSSEN))	Nasopharyngeal reaction	2,192	0,794	0.888			2,192		0,612	1,743	0,858	2,743	1,052	Other
COVID19 (COVID19 (JANSSEN))	OT label use	1,23	1,23	0.864			1,23		1,195	1,195	1,211	1,211	1,903	Not an AE
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,753	1,362	0.937			1,753		1,362	1,501	1,001	2,243	1,213	Other
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,053	1,864	0.934			0,509		1,533	2,168	1,126	2,533	1,426	Not an AE
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	2,928	1,412	0.878			0,607		1,052	1,581	2,236	2,367	1,953	Reviewed, Regulatory Action

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, March 29, 2022 6:11:20 AM
Attachments: [USST_20220325.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 3/25/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 5, 2022 6:42:16 AM
Attachments: [USST_20220401.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/1/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,

David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 12, 2022 5:44:45 AM
Attachments: [USST_20220408.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/8/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBIS 20220409	US Serious EBIS 20220409	US Fatal EBIS 20220409	US Infant EBIS 20220409	US Child EBIS 20220409	US Teen EBIS 20220409	US Adult EBIS 20220409	US Adult2 EBIS 20220409	US Adult3 EBIS 20220409	US Female EBIS 20220409	US Male EBIS 20220409	Comment	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1,515	1,591	0.876				1,603	1,603	1,603	1,603	1,603	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2,125	1,591	0.876				1,624	2,079	2,003	2,765	1,446	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2,064	1,337	1,016				1,867	2,074	1,867	2,389	1,732	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	0,855	0,877	0,877				0,979	0,978	0,684	0,617	0,617	Other	
COVID19 (COVID19 (JANSSEN))	Adverse event	2,016	1,094	0,876				0,914	0,883	0,732	1,891	1,891	1,432 Not an AE	
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1,905	0,08	0,08				1,905	1,907	1,905	1,905	1,905	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2,473	1,834	0,903				2,086	2,023	2,095	3,485	1,493	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2,159	1,496	0,879				1,863	1,785	1,321	2,339	1,432 Not an AE		
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	1,621	1,621	1,621				1,621	1,621	1,621	1,621	1,621	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary normal	1,794	1,307	0,906				1,135	2,182	1,454	2,075	1,34	Other	
COVID19 (COVID19 (JANSSEN))	Anion gap decreased	2,352	0,877	0,877				0,797	1,594	1,594	1,594	1,594	Not an AE	
COVID19 (COVID19 (JANSSEN))	Antibody test	2,212	1,064	0,612				1,815	2,029	2,222	2,416	1,662	Other	
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	1,730	1,722	0,881				1,509	2,333	1,298	2,416	1,429	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Areflexia	1,432	1,133	0,876				1,284	1,284	1,303	2,14	2,14	Other	
COVID19 (COVID19 (JANSSEN))	Atherosclerotic carotid abnormal	1,89	1,044	0,88	0,61			0,369	1,772	1,772	2,406	1,334	Other	
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1,792	1,432	0,926				1,601	2,321	1,78	2,193	1,335	Other	
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1,759	1,017	0,917				1,434	1,846	1,841	1,135	1,401	Other	
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1,876	1,365	0,939				1,35	2,021	1,891	2,22	1,462	Other	
COVID19 (COVID19 (JANSSEN))	Blood chloride decreased	1,843	1,251	0,914				1,068	2,068	1,927	1,936	1,936	Other	
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1,836	1,333	0,948				0,42	1,223	2,063	1,905	2,149	1,381	Other
COVID19 (COVID19 (JANSSEN))	Blood flow increased	2,922	1,929	1,492				1,492	1,904	1,904	4,099	1,055	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1,801	1,31	0,921				1,081	1,902	1,905	2,416	1,172	Other	
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1,699	1,219	0,92				1,206	1,488	2,071	1,882	1,229	Other	
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1,815	1,317	0,9	0,69			1,346	2,024	1,71	1,917	1,617	Not an AE	
COVID19 (COVID19 (JANSSEN))	Blood urea decreased	1,548	1,334	0,88				1,371	1,975	1,209	2,029	1,903	Other	
COVID19 (COVID19 (JANSSEN))	Brain edema	1,855	1,062	0,912				1,044	2,061	1,769	2,087	1,635	Other	
COVID19 (COVID19 (JANSSEN))	Brain pneumonia	1,545	1,269	0,92				1,208	1,664	0,603	2,006	0,785	Other	
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2,096	1,402	1,082				1,748	2,198	1,954	2,236	1,937	Other	
COVID19 (COVID19 (JANSSEN))	CHF protein increased	2,703	2,084	1,594				1,189	3,011	2,038	2,292	2,292	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	CHF red blood cell count positive	2,054	1,743	0,873				1,398	1,944	0,984	1,992	1,478	Other	
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2,309	1,603	1,028				1,684	1,916	1,468	3,348	1,139	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2,834	1,922	1,381				1,519	1,599	1,168	3,893	1,084	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2,301	1,626	0,876				1,115	1,282	1,605	3,199	1,225	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	1,929	1,271	0,876				1,206	1,811	2,289	3,229	2,289	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1,707	1,037	0,937				0,332	1,889	1,843	2,058	1,981	Confounded-Indication	
COVID19 (COVID19 (JANSSEN))	Computed tomography head abnormal	2,916	2,058	1,498				1,658	2,307	1,902	3,097	2,097	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Computed tomography head normal	1,991	1,355	0,91	0,611			1,715	1,97	1,857	2,246	1,558	Not an AE	
COVID19 (COVID19 (JANSSEN))	Computed tomography thorax abnormal	2,096	1,405	0,919				0,449	1,14	2,044	1,992	2,223	1,688	Reviewed - Regulatory Action
COVID19 (COVID19 (JANSSEN))	Death	1,591	1,591	1,591				1,591	1,591	1,591	1,591	1,591	1,591	Reviewed - Regulatory Action
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2,584	1,774	0,979				2,178	2,287	3,022	3,309	2,003	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	1,926	1,39	0,92				1,19	2,029	2,127	1,949	2,029	Labelled	
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1,759	1,297	0,902				1,243	2,144	1,804	2,046	1,318	Other	
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1,788	1,137	0,92	0,61			0,287	1,268	2,133	1,701	2,066	1,388	Other
COVID19 (COVID19 (JANSSEN))	Fatigue	1,777	1,062	0,843				1,189	1,448	0,965	1,939	1,636	Labelled	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2,292	1,29	0,891				2,195	2,164	1,902	2,336	1,895	Other	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2,145	1,299	0,926				1,299	2,099	2,099	2,429	2,099	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1,93	1,089	0,875				0,427	1,686	2,056	1,021	1,19	3,58	Not an AE
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2,281	1,063	0,888				2,261	1,738	1,738	2,271	1,614	Labelled	
COVID19 (COVID19 (JANSSEN))	Globulins increased	1,876	1,275	0,874				1,275	1,874	1,448	2,173	1,243	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1,71	1,224	0,907				1,222	1,469	1,446	2,398	1,065	Other	
COVID19 (COVID19 (JANSSEN))	Guttin-Barré syndrome	2,338	1,465	0,926				1,428	1,865	1,665	2,137	1,665	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Haematocrit decreased	1,814	1,289	0,942	0,606			1,489	2,05	1,798	2,198	1,419	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1,757	1,252	0,929	0,606			1,381	1,988	1,672	2,109	1,399	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	3,029	2,081	1,491				3,029	3,029	3,029	3,029	3,029	Not an AE	
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,177	3,473	2,061	0,501			4,713	5,818	0,74	7,175	2,705	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Hypoxia	1,902	1,044	0,874				1,809	1,809	1,809	2,068	1,648	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2,088	1,751	0,869				1,915	2,052	1,424	2,228	1,708	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Intensive care	1,396	1,396	1,396				1,396	2,099	2,099	2,016	2,292	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1,845	1,245	0,865	0,746			1,245	1,952	1,45	1,23	1,29	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	2,015	1,227	0,878				1,389	2,064	1,914	2,085	1,252	Not an AE	
COVID19 (COVID19 (JANSSEN))	Inguinal vein thrombosis	1,987	1,462	0,919				1,462	1,143	0,71	1,711	1,711	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1,931	1,355	0,866				1,272	2,16	1,817	1,697	1,697	Not an AE	
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2,095	1,692	1,078				1,075	2,728	2,728	1,044	1,181	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Lung capacity	1,723	1,257	0,913				1,257	1,723	1,723	1,969	1,969	Other	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1,668	1,124	0,94	0,607			1,009	2,089	1,853	2,078	1,306	Other	
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1,362	1,099	0,869				1,362	1,603	1,603	2,044	1,903	Other	
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,075	1,496	0,908				1,787	1,884	2,315	2,435	1,616	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,075	1,463	0,939	0,612			1,254	2,29	1,188	2,333	1,413	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1,898	1,396	0,92				1,396	2,362	1,584	2,179	1,862	Other	
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2,127	1,537	1,022	0,61			0,469	2,258	1,986	2,102	1,987	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1,543	1,028	0,878				1,028	1,49	1,963	2,135	1,963	Other	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1,497	1,202	0,888				1,132	1,649	1,641	2,227	1,819	Other	
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1,713	1,271	0,912				1,106	2,096	1,792	1,985	1,404	Other	
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	2,274	1,607	0,976				1,607	1,844	0,912	2,144	1,072	Other	
COVID19 (COVID19 (JANSSEN))	OT label use	1,33	0,607	0,884				799	1,197	1,294	0,885	1,448	1,924	Not an AE
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1,792	1,309	0,919				1,309	1,294	1,294	2,21	2,21	Other	
COVID19 (COVID19 (JANSSEN))	Pain assessment	2,529	0,865	0,503				1,528	2,159	1,116	2,194	1,421	Not an AE	
COVID19 (COVID19 (JANSSEN))	Peripneal embolism	2,919	1,415	0,873				0,668	1,051	1,973	2,232	0,903	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Platelet count	2,784	2,029	1,917	0,611			1,791	2,909	2,054	3,016	1,864	Not an AE	
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1,857	1,3	0,908	0,607			1,447	2,093	1,572	2,192	1,448	Reviewed - Regulatory Action	
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2,723	1,863	0,902				2,063	2,729	2,142	3,176	1,664	Not an AE	
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	6,024	3,426	0,874				4						

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, April 19, 2022 6:42:57 AM
Attachments: [USST_20220415.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/15/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020-2045	US Serious EB05 2020-2045	US Fatal EB05 2020-2045	US Infant EB05 2020-2045	US Child EB05 2020-2045	US Teen EB05 2020-2045	US Adult EB05 2020-2045	US Adult EB05 2020-2045	US Adult EB05 2020-2045	US Female EB05 2020-2045	US Male EB05 2020-2045	Comment
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,015	1,957					1,957	2,015				2,015 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,118	1,571	0,881				1,612	2,044				2,118 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,083	1,234	0,914				1,44	1,44				2,083 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	2,852	0,968	0,854				0,972	0,715				2,852 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,016	1,091	0,89				0,907	0,85				2,016 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	1,934	1,3	0,906				1,3	1,3				1,934 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,487	1,831	0,909				2,136	2,012				2,487 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,148	1,458	0,885				1,991	1,732				2,148 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	2,42	0,631	0,912				0,912	2,202				2,42 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Anion gap decreased	1,784	1,309	0,939				1,112	2,197				1,784 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Antibody test	2,371	0,823	0,879				0,599	1,084				2,371 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,211	1,474	0,971	0,619			1,812	2,047				2,211 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Areflexia	2,03	1,099	0,802				1,099	2,421				2,03 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Atrioventricular conduction abnormal	1,722	1,125	0,863				1,133	1,265				1,722 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Basophil count decreased	1,871	1,411	0,887		0,616		0,366	1,184				1,871 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Basophil percentage decreased	1,784	1,408	0,927		0,615		1,144	2,295				1,784 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,756	1,267	0,92				1,415	1,661				1,756 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,875	1,338	0,941				1,326	2,113				1,875 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood chloride decreased	1,844	1,249	0,943				1,249	1,541				1,844 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,813	1,312	0,948				1,201	2,033				1,813 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	2,24	2,165	0,958				1,743	1,933				2,24 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,807	1,31	0,925				1,074	1,929				1,807 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,679	1,226	0,938				1,2	1,51				1,679 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood sodium decreased	1,816	1,316	0,903	0,616			1,328	1,732				1,816 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,638	1,32	0,887				1,352	1,988				1,638 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,654	1,257	0,911				1,023	2,007				1,654 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Brain edema	1,535	1,263	0,926				1,196	1,591				1,535 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,018	1,402	0,882				1,761	2,2				2,018 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	CHF protein increased	2,624	2,019	1,247				2,078	3,07				2,624 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral haemorrhage	2,325	1,588	0,934				1,708	1,902				2,325 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral mass effect	2,863	1,933	0,927				1,381	1,601				2,863 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral thrombosis	2,322	1,719	0,882				1,278	1,326				2,322 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Cerebral sinus thrombosis	2,329	2,191	0,916				2,029	2,506				2,329 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,708	1,27	0,811				2,419	2,887				1,708 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head abnormal	3,254	2,663	1,663	0,617			2,114	2,299				3,254 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram head normal	1,985	1,349	0,871				1,349	1,71				1,985 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Computerized tomogram thorax abnormal	2,057	1,403	0,925				1,393	2,049				2,057 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Death	1,589	1,165	0,961				1,169	1,608				1,589 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,588	2,781	0,998				2,185	2,272				2,588 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	1,914	1,395	1,189				1,388	2,108				1,914 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,755	1,298	0,925				1,285	2,105				1,755 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,763	1,357	0,92	0,616			1,254	2,114				1,763 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fatigue	1,78	0,843	0,889				1,102	1,461				1,78 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,284	1,931	0,968				2,028	2,192				2,284 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	1,155	1,057	0,868	0,618			1,709	2,298				1,155 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,917	1,091	0,439				1,466	2,244				1,917 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Gaze palsy	2,288	1,06	0,884				2,209	1,242				2,288 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Gilvins increased	1,844	1,254	0,898				1,243	1,706				1,844 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,691	1,211	0,877				1,223	1,427				1,691 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Guttain-Barré syndrome	2,335	1,842	0,939				1,642	3,075				2,335 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,811	1,262	0,941	0,612			1,505	2,049				1,811 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,753	1,245	0,866	0,613			1,366	1,98				1,753 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test	6,527	3,709	0,997				4,18	5,604				6,527 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	1,901	1,388	0,866				1,056	1,486				1,901 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	1,901	1,388	0,866				1,056	1,486				1,901 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Immunoglobulin therapy	2,08	0,911	0,873				1,371	1,564				2,08 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,827	1,392	1,063				1,405	2,09				1,827 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio increased	1,818	1,387	1,031	0,754			1,521	1,436				1,818 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	International normalized ratio normal	2,12	1,387	0,884				1,387	2,029				2,12 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,92	1,465	0,883				1,384	1,123				1,92 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,837	1,362	0,973				1,275	2,174				1,837 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,053	1,635	1,029				2,737	1,629				2,053 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1,733	1,265	0,943				1,174	1,883				1,733 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,675	1,239	0,914				1,096	1,87				1,675 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage increased	1,345	1,095	0,868	0,613			0,998	1,488				1,345 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,065	1,492	0,913				1,513	2,198				2,065 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,066	1,426	0,94	0,619			1,234	2,283				2,066 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin increased	1,689	1,227	0,913				1,093	1,981				1,689 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,882	1,324	0,914				1,174	1,92				1,882 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,118	1,516	1,023				1,106	2,252				2,118 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,542	1,224	0,917	0,616			1,224	1,917				1,542 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,479	1,185	0,863				1,103	1,616				1,479 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,718	1,27	0,915				1,097	2,103				1,718 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Non-specific reaction	2,303	0,784	0,811				0,744	0,912				2,303 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	OT label use	1,133	0,623	0,895				1,213	1,207				1,133 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,781	0,763	0,883				3,431	0,883				1,781 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,546	0,872	0,939				1,539	2,209				2,546 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Peripartum embolism	3,204	1,389	0,879				0,656	1,034				3,204 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count	2,796	2,024	0,92	0,617			1,761	2,938				2,796 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count decreased	1,884	1,3	0,911	0,613			1,442	2,08				1,884 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet count normal	2,711	1,851	0,908				2,077	2,15				2,711 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Platelet factor 4	6,014	3,463	0,881				4,296	4,57				6,014 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Positive airway pressure therapy	1,781	1,27	0,948				1,072	1,996				1,781 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Product administered to patient of inappropriate age	1,616	0,811	0,88		0,72		2,053	1,002				1,616 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Prolonged labour	1,1	1,049	0,89				4,078	2,328				1,1 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Prothrombin time prolonged	1,842	1,427	0,926	0,753			1,431	2,328				1,842 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pulmonary embolism	2,226	1,057	0,945	0,619			1,752	2,04				2,226 Reviewed, Regulatory Action
COVID-19 (COVID-19 (JANSSEN))	Pulmonary thrombosis	2,048	1,438	0,907</									

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 3, 2022 6:23:48 AM
Attachments: [USST_20220429.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 4/29/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 10, 2022 5:46:09 AM
Attachments: [USST_20220506.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/6/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020Q06	US Series EB05 2020Q6	US Fatal EB05 2020Q06	US Infant EB05 2020Q06	US Child EB05 2020Q06	US Teen EB05 2020Q06	US Adult EB05 2020Q06	US Adult EB05 2020Q06	US Adult EB05 2020Q06	US Adult EB05 2020Q06	US Female EB05 2020Q06	US Male EB05 2020Q06	Comment
COVID19 (COVID19 (JANSEN))	Activated partial thromboplastin time prolonged	2,175	0.92					0.31						1.54 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Activated partial thromboplastin time shortened	2,092	1.562					1.609	2,056	2			2,763	1.428 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Acute respiratory distress syndrome	2,081	1.24					0.79	1,807	1			1,918	1.992 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Acute respiratory failure	2,099	1,323					1,43	2,023	1,979			2,445	1.72 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Adverse drug reaction	3,336	0.98					0.529	1,015	0,717			2,622	1.515 Other
COVID19 (COVID19 (JANSEN))	Adverse event	2,005	1,889						1,607	2,294			2,173	1.878
COVID19 (COVID19 (JANSEN))	Albumin CSE increased	2,304	1,969						1,444	1,444			0,907	1,671
COVID19 (COVID19 (JANSEN))	Angiogram abnormal	1,918	1,293					0.907	1,306	1,444			1,681	1,318 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Angiogram cerebral abnormal	2,037	1,811				0.489	1,811	2,119	1,955			2,141	1,493 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Angiogram cerebral normal	2,115	1,428					1,844	1,787	1,291			2,209	1,448 Not an AE
COVID19 (COVID19 (JANSEN))	Angiogram pulmonary abnormal	2,304	1,635				0.415	1,607	2,294	1,607			2,236	1,922 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Anion gap decreased	1,809	1,368					0.366	1,103	2,229			2,083	1,368 Other
COVID19 (COVID19 (JANSEN))	Antiobesity therapy	2,109	0,823					0.827	1,081	1,862			1,987	1,566 Not an AE
COVID19 (COVID19 (JANSEN))	Anticoagulant therapy	2,117	0.974				0.619	0.423	1,471	2,447			2,753	1,823 Other
COVID19 (COVID19 (JANSEN))	Arteritis	1,719	1,719					0.905	2,482	2,324			1,456	1,456 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Arteriovenous carotid abnormal	1,976	1,865					1,303	1,231	1,427			2,244	1,028 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Basophil count decreased	1,392	0.922		0.616			1,175	2,324	1,781			2,363	1,307 Other
COVID19 (COVID19 (JANSEN))	Basophil percentage decreased	1,788	1,41		0.616			1,148	2,325	1,756			2,195	1,328 Other
COVID19 (COVID19 (JANSEN))	Blood albumin decreased	1,926	1,296					1,309	1,456	1,746			2,169	1,386 Other
COVID19 (COVID19 (JANSEN))	Blood calcium decreased	1,864	1,349					0,948	1,349	2,109			1,868	2,2
COVID19 (COVID19 (JANSEN))	Blood chloride increased	1,923	1,927					0,469	1,227	2,026			1,469	1,927 Other
COVID19 (COVID19 (JANSEN))	Blood fibrinogen decreased	2,809	1,984					0,503	1,747	2,171			0,885	4,054
COVID19 (COVID19 (JANSEN))	Blood magnesium increased	1,81	1,312					0,173	1,08	1,972			1,771	2,417
COVID19 (COVID19 (JANSEN))	Blood potassium decreased	1,693	1,214					0,937	1,21	1,52			2,027	1,881
COVID19 (COVID19 (JANSEN))	Blood sodium decreased	1,827	1,331			0.616		1,31	2,02	1,74			1,841	1,604 Not an AE
COVID19 (COVID19 (JANSEN))	Blood urea increased	1,991	1,267					0,909	1,029	1,954			1,534	1,605 Other
COVID19 (COVID19 (JANSEN))	Brain edema	1,558	1,246					1,196	1,555	0,602			2,011	0,77 Other
COVID19 (COVID19 (JANSEN))	COVID-19 pneumonia	2,204	1,409					1,807	2,221	2,021			2,393	1,962 Other
COVID19 (COVID19 (JANSEN))	CSF protein increased	2,071	1,792					1,792	2,002	1,021			2,469	1,919 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Cerebral haemorrhage	2,218	1,583					0,526	1,711	1,899			1,471	1,136 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Cerebral mass effect	2,182	1,188					0,533	1,384	1,716			1,117	1,144 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Cerebral thrombosis	1,741	0,882					1,364	1,365	1,266			1,343	1,266 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Cerebral venous sinus thrombosis	3,292	2,147					0,529	2,48	2,342			3,807	1,226 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Chest X-ray abnormal	1,867	1,363					1,186	2,017	1,451			1,957	1,927 Confirmed indication
COVID19 (COVID19 (JANSEN))	Computed tomogram head abnormal	1,657	0,968			0.618		0,613	2,246	2,206			2,341	1,717 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Computed tomogram head normal	2,005	1,465					1,265	1,714	1,843			2,363	1,943 Not an AE
COVID19 (COVID19 (JANSEN))	Computed tomogram thorax abnormal	2,017	1,407					0,463	1,386	2,062			2,026	1,686 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Creatinine renal clearance decreased	2,022	1,287					0,886	1,097	0,886			1,968	1,039
COVID19 (COVID19 (JANSEN))	Death	1,832	1,195					1,195	1,195	1,026			1,599	1,312 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Deep vein thrombosis	2,601	1,784					0,465	2,194	2,28			3,097	2,022 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Endotracheal intubation	2,953	1,144					0,445	1,415	1,925			2,118	1,265 Labeled
COVID19 (COVID19 (JANSEN))	Eosinophil count decreased	1,733	1,292					0,461	1,238	2,086			1,665	1,306 Other
COVID19 (COVID19 (JANSEN))	Eosinophil percentage decreased	1,778	1,362			0.616		0,275	2,176	2,116			1,708	1,395 Other
COVID19 (COVID19 (JANSEN))	Fatigue	1,892	1,363					1,186	2,017	1,451			1,957	1,816 Labeled
COVID19 (COVID19 (JANSEN))	Fibrin D dimer	1,294	0,446					0,294	2,466	2,206			1,974	2,644
COVID19 (COVID19 (JANSEN))	Fibrin D monomer	2,147	0,881			0.619		0,298	2,119	2,499			2,469	1,695 Other
COVID19 (COVID19 (JANSEN))	Foetal exposure during pregnancy	1,968	1,082					0,438	1,656	2,041			1,229	1,328 Not an AE
COVID19 (COVID19 (JANSEN))	Glass opacity	2,088	1,412			0.756		0,604	1,72	1,238			1,435	1,732
COVID19 (COVID19 (JANSEN))	Glaucoma increased	2,027	0,894					0,406	1,207	1,7			1,235	1,927 Labeled
COVID19 (COVID19 (JANSEN))	Globulins increased	1,816	1,242					0,401	1,231	1,701			1,599	2,181
COVID19 (COVID19 (JANSEN))	Gout flare present	1,706	1,164					0,401	1,231	1,369			1,599	2,181
COVID19 (COVID19 (JANSEN))	Gout flare syndrome	2,462	1,838					0,44	1,639	3,107			1,646	2,439
COVID19 (COVID19 (JANSEN))	Haematocrit decreased	1,844	1,276		0.612			0,503	1,308	2,04			1,778	2,188
COVID19 (COVID19 (JANSEN))	Haemoglobin decreased	1,756	1,396		0.613			0,396	1,372	1,665			1,972	1,665
COVID19 (COVID19 (JANSEN))	Hepatic-induced thrombocytopenia test	3,628	0,998					0,484	5,517	4,997			7,287	3,364 Not an AE
COVID19 (COVID19 (JANSEN))	Hepatic-induced thrombocytopenia test positive	6,465	4,465					5,555	4,665	5,717			6,269	3,073 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Hypoxia	2,056	1,322					0,673	1,511	2,085			2,436	1,66 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Immunoglobulin therapy	2,068	1,172					0,111	1,485	2,349			1,896	1,686 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Interleukin ratio increased	1,339	1,107					0,022	1,428	2,11			2,068	1,686 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	International normalized ratio normal	1,739	1,225			0.754		0,388	1,549	1,943			2,317	1,279 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	International normalized ratio normal	1,929	1,305					0,388	1,549	1,943			2,317	1,279 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Intracardiac thrombus	1,767	0,909					0,84	1,408	1,996			1,594	1,594
COVID19 (COVID19 (JANSEN))	Jugular vein thrombosis	1,631	1,452		0.884			1,128	1,125	0,708			2,333	0,711 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Lumbar puncture	1,976	0,873					0,873	1,186	1,186			1,018	1,018 Not an AE
COVID19 (COVID19 (JANSEN))	Lumbar puncture abnormal	2,148	1,707					1,137	2,43	1,923			1,785	1,814 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Lung opacity	1,985	1,945					1,384	1,284	1,022			1,022	1,022
COVID19 (COVID19 (JANSEN))	Lymphocyte percentage decreased	1,881	1,234					0,19	1,022	2,094			1,824	2,065
COVID19 (COVID19 (JANSEN))	Magnetic resonance imaging head abnormal	2,065	1,477		0.912			0,477	1,768	1,877			2,139	2,323
COVID19 (COVID19 (JANSEN))	Mean cell haemoglobin concentration decreased	1,709	1,046			0.619		0,465	1,206	1,26			2,126	1,626 Other
COVID19 (COVID19 (JANSEN))	Mean cell haemoglobin decreased	1,713	1,268					0,263	1,123	1,945			2,053	0,997 Other
COVID19 (COVID19 (JANSEN))	Mean platelet volume increased	1,87	1,319					0,187	1,234	1,611			1,913	2,162
COVID19 (COVID19 (JANSEN))	Mechanical ventilation	2,282	1,027					0,282	1,164	2,291			1,993	2,126
COVID19 (COVID19 (JANSEN))	Monocyte percentage increased	1,728	1,22			0.616		0,839	1,905	1,906			1,109	1,109
COVID19 (COVID19 (JANSEN))	Neutrophil percentage decreased	1,919	1,324					0,824	1,659	1,659			2,184	0,843 Other
COVID19 (COVID19 (JANSEN))	Neutrophil percentage increased	1,206	0,252					0,252	2,104	1,763			1,989	1,989
COVID19 (COVID19 (JANSEN))	Non-specific reaction	4,048	0,744					0,744	0,610	0,610			0,610	0,610
COVID19 (COVID19 (JANSEN))	Off label use	0,602	0,892					0,105	1,182	1,305			0,932	1,467
COVID19 (COVID19 (JANSEN))	On and off phenomenon	1,783	0,764					0,517	3,445	0,963			2,289	0,789 Other
COVID19 (COVID19 (JANSEN))	Pain assessment	2,226	0,866					0,866	1,096	2,19			1,107	1,443 Not an AE
COVID19 (COVID19 (JANSEN))	Pulmonary embolism	3,17	1,394					0,88	0,656	1,034			1,593	0,95 Reviewed, Regulatory Action
COVID19 (COVID19 (JANSEN))	Platelet count	2,071	2,166			0.618		0,479	1,788	2,095			3,029	1,822 Not an AE
COVID19 (COVID19 (JANSEN))	Platelet count decreased	1,867	1,315			0.614		0,261	1,424	2,11			1,654	2,242
COVID19 (COVID19 (JANSEN))	Platelet count normal	2,568	1,836					0,451	2,059	2,761			3,161	1,689 Not an AE
COVID19 (COVID19 (JANSEN))	Platelet factor 4	5,794	3,2											

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, May 17, 2022 6:18:18 AM
Attachments: [USST_20220513.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/13/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 2020(91)	US Serious EB05 2020(91)	US Fatal EB05 2020(91)	US Infant EB05 2020(91)	US Child EB05 2020(91)	US Teen EB05 2020(91)	US Adult EB05 2020(91)	US Adult2 EB05 2020(91)	US Adult3 EB05 2020(91)	US Female EB05 2020(91)	US Male EB05 2020(91)
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	7.56	1.54					0.32	1.54	1.55	2.46	1.37
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2.04	1.54	0.883				1.59	2.07	2.14	1.46	1.46
COVID19 (COVID19 (JANSSEN))	Acute respiratory distress syndrome	2.86	1.33	0.008				0.79	1.67	1.61	1.82	1.62
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2.02	1.32	0.144				1.42	2.03	1.98	1.78	1.78
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3.43	0.975	0.888				0.973	0.718	0.881	2.622	1.485
COVID19 (COVID19 (JANSSEN))	Adverse event	1.062	1.671	0.971				0.964	0.851	0.864	1.964	1.444
COVID19 (COVID19 (JANSSEN))	Albumin CSF increased	2.226	1.907					1.304	0.906	1.41	2.006	1.624
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1.907	1.262	0.900				1.403	1.427	1.677	2.099	1.303
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2.935	0.914	0.806	0.49			1.922	1.11	1.566	1.464	1.464
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2.081	1.402	0.888				1.801	1.758	1.287	2.254	1.406
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.289	1.621	0.829				1.621	1.598	2.281	2.198	1.503
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1.808	1.365	0.91				1.103	2.091	1.478	2.091	1.303
COVID19 (COVID19 (JANSSEN))	Artbody test	2.114	0.822	0.882				0.792	1.874	1.886	2.022	1.652
COVID19 (COVID19 (JANSSEN))	Arthroclavicular therapy	2.172	1.466	0.971		0.619		1.827	2.029	2.758	1.669	1.669
COVID19 (COVID19 (JANSSEN))	Application site pain	2.001	1.734	0.902				0.635	1.006	1.032	0.678	0.764
COVID19 (COVID19 (JANSSEN))	Arteriole	2.147	1.466	0.971				0.907	2.413	2.312	1.449	1.449
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1.845	1.164	0.819				1.123	2.232	1.417	2.232	0.983
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.873	1.383	0.928		0.616		1.212	2.28	1.806	2.319	1.328
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1.79	1.458	0.944		0.616		1.463	1.903	1.794	2.307	1.342
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1.81	1.263	0.929				1.447	1.844	1.751	2.16	1.39
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1.828	1.342	0.951				1.348	2.087	1.585	2.087	1.491
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1.812	1.302	0.949				1.214	2.022	1.499	1.86	1.346
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2.814	2.199	0.897				1.749	2.173	0.888	4.063	1.039
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1.925	1.303	0.928				0.117	1.077	1.981	1.795	1.254
COVID19 (COVID19 (JANSSEN))	Blood potassium decreased	1.699	1.216	0.938		0.616		1.512	1.889	1.214	2.04	1.889
COVID19 (COVID19 (JANSSEN))	Blood sodium decreased	1.623	1.306	0.904				1.33	2.016	1.736	1.958	1.587
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1.888	1.251	0.933				1.022	2.048	1.773	2.048	1.602
COVID19 (COVID19 (JANSSEN))	Brain edema	1.58	1.269	0.910				1.196	1.937	0.603	2.118	0.806
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2.212	1.41	1.003				2.238	2.207	1.41	2.028	1.978
COVID19 (COVID19 (JANSSEN))	CSF protein increased	2.989	2.018	0.882				1.847	2.985	1.005	2.517	2.16
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.229	1.998	0.939				1.712	1.878	1.508	3.333	1.191
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.828	1.962	0.934				1.384	3.923	1.117	1.144	1.144
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	2.653	1.738	0.886				1.364	1.629	3.528	1.269	1.269
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	3.31	1.603	0.933				2.156	2.844	2.812	3.074	1.225
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1.963	1.28	0.957				1.902	1.989	1.902	1.914	1.902
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2.438	1.965	0.946		0.618		2.466	2.294	2.066	2.033	1.626
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head normal	1.999	1.338	0.916				0.381	1.711	1.983	1.841	1.265
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	2.001	1.398	0.926				1.376	2.046	2.009	2.278	1.673
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax normal	2.001	1.398	0.926				0.497	0.898	1.957	1.957	1.648
COVID19 (COVID19 (JANSSEN))	Death	1.833	1.164	0.963				1.187	1.621	1.526	2.059	1.508
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.61	1.925	0.946				2.295	2.281	1.705	2.281	2.055
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	2.055	1.147	0.987				2.096	1.874	2.083	1.832	1.832
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.771	1.288	0.927				1.232	2.054	1.696	2.067	1.325
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1.771	1.288	0.927		0.616		1.752	2.056	1.724	2.056	1.937
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.753	0.857	0.895				1.186	0.988	1.848	1.429	1.848
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.273	1.299	0.945				1.299	1.826	1.292	1.826	1.692
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	2.128	1.441	0.896		0.619		0.298	1.713	2.276	2.201	1.615
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1.934	1.081	0.886				1.136	1.979	1.979	1.979	1.289
COVID19 (COVID19 (JANSSEN))	Fetal exposure during pregnancy	2.085	1.432	0.886		0.756		0.44	1.639	1.434	1.432	1.432
COVID19 (COVID19 (JANSSEN))	Gaze palsy	2.23	1.036	0.897				0.406	2.273	1.7	1.228	2.243
COVID19 (COVID19 (JANSSEN))	Glucosuria increased	1.83	1.293	0.923				1.293	1.609	1.609	1.609	1.194
COVID19 (COVID19 (JANSSEN))	Glucose urine present	1.696	1.147	0.907				1.216	1.342	1.342	1.014	1.014
COVID19 (COVID19 (JANSSEN))	Gullström syndrome	2.473	1.842	0.884				0.842	1.133	1.432	1.432	1.133
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1.8	1.272	0.944		0.612		0.502	1.381	1.182	2.028	1.178
COVID19 (COVID19 (JANSSEN))	Haemoglobin increased	1.756	1.238	0.934		0.613		1.373	1.967	1.688	2.096	1.403
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	2.766	1.819	0.906				1.819	2.066	1.916	2.066	3.206
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.457	3.472	0.884				5.719	4.664	4.739	7.264	3.079
COVID19 (COVID19 (JANSSEN))	Hypoxia	2.076	1.332	0.984				1.011	1.511	2.095	1.922	1.685
COVID19 (COVID19 (JANSSEN))	Immunoglobulin therapy	2.069	1.937	0.977				1.719	2.445	1.397	1.704	1.704
COVID19 (COVID19 (JANSSEN))	Intensive care	1.937	1.396	0.971		0.754		0.022	1.425	2.105	2.071	1.581
COVID19 (COVID19 (JANSSEN))	International normalized ratio increased	1.778	1.22	0.923				1.778	1.927	1.927	1.434	1.289
COVID19 (COVID19 (JANSSEN))	International normalized ratio normal	1.897	1.198	0.889				1.384	2.032	0.919	1.248	1.248
COVID19 (COVID19 (JANSSEN))	Intracardiac thrombus	2.628	1.759	0.871				0.84	1.402	1.992	1.677	1.595
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1.83	1.33	0.917				1.713	2.53	1.714	1.714	1.749
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.875	1.36	0.877				1.264	1.195	1.974	1.617	1.617
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2.147	1.477	0.917				1.125	2.834	1.023	1.834	1.834
COVID19 (COVID19 (JANSSEN))	Lung opacity	1.976	1.281	0.945				1.377	1.977	1.377	2.318	1.3
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1.681	1.223	0.93		0.614		0.188	0.998	2.028	1.839	2.028
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage increased	1.414	1.097	0.917				0.109	1.421	1.621	1.621	1.621
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.056	1.468	0.914				0.475	1.764	1.866	2.132	1.592
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head normal	1.844	1.303	0.943		0.619		0.463	1.243	1.243	1.243	1.854
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	1.701	1.258	0.923				1.117	1.939	2.04	1.496	0.991
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1.866	1.318	0.917				0.319	2.316	1.876	2.107	1.394
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2.059	1.019	0.889				1.019	1.178	2.278	1.174	2.015
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1.521	1.214	0.918		0.616		0.845	1.173	1.915	1.058	1.105
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	1.833	1.298	0.923				1.298	1.645	1.645	1.645	0.865
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1.722	1.262	0.929				0.25	2.088	1.981	1.775	1.4
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	4.051	0.787	0.895				0.744	0.812	0.961	2.981	1.076
COVID19 (COVID19 (JANSSEN))	Off-label use	2.029	0.699	0.895				1.195	1.339	1.473	1.339	1.975
COVID19 (COVID19 (JANSSEN))	On and off phenomenon	1.794	0.795	0.875				3.446	0.982	0.982	2.288	2.288
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.227	1.807	0.957				1.506	2.219	1.169	2.219	1.445
COVID19 (COVID19 (JANSSEN))	Peripheral embolism	3.087	1.362	0.884				0.656	2.246	1.034	1.54	0.951
COVID19 (COVID19 (JANSSEN))	Platelet count	2.66	2.187	0.918		0.618		0.48	2.864	2.725	3.025	1.862
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.872	1.317	0.922				1.446	1.646	2.146	1.646	1.646
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.562	1.182	0.901				2.099	2.767	2.134	1.591	1.689
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	0.782	0.288	0.895				4.296	4.645	0.805	5.733	2.291
COVID19 (COVID19 (JANSSEN))	Poor quality product administered	1.3						0.88	1.957	1.993	1.429	2.022
COVID19 (COVID19 (JANSSEN))	Portal vein thrombosis	2.072	1.425	0.886				0.859	1.646	1.626	2.024	1.268
COVID19 (COVID19 (JANSSEN))	Positive airway pressure therapy	2.045	0.953	0.923				1.014	2.083	1.664	2.267	1.613
COVID19 (COVID19 (JANSSEN))	Product administered to patient of inappropriate age	1.772	0.832	0.885			0.72	2.063	0.041	0.002	0.514	1.832
COVID19 (COVID19 (JANSSEN))	Prolonged labour	5.177	1.345	0.905				1.345	5.05	5.149	1.671	1.832
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1.925	0.941	0.299	0.754			2.283	1.657	2.448	1.657	1.454
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.237	1.108	0.918				1.773	2.066	2.616	2.616	1.942
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.286	1.482	0.909				1.726	1.631	1.913	2.161	1.878
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1.806	1.276	0.932		0.614		0.584	1.36	2.024	1.67	1.501
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	1.959	1.319	0.933				0.286	1.303	2.118	1.789	1.425
COVID19 (COVID19 (JANSSEN))	Russell's viper venom time abnormal	1.368	1.004	0.889				2.691	0.505	0.505	1.08	0.73
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2.562	1.648	0.889				1.774	1.986	2.		

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, May 24, 2022 6:43:28 AM
Attachments: [USST_20220520.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/20/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB06 20220520	US Serious EB06 20220520	US Fatal EB06 20220520	US Infant EB06 20220520	US Child EB06 20220520	US Teen EB06 20220520	US Adult EB06 20220520	US Adult EB06 20220520	US Adult EB06 20220520	US Female EB06 20220520	US Male EB06 20220520
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time prolonged	2,174	1,371					2,375	1,952	2,044	2,027	1,411
COVID-19 (COVID-19 (JANSSEN))	Activated partial thromboplastin time shortened	2,107	1,538	0,883				1,583	2,044	1,883	2,727	1,411
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory distress syndrome	2,887	1,338	0,289				1,249	1,679	1,821	1,811	1,747
COVID-19 (COVID-19 (JANSSEN))	Acute respiratory failure	2,107	1,386	1,017				1,458	2,046	1,991	2,465	1,478
COVID-19 (COVID-19 (JANSSEN))	Adverse drug reaction	3,339	0,974	0,889				0,969	0,716	0,679	2,619	1,478
COVID-19 (COVID-19 (JANSSEN))	Adverse event	2,169	1,916	1,084				1,092	1,884	1,884	1,877	1,688
COVID-19 (COVID-19 (JANSSEN))	Albumin CBF increased	2,232	1,904					1,405	1,411		0,907	1,625
COVID-19 (COVID-19 (JANSSEN))	Angiogram abnormal	1,152	1,201	0,908				1,432	1,469	1,669	2,149	1,296
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral abnormal	2,658	2,658	0,914			0,488	2,482	1,906	1,948	2,082	3,438
COVID-19 (COVID-19 (JANSSEN))	Angiogram cerebral normal	2,066	1,383	0,889				1,779	1,75	1,283	2,218	1,405
COVID-19 (COVID-19 (JANSSEN))	Angiogram pulmonary abnormal	2,359	1,916					1,631		2,225	2,471	1,973
COVID-19 (COVID-19 (JANSSEN))	Anion gap decreased	1,813	1,137	0,91				1,117	2,234	1,464	1,128	1,339
COVID-19 (COVID-19 (JANSSEN))	Antibody test	2,118	0,823	0,883				0,969	1,58	1,905	2,003	1,658
COVID-19 (COVID-19 (JANSSEN))	Anticoagulant therapy	2,177	1,463	0,973			0,619	0,847	2,039	2,296	2,752	1,657
COVID-19 (COVID-19 (JANSSEN))	Application site pain	2,004		0,99				0,59	0,636	1,036	0,778	1,433
COVID-19 (COVID-19 (JANSSEN))	Arrhythmia	2,128	1,709	0,801				0,847	2,418	1,338	2,315	1,433
COVID-19 (COVID-19 (JANSSEN))	Arterogram carotid abnormal	1,847	1,163	0,89				1,213	1,231	1,419	2,236	0,983
COVID-19 (COVID-19 (JANSSEN))	Asplough count decreased	1,884	1,391	0,931			0,616	0,36	1,179	2,251	1,858	2,325
COVID-19 (COVID-19 (JANSSEN))	Asplough count increased	1,796	1,413	0,947				1,174	1,077	1,976	1,977	2,187
COVID-19 (COVID-19 (JANSSEN))	Blood albumin decreased	1,821	1,268	0,83				0,395	1,485	1,847	1,755	2,168
COVID-19 (COVID-19 (JANSSEN))	Blood calcium decreased	1,975	1,352	0,954				0,374	1,261	2,103	1,893	2,19
COVID-19 (COVID-19 (JANSSEN))	Blood chloride increased	1,823	1,309	0,963				1,232	2,027	1,872	1,872	1,359
COVID-19 (COVID-19 (JANSSEN))	Blood fibrinogen decreased	2,801	2,196	0,897				0,922	1,75	2,176	0,881	4,054
COVID-19 (COVID-19 (JANSSEN))	Blood magnesium increased	1,854	1,18	0,929				1,077	1,976	1,751	1,751	2,357
COVID-19 (COVID-19 (JANSSEN))	Blood potassium decreased	1,704	1,217	0,938			0,616	0,513	1,024	1,522	2,025	1,888
COVID-19 (COVID-19 (JANSSEN))	Blood sodium increased	1,824	1,305	0,905				1,35	2,005	1,795	1,951	1,994
COVID-19 (COVID-19 (JANSSEN))	Blood urea increased	1,648	1,315	0,895				0,885	1,36	1,938	1,216	2,008
COVID-19 (COVID-19 (JANSSEN))	Blood urea decreased	1,898	1,256	0,914				1,041	2,659	1,78	2,127	1,889
COVID-19 (COVID-19 (JANSSEN))	Brain edema	1,578	1,059	0,883				1,599	1,59	1,902	2,002	2,884
COVID-19 (COVID-19 (JANSSEN))	COVID-19 pneumonia	2,224	1,411	1,083				1,893	2,232	2,042	2,409	1,985
COVID-19 (COVID-19 (JANSSEN))	CRP protein increased	2,389	2,014	0,988				1,844	2,169	1,003	2,588	2,162
COVID-19 (COVID-19 (JANSSEN))	Cerebral haemorrhage	2,215	1,576	0,938				0,524	1,713	1,855	1,507	3,311
COVID-19 (COVID-19 (JANSSEN))	Cerebral mass effect	2,819	1,972	0,929				0,532	1,385	1,721	1,165	3,835
COVID-19 (COVID-19 (JANSSEN))	Cerebral oedema	2,696	1,736	0,887				1,476	1,887	1,633	3,409	2,023
COVID-19 (COVID-19 (JANSSEN))	Cerebral sinus thrombosis	3,304	2,149	0,929				0,528	2,504	2,348	0,879	1,226
COVID-19 (COVID-19 (JANSSEN))	Chest X-ray abnormal	1,973	1,397	0,937				0,331	1,388	1,985	1,935	1,861
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram head abnormal	2,444	1,656	0,964			0,618	0,609	2,148	2,313	2,036	3,073
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram head normal	1,894	1,383	0,918				0,378	1,724	1,807	1,835	2,273
COVID-19 (COVID-19 (JANSSEN))	Computed tomogram thorax abnormal	2,051	1,365	0,927				0,365	1,927	1,927	1,927	2,284
COVID-19 (COVID-19 (JANSSEN))	Creatinine renal clearance decreased	2,049	1,289	0,89				0,498	0,897	0,897	2,023	1,691
COVID-19 (COVID-19 (JANSSEN))	Death	1,849	1,117	0,865				0,441	1,117	1,527	1,545	1,727
COVID-19 (COVID-19 (JANSSEN))	Deep vein thrombosis	2,618	1,798	1,035				0,456	2,233	2,285	3,114	3,298
COVID-19 (COVID-19 (JANSSEN))	Endotracheal intubation	2,807	1,375	1,139				0,395	1,423	2,097	1,899	2,117
COVID-19 (COVID-19 (JANSSEN))	Eosinophil count decreased	1,791	1,067	0,813				0,363	1,291	1,633	2,059	1,863
COVID-19 (COVID-19 (JANSSEN))	Eosinophil percentage decreased	1,803	1,271	0,934			0,616	0,271	1,271	2,083	1,776	2,017
COVID-19 (COVID-19 (JANSSEN))	Fatigue	1,754	1,239	0,937				1,189	1,663	1,854	1,947	1,868
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer	2,266	1,278	0,961				0,442	2,182	1,152	1,964	1,684
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer increased	2,139	1,453	0,985			0,619	0,295	1,726	2,289	2,21	2,163
COVID-19 (COVID-19 (JANSSEN))	Fibrin D dimer normal	1,933	1,198	0,877				0,437	1,198	1,973	1,103	1,29
COVID-19 (COVID-19 (JANSSEN))	Foetal exposure during pregnancy	2,089	1,438	0,964				0,654	1,438	1,438	1,419	1,727
COVID-19 (COVID-19 (JANSSEN))	Glassy sputum	2,224	1,303	0,887				0,405	2,274	1,7	1,216	2,124
COVID-19 (COVID-19 (JANSSEN))	Globulins increased	1,845	1,259	0,907				0,401	1,723	1,585	2,237	1,2
COVID-19 (COVID-19 (JANSSEN))	Glucose urine present	1,711	1,155	0,91				1,215	1,425	1,341	2,111	1,038
COVID-19 (COVID-19 (JANSSEN))	Gullain-Barre syndrome	2,483	1,843	0,984				0,438	1,843	2,067	2,333	2,023
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin decreased	1,802	1,214	0,926			0,612	0,501	1,314	2,026	1,783	2,175
COVID-19 (COVID-19 (JANSSEN))	Haemoglobin increased	1,761	1,239	0,937			0,613	0,383	1,239	1,907	1,674	2,039
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test	5,709	3,612	0,901				4,482	5,521	4,283	7,268	3,477
COVID-19 (COVID-19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6,144	3,303	0,884			0,554	4,216	5,527	4,739	7,655	2,339
COVID-19 (COVID-19 (JANSSEN))	Hypoxia	2,082	1,331	0,911				2,034	2,007	1,933	2,494	1,688
COVID-19 (COVID-19 (JANSSEN))	Immunoglobulin therapy	2,077	1,725	0,883				0,011	1,927	2,557	1,397	2,241
COVID-19 (COVID-19 (JANSSEN))	Intensive care	1,937	1,067	0,823				0,022	1,393	2,032	2,342	1,713
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio increased	1,767	1,209	0,893			0,754	0,384	1,153	1,92	2,295	1,258
COVID-19 (COVID-19 (JANSSEN))	International normalised ratio normal	1,916	1,216	0,889				0,584	1,364	2,026	2,026	1,246
COVID-19 (COVID-19 (JANSSEN))	Intracranial thrombus	2,624	1,478	0,911				0,84	1,403	0,993	1,708	1,971
COVID-19 (COVID-19 (JANSSEN))	Jugular vein thrombosis	1,831	1,245	0,888				1,373	1,125	0,711	2,346	0,712
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture	1,862	1,182	0,895				1,122	1,852	1,768	1,611	1,978
COVID-19 (COVID-19 (JANSSEN))	Lumbar puncture abnormal	2,149	1,705					1,122	2,841	1,028	1,777	1,822
COVID-19 (COVID-19 (JANSSEN))	Lung opacity	1,983	1,087	0,849				1,607	1,237	1,991	2,359	1,521
COVID-19 (COVID-19 (JANSSEN))	Lymphocyte percentage decreased	1,685	1,231	0,911			0,191	1,091	2,074	1,859	2,059	1,688
COVID-19 (COVID-19 (JANSSEN))	Magnetic resonance imaging head abnormal	2,061	1,47	0,917				1,177	1,877	2,127	2,341	1,592
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2,023	1,386	0,918			0,619	0,441	1,386	1,641	2,336	1,927
COVID-19 (COVID-19 (JANSSEN))	Mean cell haemoglobin increased	1,697	1,255	0,924				0,275	1,135	1,92	1,492	0,976
COVID-19 (COVID-19 (JANSSEN))	Mean platelet volume increased	1,874	1,226	0,915				0,316	1,154	2,319	1,61	2,03
COVID-19 (COVID-19 (JANSSEN))	Mechanical ventilation	2,283	1,513	0,923				0,462	1,513	2,074	2	2,117
COVID-19 (COVID-19 (JANSSEN))	Monocyte percentage increased	1,533	1,033	0,821			0,616	0,21	0,846	1,932	1,985	2,163
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage decreased	1,52	1,186	0,886				0,182	1,186	1,454	1,313	0,848
COVID-19 (COVID-19 (JANSSEN))	Neutrophil percentage increased	1,729	1,265	0,932				0,249	2,108	1,801	1,801	1,411
COVID-19 (COVID-19 (JANSSEN))	Nonspecific reaction	4,027	0,787	0,895				0,745	0,612	0,612	2,867	1,076
COVID-19 (COVID-19 (JANSSEN))	Oral use	2,041	1,092	0,892				1,193	1,092	0,961	1,468	2,024
COVID-19 (COVID-19 (JANSSEN))	On and off phenomenon	1,785	0,755	0,893				3,449	0,983		2,288	
COVID-19 (COVID-19 (JANSSEN))	Pain assessment	2,223	0,861					1,506	2,222	1,106	2,117	1,441
COVID-19 (COVID-19 (JANSSEN))	Peripheral embolism	3,096	1,359	0,885				0,647	1,034	1,541	2,283	0,951
COVID-19 (COVID-19 (JANSSEN))	Platelet count	2,665	2,176	0,918			0,618	0,476	1,841	2,869	2,75	3,047
COVID-19 (COVID-19 (JANSSEN))	Platelet count decreased	1,569	1,31	0,923				1,261	1,444	1,71	1,655	2,375
COVID-19 (COVID-19 (JANSSEN))	Platelet count normal	2,554	1,812	0,902				0,45	2,085	1,978	2,13	3,139
COVID-19 (COVID-19 (JANSSEN))	Platelet factor 4	5,750	3,367	0,866				4,862	4,962	4,962	5,752	2,267
COVID-19 (COVID-19 (JANSSEN))	Poor quality product administered	1,326						0,879	1,98	1,357	1,452	2,05
COVID-19 (COVID-19 (JANSSEN))	Portal vein thrombosis	2,075	1,427	0,887				0,889	1,647	1,027	2,027	2,208
COVID-19 (COVID-19 (JANSSEN))	Positive airway pressure therapy	2,06	1,207	0,865				2,06	1,013	1,677	1,677	2,253
COVID-19 (COVID-19 (JANSSEN))	Product administered to patient of inappropriate age	1,767	0,833	0,886			0,719	0,299	0,4	0,002	0,515	1,686
COVID-19 (COVID-19 (JANSSEN))	Prolonged labour	5,178	1,336					0,544	2,315	1,663	5,15	1,455
COVID-19 (COVID-19 (JANSSEN))	Profibrinolytic time prolonged	1,932	1,394	0,94			0,754	0,297	1,04	1,603	2,466	1,455
COVID-19 (COVID-19 (JANSSEN))	Pulmonary embolism	2,244	1,266	0,906			0,619	0,589	1,78	2,068	2,027	2,911
COVID-19 (COVID-19 (JANSSEN))	Pulmonary thrombosis	2,295	1,477	0,909				1,756	1,63	1,919	2,16	1,993
COVID-19 (COVID-19 (JANSSEN))	Red blood cell count decreased	1,805	1,324	0,929			0,613	0,562	2,034	1,969	2,034	1,505
COVID-19 (COVID-19 (JANSSEN))	Red cell distribution width increased	1,949	1,309	0,932				0,288	2,113	1,793	2,279	1,418
COVID-19 (COVID-19 (JANSSEN))	Russel's viper venom time abnormal	1,368	1,00									

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Wednesday, June 1, 2022 6:12:15 AM
Attachments: [USST_20220530.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 5/30/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 7, 2022 6:00:24 AM
Attachments: [USST_20220603.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/3/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EBRS 20220603	US Serious EBRS 20220603	US Fatal EBRS 20220603	US Infant EBRS 20220603	US Child EBRS 20220603	US Teen EBRS 20220603	US Adult EBRS 20220603	US Adult EBRS 20220603	US Adult EBRS 20220603	US Female EBRS 20220603	US Male EBRS 20220603
COVID-19 (COVID19) (JANSSEN)	Activated partial thromboplastin time prolonged	2.23	1.51	0.879	0.37	1.557	2.475	2.054	1.953	2.678	1.396	1.396
COVID-19 (COVID19) (JANSSEN)	Activated partial thromboplastin time shortened	2.04	1.499	0.879	0.37	1.557	2.475	2.054	1.953	2.678	1.396	1.396
COVID-19 (COVID19) (JANSSEN)	Acute respiratory distress syndrome	0.068	0.068	0.068	0.068	0.068	0.068	0.068	0.068	0.068	0.068	0.068
COVID-19 (COVID19) (JANSSEN)	Acute respiratory failure	2.117	1.322	0.107	0.454	1.469	2.064	1.996	2.465	1.781	1.781	1.781
COVID-19 (COVID19) (JANSSEN)	Allergic drug reaction	0.395	0.395	0.395	0.395	0.395	0.395	0.395	0.395	0.395	0.395	0.395
COVID-19 (COVID19) (JANSSEN)	Allergic event	2.615	1.683	0.187	0.689	1.447	2.021	1.962	2.465	1.781	1.781	1.781
COVID-19 (COVID19) (JANSSEN)	Albumin CDF increased	2.146	1.688	0.187	0.689	1.447	2.021	1.962	2.465	1.781	1.781	1.781
COVID-19 (COVID19) (JANSSEN)	Angiogram cerebral abnormal	0.138	0.138	0.138	0.138	0.138	0.138	0.138	0.138	0.138	0.138	0.138
COVID-19 (COVID19) (JANSSEN)	Angiogram cerebral normal	2.536	1.785	0.913	0.488	2.329	1.933	2.077	2.387	1.505	1.505	1.505
COVID-19 (COVID19) (JANSSEN)	Angiogram normal	0.267	0.267	0.267	0.267	0.267	0.267	0.267	0.267	0.267	0.267	0.267
COVID-19 (COVID19) (JANSSEN)	Angiogram pulmonary abnormal	2.3	1.813	0.911	0.415	1.652	2.269	2.207	2.471	1.942	1.942	1.942
COVID-19 (COVID19) (JANSSEN)	Anticoagulant therapy	0.814	0.814	0.814	0.814	0.814	0.814	0.814	0.814	0.814	0.814	0.814
COVID-19 (COVID19) (JANSSEN)	Antibody test	2.137	0.881	0.625	0.415	1.652	2.269	2.207	2.471	1.942	1.942	1.942
COVID-19 (COVID19) (JANSSEN)	Anticoagulant therapy	1.456	0.972	0.619	0.415	1.652	2.269	2.207	2.471	1.942	1.942	1.942
COVID-19 (COVID19) (JANSSEN)	Application site pain	2.062	1.186	0.9	0.829	1.846	2.086	2.086	2.471	1.942	1.942	1.942
COVID-19 (COVID19) (JANSSEN)	Arteritis	2.282	1.684	0.9	0.829	1.846	2.086	2.086	2.471	1.942	1.942	1.942
COVID-19 (COVID19) (JANSSEN)	Arteriovenous cannula abnormal	0.854	0.854	0.854	0.854	0.854	0.854	0.854	0.854	0.854	0.854	0.854
COVID-19 (COVID19) (JANSSEN)	Basophil count decreased	1.872	1.373	0.933	0.616	0.359	1.157	2.295	1.886	2.329	1.328	1.328
COVID-19 (COVID19) (JANSSEN)	Basophil percentage decreased	1.777	1.391	0.944	0.616	0.252	1.125	2.298	1.932	2.198	1.32	1.32
COVID-19 (COVID19) (JANSSEN)	Blood albumin decreased	1.836	1.275	0.93	0.359	1.157	1.85	2.295	1.775	2.201	1.413	1.413
COVID-19 (COVID19) (JANSSEN)	Blood albumin increased	1.978	1.348	0.955	0.372	1.372	2.098	1.992	2.196	1.519	1.519	1.519
COVID-19 (COVID19) (JANSSEN)	Blood chloride increased	1.817	1.302	0.952	0.461	1.244	2.009	1.863	2.15	1.354	1.354	1.354
COVID-19 (COVID19) (JANSSEN)	Blood ferritin	1.852	1.198	0.878	0.579	0.929	2.01	0.588	1.609	1.829	1.107	1.107
COVID-19 (COVID19) (JANSSEN)	Blood fibrinogen decreased	2.756	2.756	2.756	2.756	2.756	2.756	2.756	2.756	2.756	2.756	2.756
COVID-19 (COVID19) (JANSSEN)	Blood magnesium increased	1.788	1.281	0.927	0.186	1.081	1.935	1.744	2.342	1.211	1.211	1.211
COVID-19 (COVID19) (JANSSEN)	Blood sodium decreased	1.858	1.301	0.902	0.186	1.081	2.011	1.734	1.659	1.659	1.659	1.659
COVID-19 (COVID19) (JANSSEN)	Blood urea decreased	1.645	1.314	0.863	0.358	1.158	1.943	1.208	2.032	1.584	1.584	1.584
COVID-19 (COVID19) (JANSSEN)	Blood urea increased	1.9	1.251	0.915	0.186	1.081	2.051	1.734	2.113	1.654	1.654	1.654
COVID-19 (COVID19) (JANSSEN)	COVID-19 pneumonia	2.243	1.08	0.882	1.91	2.252	2.057	2.057	2.419	2.009	2.009	2.009
COVID-19 (COVID19) (JANSSEN)	CRP protein increased	2.018	2.018	2.018	2.018	2.018	2.018	2.018	2.018	2.018	2.018	2.018
COVID-19 (COVID19) (JANSSEN)	Central venous catheter	2.532	1.532	0.538	0.525	1.713	1.85	1.611	3.341	1.617	1.617	1.617
COVID-19 (COVID19) (JANSSEN)	Central mass effect	2.886	1.99	0.927	0.286	1.186	1.263	3.612	3.612	1.199	1.199	1.199
COVID-19 (COVID19) (JANSSEN)	Central thrombosis	2.704	2.704	2.704	2.704	2.704	2.704	2.704	2.704	2.704	2.704	2.704
COVID-19 (COVID19) (JANSSEN)	Central venous sinus thrombosis	2.356	2.171	0.919	0.528	2.356	2.444	0.88	3.01	1.276	1.276	1.276
COVID-19 (COVID19) (JANSSEN)	Chest X-ray abnormal	1.978	0.913	0.398	0.193	1.198	1.936	2.098	2.108	2.098	2.098	2.098
COVID-19 (COVID19) (JANSSEN)	Computed tomogram head abnormal	2.444	1.833	0.945	0.618	0.605	2.132	2.202	2.067	3.041	1.737	1.737
COVID-19 (COVID19) (JANSSEN)	Computed tomogram head normal	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982
COVID-19 (COVID19) (JANSSEN)	Computed tomogram thorax abnormal	2	1.381	0.888	0.488	2.248	2.042	2.022	2.449	1.129	1.129	1.129
COVID-19 (COVID19) (JANSSEN)	Computed tomogram thorax normal	1.918	1.918	1.918	1.918	1.918	1.918	1.918	1.918	1.918	1.918	1.918
COVID-19 (COVID19) (JANSSEN)	Crusts oral clearance decreased	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982	1.982
COVID-19 (COVID19) (JANSSEN)	Death	1.169	0.862	0.223	0.688	1.223	1.682	1.682	1.682	1.682	1.682	1.682
COVID-19 (COVID19) (JANSSEN)	Deep vein thrombosis	2.637	1.807	1.108	0.464	2.268	2.289	3.172	3.322	2.059	2.059	2.059
COVID-19 (COVID19) (JANSSEN)	Endometrial stimulation	0.958	0.958	0.958	0.958	0.958	0.958	0.958	0.958	0.958	0.958	0.958
COVID-19 (COVID19) (JANSSEN)	Eosinophil count increased	1.704	1.206	0.93	0.04	1.244	2.018	1.774	2.093	1.337	1.337	1.337
COVID-19 (COVID19) (JANSSEN)	Eosinophil percentage decreased	1.796	1.447	0.965	0.266	1.257	1.937	2.077	2.077	1.796	1.796	1.796
COVID-19 (COVID19) (JANSSEN)	Fatigue	1.757	0.895	0.616	0.181	1.04	1.457	0.978	1.852	1.428	1.428	1.428
COVID-19 (COVID19) (JANSSEN)	Fatigued	2.272	1.524	0.974	0.266	1.257	2.179	2.524	2.729	2.524	2.524	2.524
COVID-19 (COVID19) (JANSSEN)	Fibrin D dimer increased	2.147	0.984	0.619	0.266	1.171	2.312	2.018	2.53	1.825	1.825	1.825
COVID-19 (COVID19) (JANSSEN)	Fibrin D dimer normal	1.937	1.675	0.888	0.438	1.628	2.011	1.628	2.172	1.238	1.238	1.238
COVID-19 (COVID19) (JANSSEN)	Fetal exposure during pregnancy	2.251	1.251	0.756	0.266	1.171	2.011	1.628	2.172	1.238	1.238	1.238
COVID-19 (COVID19) (JANSSEN)	Gaze palsy	2.21	1.021	0.885	0.465	2.274	1.882	1.213	2.224	1.578	1.578	1.578
COVID-19 (COVID19) (JANSSEN)	Glucose present	1.846	1.846	1.846	1.846	1.846	1.846	1.846	1.846	1.846	1.846	1.846
COVID-19 (COVID19) (JANSSEN)	Glucose urea present	1.712	1.156	0.881	0.437	1.102	1.408	1.373	2.182	1.068	1.068	1.068
COVID-19 (COVID19) (JANSSEN)	Guttal-Barré syndrome	2.488	2.488	2.488	2.488	2.488	2.488	2.488	2.488	2.488	2.488	2.488
COVID-19 (COVID19) (JANSSEN)	Haematocrit decreased	1.806	1.271	0.941	0.613	0.235	2.02	1.874	2.181	1.43	1.43	1.43
COVID-19 (COVID19) (JANSSEN)	Haemoglobin decreased	1.806	1.271	0.941	0.613	0.235	2.02	1.874	2.181	1.43	1.43	1.43
COVID-19 (COVID19) (JANSSEN)	Heparin-induced thrombocytopenia test	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39
COVID-19 (COVID19) (JANSSEN)	Heparin-induced thrombocytopenia test positive	1.527	0.885	0.619	0.266	1.171	1.628	1.432	1.767	1.373	1.373	1.373
COVID-19 (COVID19) (JANSSEN)	Hypoxia	2.478	3.207	0.883	0.554	4.206	3.734	0.374	7.054	2.479	2.479	2.479
COVID-19 (COVID19) (JANSSEN)	Immunoglobulin therapy	0.169	0.169	0.169	0.169	0.169	0.169	0.169	0.169	0.169	0.169	0.169
COVID-19 (COVID19) (JANSSEN)	Intensive care	1.713	0.881	0.619	0.041	1.209	2.546	1.074	2.227	1.711	1.711	1.711
COVID-19 (COVID19) (JANSSEN)	International normalized ratio increased	1.945	1.489	0.964	0.266	1.171	1.454	2.044	2.384	2.044	2.044	2.044
COVID-19 (COVID19) (JANSSEN)	International normalized ratio normal	1.76	1.202	0.889	0.382	1.528	1.891	1.433	2.202	1.258	1.258	1.258
COVID-19 (COVID19) (JANSSEN)	Intracardiac thrombosis	2.97	1.774	0.887	0.266	1.171	1.454	2.044	2.384	2.044	2.044	2.044
COVID-19 (COVID19) (JANSSEN)	Jugular vein thrombosis	1.84	1.389	0.887	0.173	1.178	1.719	1.719	2.289	0.717	0.717	0.717
COVID-19 (COVID19) (JANSSEN)	Lumbar puncture abnormal	2.043	1.69	0.93	0.613	1.122	2.801	1.031	1.774	1.816	1.816	1.816
COVID-19 (COVID19) (JANSSEN)	Lumbar puncture normal	1.938	1.938	1.938	1.938	1.938	1.938	1.938	1.938	1.938	1.938	1.938
COVID-19 (COVID19) (JANSSEN)	Lung opacity	2.04	1.282	0.949	0.182	1.425	1.73	2.013	2.38	1.523	1.523	1.523
COVID-19 (COVID19) (JANSSEN)	Lymphocyte percentage decreased	1.976	1.025	0.619	0.182	1.096	1.973	1.973	1.963	1.963	1.963	1.963
COVID-19 (COVID19) (JANSSEN)	Magnetic resonance imaging head abnormal	2.08	1.485	0.916	0.182	1.096	1.872	2.142	2.338	1.595	1.595	1.595
COVID-19 (COVID19) (JANSSEN)	Magnetic resonance imaging head normal	1.372	0.833	0.569	0.182	1.096	1.872	2.142	2.338	1.595	1.595	1.595
COVID-19 (COVID19) (JANSSEN)	Mean cell haemoglobin concentration decreased	1.702	1.251	0.922	0.619	0.182	1.17	1.918	1.475	2.073	0.974	0.974
COVID-19 (COVID19) (JANSSEN)	Mean platelet volume increased	1.846	1.288	0.91	0.374	1.147	2.274	1.579	2.074	1.395	1.395	1.395
COVID-19 (COVID19) (JANSSEN)	Mechanical ventilation	2.92	1.92	0.978	0.266	1.171	2.068	2.068	2.068	2.136	1.617	1.617
COVID-19 (COVID19) (JANSSEN)	Monocyte percentage increased	1.533	1.223	0.918	0.207	0.855	1.931	1.981	2.102	1.118	1.118	1.118
COVID-19 (COVID19) (JANSSEN)	Neutrophil percentage decreased	1.522	1.024	0.884	0.199	1.132	1.607	1.607	1.607	1.607	1.607	1.607
COVID-19 (COVID19) (JANSSEN)	Neutrophil percentage increased	1.722	1.259	0.929	0.209	1.068	2.068	1.808	1.983	1.405	1.405	1.405
COVID-19 (COVID19) (JANSSEN)	Non-specific reaction	4.088	0.788	0.569	0.182	1.096	1.872	2.142	2.338	1.595	1.595	1.595
COVID-19 (COVID19) (JANSSEN)	Off label use	2.072	0.986	0.885	0.846	1.219	1.387	0.985	1.489	2.085	2.085	2.085
COVID-19 (COVID19) (JANSSEN)	On and off phenomenon	1.767	0.751	0.569	0.348	1.408	1.985	2.249	2.249	1.767	1.767	1.767
COVID-19 (COVID19) (JANSSEN)	Oral assessment	2.259	0.861	0.569	0.515	1.906	2.506	1.11	2.173	1.447	1.447	1.447
COVID-19 (COVID19) (JANSSEN)	Pregnant embryo	3.089	1.355	0.883	0.687	0.687	1.038	1.561	2.268	0.951	0.951	0.951
COVID-19 (COVID19) (JANSSEN)	Platelet count	2.817	1.148	0.388	0.882	1.821	2.21	1.964	2.791	2.605	2.605	2.605
COVID-19 (COVID19) (JANSSEN)	Platelet count decreased	1.87	1.303	0.92	0.479	1.832	2.1	1.864	2.044	1.469	1.469	1.469
COVID-19 (COVID19) (JANSSEN)	Platelet count normal	2.951	1.808	0.901	0.687	2.069	2.74	2.172	3.152	1.603	1.603	1.603
COVID-19 (COVID19) (JANSSEN)	Platelet factor 4	5.8	3.284	0.885	4.291							

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 14, 2022 6:37:03 AM
Attachments: [USST_20220610.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/10/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 21, 2022 7:15:05 AM
Attachments: [USST_20220617.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/17/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB05 20220617	US Barouq EB05 20220617	US Falmi EB05 20220617	US Infant EB05 20220617	US Child EB05 20220617	US Teen EB05 20220617	US Adult EB05 20220617	US Adult EB05 20220617	US Adult EB05 20220617	US Female EB05 20220617	US Male EB05 20220617
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time prolonged	1.942	1.943				1.377	1.544	1.895	1.929	2.623	1.382
COVID19 (COVID19 (JANSSEN))	Activated partial thromboplastin time shortened	2.011	1.477	0.877				1.544	1.895	1.929	2.623	1.382
COVID19 (COVID19 (JANSSEN))	Acute respiratory distress syndrome	2.094	1.279	0.974				0.779	1.023	1.781	1.602	1.881
COVID19 (COVID19 (JANSSEN))	Acute respiratory failure	2.111	1.317	1.016				0.522	0.759	1.094	2.439	1.754
COVID19 (COVID19 (JANSSEN))	Adverse drug reaction	3.375	0.966	0.886				0.779	2.031	0.977	2.626	1.448
COVID19 (COVID19 (JANSSEN))	Adverse event	1.085	1.085	1.085				2.342	0.969	0.779	1.892	1.179
COVID19 (COVID19 (JANSSEN))	Albumin CSF increased	2.05	1.805					1.382	1.382		0.894	1.561
COVID19 (COVID19 (JANSSEN))	Angiogram abnormal	1.924	1.273	0.908			0.487	1.48	1.48	1.676	2.126	1.322
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral abnormal	2.602	1.911	1.911				2.052	1.901	2.007	1.407	2.325
COVID19 (COVID19 (JANSSEN))	Angiogram cerebral normal	2.063	1.361	0.887				1.782	1.753	1.247	2.162	1.456
COVID19 (COVID19 (JANSSEN))	Angiogram pulmonary abnormal	2.281	1.609	1.609				1.672	2.228	2.044	2.173	2.448
COVID19 (COVID19 (JANSSEN))	Arion gap decreased	1.788	1.336	0.911				0.359	1.138	1.448	2.117	1.317
COVID19 (COVID19 (JANSSEN))	Artbody test	2.164	0.824	0.882				0.968	0.867	1.563	2.113	2.291
COVID19 (COVID19 (JANSSEN))	Anticoagulant therapy	2.173	1.403	0.947	0.62			0.414	1.843	2.018	2.844	2.75
COVID19 (COVID19 (JANSSEN))	Application site pain	2.004	0.561	0.902				0.561	0.636	0.678	1.037	0.704
COVID19 (COVID19 (JANSSEN))	Arteriosclerosis	2.055	1.657	0.902				0.97	2.225	1.315	2.15	1.425
COVID19 (COVID19 (JANSSEN))	Arteriogram carotid abnormal	1.811	1.139	0.888				1.203	1.207	1.406	2.193	0.966
COVID19 (COVID19 (JANSSEN))	Basophil count decreased	1.84	1.348	0.93	0.617			0.354	1.127	2.189	1.87	2.288
COVID19 (COVID19 (JANSSEN))	Basophil percentage decreased	1.753	1.308	0.938				0.251	1.108	2.238	1.801	2.173
COVID19 (COVID19 (JANSSEN))	Blood albumin decreased	1.81	1.257	0.925				0.299	1.511	1.833	1.734	2.165
COVID19 (COVID19 (JANSSEN))	Blood calcium decreased	1.854	1.332	0.949				0.369	1.354	2.076	1.869	2.173
COVID19 (COVID19 (JANSSEN))	Blood chloride increased	1.788	1.288	0.954				0.459	1.249	1.971	1.84	2.141
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen	1.852	1.157	0.879				0.979	2.008	0.959	1.698	1.156
COVID19 (COVID19 (JANSSEN))	Blood fibrinogen decreased	2.696	2.12	0.986				1.744	2.032	0.87	3.932	1.026
COVID19 (COVID19 (JANSSEN))	Blood magnesium increased	1.757	1.257	0.922				0.166	1.027	1.732	2.286	2.286
COVID19 (COVID19 (JANSSEN))	Blood uric acid decreased	1.639	1.307	0.993				1.353	1.949	1.198	2.016	0.975
COVID19 (COVID19 (JANSSEN))	Blood urea increased	1.887	1.444	0.912				1.093	2.028	1.772	2.09	1.631
COVID19 (COVID19 (JANSSEN))	COVID-19 pneumonia	2.266	1.462	1.071				1.886	2.225	2.06	2.42	1.999
COVID19 (COVID19 (JANSSEN))	CHF protein increased	2.061	1.684	0.982				1.896	2.463	0.991	2.935	2.133
COVID19 (COVID19 (JANSSEN))	Cerebral haemorrhage	2.232	1.586	0.939			0.523	1.776	1.831	1.503	3.332	1.172
COVID19 (COVID19 (JANSSEN))	Cerebral mass effect	2.789	1.35	0.924				1.531	1.627	1.298	3.794	1.19
COVID19 (COVID19 (JANSSEN))	Cerebral thrombosis	1.737	0.886	0.886				1.352	1.356	1.628	3.625	2.369
COVID19 (COVID19 (JANSSEN))	Cerebral venous sinus thrombosis	1.358	2.171	0.919			0.527	2.085	2.443	0.872	3.007	1.271
COVID19 (COVID19 (JANSSEN))	Chest X-ray abnormal	1.867	1.867	0.929				1.867	1.867	1.867	2.081	1.867
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head abnormal	2.42	1.636	0.961	0.618		0.6	2.124	2.267	2.045	3.004	1.722
COVID19 (COVID19 (JANSSEN))	Computerized tomogram head normal	1.968	1.368	0.916				1.711	1.933	1.627	2.249	2.249
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax abnormal	1.986	1.373	0.926			0.457	1.397	2.033	1.966	2.241	1.661
COVID19 (COVID19 (JANSSEN))	Computerized tomogram thorax normal	2.036	1.281	0.889				0.495	0.888	2.089	1.056	1.783
COVID19 (COVID19 (JANSSEN))	Death	1.873	1.171	0.922				1.171	1.632	1.684	2.089	2.089
COVID19 (COVID19 (JANSSEN))	Deep vein thrombosis	2.643	1.801	1.06			0.483	2.271	2.297	3.159	3.323	2.069
COVID19 (COVID19 (JANSSEN))	Endotracheal intubation	2.04	1.247	0.926				1.247	2.065	1.732	2.249	2.249
COVID19 (COVID19 (JANSSEN))	Eosinophil count decreased	1.725	1.273	0.926	0.616			0.041	1.217	1.737	2.073	1.317
COVID19 (COVID19 (JANSSEN))	Eosinophil percentage decreased	1.755	1.316	0.934				0.265	1.223	2.032	1.748	2.053
COVID19 (COVID19 (JANSSEN))	Feeling cold	1.755	1.316	0.934				1.755	1.452	1.452	1.875	1.85
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer	2.267	1.275	0.899				0.504	2.175	2.143	1.946	1.702
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer increased	1.927	1.427	0.927	0.619			2.269	2.269	2.195	2.513	1.61
COVID19 (COVID19 (JANSSEN))	Fibrin D dimer normal	1.942	1.062	0.886				0.437	0.63	2.036	1.208	1.198
COVID19 (COVID19 (JANSSEN))	Fetal exposure during pregnancy	2.323	1.418	0.916			0.757	0.676	1.873	1.023	1.637	1.843
COVID19 (COVID19 (JANSSEN))	Glaze patch	2.219	1.633	0.997				0.403	1.697	1.216	2.224	2.224
COVID19 (COVID19 (JANSSEN))	Globulins increased	1.855	1.263	0.913				0.397	1.277	1.738	1.6	2.219
COVID19 (COVID19 (JANSSEN))	Gout-Barre syndrome	1.695	1.47	0.912				1.695	1.427	1.627	2.138	1.738
COVID19 (COVID19 (JANSSEN))	Gout-Barre syndrome	2.458	1.824	0.944				0.436	1.623	3.075	2.413	2.174
COVID19 (COVID19 (JANSSEN))	Haemoglobin decreased	1.793	1.263	0.941	0.613			1.329	1.999	1.777	2.166	1.422
COVID19 (COVID19 (JANSSEN))	Haemoglobin increased	1.743	1.743	0.927				1.743	1.207	1.631	2.073	1.873
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test	5.71	3.604	0.9	0.613			0.516	5.516	0.967	2.906	3.317
COVID19 (COVID19 (JANSSEN))	Heparin-induced thrombocytopenia test positive	6.444	3.289	0.883				0.552	6.289	0.722	3.739	7.05
COVID19 (COVID19 (JANSSEN))	Hypoxia	2.073	1.313	0.957				1.488	2.08	1.936	2.45	1.684
COVID19 (COVID19 (JANSSEN))	Immunglobulin therapy	2.09	1.722	0.924			0.011	1.463	2.343	2.863	2.213	1.741
COVID19 (COVID19 (JANSSEN))	Interosseous catheter	1.84	1.384	0.927				1.463	2.097	2.027	2.085	1.855
COVID19 (COVID19 (JANSSEN))	International normalised ratio increased	1.73	1.187	0.886	0.755		0.381	1.508	1.852	1.407	2.257	1.237
COVID19 (COVID19 (JANSSEN))	International normalised ratio normal	1.929	1.392	0.929				1.929	2.072	0.969	2.052	1.622
COVID19 (COVID19 (JANSSEN))	Intracardiac thrombus	2.699	1.814	0.924				1.814	1.421	0.994	1.771	1.622
COVID19 (COVID19 (JANSSEN))	Jugular vein thrombosis	1.867	1.377	0.887				1.377	1.811	1.712	2.268	1.627
COVID19 (COVID19 (JANSSEN))	Lumbar puncture	1.865	1.352	0.876				1.352	2.18	1.006	1.652	1.758
COVID19 (COVID19 (JANSSEN))	Lumbar puncture abnormal	2.141	1.685	0.946				1.156	1.815	0.704	1.752	1.837
COVID19 (COVID19 (JANSSEN))	Lung opacity	1.989	1.423	0.948				1.423	1.709	1.669	2.923	1.61
COVID19 (COVID19 (JANSSEN))	Lymphocyte percentage decreased	1.669	1.22	0.924			0.183	0.481	2.036	1.895	2.05	1.297
COVID19 (COVID19 (JANSSEN))	Magnetic resonance imaging head abnormal	2.057	1.466	0.915				1.769	1.879	2.117	2.323	1.803
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin concentration decreased	2.006	1.35	0.931	0.619			1.288	2.456	1.818	1.834	2.354
COVID19 (COVID19 (JANSSEN))	Mean cell haemoglobin increased	1.7	1.249	0.918				0.233	1.171	1.909	2.483	2.065
COVID19 (COVID19 (JANSSEN))	Mean platelet volume increased	1.813	1.307	0.927				1.813	2.207	1.533	2.036	0.979
COVID19 (COVID19 (JANSSEN))	Mechanical ventilation	2.279	1.507	0.927				1.156	2.249	1.403	2.111	2.038
COVID19 (COVID19 (JANSSEN))	Monocyte percentage increased	1.919	1.204	0.919	0.616			0.836	1.891	1.927	2.107	1.099
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage decreased	2.361	0.981	0.881				1.315	1.589	1.667	2.135	1.099
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1.552	1.187	0.894				0.315	1.589	1.997	2.107	0.85
COVID19 (COVID19 (JANSSEN))	Neutrophil percentage increased	1.716	1.305	0.926				0.265	2.049	1.893	1.875	1.875
COVID19 (COVID19 (JANSSEN))	Non-specific reaction	4.081	0.789	0.881				0.745	0.613	1.034	1.017	1.076
COVID19 (COVID19 (JANSSEN))	Oral label use	2.101	0.6	0.895			4.856	1.236	1.46	1.894	3.078	2.126
COVID19 (COVID19 (JANSSEN))	Oral and/or phenothion	1.768	1.768	0.922				1.768	1.768	0.982	2.246	1.44
COVID19 (COVID19 (JANSSEN))	Pain assessment	2.204	0.858	0.881			0.514	1.495	2.232	1.036	2.133	1.444
COVID19 (COVID19 (JANSSEN))	Peripneumonia	3.085	1.36	0.984				0.657	1.034	1.565	2.309	0.951
COVID19 (COVID19 (JANSSEN))	Platelet count	2.653	2.154	0.917	0.618			0.477	1.864	2.883	2.619	3.01
COVID19 (COVID19 (JANSSEN))	Platelet count decreased	1.866	1.297	0.896	0.614			0.256	1.453	2.085	1.649	1.468
COVID19 (COVID19 (JANSSEN))	Platelet count normal	2.645	1.806	0.916				2.092	2.092	1.725	3.08	1.17
COVID19 (COVID19 (JANSSEN))	Platelet factor 4	5.802	3.271	0.889				1.428	4.288	0.873	5.732	2.273
COVID19 (COVID19 (JANSSEN))	Pulial vein thrombosis	2.253	1.671	0.985				0.959	1.863	1.97	1.93	2.368
COVID19 (COVID19 (JANSSEN))	Positive airway pressure therapy	2.084	1.298	0.956				1.003	2.102	1.709	2.243	1.651
COVID19 (COVID19 (JANSSEN))	Product administered to patient of inappropriate age	1.751	0.834	0.885			0.705	2.06	1.038	0.511	1.67	1.816
COVID19 (COVID19 (JANSSEN))	Prepared abate	1.184	1.332					0.554	1.332		1.57	1.57
COVID19 (COVID19 (JANSSEN))	Protein total decreased	1.765	1.208	0.924	0.617			0.326	1.418	1.597	1.7	2.006
COVID19 (COVID19 (JANSSEN))	Prothrombin time prolonged	1.9	1.365	0.934	0.754			0.293	1.444	2.26	1.627	2.424
COVID19 (COVID19 (JANSSEN))	Pulmonary embolism	2.248	1.582	1.048	0.62			1.806	2.064	2.613	2.528	1.91
COVID19 (COVID19 (JANSSEN))	Pulmonary thrombosis	2.312	1.482	0.91				1.676	1.69	1.52	2.223	1.871
COVID19 (COVID19 (JANSSEN))	Red blood cell count decreased	1.775	1.252	0.887	0.614			1.345	1.928	1.659	2.013	1.477
COVID19 (COVID19 (JANSSEN))	Red cell distribution width increased	1.935	1.294	0.928	0.618			0.277	1.284	1.785	2.228	1.402
COVID19 (COVID19 (JANSSEN))	Russell's viper venom time abnormal	3.288	0.984	0.888				0.984	0.966	0.666	1.068	0.725
COVID19 (COVID19 (JANSSEN))	Superficial vein thrombosis	2.41	1.798	0.892				0.532	2.003	1.752	2.627	1.83

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: RE: Weekly data mining
Date: Tuesday, June 28, 2022 6:49:02 AM
Attachments: [USST_20220624.xls](#)

Sorry – forgot attachment

From: Menschik, David
Sent: Tuesday, June 28, 2022 6:48 AM
To: Shimabukuro, Tom (CDC) <ayv6@cdc.gov>; Su, John (CDC) <ezu2@cdc.gov>; Moro, Pedro L (CDC) <psm9@cdc.gov>
Cc: Zinderman, Craig E <Craig.Zinderman@fda.hhs.gov>; Nair, Narayan <Narayan.Nair@fda.hhs.gov>; Alimchandani, Meghna <Meghna.Alimchandani@fda.hhs.gov>; Broder, Karen R (CDC) <krb2@cdc.gov>; Mcneil, Michael M (CDC) <mmm2@cdc.gov>; Lale, Allison (CDC) <rgo3@cdc.gov>
Subject: Weekly data mining

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 6/24/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

From: [Menschik, David](#)
To: [Shimabukuro, Tom \(CDC\)](#); [Su, John \(CDC\)](#); [Moro, Pedro L \(CDC\)](#)
Cc: [Zinderman, Craig E](#); [Nair, Narayan](#); [Alimchandani, Meghna](#); [Broder, Karen R \(CDC\)](#); [Mcneil, Michael M \(CDC\)](#); [Lale, Allison \(CDC\)](#)
Subject: Weekly data mining
Date: Tuesday, July 5, 2022 7:41:46 AM
Attachments: [USST_20220701.xls](#)

Good morning all,

Attached please find a list of all (i.e., unvetted and regardless of notability) PTs with data mining alerts (i.e., EB05 \geq 2) for all SARS-CoV-2 vaccine VAERS reports from our weekly 'US Signals Summary Table' ('as of date' 7/1/22). Please feel free to share this hypothesis generating output with your team/command chain, though this is not intended to be shared more broadly.

Thanks,
David

THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

Drug	Event	US EB02 2022/07/01	US Serious EB02 2022/07/01	US Fatal EB02 2022/07/01	US Infant EB02 2022/07/01	US Child EB02 2022/07/01	US Teen EB02 2022/07/01	US Adult EB02 2022/07/01	US Adult EB02 2022/07/01	US Adult EB02 2022/07/01	US Female EB02 2022/07/01	US Male EB02 2022/07/01
COVID-19 (COVID19 (ANSSENS))	Activated partial thromboplastin time prolonged	1.45	1.45					1.47	1.45	1.56	1.56	1.42
COVID-19 (COVID19 (ANSSENS))	Activated partial thromboplastin time shortened	2.019	1.484	0.869				1.536	1.967	1.989	2.886	1.366
COVID-19 (COVID19 (ANSSENS))	Acute respiratory distress syndrome	2.045	1.283	0.763				1.743	1.743	1.988	2.246	1.571
COVID-19 (COVID19 (ANSSENS))	Acute respiratory failure	1.126	1.322	1.028				1.033	2.071	1.986	2.425	1.794
COVID-19 (COVID19 (ANSSENS))	Adverse drug reaction	3.965	0.985	0.565			0.522	1.859	0.707	0.736	2.654	1.443
COVID-19 (COVID19 (ANSSENS))	Adverse event	2.44	0.886	0.488				1.068	0.968	1.033	1.834	1.714
COVID-19 (COVID19 (ANSSENS))	Angiogram abnormal	1.9	1.252	0.903				1.486	1.434	1.672	2.004	1.309
COVID-19 (COVID19 (ANSSENS))	Angiogram cerebral abnormal	2.806	1.764	1.065				2.386	1.948	2.044	2.644	1.611
COVID-19 (COVID19 (ANSSENS))	Angiogram cerebral normal	2.091	1.362	0.801			0.485	1.781	1.828	1.228	2.145	1.522
COVID-19 (COVID19 (ANSSENS))	Angiogram coronary abnormal	2.997	1.607	0.977	0.619			2.605	1.977	2.295	2.205	2.025
COVID-19 (COVID19 (ANSSENS))	Arhin gap decreased	1.756	1.346	0.91				1.142	2.144	1.424	2.149	1.311
COVID-19 (COVID19 (ANSSENS))	Arthralgia	0.866	0.893	0.633				1.063	1.063	1.063	1.865	1.063
COVID-19 (COVID19 (ANSSENS))	Arthrocentesis therapy	2.176	1.45	0.619	0.619			1.844	2.026	2.25	2.733	1.674
COVID-19 (COVID19 (ANSSENS))	Aspiration site pain	2.047	1.642	0.866				0.867	2.027	1.307	1.027	1.42
COVID-19 (COVID19 (ANSSENS))	Asterogram carotid abnormal	1.707	1.131	0.68				1.203	1.2	1.307	2.158	0.962
COVID-19 (COVID19 (ANSSENS))	Asterogram decreased	1.833	1.341	0.894	0.617		0.351	1.132	2.386	1.833	2.246	1.52
COVID-19 (COVID19 (ANSSENS))	Basophil percentage decreased	1.748	1.357	0.941			0.616	1.091	2.225	1.732	2.135	1.326
COVID-19 (COVID19 (ANSSENS))	Blood alkalinity decreased	1.944	1.276	0.827				1.664	1.664	1.777	2.19	1.435
COVID-19 (COVID19 (ANSSENS))	Blood calcium decreased	1.871	1.343	0.928				1.363	2.077	1.907	2.138	1.52
COVID-19 (COVID19 (ANSSENS))	Blood chloride decreased	1.976	1.254	0.824				1.111	2.032	1.603	1.944	1.586
COVID-19 (COVID19 (ANSSENS))	Blood chloride increased	1.702	1.284	0.91				1.237	1.948	1.85	2.122	1.322
COVID-19 (COVID19 (ANSSENS))	Blood folate increased	1.965	1.152	0.689				0.929	2.157	0.655	1.625	1.211
COVID-19 (COVID19 (ANSSENS))	Blood folate decreased	2.795	1.686	1.041				1.741	2.031	0.958	1.698	1.127
COVID-19 (COVID19 (ANSSENS))	Blood lactate dehydrogenase increased	1.707	1.244	0.895	0.619		0.151	1.186	2.025	1.309	1.763	1.416
COVID-19 (COVID19 (ANSSENS))	Blood magnesium increased	1.772	1.27	0.82				1.722	1.693	1.763	1.733	1.217
COVID-19 (COVID19 (ANSSENS))	Blood potassium decreased	1.7	1.218	0.84			0.616	1.256	1.487	2.058	1.897	1.245
COVID-19 (COVID19 (ANSSENS))	Blood sodium decreased	1.941	1.306	0.901				1.205	2.016	1.744	1.975	1.51
COVID-19 (COVID19 (ANSSENS))	Blood sodium increased	1.687	1.098	0.627				1.359	2.101	2.019	1.924	1.524
COVID-19 (COVID19 (ANSSENS))	Blood urea decreased	1.933	1.267	0.869				1.389	2.066	1.204	0.936	0.936
COVID-19 (COVID19 (ANSSENS))	Blood urea increased	1.911	1.269	0.819			0.285	1.087	2.064	1.788	2.111	1.658
COVID-19 (COVID19 (ANSSENS))	COVID-19 pneumonia	2.253	1.407	0.882				1.966	2.264	2.059	2.439	2.018
COVID-19 (COVID19 (ANSSENS))	CHF worse increased	2.865	1.993	1.073				1.85	3.066	3.066	3.073	2.14
COVID-19 (COVID19 (ANSSENS))	Catheter dislodged thrombolysis	1.775	1.232	0.832			0.832	0.456	1.736	0.806	0.806	0.611
COVID-19 (COVID19 (ANSSENS))	Central venous catheter thrombosis	2.23	1.168	0.627				1.768	1.968	1.5	3.173	1.919
COVID-19 (COVID19 (ANSSENS))	Central vein occlusion	2.755	1.928	1.02				1.838	1.618	1.254	3.899	1.192
COVID-19 (COVID19 (ANSSENS))	Central venous sinus thrombosis	2.71	1.868	0.938				2.1	1.844	1.584	1.271	1.063
COVID-19 (COVID19 (ANSSENS))	Chest X-ray abnormal	3.357	2.172	1.279				2.579	2.441	0.873	1.924	1.192
COVID-19 (COVID19 (ANSSENS))	Chest X-ray normal	0.924	0.924	0.924				1.369	1.984	1.903	1.836	1.063
COVID-19 (COVID19 (ANSSENS))	Completed bronchus head abnormal	2.4	1.4	0.659	0.618			2.555	2.055	2.017	2.667	1.714
COVID-19 (COVID19 (ANSSENS))	Completed bronchus head normal	1.988	1.332	0.916				1.734	1.962	1.8	2.258	1.531
COVID-19 (COVID19 (ANSSENS))	Completed bronchus thorax abnormal	2.008	1.364	0.867				1.406	2.064	1.874	2.074	1.406
COVID-19 (COVID19 (ANSSENS))	Coagulation renal clearance decreased	1.841	1.241	0.845				0.495	0.859	2.007	1.043	1.707
COVID-19 (COVID19 (ANSSENS))	Death	1.871	1.171	0.644				1.071	1.644	1.644	1.974	1.071
COVID-19 (COVID19 (ANSSENS))	Deep vein thrombosis	2.951	1.862	1.048			0.461	2.27	2.266	3.199	3.306	2.087
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation	0.265	0.265	0.265				0.265	0.265	0.265	1.989	0.265
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation decreased	1.787	1.285	0.932				1.214	2.04	1.737	2.38	1.388
COVID-19 (COVID19 (ANSSENS))	Endotracheal intubation increased	1.781	1.329	0.827	0.616		0.249	1.218	2.06	1.777	2.072	1.389
COVID-19 (COVID19 (ANSSENS))	Feeding oral	1.757	0.84	0.484				1.181	2.023	1.452	0.862	0.862
COVID-19 (COVID19 (ANSSENS))	Film D dimer	2.274	1.281	0.893				0.502	2.179	2.147	1.965	2.532
COVID-19 (COVID19 (ANSSENS))	Film D dimer normal	0.299	0.299	0.299	0.619			1.715	2.293	2.293	2.293	1.715
COVID-19 (COVID19 (ANSSENS))	Film D dimer raised	1.945	1.099	0.685				1.654	2.017	1.104	2.184	1.296
COVID-19 (COVID19 (ANSSENS))	Fetal exposure during pregnancy	2.239	1.462	0.842			0.757	1.642	1.642	1.642	1.642	1.642
COVID-19 (COVID19 (ANSSENS))	Gait palsy	1.031	0.89	0.52				2.305	1.696	1.215	2.214	1.604
COVID-19 (COVID19 (ANSSENS))	Gidolium increased	2.967	1.798	1.068				1.31	1.798	1.686	2.274	1.276
COVID-19 (COVID19 (ANSSENS))	Gidolium urea present	1.741	1.012	0.612				1.178	1.937	1.937	1.937	1.178
COVID-19 (COVID19 (ANSSENS))	Gullström-Bare syndrome	2.448	1.818	0.887				1.617	3.042	1.622	2.393	1.499
COVID-19 (COVID19 (ANSSENS))	Haematuria decreased	1.804	1.067	0.627				1.326	2.017	1.789	2.127	1.269
COVID-19 (COVID19 (ANSSENS))	Haemoglobin decreased	1.78	1.234	0.845	0.613		0.421	0.946	1.942	1.678	2.081	1.289
COVID-19 (COVID19 (ANSSENS))	Heparin-induced thrombocytopenia test	0.706	0.706	0.706				0.706	0.706	4.146	1.946	0.706
COVID-19 (COVID19 (ANSSENS))	Heparin-induced thrombocytopenia test positive	6.145	3.251	0.875			0.55	1.059	2.027	0.74	7.043	2.491
COVID-19 (COVID19 (ANSSENS))	Hypoxia	0.293	0.293	0.293				0.293	0.293	0.293	1.946	0.293
COVID-19 (COVID19 (ANSSENS))	Immunoassay therapy	2.103	1.723	1.073				1.972	1.972	1.972	2.2	1.751
COVID-19 (COVID19 (ANSSENS))	Intensive care	0.268	0.268	0.268				0.268	0.268	2.13	2.083	0.268
COVID-19 (COVID19 (ANSSENS))	International normalized ratio increased	1.758	1.168	0.822	0.755		0.377	1.89	1.49	1.429	1.521	1.251
COVID-19 (COVID19 (ANSSENS))	International normalized ratio normal	1.951	1.239	0.885				1.396	2.057	1.605	2.102	1.605
COVID-19 (COVID19 (ANSSENS))	International normalized ratio decreased	0.874	0.778	0.478				0.778	1.422	0.895	1.627	0.895
COVID-19 (COVID19 (ANSSENS))	Jugular vein thrombosis	1.833	1.377	0.979				1.389	1.116	0.712	2.297	1.807
COVID-19 (COVID19 (ANSSENS))	Lumbar puncture	1.945	1.345	0.869				1.945	1.945	1.945	1.945	1.945
COVID-19 (COVID19 (ANSSENS))	Lumbar puncture abnormal	2.104	1.666	1.048				1.118	2.852	1.753	1.827	1.827
COVID-19 (COVID19 (ANSSENS))	Lung opacity	0.265	0.265	0.265				0.265	1.715	0.265	1.983	0.265
COVID-19 (COVID19 (ANSSENS))	Lymphocyte percentage decreased	1.887	1.229	0.933				0.927	2.084	1.87	2.074	1.304
COVID-19 (COVID19 (ANSSENS))	Magnetic resonance imaging head abnormal	2.059	1.466	0.946			0.246	1.758	1.897	2.086	2.297	1.691
COVID-19 (COVID19 (ANSSENS))	Magnetic resonance imaging head normal	0.217	0.217	0.217	0.619			0.217	1.354	0.217	1.698	0.217
COVID-19 (COVID19 (ANSSENS))	Mean cell haemoglobin concentration decreased	1.272	1.27	0.857				1.181	1.884	1.59	2.1	0.962
COVID-19 (COVID19 (ANSSENS))	Mean cell haemoglobin increased	1.828	1.326	0.878				1.326	1.975	1.556	2.128	1.556
COVID-19 (COVID19 (ANSSENS))	Mechanical ventilation	2.284	1.503	0.92				1.268	2.048	2.048	2.086	2.086
COVID-19 (COVID19 (ANSSENS))	Monocyte percentage increased	1.574	0.918	0.518	0.618			0.857	1.893	1.995	1.995	1.171
COVID-19 (COVID19 (ANSSENS))	Neonatal dyspnea	2.377	0.985	0.585	0.62			1.107	1.59	1.69	0.876	1.117
COVID-19 (COVID19 (ANSSENS))	Neutrophil percentage decreased	1.518	1.305	0.886				1.104	2.089	1.803	1.803	0.882
COVID-19 (COVID19 (ANSSENS))	Neutrophil percentage increased	1.728	1.258	0.832				1.104	2.089	1.803	1.972	1.406
COVID-19 (COVID19 (ANSSENS))	Non-specific reaction	4.088	0.789	0.481				0.811	1.485	1.04	3.028	1.076
COVID-19 (COVID19 (ANSSENS))	Off test use	2.113	0.601	0.388				0.982	0.982	0.982	2.244	0.982
COVID-19 (COVID19 (ANSSENS))	On and off phenoxenon	1.767	0.751	0.452				1.423	0.982	0.982	2.244	1.076
COVID-19 (COVID19 (ANSSENS))	Pain assessment	2.206	0.867	0.503				1.493	2.039	1.039	2.176	1.405
COVID-19 (COVID19 (ANSSENS))	Peripheral embolism	3.052	1.38	0.875				0.657	0.657	1.572	2.268	0.951
COVID-19 (COVID19 (ANSSENS))	Phallic coat	2.17	0.914	0.544	0.618			0.653	2.915	2.713	3.14	1.253
COVID-19 (COVID19 (ANSSENS))	Phallic coat decreased	1.889	1.306	0.915	0.614			1.488	2.102	1.664	2.265	1.491
COVID-19 (COVID19 (ANSSENS))	Phallic coat normal	2.555	1.798	0.994			0.448	1.201	2.692	2.219	3.174	1.798
COVID-19 (COVID19 (ANSSENS))	Phallic coat 4	0.78	0.343	0.181				0.653	1.463	0.785	1.625	2.28
COVID-19 (COVID19 (ANSSENS))	Portal vein thrombosis	2.244	1.652	0.877				0.858	1.889	1.032	2.137	1.335
COVID-19 (COVID19 (ANSSENS))	Positive airway pressure therapy	0.866	0.866	0.866				0.866	2.123	1.796	2.086	1.692
COVID-19 (COVID19 (ANSSENS))	Product administered to patient of inappropriate age	1.78	0.835	0.477	0.693			0.037	0.002	0.506	1.67	1.812
COVID-19 (COVID19 (ANSSENS))	Prophylactic therapy	0.504	0.504	0.504				0.504	0.504	0.504	1.507	0.504
COVID-19 (COVID19 (ANSSENS))	Protein total decreased	1.805	1.227	0.833	0.616			1.446	1.646	1.744	2.036	1.646
COVID-19 (COVID19 (ANSSENS))	Prothrombin time prolonged	0.917	0.917	0.917				0.917	2.227	1.664	2.474	1.499
COVID-19 (COVID19 (ANSSENS))	Pulmonary embolism	2.261	1.588	0.985				1.819	2.071	2.632	2.529	1.625
COVID-19 (COVID19 (ANSSENS))	Pulmonary embolism decreased	2.341	1.514	0.905			0.614					